0001213900-15-004383.txt : 20150611 0001213900-15-004383.hdr.sgml : 20150611 20150611110130 ACCESSION NUMBER: 0001213900-15-004383 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150611 DATE AS OF CHANGE: 20150611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIFESTYLE MEDICAL NETWORK, INC. CENTRAL INDEX KEY: 0001307140 STANDARD INDUSTRIAL CLASSIFICATION: TELEVISION BROADCASTING STATIONS [4833] IRS NUMBER: 131026995 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52408 FILM NUMBER: 15925132 BUSINESS ADDRESS: STREET 1: 1809 E. BROADWAY ST. STREET 2: SUITE 175 CITY: OVIEDO STATE: FL ZIP: 32765 BUSINESS PHONE: 407-620-1063 MAIL ADDRESS: STREET 1: 1809 E. BROADWAY ST. STREET 2: SUITE 175 CITY: OVIEDO STATE: FL ZIP: 32765 FORMER COMPANY: FORMER CONFORMED NAME: EMERGING MEDIA HOLDINGS INC DATE OF NAME CHANGE: 20070104 FORMER COMPANY: FORMER CONFORMED NAME: Beverly Hills Film Studios Inc DATE OF NAME CHANGE: 20041027 10-K 1 f10k2015_lifestylemedical.htm ANNUAL REPORT

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-K

 

☒  ANNUAL REPORT PURSUANT TO SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: December 31, 2014

 

OR

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 000-52408

 

LIFESTYLE MEDICAL NETWORK INC.

(Exact name of Registrant as Specified in Its Charter)

 

Nevada   90-0821766
(State or other jurisdiction of   (I.R.S. Employer
Incorporation or organization)   Identification No.)

 

424 E. Central Blvd., Orlando, FL   32801
(Address of principal executive offices)   (Zip Code)

 

Issuer's Telephone Number, Including Area Code:  (407) 514-1260

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001 par value per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐  No ☒

 

Indicate by checkmark if the registrant is not required to file reports to Section 13 or 15(d)Of the Act. ☐ Yes  ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐  No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company. (Check One):

 

Large accelerated filer  ☐   Accelerated filer  ☐
     
Non-accelerated filer    ☐   Smaller reporting company  ☒

(Do not check if a smaller reporting company)

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes  ☒ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $3,378,296.

 

Number of shares of Common Stock issued and outstanding as of May 28, 2015: 31,835,101 shares.

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I 1
Item 1. Business. 1
Item 1A. Risk Factors. 5
Item 1B. Unresolved Staff Comments. 10
Item 2. Properties. 10
Item 3. Legal Proceedings. 10
Item 4. Mine Safety Disclosures. 10
PART II 11
Item 5. Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities. 11
Item 6. Selected Financial Data. 11
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. 12
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 14
Item 8. Financial Statements and Supplementary Data. 15
Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure. 33
Item 9A. Controls and Procedures. 33
Item 9B. Other Information. 33
PART III 34
Item 10. Directors, Executive Officers, and Corporate Governance. 34
Item 11. Executive Compensation. 37
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 37
Item 13. Certain Relationships and Related Transactions, and Director Independence. 40
Item 14.  Principal Accountant Fees and Services. 42
PART IV 43
Item 15. Exhibits and Financial Statement Schedules. 43
SIGNATURES 45

 

 
 

 

PART I

 

Item 1. Business.

 

General

 

Throughout this Form 10-K, the terms "we," "us," "our," and the "Company" refer to Lifestyle Medical Network Inc., a Nevada corporation, and, unless the context indicates otherwise, includes our subsidiaries.

 

The Company was incorporated in the State of Nevada on September 3, 2003, under the name Beverly Hills Film Studios, Inc. and changed its name to Emerging Media holdings, Inc. on September 28, 2006. On September 30, 2006, we effectuated a share exchange whereby we acquired all of the outstanding equity interests in our wholly-owned subsidiary, IM “Media Alianta” SRL, the 100% owner of SA “Analiticmedia-Grup”, both Moldovan companies ("AMG"), and on May 2, 2008, the Company acquired the common stock of “TNT-Bravo” channel-ICS “Media Top Prim” SRL, the exclusive operator in Moldova of Russian channel TNT programs owned by Gazprom Media. Effective July 31, 2012, the name of our Company was changed from Emerging Media Holdings, Inc. to Lifestyle Medical Network Inc.  

 

On December 29, 2011, we closed an acquisition of 100% of the outstanding shares of Lifestyle Medical Corp. (“Lifestyle Medical”), which has rights to technologies and practices licensed to its subsidiary, Elite Professional IP Licensing, LLC (“Elite”), pursuant to an October 5, 2010 License Agreement with Modular Properties Limited, Inc. (the “License Agreement”). On February 2, 2012, we completed acquisition of the rights to our licensed men’s medical clinic operating technologies and processes, by acquiring from Worldwide Medassets, Ltd. (SAL) the full assignment of rights to the License Agreement. Pursuant to the License Agreement we are licensed intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States. On December 29, 2011, we also completed the sale of our remaining Moldova media subsidiaries in exchange for the assumption of the liabilities of the subsidiaries and 250,000 shares of our common stock.

 

Our Business

 

As of the date of this report, we are focusing our efforts, through our consulting subsidiaries, on contracting to provide management and professional consulting services, and licensing medical and health technologies, to healthcare companies. We also we intend to open, operate and acquire men’s medical and health clinics, if financing is available and the profile of the clinics’ services is consistent with the types of medical businesses we view as favorable for acquisition. We have not entered into any further agreements relating to any such new consulting or licensing arrangements, or in the acquisition of any medical or health clinic business.

 

Recent Developments—Management Agreements with Houston Clinics

 

On April 14, 2014, we had entered into an agreement providing for the acquisition by the Company from the owner of six medical clinics in Houston, Texas, of which one primary care and one skin care clinic are located in leased facilities, and three primary care medical clinics and one skin care clinic are located in three separate buildings. That agreement has been terminated, and our deposit refunded, and the agreement has been superseded by further agreements pursuant to which  Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of the clinics in Houston, Texas, has purchased, effective April 1, 2015, the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”) that own the six clinics. In view of the regulatory requirements associated with the operation of this type of medical practice, we believe that the ownership of the MED-CURE Companies by a licensed medical professional with the Company operating as an outside consultant was a preferred structure to that of purchasing the facilities directly.

 

1
 

 

The MED-CURE Companies were purchased by Dr. Moomaw directly from the owner for a purchase price of $2,500,000, utilizing local bank financing. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. The MED-CURE Companies have agreed effective April 1, 2015, to enter into management agreements with the Company, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies’ clinics’ offices have been restructured, with our real estate subsidiary, Lifestyle Texas Real Estate, LLC, leasing the properties and then subleasing the properties back to the Med-Cure Companies.

 

Through our subsidiary, Regional Professional Alliance, Inc., a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management. Through Lifestyle Texas Licensing, LLC (“Lifestyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men’s health and weight management.

 

Facilities We Manage and Services Provided

 

The six Houston, Texas, medical clinics that we advise on operations through management and professional medical consulting agreements are all walk-in family practice clinics, but do not provide any obstetrics. Each is staffed by either a Doctor of Medicine (M.D.), that is normally board certified in either Family Medicine or Internal Medicine, a Physicians' Assistant (P.A. or P.A.-C) or a Nurse Practitioner. The medical clinics provide a wide range of family health care, including the routine diagnosis and treatment and management of flu, sore throats, diabetes, high blood pressure, etc. as well as pediatric care, gynecology, screenings of various types, specialist referrals, physical exams for life, school, work, immigration, etc. The medical clinics are also equipped to handle minor emergencies such as fractures, cuts and back injuries and to provide physical therapy. Two popular services are weight control and corporate medical services such as industrial medicine and work injuries, drug and alcohol screening. The medical clinics each have an x-ray machine and processor, and lab facilities on premises capable of some blood tests, urinalysis, microscopic examination and EKG. The clinics accept most insurance plans, PPOs, HMOs, Medicaid and Medicare, Workers' Compensation and Personal Injury I Accidents with appropriate Letter of Protection.

 

Our director who purchased the clinics, Dr. Ronald Moomaw, has a wealth of knowledge in medical operations and management including serving as the chief psychiatrist for the state of Ohio Department of Rehabilitation and Correction for eight years, where his responsibilities included oversight of all psychiatrists, psychologists, nurses, social workers and other mental health care providers that provide services to 32 institutions, 51,000 inmates and a $11 million budget for psychiatric medication. In fiscal year 2007-2008 he instituted changes that saved the state over one million dollars without decreasing services. Dr. Moomaw, who is based in Houston, would work closely with the Company with respect to the Company’s implementation of its responsibilities under the management and professional medical consulting agreements.

 

Management believes we can improve efficiencies and increase operating margins for medical and health clinics by utilizing our management’s expertise and experience within existing programs and their expertise in improving performance at underperforming facilities, and that the efficiencies can be realized by investing in growth in strong markets, addressing capital-constrained facilities that have underperformed and improving management systems. If we acquire additional consulting and licensing clients, the additional facilities would give us an opportunity to develop a marketing strategy in many markets which should help us increase the geographic footprint from which our existing facilities attract patients and referrals.

 

Additionally, we are looking to expand the types of medical and health therapeutic technologies to which we have rights, and which we are able to license to medical and health clinics that we manage.

 

2
 

 

We plan to seek to increase revenue at our current client facilities by providing a broader range of services to new and existing patients and clients.

 

Elite License Agreement

 

The License Agreement, under which our wholly-owned subsidiary, Elite Professional IP Licensing, LLC, is the licensee, provides for the license of the Licensed Rights, consisting generally of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States. The License Agreement provides for a fee of 4% of gross receipts of us as Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, October 5, 2010.

 

Competition

 

The healthcare industry, including the market for outpatient clinic facilities, is competitive. There is competition from other medical and health clinics and individual practitioners in the market areas for the clinics we manage and license, as well as generally from medical practices and hospitals. Competitors may have existing relationships with the medical community which may be superior ours or to those of our clinics.

 

Governmental Regulation

 

The healthcare industry is subject to numerous laws, regulations and rules including, among others, those related to government healthcare program participation requirements, various licensure and accreditation standards, reimbursement for patient services, health information privacy and security rules, and government healthcare program fraud and abuse provisions. Providers that are found to have violated any of these laws and regulations may be excluded from participating in government healthcare programs, subjected to significant fines or penalties and/or required to repay amounts received from the government for previously billed patient services.

 

Prohibition Against Practice of Medicine

 

The establishment, marketing and operation of medical and health clinics are subject to laws prohibiting the practice of medicine by non-physicians and the rebate or division of fees between physicians and non-physicians. They also limit the manner in which patients may be solicited. We believe our plan to provide management and professional medical consulting services to medical facilities will not result in the Company being considered as engaged in the practice of medicine. There can be no assurance, however, that state authorities or courts will not determine in the future that we are engaged in the unauthorized practice of medicine. Such a determination could have a materially adverse effect upon the Company and would prohibit us from continuing our current advisory services to medical and health clinics.

 

Licensing and Certification

 

All of the healthcare facilities that we advise must comply with various federal, state and local licensing and certification regulations and undergo periodic inspection by licensing agencies to certify compliance with such regulations. The initial and continued licensure of these facilities and certification to participate in government healthcare programs depends upon many factors including various state licensure regulations relating to quality of care, environment of care, equipment, services, staff training, personnel and the existence of adequate policies, procedures and controls.

 

Audits

 

Government healthcare program participating healthcare facilities are subject to federal and state audits to validate the accuracy of claims submitted to the government healthcare programs. If these audits identify overpayments, facilities that we advise as manager could be required to make substantial repayments, subject to various administrative appeal rights.

 

3
 

 

Federal False Claims Act and Other Fraud and Abuse Provisions

 

The Social Security Act also imposes criminal and civil penalties for submitting false claims to the government healthcare programs. Violations of the federal False Claims Act are punishable by fines of up to three times the actual damages sustained by the government, plus mandatory civil penalties. Whistleblower provisions allow private individuals to bring actions on behalf of the government by alleging that the defendant has defrauded the federal government. Further, a number of states have adopted their own false claims provisions as well as their own whistleblower provisions whereby a private party may file a civil lawsuit on behalf of the state. Further, the Health Insurance Portability and Accountability Act (“HIPAA”) broadened the scope of the fraud and abuse laws by adding several criminal provisions for healthcare fraud offenses that apply to all health benefit programs, whether or not payments under such programs are paid pursuant to federal programs. HIPAA also introduced enforcement mechanisms to prevent fraud and abuse under Medicare. There are civil penalties for prohibited conduct, including, but not limited to, billing for medically unnecessary products or services.

 

HIPAA Administrative Simplification and Privacy and Security Requirements

 

The administrative simplification provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, require the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry. HIPAA also established federal rules protecting the privacy and security of individually identifiable patient health information. The privacy and security regulations control the use and disclosure of patient health information and the rights of patients to understand and control how such patient health information is used and disclosed. Violations of HIPAA can result in both criminal and civil fines and penalties. The HIPAA security regulations require healthcare providers to implement administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of patient health information.

 

Patient Protection and Affordable Care Act

 

On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act (the “ACA”). The Healthcare and Education Reconciliation Act of 2010 (the “Reconciliation Act”), which contains a number of amendments to the PPACA, was signed into law on March 30, 2010. Two primary goals of the ACA, combined with the Reconciliation Act (collectively referred to as the “Health Reform Legislation”), are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses.

 

The Health Reform Legislation expands coverage of uninsured individuals and provides for significant reductions in the growth of Medicare program payments, material decreases in Medicare and Medicaid disproportionate share hospital payments, and the establishment of programs where reimbursement is tied in part to patient outcomes. Based on Congressional Budget Office estimates, the Health Reform Legislation, as enacted, is expected to expand health insurance coverage to approximately 32 to 34 million additional individuals through a combination of public program expansion and private sector health insurance reforms.

 

Risk Management and Insurance

 

The clinics we manage could be subject to claims that their services have resulted in injury to patients or clients or other adverse effects. While management believes that the clinics we manage provide quality care to patients and clients in their facilities and that we materially comply with all applicable regulatory requirements, an adverse determination in a legal proceeding or government investigation could have a material adverse effect on the business, financial condition or results of operations of the clinics we manage.

 

4
 

 

Environmental Matters

 

The clinics to which we provide consulting services are subject to various federal, state and local environmental laws that: (i) regulate certain activities and operations that may have environmental or health and safety effects, such as the handling, storage, transportation, treatment and disposal of medical waste products generated at our facilities, the identification and warning of the presence of asbestos-containing materials in buildings, as well as the removal of such materials, the presence of other hazardous substances in the indoor environment, and protection of the environment and natural resources in connection with the development or construction of the facilities; (ii) impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and off-site, or other releases of hazardous materials or regulated substances; and (iii) regulate workplace safety. Some of the clinic facilities may generate infectious or other hazardous medical waste due to the illness or physical condition of our patients. The management of infectious medical waste is subject to regulation under various federal, state and local environmental laws, which establish management requirements for such waste. These requirements include record-keeping, notice and reporting obligations.

 

Insurance

 

The clinics with which we have management agreements maintain worker compensation insurance coverage on a claims-made basis of $1,000,000, and medical professional coverage. Coverage is maintained for general liability and auto claims of up to $1,000,000, depending on the type of claim, a general aggregate of $2,000,000 for particular classes of claims, and an umbrella policy limit of $5,000,000.

 

Employees

 

As of December 31, 2014, we employed one person, our Chief Executive Officer.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth elsewhere in this annual report, you should carefully consider the following factors when evaluating us. An investment in the Company will be subject to risks inherent in our business. If any of the following risks actually occurs, our business, financial condition and results of future operations could suffer. In such case, the trading price of our shares could decline, and you could lose all or part of your investment.

 

General

 

WE HAVE RECENTLY ENTERED INTO AGREEMENTS PROVIDING MANAGEMENT SUPPORT FOR A LIMITED NUMBER OF CLINICS. WE WILL REQUIRE FINANCING TO PROCEED WITH OUR PLANNED PROGRAM TO ESTABLISH OR ACQUIRE HEALTHCARE FACILITIES AND TO EXPAND OUR MEDICAL MANAGEMENT CONSULTING PRACTICES IN THE HEALTHCARE INDUSTRY.

 

We have commenced providing management consulting services for the operations of six medical and health clinics through management agreements at present. We will require substantial additional financing to start up or to acquire one or more medical facility businesses, as well as additional capital to grow our consulting services businesses, and there is no assurance that such financing or additional capital will be available to us.

 

We operate in a highly competitive industry IN WHICH WE ARE A SMALL ENTERPRISE COMPARED TO OUR COMPETITORS, and competition may lead to declines in patient volumes in FACILITIES we manage and reductions in our management fees.

 

The healthcare industry, in which the Company is a very small factor, is highly competitive, and competition among healthcare providers (including hospitals) for patients, physicians and other healthcare professionals has intensified in recent years. Most of our competitors are much larger and better financed companies. If our competitors are better able to attract patients, recruit and retain physicians and other healthcare professionals, expand services or obtain favorable managed care contracts at their facilities, we may experience a decline in patient volume in our managed facilities and our results of operations may be adversely affected.

 

5
 

 

IF WE FAIL TO COMPLY WITH EXTENSIVE LAWS AND GOVERNMENT REGULATIONS GOVERNING THE OPERATION OF HEALTH CARE FACILITIES, WE OR FACILITIES TO WHICH WE PROVIDE MANAGEMENT SUPPORT COULD SUFFER PENALTIES OR BE REQUIRED TO MAKE SIGNIFICANT CHANGES TO OUR OPERATIONS.

 

The health care industry is required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things,

 

  licensure and certification;
     
  adequacy and quality of health care services;
     
  qualifications of health care and support personnel;
     
  quality of equipment;
     
  confidentiality, maintenance and security issues associated with medical records and claims processing;
     
  relationships with physicians and other referral sources;
     
  operating policies and procedures;
     
  addition of facilities and services; and
     
  billing for services.

 

FAILURE TO COMPLY WITH LAWS GOVERNING THE TRANSMISSION AND PRIVACY OF HEALTH INFORMATION COULD SUBJECT MANAGED CLINICS TO CIVIL AND CRIMINAL PENALTIES.

 

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires medical facilities to comply with standards for the exchange of health information within our company and with third parties, such as payors, business associates and patients. These include standards for common health care transactions, such as:

 

  claims information, plan eligibility, payment information and the use of electronic signatures;
     
  unique identifiers for providers, employers, health plans and individuals; and
     
  security, privacy and enforcement.

 

The Department of Health and Human Services has released final rules to implement a number of these requirements, and several HIPAA initiatives have become effective, including privacy protections, transaction standards, and security standards. If facilities we manage fail to comply with these standards, they could be subject to criminal penalties and civil sanctions.

 

HEALTH CARE FACILITIES MAY BE SUBJECT TO SANCTIONS AND PENALTIES IF THEIR OPERATIONS FAIL TO COMPLY WITH OCCUPATIONAL HEALTH AND SAFETY REGULATIONS.

 

Health care facilities are subject to a wide variety of federal, state and local occupational health and safety laws and regulations. The types of regulatory requirements faced by health care providers such as us include:

 

  air and water quality control requirements;
     
  occupational health and safety requirements (such as standards regarding blood-borne pathogens and ergonomics) and waste management requirements;

 

6
 

     
  specific regulatory requirements applicable to radioactive substances;
     
  requirements for providing notice to employees and members of the public about hazardous materials; and wastes; and
     
  certain other requirements.

 

Failure to comply with these standards may result in sanctions and penalties.

 

HEALTH CARE facilities may be subject to liabilities from claims brought against them.

 

Facilities for which we provide management and professional medical consulting services are subject to medical malpractice lawsuits and other legal actions in the ordinary course of business. Some of these actions may involve large claims, as well as significant defense costs. We cannot predict the outcome of these lawsuits or the effect that findings in such lawsuits may have on us as manager. All professional and general liability insurance purchased is subject to policy limitations. If such policy limitations should be partially or fully exhausted in the future, or payments of claims exceed our estimates or are not covered by our insurance, it could have a material adverse effect on our business, financial condition or results of operations.

 

the revenues and results of our CONsulting operations AS MANAGER will be significantly affected by payments received BY MANAGED FACILITIES from the government and third-party payors.

 

A significant portion of the revenues of the clinics for which we provide consulting services is from government healthcare programs, principally Medicare and Medicaid. Changes in these government programs in recent years have resulted in limitations on reimbursement and, in some cases, reduced levels of reimbursement for healthcare services. Payments from federal and state government healthcare programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions, all of which could materially increase or decrease program payments, as well as affect the cost of providing service to patients and the timing of payments to facilities. If the rates paid or the scope of services covered by government payors are reduced, there could be a material adverse effect on our business, financial condition and results of operations.

 

A worsening of the economic and employment conditions in the United States could materially affect the business and future results of operations of facilities providing HEALTH CARE services.

 

During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at the federal, state and local levels have decreased, and may continue to decrease, spending for health and human service programs, including Medicare and Medicaid, which are significant payor sources for medical facilities. This may result in our inability to access the capital markets on acceptable terms at a time when we would like, or need, access to those markets, which could have a negative impact on our growth plans.

 

If we fail to comply with extensive laws and government regulations, our MANAGED clinics could suffer penalties or be required to make significant changes to their operations.

 

The medical industry is required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things: billing practices and prices for services; relationships with physicians and other referral sources; necessity and quality of medical care; condition and adequacy of facilities; qualifications of medical and support personnel; confidentiality, maintenance and security issues associated with health-related information and PHI; the screening, stabilization and/or transfer of patients who have emergency medical conditions; certification, licensure and accreditation of our facilities; operating policies and procedures; activities regarding competitors; and addition or expansion of facilities and services.

 

7
 

 

Among these laws are the Anti-Kickback Statute, the Stark Law, the federal False Claims Act and similar state laws. These laws, and particularly the Anti-Kickback Statute and the Stark Law, impact the relationships with physicians and other potential referral sources.

 

The construction and operation of healthcare facilities are subject to extensive federal, state and local regulation relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, fire prevention, rate-setting, compliance with building codes and environmental protection. Additionally, such facilities are subject to periodic inspection by government authorities to assure their continued compliance with these various standards. If we fail to adhere to these standards, we could be subject to monetary and operational penalties. If any of our managed healthcare facilities lose their accreditation or any of our new facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid.

 

HEALTH CARE Facilities may be required to spend substantial amounts to comply with legislative and regulatory initiatives relating to privacy and security of patient health information.

 

There are currently numerous legislative and regulatory initiatives at the federal and state levels addressing patient privacy and information security concerns. In particular, federal regulations issued under HIPAA require facilities we manage to comply with standards to protect the privacy, security and integrity of protected health information. These regulations have imposed extensive administrative requirements, technical and physical information security requirements, restrictions on the use and disclosure of protected health information and related financial information and have provided patients with additional rights with respect to their health information. Compliance with these regulations requires substantial expenditures by facilities to which we provide management services, which could negatively impact our business, financial condition or results of operations.

 

Violations of the privacy and security regulations could subject our inpatient facilities to civil penalties for each violation of the privacy and security regulations as well as criminal penalties.

 

We are subject to uncertainties regarding recent health reform and budget legislation.

 

The Health Reform Legislation also contains provisions aimed at reducing fraud and abuse in healthcare. The Health Reform Legislation amends several existing laws, including the federal Anti-Kickback Statute and the False Claims Act, making it easier for government agencies and private plaintiffs to prevail in lawsuits brought against healthcare providers. Congress revised the intent requirement of the Anti-Kickback Statute to provide that a person is not required to “have actual knowledge or specific intent to commit a violation of the Anti-Kickback Statute in order to be found guilty of violating such law. The Health Reform Legislation also provides that any claims for items or services that violate the Anti-Kickback Statute are also considered false claims for purposes of the federal civil False Claims Act.

 

We cannot predict the impact the Health Reform Legislation may have on our proposed business, results of operations, cash flow, capital resources and liquidity, or whether facilities that we advise will be able to adapt successfully to the changes required by the Health Reform Legislation.

 

Our MANAgED facilities will face competition for staffing that may increase THEIR labor costs and reduce our profitability.

 

Our operations will depend on the efforts, abilities, and experience of our facilities’ management and medical support personnel, as well as of other professionals. These facilities compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the daily operations of their our business.

 

8
 

 

We depend heavily on key management personnel, and the departure of one or more of our key executives or a significant portion of our local facility management personnel could harm our business.

 

The expertise and efforts of Christopher Smith, our Chief Executive Officer, and of Dr. Ronald Moomaw, our principal medical director, are critical to the success of our business. The loss of the services of one or more of these executives or of a significant portion of the management personnel of managed facilities could significantly undermine our management expertise and our ability to provide efficient, quality healthcare services at our managed facilities, which could harm our business.

 

We could face risks associated with, or arising out of, environmental, health and safety laws and regulations.

 

Facilities for which we provide operational and medical consulting services are subject to various federal, state and local laws and regulations that:

 

  regulate certain activities and operations that may have environmental or health and safety effects, such as the generation, handling and disposal of medical wastes;
     
  impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and off-site, or other releases of hazardous materials or regulated substances; and
     
  regulate workplace safety.

 

Compliance with these laws and regulations could increase the costs of operation and result in the reduction of our management fees. Violation of these laws may subject our managed facilities to significant fines, penalties or disposal costs, which could negatively impact their results of operations, financial condition or cash flows.

 

Our acquisition strategy exposes us to a variety of operational and financial risks.

 

A principal element of our business strategy is to grow by increasing the number of facilities we manage or acquiring other companies and assets in the healthcare industry. Growth, especially rapid growth, through adding client facilities or acquisitions exposes us to a variety of operational and financial risks.

 

An increase in uninsured and underinsured patients or the deterioration in the collectability of the accounts of such patients could harm the results of operations of managed facilities and our revenues from management fees.

 

Collection of receivables from third-party payors and patients is critical to the operating performance of the facilities for which we provide consulting services. Our primary collection risks relate to uninsured patients and the portion of the bill that is the patient’s responsibility, which primarily includes co-payments and deductibles. If facilities we manage experience unexpected increases in the growth of uninsured and underinsured patients or in bad debt expenses, their results of operations will be harmed.

 

A cyber security incident involving managed facilities could cause a violation of HIPAA, breach of member privacy, or other negative impacts.

 

A cyber-attack that bypasses information technology security systems causing a security breach, loss of data subject to privacy laws, loss of proprietary business information, or a material disruption of our managed facilities’ business systems, could have a material adverse impact on the business, financial condition or results of operations of such facilities.

 

9
 

 

Item 1B. Unresolved Staff Comments.

 

Not applicable.

 

Item 2. Properties.

 

The Company formerly leased its offices in Orlando, Florida. The lease expired during 2014. In connection with the transaction with Medcure, the Company entered into a lease agreement with the former owner of the MED-CURE Companies, pursuant to which the Company is leasing the premises occupied by the clinics operated by the MED-CURE Companies from their former owner, and subleasing these premises back to the clinics. Our medical consulting services are managed from the MED-CURE Companies’ offices. See “Item 13. Certain Relationships and Related Transactions, and Director Independence—Agreements with MED-CURE Companies” for details of these leasing arrangements.

 

Item 3. Legal Proceedings.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

10
 

 

PART II

 

Item 5. Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities.

 

Our common stock is traded over-the-counter on OTC Markets Group under the symbol “LMNK”. The following table sets forth, for the periods indicated, the high and low bid prices of our common stock (commencing our recapitalization), as reported in published financial sources. Quotations reflect inter-dealer prices, without retail mark-up, mark-down, commission, and may not represent actual transactions.

 

Fiscal Year Ended December 31, 2012  High   Low 
Quarter Ended March 31, 2012   .60    .12 
Quarter Ended June 30, 2012   1.05    .33 
Quarter Ended September 30, 2012   .80    .31 
Quarter Ended December 31, 2012   .51    .05 
Fiscal Year Ended December 31, 2013          
Quarter Ended March 31, 2013   .23    .09 
Quarter Ended June 30, 2013   .18    .10 
Quarter Ended September 30, 2013   .10    .02 
Quarter Ended December 31, 2013   .25    .02 
Fiscal Year Ended December 31, 2014          
Quarter Ended March 31, 2014   .15    .03 
Quarter Ended June 30, 2014   .35    .05 
Quarter Ended September 30, 2014   .25    .05 
Quarter Ended December 31, 2014   .25    .05 
Fiscal Year Ended December 31, 2015          
Quarter Ended March 31, 2015   .095    .03 

 

Holders

 

As of May 28, 2015, there were approximately 138 holders of record of our common stock.

 

Dividends

 

We do not anticipate paying cash dividends in the foreseeable future. Our current policy is to retain any earnings to finance our future development and growth. We may reconsider this policy from time to time in light of conditions then existing, including our earnings performance, financial condition and capital requirements. Any future determination to pay cash dividends will be at the discretion of our board of directors and will depend upon our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors deems relevant.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

We do not currently have any type of equity compensation plan for our employees, officers or directors.

 

Item 6. Selected Financial Data.

 

Not applicable.

 

11
 

 

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

 

Disclosure regarding forward-looking statements

 

Throughout this report, we make statements that may be deemed "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities, events, outcomes and other matters that the Company plans, expects, intends, assumes, believes, budgets, predicts, forecasts, projects, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements. These forward-looking statements are based on management's current belief, based on currently available information, as to the outcome and timing of future events. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in this report.

 

General

 

Organization

 

The Company was incorporated in the State of Nevada on September 3, 2003, under the name Beverly Hills Film Studios, Inc. and changed its name to Emerging Media holdings, Inc. on September 28, 2006. On September 30, 2006, we effectuated a share exchange whereby we acquired all of the outstanding equity interests in our wholly-owned subsidiary, IM “Media Alianta” SRL, the 100% owner of SA “Analiticmedia-Grup”, both Moldovan companies ("AMG"), and on May 2, 2008, the Company acquired the common stock of “TNT-Bravo” channel-ICS “Media Top Prim” SRL, the exclusive operator in Moldova of Russian channel TNT programs owned by Gazprom Media. The name of our Company was changed from Emerging Media Holdings, Inc. to Lifestyle Medical Network Inc., effective on July 31, 2012.

 

On July 11, 2012, through a merger with our wholly-owned Nevada subsidiary, Lifestyle Medical Network Inc.,

 

Acquisition of Lifestyle Medical Corp.

 

On December 29, 2011, we closed an acquisition of 100% of the outstanding shares of Lifestyle Medical Corp. (“Lifestyle Medical”), which has rights to technologies and practices licensed to its subsidiary, Elite Professional IP Licensing, LLC (“Elite”), pursuant to an October 5, 2010 License Agreement with Modular Properties Limited, Inc. (the “License Agreement”). The consideration paid by the Company for the acquisition of Lifestyle Medical was 5,000,000 shares of our common stock paid to the holders of a majority of the outstanding shares of LMC, valued at $2,500,000. On February 2, 2012, we completed acquisition of the rights to our licensed men’s medical clinic operating technologies and processes, by acquiring from Worldwide Medassets, Ltd. (SAL) the full assignment of rights to the License Agreement, by the issuance of 19,000,000 shares of our common stock in exchange for the satisfaction of the outstanding $3,000,000 principal balance on the note issued to Worldwide Medassets, Ltd. in connection with the assignment of rights to the License Agreement to Elite.

 

On December 29, 2011, we completed the sale of our remaining Moldova media subsidiaries in exchange for the assumption of the liabilities of the subsidiaries and 250,000 shares of our common stock.

 

Recent Developments

 

Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of two medical practices in Houston, Texas, has purchased the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”), effective April 1, 2015. The MED-CURE Companies were purchased by Dr. Moomaw directly from the owner, Dr. Nazmudin Keshwani, for a purchase price of $2,500,000, utilizing local bank financing. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. The MED-CURE Companies have agreed, effective April 1, 2015, to enter into management agreements with the Company, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies’ clinics’ offices were restructured, with our real estate subsidiary, Lifestyle Texas Real Estate, LLC, leasing the properties and then subleasing the properties back to the Med-Cure Companies.

 

12
 

 

Through our subsidiary, Regional Professional Alliance, Inc., a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management. Through Lifestyle Texas Licensing, LLC (“Lifestyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men’s health and weight management.

 

Throughout this Form 10-K, the terms "we," "us," "our," "LMN" and the "Company" refer to Lifestyle Medical Network Inc., a Nevada corporation, and, unless the context indicates otherwise, includes our subsidiaries.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our plan of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect our reported results of operations and the amount of reported assets and liabilities.

 

Some accounting policies involve judgments and uncertainties to such an extent that there is reasonable likelihood that materially different amounts could have been reported under different conditions, or if different assumptions had been used. Actual results may differ from the estimates and assumptions used in the preparation of our consolidated financial statements.

 

Note 1 to our audited Financial Statements included in this Report discusses the most significant policies we apply, or intend to apply, in preparing our consolidated financial statements, some of which are subject to alternative treatments under accounting principles generally accepted in the United States of America.

 

New Financial Accounting Standards

 

For a summary of new financial accounting standards applicable to the Company, please refer to the accompanying notes to the financial statements.

 

PLAN OF OPERATION

 

Through our consulting subsidiaries, we plan to contract to provide management and professional consulting services, and to license medical and health technologies, to medical and health clinic operating companies. We also we intend to open, operate and acquire men’s medical and health clinics, if financing is available and the profile of the clinics’ services is consistent with the types of medical businesses we view as favorable for acquisition.

 

13
 

 

RESULTS OF OPERATIONS

 

YEAR ENDED DECEMBER 31, 2014 COMPARED TO THE YEAR ENDED DECEMBER 31, 2013

 

During the year ended December 31, 2014, we incurred a net loss of $489,202, as compared with a net loss of $423,225 for the year ended December 31, 2013, principally due to interest expense of $59,250 and $429,952 in general and administrative expense, for the year ended December 31, 2014, as compared with interest expense of $17,500 and general and administrative expense of $405,725 in 2013.

 

LIQUIDITY AND FINANCIAL RESOURCES

 

At December 31, 2014, we had a working capital deficiency of approximately $1.3 million. At December 31, 2014, we had total assets of approximately $207,000. We had $163 cash at December 31, 2014. Net cash used in operating activities in 2014 was $266,583; net cash used in investing activities was $100,000 for a deposit on acquisition; and net cash from financing activities was $346,772 in 2014, after receipt of related party loans and short term debt.

 

Our operations have never been profitable, and it is expected that we will continue to incur operating losses in the future. In 2014, we generated revenues of $-0-, incurred operating expenses of approximately $430,000, and had a net loss of $489,202. As of December 31, 2014, we had $163 cash on hand to fund operations. There is no assurance that we will operate profitably in the future.

 

We will have to obtain significant additional capital to continue with our proposed business. There is no assurance that we will be able to obtain sufficient capital to implement either of our alternative business plans. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Off Balance Sheet Arrangements

 

We do not currently have any off balance sheet arrangements falling within the definition of Item 303(c) of Regulation S-B.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

14
 

 

Item 8. Financial Statements and Supplementary Data.

 

 

 

 

 

 

 

 

LIFESTYLE MEDICAL NETWORK INC.

CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2014 and 2013

 

 

 

 

 

 

 

15
 

 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page
   
Consolidated Financial Statements  
   
Reports of Independent Registered Pubic Accounting Firms 17
   
Consolidated Balance Sheets as of December 31, 2014 and 2013 18
   
Consolidated Statements of Operations for the Years Ended December 31, 2014 and 2013 19
   
Consolidated Statement of Stockholders Deficiency for the Years Ended December 31, 2014 and 2013. 20
   
Consolidated Statements of Cash Flows for the Years Ended December 31, 2014  and 2013 21
   
Notes to the Consolidated Financial Statements 22

 

16
 

 

REPORT OF SADLER, GIBB & ASSOCIATES, LLC

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and shareholders’

Lifestyle Medical Network, Inc.

 

We have audited the accompanying consolidated balance sheets of Lifestyle Medical Network, Inc. (“the Company”) as of December 31, 2014 and 2013 and the related consolidated statements of operations, stockholders’ deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.  

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Lifestyle Medical Network, Inc. as of December 31, 2014 and 2013, and the results of their operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has recurring net losses, an accumulated deficit of $8,535,129 and a working capital deficit, all of which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Sadler, Gibb & Associates, LLC

 

Salt Lake City, UT

June 9, 2015

 

 

17
 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 
   December 31, 
   2014   2013 
         
ASSETS
         
CURRENT ASSETS:        
Cash and cash equivalents  $163   $19,974 
Loan receivable - net of allowance of $42,500   -    - 
Deposit on acquisition   100,000    - 
Prepaid expenses   16,000    3,750 
Total Current Assets   116,163    23,724 
           
Property, plant and equipment - net   1,767    2,667 
Intangible assets - net   88,893    94,448 
Other assets   -    6,000 
TOTAL ASSETS  $206,823   $126,839 
           
LIABILITIES AND STOCKHOLDERS' DEFICIENCY          
           
CURRENT LIABILITIES:          
Short-term debt to related parties  $1,050,905   $779,133 
Short-term debt   251,000    176,000 
Accounts payable and accrued expenses   127,944    88,310 
Total Current Liabilities   1,429,849    1,043,443 
           
Commitments and Contingencies   -    - 
           
STOCKHOLDERS' DEFICIENCY:          
Common stock, $.001 par value, 200,000,000 shares          
authorized; 26,085,101 and 25,835,101 shares issued and 26,084,983 and 25,834,983          
shares outstanding at December 31, 2014 and 2013, respectively   26,085    25,835 
Additional paid-in-capital   7,295,255    7,112,725 
Accumulated deficit   (8,535,129)   (8,045,927)
Less: Cost of common stock in treasury, 118 and 118 shares          
at December 31, 2014 and 2013, respectively   (9,237)   (9,237)
Total Stockholders' Deficiency   (1,223,026)   (916,604)
           
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY  $206,823   $126,839 

 

See notes to consolidated financial statements

 

18
 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
         
   For the Years Ended 
   December 31, 
   2014   2013 
Revenues  $-   $- 
           
Costs and expenses:          
Selling, general and administrative expenses   429,952    405,725 
Total Costs and expenses   429,952    405,725 
           
Loss from operations   (429,952)   (405,725)
           
Other income (expense):          
Interest expense   (59,250)   (17,500)
Loss on extinguishment of debt   -    - 
Total Other income (expense)   (59,250)   (17,500)
           
Loss from operations before provision for income taxes   (489,202)   (423,225)
           
Provision for income taxes   -    - 
           
Net loss  $(489,202)  $(423,225)
           
Loss per common share  $(0.02)  $(0.02)
           
Weighted average common shares outstanding          
- basic and diluted          
    26,061,813    25,333,238 

 

See notes to consolidated financial statements

 

19
 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY
                         
       Common Stock   Additional         
       Number of       Paid   Accumulated   Treasury 
   Total   Shares   Amount   In Capital   Deficit   Stock 
Balance, January 1, 2013  $(672,709)   25,205,101   $25,205   $6,934,025   $(7,622,702)  $(9,237)
                               
Issuance of common stock as incentive for debt   10,000    500,000    500    9,500           
                               
Issuance of common stock for services   11,550    130,000    130    11,420           
                               
Amortization of warrants issued for services   157,780              157,780           
                               
Net loss for the year ended December 31, 2013   (423,225)                  (423,225)     
                               
Balance, December 31, 2013   (916,604)   25,835,101    25,835    7,112,725    (8,045,927)   (9,237)
                               
Issuance of common stock as incentive for debt   25,000    250,000    250    24,750           
                               
Amortization of warrants issued for services   157,780              157,780           
                               
Net loss for the year ended December 31, 2014   (489,202)                  (489,202)     
                               
Balance, December 31, 2014  $(1,223,026)   26,085,101   $26,085   $7,295,255   $(8,535,129)  $(9,237)

 

See notes to consolidated financial statements

 

20
 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
         
   For The Years Ended 
   December 31, 
   2014   2013 
Cash flows from operating activities:        
Net loss  $(489,202)  $(423,225)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization   5,555    5,552 
Depreciation   900    38 
Non-cash compensation   182,780    179,330 
Changes in operating assets and liabilities:          
Increase in prepaid expenses   (12,250)   (1,284)
Decrease in other assets   6,000    - 
Increase in accounts payable and accrued expenses   39,634    44,297 
Expenses paid on behalf of the company   -    21,933 
           
Net Cash Used In Operating Activities   (266,583)   (173,359)
           
Cash flows from investing activities:          
Deposit on acquisition  $(100,000)     
Purchase of property, plant and equipment   -    (2,705)
           
Net Cash Used In Investing Activities   (100,000)   (2,705)
           
Cash flows from financing activities:          
Proceeds from related parties   271,772    170,000 
Proceeds from short-term debt   75,000    30,000 
Repayment of debt   -    (4,000)
           
Net Cash Provided by Financing Activities   346,772    196,000 
           
Net increase (decrease) in cash   (19,811)   19,936 
           
Cash and cash equivalents - Beginning of year   19,974    38 
           
Cash and cash equivalents - End of year  $163   $19,974 

 

See notes to consolidated financial statements

 

21
 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2014 AND 2013

 

1.Organization

 

Lifestyle Medical Network Inc. and Subsidiaries (the “Company” or “Lifestyle”) was incorporated in the State of Nevada.  The Company directs its operations through its subsidiaries.  The Company operates its business under a License related to patent rights used in connection with the operations of medical clinics that provide medical services related to men's health, with proprietary trade names and logo designs.

 

Going Concern

 

The consolidated financial statements for the year ended December 31, 2014 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.  The Company has a past history of recurring losses from operations and is a development stage company.  The Company will require additional funding to execute its future strategic business plan.  Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure.  These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

The Company has agreed to enter into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2015.

 

Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.

 

Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accepted accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.  On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results could differ from those estimates.

 

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the literature.  In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred.  That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values.   

 

22
 

 

Evaluation of Long-lived Assets

 

Licenses represent an important component of the Company’s total assets.  The Company amortizes its license on a straight-line basis over the estimated useful lives of the assets.  Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

 

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States of America.

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

 

Concentration of Credit Risk

 

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash.

 

The Company's cash and cash equivalents are concentrated primarily in banks in the United States of America.  At times, such deposits could be in excess of insured limits.  Management believes that the financial institutions that hold the Company’s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to these financial instruments.

 

Earnings Per Share

 

Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period.  Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period.  Potential common shares consist of outstanding common stock purchase warrants.  For the years ended December 31, 2014 and 2013, there were 2,400,000 and 2,400,000 potential common shares, respectively, that were not included in the calculation of diluted earnings per share as their effect would be anti-dilutive.

 

23
 

 

New Financial Accounting Standards

 

In June 2014, the FASB issued ASC 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consideration”. The guidance eliminates the definition of a development stage entity thereby remaining the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of September 30, 2014.

  

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  ASC 820 describes three levels of inputs that may be used to measure fair value.

 

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.  The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date.  The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability.  ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are defined as follows:

 

  Level 1  - Observable inputs such as quoted market prices in active markets
     
  Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable
     
  Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions

 

As of December 31, 2014, there were no financial assets or liabilities that required disclosure.

 

2.INTANGIBLES

 

The MPL License Agreement

 

The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States (the “Licensed Rights”). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.

 

24
 

 

Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.

 

The components of intangible assets are as follows:

 

License Agreements    
     
Balance January 1, 2011  $- 
      
Acquisition of license   6,000,000 
      
Amortization for the period May 8, 2011 through December 31, 2011   (200,000)
      
Balance December 31, 2011   5,800,000 
      
Amortization for the year ended December 31, 2012   (307,692)
      
Impairment charge   (5,392,308)
      
Balance December 31, 2012   100,000 
      
Amortization for the year ended December 31, 2013   (5,552)
      
Balance December 31, 2013   94,448 
      
Amortization for the year ended December 31, 2014   (5,555)
      
Balance December 31, 2014  $88,893 

  

Amortization expense for the years ended December 31, 2014 and 2013 amounted to $5,555 and $5,552, respectively.

 

Estimated amortization expense for intangible assets for the next five years is as follows:

  

Year Ending  Amortization 
December 31,  Expense 
2015  $5,555 
2016   5,555 
2017   5,555 
2018   5,555 
2019   5,555 

 

25
 

 

3.LOAN RECEIVABLE

 

On February 3, 2012, LMC loaned $32,000 to Health Clinics of Florida, LLC. On April 9, 2012 and August 10, 2012, LMC advanced an additional $10,500. The unsecured notes are interest free and due June 15, 2013. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. The manager of Health Clinics of Florida, LLC is a shareholder of the Company. As of December 31, 2012, the Company recorded a reserve for the full amount of the receivable reducing the balance to $-0-.

 

4.DEBT

 

Short-term debt as of December 31, 2014 and 2013 were as follows:

  

   December 31, 
   2014   2013 
Short-term Debt to Related Parties        
         
Unsecured promissory note, interest free, due June 15, 2015 (1)  $200,000   $200,000 
           
Unsecured promissory note, interest free, due June 15, 2015 (2)   75,000    75,000 
          
Unsecured promissory note, interest free, due June 15, 2015 (2)   60,000    60,000 
           
Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)   75,000    75,000 
           
Unsecured promissory notes, interest free due June 15, 2015 (4)   347,200    347,200 
          
Unsecured promissory note, interest free, due June 30, 2015 (5)   193,705    21,933 
          
Unsecured promissory note, interest free, due June 15, 2015 (9)   100,000    - 
    1,050,905    779,133 
Less: Current portion   1,050,905    779,133 
   $-   $- 

 

   December 31, 
   2014   2013 
Short-term Debt        
         
Unsecured promissory note, interest free, due on demand (6)  $26,000   $26,000 
           
Secured promissory note, interest @ 12%   per annum, due December 15, 2015 (7)   150,000    150,000 
           
Unsecured promissory note, interest @ 10%,   due December 15, 2015 (8)   75,000    - 
   $251,000   $176,000 
Less: Current portion   251,000    176,000 
   $-   $- 

 

26
 

 

(1)On January 5, 2012, LMC borrowed $200,000 from the Dellinger Fund, a shareholder of the Company. The note is interest free and has been extended to June 15, 2015. In the event of default, the Dellinger Fund has the right to request and will be granted the issuance of two million shares of the Company's common stock.

 

(2)On February 3, 2012 and March 1, 2012, LMC borrowed $75,000 and $60,000, respectively, from the Dellinger Fund, a shareholder of the Company. The unsecured notes are interest free and are due June 15, 2015. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.

 

(3)On April 3, 2012, LMC borrowed $75,000 from the Dellinger Fund, a shareholder of the Company. The unsecured note bears interest @ 10% per annum and is due June 15, 2015. In the event of default, interest on the outstanding balance shall continue to accrue at a rate of ten percent (10%) per annum from the date of the default.

 

(4)On various dates from March 23, 2012 through November 26, 2012, LMC borrowed $327,200 from the Dellinger Fund, a shareholder of the Company. In February 2013, LMC borrowed an additional $20,000. The unsecured notes are interest free and are due June 15, 2015. In the event of a default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.

 

On April 17, 2015, the Dellinger Fund notes in the amount of $757,200 plus accrued interest were converted into 6,000,000 shares of the Company’s common stock. See Note 11.

 

(5)During the year ended December 31, 2013 and 2014, Saddleworth Ventures LLC, a related party, paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advances are unsecured, interest free and are due June 30, 2015.

 

(6)On May 13, 2013, LMC borrowed $30,000 from Forbes Investment, LLP. The unsecured note is interest free and payable upon demand. In December 2013, LMC repaid $4,000 against the outstanding balance.

 

(7)On October 16, 2013, LMC borrowed $150,000 from Edmund Malits, a shareholder of the Company. The secured note bears interest @ 12% per annum and interest and principal are payable in full on or before February 16, 2014. LMC provided the Corporation’s shell on the OTCBB as collateral for the loan. In addition, LMC issued Edmund Malits 500,000 shares of the Company’s common stock with a fair value of $10,000. The note has been extended to December 15, 2015.

 

(8)On February 4, 2014, the Company executed an unsecured promissory note with Curt Maes and received $75,000. The promissory note bears interest @ 10% per annum and both principal and interest are payable on or before December 15, 2015. As additional consideration, the Company issued Curt Maes 250,000 shares of the Company’s common stock valued @ $25,000.

 

(9)In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015.  Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company’s common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11.

 

Interest expense for the years ended December 31, 2014 and 2013 amounted to $59,250 and $17,500, respectively.

 

27
 

 

5.ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

   December 31, 
   2014   2013 
Interest  $47,150   $16,650 
Salaries - Officer   20,000    13,250 
Rent   -    22,418 
Other   60,794    35,992 
   $127,944   $88,310 

 

6.INCOME TAXES

 

The Company adopted the provisions of ASC 740, "Income Taxes", ("ASC 740").  As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits.  The Company believes there are no potential uncertain tax positions and all tax returns are correct as filed.  Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet.  Included in any liability for uncertain tax positions, the Company will also setup a liability for interest and penalties.  The Company’s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current provision for income taxes.

 

There is no U.S. tax provision due to losses from U.S. operations during the nine months ended September 30, 2014 and 2013.  Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company's assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S.  Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.  The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.

 

The provision for income taxes consist of the following:

 

    Years Ended 
    December 31, 
    2014    2013 
Current           
Federal   $-   $- 
Foreign    -    - 
    -    - 
Deferred           
Federal    -    - 
Foreign    -    - 
   $-   $- 

 

A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:

 

   Years Ended 
   December 31, 
   2014   2013 
Book income (loss) from operations  $(166,329)  $(143,897)
Common stock issued for services   8,415    7,113 
Warrants issued for services   53,645    53,645 
Change in valuation allowance   104,269    83,139 
Income tax expense  $-   $- 

 

28
 

 

As of December 31, 2014, the Company recorded a deferred tax asset associated with a net operating loss (“NOL”) carryforward of approximately $2.7 million that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company’s NOL expires in 2032. The valuation allowance increased by $104,269 during the year ended December 31, 2014.

 

The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:

 

   2014   2013 
           
Net operating loss carry forwards (expire through 2032)  $(2,712,745)  $(2,546,416)
Common stock issued for services   17,395    8,980 
Warrants issued for services   156,316    102,671 
Impairment expense   1,833,385    1,833,385 
Total gross deferred tax asset/liabilities   (705,649)   (601,380)
           
Valuation allowance   705,649    601,380 
Net deferred taxes   -    - 

 

Section 382 of the U.S. Internal Revenue Code imposes an annual limitation on the availability of NOL carryforwards to offset taxable income when an ownership change occurs.  The Company's reverse capitalization meets the definition of an ownership change and some of the NOL's will be limited.

 

7.STOCKHOLDERS' EQUITY

 

On February 4, 2014, the Company issued Curt Maes 250,000 shares of the Company’s common stock with a fair value of $25,000 as incentive for debt financing.

 

During the year ended December 31, 2013, the Company issued 130,000 shares and recorded compensation expense of $11,550.

 

In October 2013, the Company issued Edmund Malits 500,000 shares of the Company’s common stock with a fair value of $10,000 as incentive for debt financing.

 

8.WARRANTS

 

On February 6, 2012, the Company issued warrants as compensation to a third party to purchase 2,400,000 shares of the Company's common stock for services performed. The warrants expire February 6, 2017. The estimated value of the compensatory warrants was determined using the Black Scholes pricing model using the following assumptions: Expected term of 3 years, a risk free interest rate of 0.32%, a dividend yield of -0-% and volatility of 432%. The fair value of the warrant amounted to $479,912 to be amortized over 3 years. The Company recorded an expense of $157,780 and $157,780 on the Company’s consolidated statement of operations for the years ended December 31, 2014 and 2013, respectively.

 

29
 

 

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.

 

      Weighted Average         
       Exercise   Remaining   Intrinsic 
   Shares   Price   Life   Value 
Outstanding, January 1, 2014  2,400,000   $0.20         
Granted   -    -           
Expired/Cancelled   -    -           
Exercised   -    -           
Outstanding - period ending December 31, 2014   2,400,000   $0.20    2.1 years   $- 
Exercisable - period ending December 31, 2014   2,400,000   $0.20    2.1 years   $- 

  

9.RELATED PARTY TRANSACTIONS

 

a)During the years ended December 31, 2014 and 2013, Saddleworth Ventures LLC paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advance are unsecured, interest free and due June 30, 2015. As of December 31, 2014, no repayments have been made.
   
  b)

During the year ended December 31, 2012, the Company received $737,200 in advances from the Dellinger Fund, a shareholder of the Company. During the year ended December 31, 2013, the Dellinger Fund advanced an additional $20,000.  The majority of these advances are interest free.  The Company recorded interest expense for the years ended December 31, 2014 and 2013 in the amount of $7,500 and $7,500, respectively, on the advances that were not interest free.  See Note 4 for further information.

     
c)In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due June 15, 2015.  Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company’s common stock at a price of $0.10 per share. See Note 4 for further information.

 

10.COMMITMENTS AND CONTINGENCIES

 

Leases

 

The Company formerly leased its offices in Orlando, Florida. The lease expired during 2014. In connection with the transaction with MedCure, the Company entered into a lease agreement with the former owner of MedCure. The Company will lease the clinics from the former owner of MedCure for five years with a five year renewal option at a monthly rental of $22,631.

 

The Company also entered into a lease agreement with MedCure whereby MedCure will sublease the clinics from the Company at a monthly rental of $25,500. The term of the lease will be for five years with a renewal option for an additional five years.

 

30
 

 

Future minimum lease payments and rental income under these agreements are as follows:

 

Rental Income    
Years Ended December 31,    
2015  $229,500 
2016   324,000 
2017   348,000 
2018   372,000 
2019   382,500 
Thereafter   96,000 
Total  $1,752,000 
      
Rental Expense     
Years Ended December 31,     
2015  $203,679 
2016   271,572 
2017   271,572 
2018   271,572 
2019   271,572 
Thereafter   67,893 
Total  $1,357,860 

 

Rent expense was $33,500 and $41,500 for the years ending December 31, 2014 and 2013, respectively.

 

Consulting Agreements

 

a)In January 2012, Lifestyle entered into a consulting agreement with Saddleworth Ventures LLC ("Consultant"). The Consultant will provide services for management consulting, business advisory, shareholder information and public relations. The term of the agreement is for three years. Upon execution of the agreement, Lifestyle issued a payment to the Consultant in the amount of $25,000. Additional cash fees or reimbursement of expenses shall be agreed upon by Lifestyle and the Consultant from time to time during the term of the agreement. Consulting fees for the years ended December 31, 2014 and 2013 amounted to $-0- and $-0-, respectively.

 

b)During 2014, 2013 and 2012, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the years ended December 31, 2014 and 2013, consulting services amounted to $67,500 and $38,176, respectively.

 

c)On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith ("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Lifestyle will pay Smith minimum compensation of $60K per year. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the years ended December 31, 2014, and 2013, payroll-officer amounted to $60,000 and $60,000, respectively.

 

31
 

 

11.SUBSEQUENT EVENTS

 

Material Agreements

 

Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of two medical practices in Houston, Texas, has purchased the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”), effective April 1, 2015. The MED-CURE Companies were purchased by Dr. Moomaw directly from the owner, Dr. Nazmudin Keshwani, for a purchase price of $2,500,000, utilizing local bank financing.

 

The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Dr. Keshwani has entered into employment contracts extending through December 31, 2015, with the MED-CURE Companies as a “physician employee”, pursuant to which he will perform medical services as are required for operations of the clinics. The MED-CURE Companies have agreed to enter into management agreements with the Company which will be effective as of April 1, 2015, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the remaining amounts distributed to the doctors are no less than a specified floor percentage of gross revenues.

 

Through our subsidiary, Regional Professional Alliance, Inc. , a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have agreed to enter into a Regional Medical Director Agreement, which will be effective as of April 1, 2015, with Dr. Moomaw, pursuant to which Lifestyle Professional Alliance would provide the services of Dr. Moomaw for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management.

 

Through Lifestyle Texas Licensing, LLC (“Lifestyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men’s health.

 

Issuance of Warrants

 

In connection with the engagement of our director, Dr. Ronald Moomaw, under a Regional Medical Director Agreement with RPA, at a Board of Directors meeting, held on April 17, 2015, the Board authorized the issuance Dr. Moomaw of a seven year stock purchase warrant, expiring April 17, 2022, to purchase 5,000,000 shares of our common stock, at an exercise price of $.09 per share, valued at $465,000.

.

Conversion of Debt

 

At the Board meeting held on April 17, 2015, our Board approved the conversion by the Company of $757,200 principal amount plus accrued interest of Company debt held by The Dellinger Fund, into an aggregate of 6,000,000 shares of common stock.

 

Refund of Deposit

 

On April 10, 2015, the Company received from Dr. Nazmudin Keshwani a refund of the $100,000 deposit made by the Company in February 14, 2014, in connection with the Company’s previous negotiations to acquire the MED-CURE Companies.

 

Convertible Promissory Note

 

On April 28, 2015, the Company issued a convertible promissory note to Ray Meadow and received proceeds of $250,000. The promissory note bears interest @ 12% per anum and matures one year from the date of issuance. At any time, the holder of the note, at his sale option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company at a conversion price of $0.15 per share, the fair value of the common stock at the date of the advance.

 

32
 

 

Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A. Controls and Procedures.

 

Controls and Procedures

 

As supervised by our board of directors and our principal executive and principal financial officers, management has established a system of disclosure controls and procedures and has evaluated the effectiveness of that system. The system and its evaluation are reported on in the below Management's Annual Report on Internal Control over Financial Reporting. Our principal executive and financial officer has concluded that our disclosure controls and procedures (as defined in the 1934 Securities Exchange Act Rule 13a-15(e)) as of December 31, 2014, are not effective, based on the evaluation of these controls and procedures required by paragraph (b) of Rule 13a-15.

 

Management's Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Securities Exchange Act of 1934 (the "Exchange Act"). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

 

Management assessed the effectiveness of internal control over financial reporting as of December 31, 2014. We carried out this assessment using the criteria of the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework. Management concluded in this assessment that as of December 31, 2014, our internal control over financial reporting is not effective.

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm, pursuant to rules of the Securities and Exchange Commission that permit us to provide only management's report in this annual report.

 

There have been no significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information.

 

None.

 

33
 

 

PART III

 

Item 10. Directors, Executive Officers, and Corporate Governance.

 

The following table sets forth the names, positions and ages of our executive officers and directors as of as of June 1, 2014.

 

Name 

Age

 

Title 

         
Christopher P. Smith   51   President and Chief Executive Officer, Secretary, Chief Financial Officer and Director
         
Adam Sachs   47  

Assistant Secretary and Director

         
Ronald C. Moomaw   61   Director

  

Set forth below is a brief description of the background of each of our executive officers and directors, based on the information provided to us by them.

 

Mr. Smith was elected a director, and appointed as our President and Chief Executive Officer, on February 4, 2012, in connection with the acquisition by the Company on December 29, 2011 of all of the outstanding capital stock of Lifestyle Medical Corporation (LMC). Mr. Smith has served as the President of LMC which, since its formation on November 14, 2011, acquired two companies that license and manage men’s health clinics prior to LMC’s acquisition by the Company. Mr. Smith also served as the President of Men’s Medical Corporation since its inception on August 6, 2010. Our planned acquisition of this company was terminated on May 31, 2011, by agreement of all parties, one primary reason being that Men’s Medical Corporation was unable to provide audited financial statements reflecting the acquisition of a minimum of three men’s health clinics, as agreed by the parties and required by the acquisition agreement. Mr. Smith has also been the Managing Member of Saddleworth Ventures LLC, a financial consulting firm, since March 30, 2006.  He graduated from Flagler College with a Bachelor of Arts degree in 1995 majoring in business and economics.  From 2005 until the formation of Saddleworth Ventures LLC, Mr. Smith worked as an independent financial consultant on various projects in the medical field.

 

Adam Sachs, from September, 2011 to the present, has been the District Manager for a ten store market covering two states for Sears Holding Company. From 1993 to September, 2011, Mr. Sachs was with Best Buy, an International Fortune 100 retailer of computers, consumer electronics appliances and services, his last position from June, 2007 to September, 2011, being the Director, International Retail Operations, in Richfield, Minnesota.  From February, 2006 to June, 2007, Mr. Sachs was a Market Director for Best Buy for a 12-state (plus Puerto Rico) region with 225 stores, and prior thereto from 2006 was District Manager, Sales for a 12 big-box store territory. From 2001 to 2006 Mr. Sachs held various Regional Manager positions for with Best Buy, in the areas of Product Processing, Customer-Centricity, Marketing, and Merchandising.

 

Ronald C. Moomaw graduated from Ohio University Heritage College of Osteopathic Medicine in 1980, and completed a combined civilian/ military residency at Wright Patterson AFB.  Dr. Moomaw is Board certified in Psychiatry and a fellow of the American College of Neuropsychiatry. He presently works as a Flight Surgeon/ Psychiatrist for NASA at the Johnson Space Center, Houston, Texas.  He is the chairman of the JSC Ethics Committee and sits on the Aerospace Medical Board.  He trains and works with astronauts before, during and after flights, and provides direct psychiatric support for astronauts and their families. He is involved in the area of fatigue management both for the terrestrial environment and for isolation and communication delays for long-duration space flight.  Specifically, he studies the psychological components of fatigue and circadian desynchrony— jetlag and shift lag—and the development of countermeasures.

 

34
 

 

Dr. Moomaw’s background is diverse. He served as a major in the U.S. Air Force as a psychiatrist, operated his own private practice, served as medical director of two free-standing psychiatric emergency rooms, developed an in-patient psych unit, and served as the chief psychiatrist for the State of Ohio Department of Correction. He is a governing Board member for the National Commission for Correctional Health Care, and currently serves as assistant professor at the University of Texas Medical Branch, assistant professor at Ohio University Heritage College Osteopathic Medicine, incident command director for Wyle Engineering and Integrated Services, and president of the Houston Osteopathic Medical Association.

 

No director, director nominee, officer or affiliate of the Company, owner of record or beneficially of more than five percent of any class of our voting securities has, to our knowledge, during the last five years: (1) been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors); or (2) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, U.S. federal or state securities laws or finding any violations with respect to such laws.

 

Corporate Governance

 

Directors are elected at the annual stockholder meeting or appointed by our Board of Directors and serve for one year or until their successors are elected and qualified. When a new director is appointed to fill a vacancy created by an increase in the number of directors, that director holds office until the next election of one or more directors by stockholders. Officers are appointed by our Board of Directors and their terms of office are at the discretion of our Board of Directors.

 

Committees of our Board of Directors

 

We do not have a separate Audit Committee. Our Board of Directors performs the functions usually designated to an Audit Committee. We intend shortly to establish an Audit Committee with one or more independent directors.

 

The Board does not have standing compensation or nominating committees. The Board does not believe a compensation or nominating committee is necessary based on the size of the Company and the current levels of compensation to corporate officers. The Board will consider establishing compensation and nominating committees at the appropriate time.

 

The entire Board of Directors participates in the consideration of compensation issues and of director nominees. To date, the Board of Directors has not formally established any criteria for Board membership. Candidates for director nominees are reviewed in the context of the current composition of the Board, the Company’s operating requirements and the long-term interests of its stockholders. In conducting this assessment, the Board of Directors considers skills, diversity, age, and such other factors as it deems appropriate given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. In particular, weight is given to experience relevant to the Company’s operations in Florida and Texas.

 

The Board’s process for identifying and evaluating nominees for director, including nominees recommended by stockholders, involves compiling names of potentially eligible candidates, conducting background and reference checks, conducting interviews with the candidate and others (as schedules permit), meeting to consider and approve the final candidates and, as appropriate, preparing an analysis with regard to particular recommended candidates.

 

35
 

 

Stockholder Communications

 

The Board has not established a formal process for stockholders to send communications, including director nominations, to the Board; however, the names of all directors are available to stockholders in this Annual Report. Any stockholder may send a communication to any member of the Board of Directors, in care of the Company, at 424 E. Central Blvd., Orlando, FL 32801 (Attention: Secretary). Director nominations submitted by a stockholder will be considered by the full Board. Each communication should clearly specify the name of the individual director or group of directors to whom the communication is addressed. Communications sent by email will be delivered directly to the Corporate Secretary, who will promptly forward such communications to the specified director addressees. Communications sent by mail will be promptly forwarded by the Corporate Secretary to the specified director addressee or, if such communication is addressed to the full Board of Directors, or to the Chairman of the Board (when one is appointed), who will promptly forward such communication to the full Board of Directors. Due to the infrequency of stockholder communications to the Board, the Board does not believe that a more formal process is necessary. However, the Board will consider, from time to time, whether adoption of a more formal process for such stockholder communications has become necessary or appropriate.

 

In general, advance notice of nominations of persons for election to our Board or the proposal of business to be considered by the shareholders must be given to our Secretary no earlier than the October 1 or later than December 1 preceding the next year's annual meeting, which would be scheduled in the month of May or June.

 

A shareholder's notice of nomination should set forth (i) as to each person whom the shareholder proposes to nominate for election or re-election as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934 (including such person's written consent to being named in the proxy statement as a nominee and to serving as a director, if elected); (ii) as to any other business that the shareholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such shareholder and the beneficial owner, if any, on whose behalf the proposal is made; and (iii) as to the shareholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (A) the name and address of such shareholder, as they appear on our books, and of such beneficial owner, (B) the number of shares of our common stock that are owned (beneficially or of record) by such shareholder and such beneficial owner, (C) a description of all arrangements or understandings between such shareholder and such beneficial owner and any other person or persons (including their names) in connection with the proposal of such business by such shareholder and any material interest of such shareholder and of such beneficial owner in such business, and (D) a representation that such shareholder or its agent or designee intends to appear in person or by proxy at our annual meeting to bring such business before the meeting.

 

Attendance of Directors at Shareholder Meetings

 

We do not have a formal policy on attendance at meetings of our shareholders; however, we encourage all Board members to attend shareholder meetings that are held in conjunction with a meeting of our Board of Directors.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our directors, executive officer and persons who beneficially own more than ten percent of our outstanding common stock to file reports with the SEC regarding initial statement of ownership, statement of changes of ownership and, where applicable, annual statement of ownership of our common stock. Such persons are required by SEC regulations to furnish us with copies of all such statements they file. The Company believes that all such required filings in the fiscal year ended December 31, 2014 have been made, with the exception of those listed below which were required to be made in 2012.

 

Both Mr. Adam Sachs and Dr. Ronald C. Moomaw were appointed as directors on September 30, 2012, and were required to file Form 3’s within 10 days of their appointment. As of the date of this report, neither of these directors has filed the required Form 3.

 

Code of Ethics

 

We have adopted a Code of Ethics and Conduct within the meaning of Item 406(b) of Regulation S-B of the Exchange Act. A copy of this Code may be obtained by requesting a copy in writing to the Company’s Secretary at 424 E. Central Blvd., Orlando, FL 32801. This Code applies to our directors and executive officers, such as our principal executive officer, principal financial officer, controller, and persons performing similar functions for us.

 

36
 

 

Item 11. Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth all compensation awarded to, earned by, or paid for all services rendered to the Company during fiscal 2012, 2013 and 2014 by our Chief Executive Officer and any executive officer who received annual compensation in salary and bonus combined in excess of $100,000 during those years. Each person below is referred to as a named executive officer.

 

SUMMARY COMPENSATION TABLE

 

Name and Principal Position  Year   Salary
($)
   Bonus
($)
   Stock Awards
($)
   Option Awards
($)
   Non-Equity Incentive
Plan Compensation
($)
   Change in Pension Value and Nonqualified Deferred Compensation Earnings
($)
   All Other Compensation   Total
($)
 
(a)  (b)   (c)   (d)   (e)   (f)   (g)   (h)   (i)   (j) 
Christopher Smith,   2012   $30,000                           $30,000 
CEO   2013   $60,000                                 $60,000 
    2014   $60,000                                 $60,000 

 

Stock Options Granted and Exercised in the Year Ended December 31, 2014

 

No stock option grants were made in the fiscal year ended December 31, 2014.

 

Director Compensation

 

Currently, our directors do not receive compensation for serving on our Board of Directors.

 

Employment Agreements

 

On June 25, 2012, the Board of Directors of the Company approved, and on July 16, 2012, the President of the Company executed, an Agreement (“Agreement”) with Christopher P. Smith, our Chief Executive Officer. The Agreement is effective July 1, 2012, for an initial term of five years, and the term is automatically extended for additional one year periods if neither party gives notice of termination at least 90 days prior to the end of the initial term or any current additional one year term.

 

37
 

 

The Agreement with Mr. Smith (referred to sometimes as the “Executive”) provides for a base salary of $60,000 per year, and provides for incentive payments as established by the Board of Directors and for a performance bonus (“Performance Bonus”) based on the sum of two components, the first of which is as follows:

 

Net Operating Profit Before  Performance    
Income Taxes  Bonus    
On the First $10 Million  2% of Net Operating Profit   0%
On the Next $40 Million  3.5% of Net Operating Profit   3.5%
On the Next $50 Million  2.5% of Net Operating Profit   2.5%
On all Amounts Over $100 Million  1.5% of Net Operating Profit     

 

The second component of the Performance Bonus is based on the Net Operating Profit before Income Taxes for all of the Company’s subsidiaries (Covered Subsidiaries) that are agreed in writing to have been identified by and presented to the Company for acquisition by the Company by Mr. Smith and as shown in the annual financial statements of the Company. This component of the Performance Bonus is calculated as ten percent (10%) of the Net Operating Profit before Income Taxes of the Company’s ownership portion of the respective Covered Subsidiaries to be verified against the audited Annual Financial Statements of the respective Covered Subsidiaries. The Net Operating Profits for purposes of this component of the Performance Bonus are not to be included in the calculation of the Net Operating Profit before Income Taxes for purposes of the Performance Bonus as to Net Operating Profit of the Company.

 

The Agreement contains provisions for discharge for "cause", including breach of the Agreement or specified detrimental conduct by Mr. Smith, in which case accrued compensation would payable as provided in the Agreement. The Agreement also provide for termination by the Executive for “good reason”, comprising events such as breach of the Agreement by the Company, assignment of duties inconsistent with the Executive’s position, transfer of the Executive’s primary office by more than 25 miles from Lake Mary, Florida, or in the event of a change in control of the Company. In the event of a termination by the Company without cause, or by the Executive for “good reason”, the Company is required to pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts:

 

A. the sum of (1) the Executive’s annual minimum salary through the date of termination to the extent not theretofore paid, (2) any annual incentive payment earned by the Executive for a prior period to the extent not theretofore paid and not theretofore deferred, (3) any annual performance bonus payment earned by the Executive for a prior period to the extent not theretofore paid and not theretofore deferred,(4) any accrued and unused vacation pay and (5) any business expenses incurred by the Executive that are unreimbursed as of the date of termination;

 

B. The product of (1) the performance bonus payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365;

 

C. the amount equal to the sum of (1) three (3) times the Executive’s annual minimum salary; (2) one (1) times the performance bonus payment and (3) one (1) times the incentive payment;

 

D. In the event Executive is not fully vested in any retirement benefits with the Company from pension, profit sharing or any other qualified or non-qualified retirement plan, the difference between the amounts Executive would have been paid if he had been vested on the date his employment was terminated and the amounts paid or owed to the Executive pursuant to such retirement plans;

 

E. The product of (1) the incentive payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; and

 

F. The present value of the amount equal to the sum of five (5) years’ Performance Bonus pay with such amount being calculated based on the Performance Bonus paid to the Employee the year prior to the date of termination.

 

38
 

 

In addition all stock options and warrants outstanding as of the date of termination and held by the Executive shall vest in full and become immediately exercisable for the remainder of their full term; all restricted stock shall no longer be restricted to the extent permitted by law, and the Company will use its best efforts, at its sole cost to register such restricted stock as expeditiously as possible; and for the remainder of the Executive’s life and the life of his spouse, the Company is required to provide the Executive continued health care benefits. The Executive is responsible for the payment of any COBRA premium, provided that the Company is required to make a lump sum payment to the Executive equal to the cost of such premiums, plus an income tax gross-up thereon so that the Executive retains an amount equal to the cost of such premiums. The Company in addition beyond the COBRA period is required to pay the Executive a lump sum cash amount equal to the present value of the cost of premiums for health care coverage as a supplement to Medicare benefits under an individual policy from a third party insurer, with such insurer to be selected by the Executive (which coverage in combination with Medicare benefits shall provide benefits to the Executive and/or his spouse which are comparable to those provided to Executive and/or his spouse under the Company’s group health plan) for the remainder of each of the lives of the Executive and/or his spouse as of the date hereof.

 

Employee Benefit Plans

 

We do not currently have any type of employee compensation plan for our employees, officers or directors. Furthermore, we do not anticipate offering any such plans in the near future.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The table below sets forth information regarding the beneficial ownership of our common stock as of May 28, 2015 by the following individuals or groups:

 

  each person or entity who we know beneficially owns more than 5.0% in the aggregate;

 

  each of our named executive officers;

 

  each of our directors; and

 

  all directors and named executive officers as a group.

  

39
 

 

The percentage of beneficial ownership in the following table is based upon 31,835,101 shares of common stock outstanding as of May 28, 2015. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. We do not have any outstanding options, warrants or other conversion rights.

 

Name of Beneficial Owner  (1)  Number of Shares Beneficially Owned   Approximate Percentage of Class Outstanding 
         
Christopher P. Smith (2)   1,262,857    3.97%
           
James Davis, Jr.
210 S. Hoagland Blvd.
Kissimmee, FL 34741
   4,224,000    13.27%
           
The Dellinger Fund
201 S. Orange Ave., Suite 1510
Orlando, FL 32801 (2)
   11,800,000    37.07%
           
Nissonis BV
1083 HP Vivaldistraat 52
Amsterdam
The Netherlands
   3,223,447    10.13%
           
Ronald C. Moomaw (3)   5,074,999    13.78%
Adam Sachs   110,000     * 
All officers and directors as a group    6,447,856    17.50%

 

* Less than 1%.

 

(1)The addresses of our executive officers and directors, and of any other stockholder for whom an address is not given, listed in the above table are c/o Lifestyle Medical Network Inc., 424 E. Central Blvd., Orlando, FL 32801.

 

(2)Christopher Smith, our Chief Executive Officer, owns 1,262,857 shares of common stock directly and controls The Dellinger Fund, which holds 11,800,000 shares of common stock. Mr. Smith has no equity interest in The Dellinger Fund. Including the holdings of The Dellinger Fund as beneficially owned by Mr. Smith in the above table, due to his control position in The Dellinger Fund, would result in Mr. Smith being deemed to own beneficially 13,062,857 shares of common stock and owning beneficially 41.03% of the outstanding class of common stock, and all officers and directors as a group being deemed to own beneficially 18,247,856 shares of common stock and 49.54% of the outstanding common stock. Mr. Smith disclaims any beneficial ownership in shares of the Company’s common stock held by The Dellinger Fund.

 

(3)Dr. Ronald C. Moomaw is a member of our board of directors. Dr. Moomaw owns 74,999 shares of common stock directly, and additionally owns beneficially 5,000,000 shares of our common stock issuable upon exercise of a common stock purchase warrant issued to him May 15, 2015, and expiring May 15, 2022.

  

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

Acquisition of Lifestyle Medical Corporation

 

On December 29, 2011, we closed an acquisition of 100% of the outstanding shares of Lifestyle Medical Corp., incorporated under the laws of Florida, pursuant to an Exchange Agreement, executed on that date, by and between the Company and Lifestyle Medical Corporation (LMC). The consideration paid by the Company for the acquisition of LMC was 5,000,000 shares of our common stock paid to the holders of a majority of the outstanding shares of LMC, valued at $2,500,000. Christopher Smith, our Chief Executive Officer and a director, received 1,262,857 shares of our common stock in this transaction, by reason of his ownership position in LMC.

 

40
 

 

Agreements with MED-CURE Companies

 

Dr. Ronald Moomaw, a director of the Company, purchased, effective April 1, 2015, the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”) that own the six clinics. The MED-CURE Companies have agreed, effective April 1, 2015, to enter into management agreements with the Company, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies.

 

The leasing arrangements for the properties leased for the clinics’ offices were restructured effective April 1, 2015, with our real estate subsidiary, Lifestyle Texas Real Estate, LLC, leasing the properties where the clinics’ offices are located from the former owner of the Med-Cure Companies, and subleasing the properties back to the Med-Cure Companies for a five year term.

 

The following table sets forth the estimated differentials in rent paid by Lifestyle Texas Real Estate, LLC to the owner of the properties leased by the MED-CURE Companies in the first year of the leases, and amounts paid in that period under the subleases by the MED-CURE Companies.

 

Property Location  Monthly Base Rent Payable Under Master Lease by Lifestyle Texas Real Estate, LLC   MonthlyAdditional Rent Payable (est. subj. to adjustment) under Master Lease by Lifestyle Texas Real Estate, LLC   Subtenant  Monthly Base Rent Payable by Subtenant In Year 1   Monthly Lease Rent Escalation Provisions  Estimated Differential for the full Year 1 between Rent Payable by Lifestyle Texas Real Estate LLC and Subtenant. 
Berry Road, Houston Texas  $3,000   $840   Med-Cure
Primary Care
Physicians PA
  $4,500   Monthly rent escalates $500 each year  $7,920 
                           
Avenue H, Rosenburg, TX  $4,500   $987   Med-Cure
Primary Care
Physicians PA
  $6,000   Monthly rent escalates $500 each year, with cap of  $7,500 per month for yrs. 4 & 5  $5,844 
                           
SW Freeway, Houston TX            Med-Cure
Primary Care
Physicians PA
  $7,500   Monthly rent escalates $500 each year, with cap of  $9,000 per month for yrs. 4 & 5     
                           
   $9,000   $4,313   Med-Cure
Anti-Aging
and Skin Care PA
  $7,500   Monthly rent escalates $500 each year, with cap of  $9,000 per month for yrs. 4 & 5  $20,244 

 

41
 

 

Through our subsidiary, Regional Professional Alliance, Inc., a physician’s professional consulting company, we entered into an agreement with Dr. Moomaw effective April 1, 2015, to provide services through Lifestyle Professional Alliance for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management. In this connection the Company on April 17, 2015, issued Dr. Moomaw a seven year stock purchase warrant, expiring April 17, 2022, to purchase 5,000,000 shares of our common stock, at an exercise price of $.09 per share.

 

Item 14.  Principal Accountant Fees and Services

 

The following table presents fees accrued for audit services and other services provided during fiscal years 2013 and 2014 by Sadler, Gibb & Associates, LLC for the audit of the Company’s 2013 and 2014 fiscal years.

 

  

2014

  

2013

 
Audit Fees  $30,000   $30,000 
Audit-related Fees          
Tax Fees          
All Other Fees          
           
Total Fees  $30,000   $30,000 

 

Audit Fees

 

Audit fees were for professional services rendered for the audit of our annual financial statements, the review of the financial statements, services in connection with our statutory and regulatory filings for fiscal 2014.

 

Audit-Related Fees

 

Audit related fees were for assurance and related services rendered that are reasonably related to the audit and reviews of our financial statements for fiscal 2014, exclusive of the fees disclosed as Audit Fees above. These fees include assistance with registration statements and consents not performed directly in connection with audits.

 

All Other Fees

 

We did not incur fees for any services, other than the fees disclosed above relating to audit and audit-related services, rendered during fiscal 2014.

 

Audit Services. Audit services include the annual financial statement audit and other procedures required to be performed by the independent auditor to be able to form an opinion on our financial statements.

 

Audit-Related Services. Audit-related services are assurance and related services that are reasonably related to the performance of the audit or review of our financial statements which historically have been provided to us by the independent auditor and are consistent with the SEC’s rules on auditor independence.

 

All Other Services. Other services are services provided by the independent auditor that do not fall within the established audit, audit-related and tax services categories.

 

42
 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules.

 

(a)(3) Exhibits

 

Exhibit No.   Description
3.1   Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-SB, filed January 23, 2007).
3.1a   Certificate of Amendment to Articles of Incorporation, filed September 12, 2011. (Incorporated by reference to the Company’s Current Report on Form 8-K, filed October 20, 2011.)
3.1b   Articles of Merger with the Company’s wholly-owned subsidiary, Lifestyle Medical Network Inc., in which merger the name of the Company, as the surviving company in the merger, was changed to Lifestyle Medical Network Inc. (Incorporated by reference to Exhibit 3.1b to the Company’s Current Report on Form 8-K, filed July 17, 2012.)
3.2   By-Laws (Incorporated by reference to Exhibit 3.2 to the Company’s Form 10-SB, filed January 23, 2007).
10.1   Distribution Agreement, dated December 29, 2006 with NTV Hungary Commercial Limited NTV Hungary Commercial Limited Liability Company (Incorporated by reference to Exhibit 10.1 to the Company’s Form 10-SB, filed January 23, 2007).
10.2   Acquisition Agreement, dated January 24, 2008, between the Company and Media Top Prim, Ltd. (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed May 5, 2008).
10.3   Additional Agreement, dated May 2, 2008, to Acquisition Agreement, dated January 24, 2008, between the Company and Media Top Prim, Ltd. (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed May 5, 2008)
10.4   Share Purchase Agreement, dated as of June 10, 2009, between the Company and IPA International Project Agency Establishment (Incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed November 4, 2009).
10.5   Agreement, dated as of February 23, 2010, between the Company and SC Stratco Group SRL. (Incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed March 8, 2010.)
10.6   Additional Agreement, dated as of March 5, 2010, between the Company and Media Top Prim Ltd. (Incorporated by reference to Exhibit 10.6 to the Company’s Annual Report on Form 10-K, filed March 31, 2010.)  
10.7   Purchase Agreement, dated August 3, 2010, between the Company and Stipula Financial, Inc. (Incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K, filed August 6, 2010.)
10.7a   Additional Agreement, dated August 13, 2010, to Purchase Agreement dated August 3, 2010, between the Company and Stipula Financial, Inc. (Incorporated by reference to Exhibit 10.7a to the Company’s Current Report on Form 8-K/A, filed August 13, 2010.)
10.8   Exchange Agreement, dated January 31, 2011, between the Company and Men’s Medical Corporation. (Incorporated by reference to Exhibit 10.8 to the Company’s Annual Report on Form 10-K, filed March 31, 2011.)
10.9   Asset Purchase Agreement, dated February 2, 2011, between the Company and Chiril Luchinsky. (Incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K, filed March 31, 2011.)
10.10   Exchange Agreement, dated December 29, 2011, between the Company and Lifestyle Medical Corporation. (Incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K, filed January 6, 2012.)
10.11   Assignment, dated May 9, 2011, of BMG Licensing Agreement to Elite Professional IP Licensing Company, LLC. (Incorporated by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K/A, filed February 15, 2012.)
10.12   License Agreement, dated October 5, 2010, between Modular Properties Limited, Inc. and Worldwide Medassets, Ltd. (Incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K/A, filed February 15, 2012.)
10.13   Stock Purchase Agreement, dated February 8, 2012, between the Company and Saddleworth Consulting, LLC. (Incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K/A, filed February 15, 2012.)
10.14   Employment Agreement, effective as of July 1, 2012, between the Company and Christopher P. Smith. (Incorporated by reference to Exhibit 10.14 to the Company’s Current Report on Form 8-K, filed July 17, 2012.)
31   Certification of Chief Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.*
32   Certification of Chief Executive Officer and Principal Financial Officer Pursuant to 18  U.S.C. Section 1350 as adopted pursuant to Section  906 of the Sarbanes-Oxley Oxley Act of 2002.**

 

* Filed herewith.
** Furnished herewith.

 

43
 

 

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

 

SEC Ref. No.   Title of Document
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Label Linkbase Document
101.PRE   XBRL Taxonomy Presentation Linkbase Document

 

The XBRL related information in Exhibits 101 to this Annual Report on Form 10-K shall not be deemed “filed” or a part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, and is not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of those sections.

 

44
 

 

SIGNATURES

 

Pursuant to the requirements of Section 12(g) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  LIFESTYLE MEDICAL NETWORK, INC
     
Date: June 11, 2015 By: /s/ Christopher Smith
    Christopher Smith, Chief Executive Officer and Principal Financial Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant in the capacities indicated, on June 11, 2015.

 

/s/ Christopher Smith  
Christopher Smith, Chief Executive Officer,  
Principal Financial Officer and Director  
   
By: /s/ Adam Sachs  
  Adam Sachs, Director  
     
By: /s/ Ronald C. Moomaw  
  Ronald C. Moomaw, Director  

 

 

45

 
EX-31 2 f10k2015ex31_lifestylemed.htm CERTIFICATION

EXHIBIT 31

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

 

I, Christopher Smith, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Lifestyle Medical Network Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

DATE:  June  11, 2015     /s/ Chris Smith         
  Christopher Smith,
  Chief Executive Officer and  Principal Financial Officer

EX-32 3 f10k2015ex32_lifestylemed.htm CERTIFICATION

EXHIBIT 32

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Lifestyle Medical Network Inc. (the "Company") on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christopher Smith, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

June 11, 2015 /s/ Chris Smith
  Christopher Smith,
  Chief Executive Officer
  and Principal Financial Officer

GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!(`88#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBH;FZA MM(O,N)%C3.,MZT`345DS:]''>/;J@8B5(@2Q&2PSGIT`JTFIVVQ3)-&K&/S2 M`V0%]<^E`%RBHX9H[B)987#HPR&'>JM[J2VZW+0OP9`XXX)/'T%`%ZBLDZU M)Y09;)BPD5&3S!D%@"N/7AOPP:M7E^;*6/S(28&.TRAA\IY[=>U`%RBLI-9> M78D=FQF=AB,R`?*5W!L_3M4\.IK+?FV\IE7+*LA(PS+C<,?C^AH`O4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%9^IQ2E[>:*(S>66!C!&3N4C// M^<$UH52U"[EMI+1(4),\VQB%S@8)/<>E`%"VTZY@:)67(2>)BP/4+%M)_.H( MM/O(K"2W\A_,DCA<,I7@IC*G/?CCMS6FVM6\:L9DEB*,5977D';N'?N.E7P< M@'!&>QH`K:?$(K4?+,I9F7%*4WXP7^ZOZ9/T-5EUFZ*JQCAQ(8W4W5E,AC6*2-E8^7M._Y5)/.<=@.G>@#,CM)DLS'#:W*/YJM;%CS&P4!F M8YZ=>O;IVJ_/(]WJ4"36=Q]G56QE1@L?RL@' M$@P&+*<]AGUY%6=1OI]/DCDQ&\#;@4P=_"ELYZ8X]*`,PV!^S7#?9KN5GVQV MV_&]"JD!B1C:,GK[59L[6Y348TEC;;#))*9?X7WCC'OR?RH;6)HV6"9[6*<=?>K$.I2R:EY3(GD-(\2$9W;E&23VP>?RH`TZ***`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"JE]:/=&`QN$,;EL]QE&7C\35NB@#G MET"X,#1EH(MS(_R9/S(ORGD?WL$UT"YVC=C=CG%+10`5EZAI\US?1RQA"N%& MYCAHL-N)7CN..U:E%`&'%I%SL"R&,>4(XXR&/S*L@8D\<'``Q[59N+*ZO"[2 M&.)OL[Q)M8G:S'KT]`/S-:=%`&)_9ER\)A\BWB6282_*_$`&W[HQR3@^G6K' MDWLNHK-<6\#1"(H`)3\I/WN-O.<*/SK3HH`Y\:).B-)##`CN74Q%R5560+UQ MR1C/Z5:M-+FM[V/7YX?$A8`@<#"EN?P!JW67K^ER:M8) M#$RJZS(^3Z`X;]":`(O^$HL0N_;-L\O?NVC'^K\S'7KBG/XELD5F(EV*&.[: M,'$8D(Z^A_.L[_A%9O[,%KYD>?MWG9R?]5]W;TZ[>*!X6F.C06CR(9%O/.=L MG!CR01T_N8%`&NFMVKVEU=9<0VP!=BO7*AN/P(I#K4<9MO.M;N);@A0SQC"$ MG`#$'C/]15/3=*O=.TYK39:SI(96D\QCR3P@Z=-O!JDGAJ^#6QD>&01-&5#2 M,?(59-VU>.?EP,GTH`FO/%#_`&@+91GR\'YI4(#D2HF5.>1RU7IO$ME!]H+I M.1"<9$?^L^;8=OKAC@UF-X,KRQX(R>,?TJ> M'P_?JPC=K?R!(LN0QW;EAV`=.F>?PI@:6B:TFJ6H+J\>OZ56T[2=1M0IE^S,3##:MM9O]6H;+ M#C[V3TJ(Z'J?V*")6M?,A@>T!+-AHF``?I]X8Z?K2`NR^)[2.9XQ!=2%6908 MX\ABH#$`Y]#FM`W*S::;F!OE>+S$;'8C(K&B\/W$,J[6C*++*PR3G:T01>W7 M(K4MK62VT*.U;#2QVXC.WH2%QQ0!/"TDMA&RL!*T8.YAD9(ZXK,;5KB*")6$ MO[N6"6SC2YA MB$V[=+(N0<#/'(ZTV2WOGN)[@0V^]T$*H9#C;DG<3CGKT^O-)-I\T:Z>(8XK M@6JE&61MN?E`ST/I0!-/JL=M(Z30S*P'R':,2OM0!!8ZI=,$\^,3F6'SD6%<,/FQ@Y..XYX[T^?7%:$_9 M8Y"^Q)-S)\JAFVX//7@\>U1IHAATR**..(S;U:8%B!*`3P3UQSGTIL&CW$5E M)"3$&9(E`!.!M=F/Z&@"XFL0/)L"2C+A58KPP+;=P]L\?B*?:ZI'>3^7#'*0 M!EG(``Y..^><5F2:3):Z=>*D2^:L9\F579F8[MR_+VY`Z50.=T@Q]TKCUYSG^=`$+:U+'=QQ2*FWS9ED/H%&5_/BIDU?RK:-KN&57:' MS-RJ-K$+N8#G/`]?0U6O]#GN9-0>.1%-QY?E9_A(^]GZBI/[(D.IF:18S%N? MY]QW;"FT+CIQ0!:N]1\NRNI;<9,#!69AE1T);CJ`#G\*!J"V\96X<2NB(Y>- M<*P9L`CDU%I4%Q;:'&-BO1Q>6@@VNJ@KO.(@LA<* M..1@X[=*`)X]9(FQ(C-"(2^]5P2V\J!C/L!4UUJ).DR74,GD&,D,)4W$$'&T MC(YS[U4?1;EHO+S$0T94G<1AA)O7IV/0^E78K>6WTXI#:0"1V):)I25YZDL1 MD_E0!%->7=E]G>X>%U>,^8B*0050L6!STR,?C4VFW4\S2Q77E^8BH^4!`PPS MC\""*IP:7`6HMUE\P[E!'S';CN<=^@%36<-Y;7"M,D;-+MC\N)+F[W;2L#%/(5?WGJ#DG'(JM=:W(@W6\+'"G=&P&X,)% M4CKCHQ_2GWNGW=W$K(HD$H'W"&^88/^R: MFGAN?[0AGBC0KY31OE\%.+RYE+X&YEP%8KNVGWQS4+W\V^YE#HEM!((<;"S,V5R>O3G%1VN MF3)?+/.IIT^GW)^U0Q"(P3R"8,6(96RN1C'(X MSF@!T.L@),;J)X_+:8K@#YE1L>O7D5:O+EX(X60#,DR(0W8$X-9EUIT[>4A4 M8-Z7RN3F-B6;/IZ5=FCN;VR!\M$FCF#HK$X8*W&3CC(%`%<7MY+?1QI)$D9N M'B(,>3A1GKG\*ENM1EAU6*V7R]K%!L(^9PQ.2/9<ZLTDD`#Y96V],@D'' MY59JKIUI]BL8H"5)4'.WIDG)Q[ GRAPHIC 5 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH MHH`****`"L32O^1EU[_>@_\`0*VZQ-*_Y&77O]Z#_P!`H`VZ***`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`ANKJ"RM9+FZE2&"-=SNYP`*\RUKXPQQ2M%HUB)5''GW!(!^BCG\S^ M%8OQ2\3RZAK+:/!(1:6AQ(`>'D[Y^G3\ZS/!W@&\\4@W+R_9;!6VF4KDN?11 M_6N>=23ERP/H<)E]"E1^L8KKT_K=EY?BYXC#Y,=BR_W?)/\`\570Z/\`&&"6 M18]7L#"#_P`MK<[@/JIY_(FKY^#^A&':+N_#_P!_>O\`+;7*:]\*-4TY>V M47\*\E`NV0#Z=_PY]J7[V.IJI957?);E?W?\#[SVFWGBNK:*X@%7JSGT`ZFH_$6NVW MAS1IM0N>=ORQQ@\R.>BC_/3-?.^LZS?^(=4>\O)&DEE95*G+HM MSU,NRUXI\TM(K\3T74?C*1(5TS2U*#H]P_)_X"/\:H1?&/5@^9M.LG7T7E)Y33?(U?[W^)O^$O'UCXJG:T6VEMKQ4,A1CN4@8!PWXCJ*ZZO,?!'@K5O M"_C&22Z1)+5K9U2XB.5)W+P1U!XKTZMJ;DU[QXV/A1A6M0=XV"BBBK.(**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/EF_G:[U*YN M'^]+*SM]2&[2*Q\-:;;P@!%MD/'O-J7B/\`LZ-_]&L1LP.AD/WC^'`_`UJ?"CPK M'=2OKUY&&2)MELK#@MW;\.@]\^E>;3RRWM[),^7FFD+-[L3FOI?0=-31]!LM M/0`>3$%;W;JQ_/-_Y&G:5<>(5OQ!JMO`864D30]CZ'G^E` M&]167XAU-](T6>\C"F1/-!Z_-GG([+3]/\1W`U)=,UBT%I=/_JV4Y1_\ M_6@#HZ*Q/$6KW&E?8?(6,^?.(VW@GCVYK;H`**XZ/6_$=_J-_!I]O9O':S&/ M+@@XR0/XO:M6"[UJ#2K^YU.&W26&,O$(^0<`GGD^U`&Y17&6FO>)Y]/74%TZ MVGMCDXCR&P#@\9SV]*Z/1M8M]:L1J-Z4`:%%<3K/C#49M7D(_?S2G]W%[=1T^O7CFM/PW=>)Y+BXM_$-G;QA%#136YX?GD=3_2I4TW M9'3+"SA3YY-+K:^MO0Z.BN7\-^(KS5_$&O6-PD*Q6$_EQ%%()&6'//L*Y^Q\ M5^,]6N=0.F:=I]Q!9SM$58E6."<=6ZX%+G1:P51MIM*UMW;?8](HKF_"WBQ/ M$)N;6>U>RU*U.)[=^W;(]LUST/BGQAJ6L:M;Z38:?/#87#1$.2K$9('5AS\M M'.K"C@JKE*+LN7>[[^9Z+17+^&/&"ZW/OVR91P([G`Z-T5OQ''X#UKE_`?BMO#.M#SB3 M87.$G7^[Z,/I_+->^WEI!?VX-?.OBWPU<>&-:DM),M`WSP2 MX^^G^(Z&N>K%QES(^BRS$0Q-!X6KV_#_`#1]'QR)+&LD;!TFC'_CV?Z5,_A9TX*/-B*:\U^9XWX6M1>^*M+MVY M5KE-WT!!-?3%?.WP]4/X[TH'M(Q_)&-?1-94-F>IGTOWT8^7ZA163J/B?1=) MNOLU_J,,$VT-L?.<'I53_A.O#'_09M_U_P`*VYEW/(CAZTE=0=O1G0T5B6GB M_P`/WUU':VNJ02SR':B+G)/Y5MT)I[$3IS@[337J%%%%,@X_693HGC&UU69< MVD\?DN_]P_YP?SKKU8.H92"I&00>"*JZEI\&J6$EI<+E''7NI[$>]%KH'^(H!_P!]"@#-\4S_`&FRT&X_YZS( M_P"8!KL:X?7$,>B^&D/4/%G_`+Y%=Q2`Y3PG_P`ACQ!_U]?^S/6[K7_("O\` M_KWD_P#037&Z7H8U?6M;)O;FW\NY/$+8SEFZ_E71/I8TGPQJ4`N9KC=%(^Z8 MY(^7&/TI@+X-_P"16M/J_P#Z&:QM%N18WOBFYAQ]G@W2#'3(WG^E9,&HZ_IW MA2W>$PQ6#LR"5!F10B0GU'4+_P#KZ'_H3TOPTXD\1'_I_/\`6D\#?\CEXO\` M^OH?^A/7.>&O"*>)9M>9]2O+79>,FR%OD;)/WAWJ%?2WF==2,)>U4W96AKOT M1T6BE-2^+.JZA8X:T@MA#+*GW6?Y1C/?[I_*G^`/^1C\7?\`7]_[,]/\'WLV MBZS-X0OH+=9(8_-MYX$V"9?5A_>]_8USFC>%D\2>(?%`?4;RT\J]88@;"MEG M^\._2A=+>8I1BU4C-VCRQL]]+JS^?X%W4+9_$/Q(OCI+@K;V:QS3(?EW[AQG MU[?\!/I15C1M93P'?S>'=86W2W6,36]W#'L,H)Q\P[GKS[44UR]=R:LL1%J- M&-XI*SM>_G_P.AZ16'XJ\-V_B?1I+.7"3+\T$N/N/_@>];E%:M)JS/'IU)4Y M*<'9H^6KZRN=*U":TN4:*X@?:P]"*]O^'7B__A(=+^QW MQ_\`KU3^)WA(:KIQUBSC_P!,M5_>A1S)&/ZCK],^U>2:%K%QH.M6VHVY.Z)\ MLN>'7NI^HKEUI3\CZJ2AFF$NOB7X/_)_UL?3M%065W#?V4%W;MNAG02(?4$9 MJ>NL^3::=F%8FE?\C+KW^]!_Z!6W6)I7_(RZ]_O0?^@4"-NN*^*@)\#S'TFC M_G7:UROQ'MS<>!-1`ZH$?\G%3/X6=6"=L33?FOS/(OAV0/'FEY_OO_Z`U?0] M?-W@J<6_C/29&.!]H5<_[W']:^D:RH?"STL^7[^+\OU9Y-\0_!^NZWXH-WI] MB9H/(1=_F*.1G/4BN-O?`?B33[*:[NM.,<$*EW;S4.!^!KZ+K!\:_P#(EZO_ M`->S4YTD[LG"9M6CR44E;1=?\SQ#P)_R/&D_]=_Z&OHVOG+P)_R/&D_]=_Z& MOHVE0^%EY]_&CZ?JPHHHK<\(R[CQ!IMIJ#V5U<"&50#EQA3D>M8!N8=:\>64 MVGGS(K6(^;,HX/WN,_B!6]J*:/L+31 M-9T:_M+>.!!-LDV#&M[_2+1HH;4*@N3O3R83ASZY`Q]?2EGO=)OS! M!,JW'F8DC4PEP.2N>G'.:8&'J]U!9_$#3Y[B58XEMCN9N@X>H]5O1XLO[?2M M.WO9QN)+F?:0,#L/U_&MNXET+4+B'SX([F61`4)@+G;N('..!G/6K6FWFF2% MK:P\M-F3Y:1[,@'!(X&1GC(H`PO&Q2&+222%C2Y&?8"MJ#Q!I-U.D$%[&\CG M"J,\FDNKC2+ZZ^PW:Q2R1M@)+&2-V,X!(QG':H$C\/6:Q7D=O;19B,\O-3LM2T'4C9W"3;+=]VW MME3C^1IJV_AZ]D$GV2U>264H=\.&WX+$$$9!QD\U*#HNGVURJ0PQ1%_)E1(O MOMC[N`.>#0!F:%8)J?@)+-\?O5D`)[-O.#^>*=X.O#=Z-)IUR/WUHQA=#_=Y MQ_4?A6WYMEINF><`L%HB[N$P`#[?C43/IEC?*RQQI=77>./+.,CDX'3)')H` MX7PUJD?@75KWPYK+F"T>4S6=RX^0J>Q/;H/H!K1- MLD9R#C8#S737\^AZG;2I?1174,3AW@\Z, MR9BCVEE!P#V-9J#5ET/1GBZ2L^W37\#F/`W_(Y>+_`/KZ'_H3 MUF>"O$>DZ'+KXU*]2!GO695()+#GH`*[RUGT6W:[N[58(G=%N+B1(\%E;)#' MCGO5)-/\+2W\P_LJT-Q'F25GM.G4Y)(QZT,I3\.O-XI M\?S>)HK>2+3;:#[/`\@P93R/ZL?;BJGA77]*T/Q%XJ.I7L=OYEZ2@8$EL,^< M`#WKT.&^LO+M!%(JI33+62XG=B'-INWMD[N=O M7(.:.1K5!]V=RK16?$K'_`&I6@E&C[L5LMR[1 M116IY@A`(((R#U!KYQ\:Z,NA>*[VSB7;`6\R(>BMR!^'3\*^CZ\+^+3HWC,! M2"4MD#>QR3_(BL:Z]VY[613DL0XK9H[WX57[7G@U87;+6LS1#/IPP_\`0C7; MUYS\'$8>'+YR/E:ZP/P5:]&JZ?P(XLQBHXJ:7<*Q-*_Y&77O]Z#_`-`K;K$T MK_D9=>_WH/\`T"K.(VZH:Y9?VEH5_98R9X'1?J0VF M>SOHIU&)(9`XSV(.:^HK2YCO+.&YB.8YHUD4^Q&17S[X^T4Z)XMNXU7$$[>? M$>VUN2/P.1^%>E?"OQ`NHZ!_9S5T2V9\_AOXT/5?F>(>!/^ M1XTG_KO_`$-?1M?.7@3_`)'C2?\`KO\`T-?1M8T/A9Z^??QH^GZL****W/", M:#'V[7`W^LRI]]OEC'Z[JS0U_%HVB.4AFD#QF&-,ID>4W!)SS712V%K/28@OV,>9O!SCS7Z8[UT<=A:Q-&T<*J8V9DQ_" M6^]CZT065M;,&AA5"$V`C^[DG'YDT`6OD-$%%FOF;U))'FOTP>#]: METW!.B!?]8'N2?\`8=>N2F/TS6N=&T MXVZP?95$:OY@`)!W8QG.![=3&[!V!)SN``!SUS@#F@"GXB97M M;>U>.21;B<*Z1KN8J`6/'X"J6AS-/+(QS]H^P1*N>N5+JW_CPK?%K`&A;RQN M@!6,_P!T$8_E4+:78L\;FW7=&YD0C((8G)_,\XH`Q[4I_9_ALC'E!P#_`+_E MM^N<_C4=@?\`B;2'(V$7FSTQYB_US6V=(L&693;+B9@S@$C)SG(]#GG(HETB MPFMHK=[9#%$,(HR,#N./7OZT`<7+N@TV2[&2OV&""0?[+IP?P8#\ZW-1E,;Z MP%#%I(K>)549)W;EX'XUN/I]I)'-&UNA290DBXX8#H/PI6L;9YO-:%3)N5MW MNN=OY9-`')[7FALX($DCDM+B@(^A`JYI30!2TK?8W4ND M.=R1()+=^_EDD;3[@\>XQ15RTTZTL6=K:$(SXW'))P.@Y[>U%`'E'AWXN7%N MJ6^N0&X0]3ERO[ MOP?Z'LNM?$?P_I5LS07:7UQCY(K)+^0+%I-R@)^],GE@?BV*]2\&?#>#0)DU#472YOUY15'R1'U&> MI]__`-=)\]1Z[&D'@\M@W&7-)_?_`,!&_P"#=$;P_P"%[2RD&)\>9-_OMR1^ M'`_"MZBBNE*RL?,5*DJDW.6["L32O^1EU[_>@_\`0*VZQ-*_Y&77O]Z#_P!` MID&W1110!R7C_P`*?\)-HNZW4?;[;+P_[8[I^/\`,5X;IFIW_A[5TN[9FAN8 M&(96'7U5AZ>U?3]<=XM^'NG^)6:ZA86FH$-)_Z[_P!#7T;7E7@WX9ZEINL6 MNJZE/%"8&WK`AWL3[GH/PS7JM71BU'4X,YKTZU9.F[V7ZA1116QY`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%8FE?\C+KW^]!_Z!6W6+I8_P"*CUP^K0_^@4`;5%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` #?__9 ` end EX-101.INS 6 lmnk-20141231.xml XBRL INSTANCE FILE 0001307140 us-gaap:LicenseAgreementTermsMember 2010-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2011-01-01 2011-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2011-12-31 0001307140 lmnk:UnsecuredPromissoryNoteMember 2012-01-05 0001307140 lmnk:UnsecuredPromissoryNoteMember 2012-01-01 2012-01-05 0001307140 lmnk:ConsultingAgreementsMember 2012-01-01 2012-01-31 0001307140 2012-02-03 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2012-02-03 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2012-02-01T00:00:00 2012-02-03T07:00:00 0001307140 2012-02-06 0001307140 2012-02-05 2012-02-06 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2012-03-01 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2012-02-02 2012-03-01 0001307140 lmnk:UnsecuredPromissoryNoteThreeMember 2012-04-03 0001307140 lmnk:UnsecuredPromissoryNoteThreeMember 2012-02-15 2012-04-03 0001307140 lmnk:ConsultingAgreementsTwoMember 2012-06-29 2012-07-01 0001307140 2012-04-08 2012-08-10 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2012-11-26 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2012-11-01 2012-11-26 0001307140 us-gaap:LicenseAgreementTermsMember 2012-01-01 2012-12-31 0001307140 2012-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2012-12-31 0001307140 us-gaap:CommonStockMember 2012-12-31 0001307140 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001307140 us-gaap:RetainedEarningsMember 2012-12-31 0001307140 us-gaap:TreasuryStockMember 2012-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2013-02-28 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2013-02-01 2013-02-28 0001307140 lmnk:UnsecuredPromissoryNoteFiveMember 2013-05-13 0001307140 lmnk:SecuredPromissoryNoteOneMember 2013-10-16 0001307140 lmnk:SecuredPromissoryNoteOneMember 2013-10-01 2013-10-16 0001307140 2013-10-01 2013-10-31 0001307140 2013-01-01 2013-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2013-01-01 2013-12-31 0001307140 lmnk:ConsultingAgreementsOneMember 2013-01-01 2013-12-31 0001307140 lmnk:ConsultingAgreementsTwoMember 2013-01-01 2013-12-31 0001307140 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001307140 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001307140 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001307140 us-gaap:TreasuryStockMember 2013-01-01 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFiveMember 2013-01-01 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSevenMember 2013-01-01 2013-12-31 0001307140 lmnk:ConsultingAgreementsMember 2013-01-01 2013-12-31 0001307140 lmnk:DellingerFundMember 2013-01-01 2013-12-31 0001307140 2013-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteTwoMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteThreeMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2013-12-31 0001307140 us-gaap:CommonStockMember 2013-12-31 0001307140 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001307140 us-gaap:RetainedEarningsMember 2013-12-31 0001307140 us-gaap:TreasuryStockMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFiveMember 2013-12-31 0001307140 lmnk:ConsultingAgreementsMember 2013-12-31 0001307140 lmnk:SecuredPromissoryNoteOneMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSixMember 2013-12-31 0001307140 us-gaap:WarrantMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSevenMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteEightMember 2013-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSixMember 2014-02-04 0001307140 2014-02-01 2014-02-04 0001307140 lmnk:UnsecuredPromissoryNoteSixMember 2014-02-01 2014-02-04 0001307140 lmnk:UnsecuredPromissoryNoteEightMember 2014-02-28 0001307140 lmnk:UnsecuredPromissoryNoteEightMember 2014-02-01 2014-02-28 0001307140 2014-06-30 0001307140 2014-01-01 2014-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2014-01-01 2014-12-31 0001307140 lmnk:ConsultingAgreementsOneMember 2014-01-01 2014-12-31 0001307140 lmnk:ConsultingAgreementsTwoMember 2014-01-01 2014-12-31 0001307140 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001307140 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001307140 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001307140 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0001307140 lmnk:SecuredPromissoryNoteOneMember 2014-01-01 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSixMember 2014-01-01 2014-12-31 0001307140 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSevenMember 2014-01-01 2014-12-31 0001307140 lmnk:ConsultingAgreementsMember 2014-01-01 2014-12-31 0001307140 lmnk:DellingerFundMember 2014-01-01 2014-12-31 0001307140 2014-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteTwoMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteThreeMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFourMember 2014-12-31 0001307140 us-gaap:CommonStockMember 2014-12-31 0001307140 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001307140 us-gaap:RetainedEarningsMember 2014-12-31 0001307140 us-gaap:TreasuryStockMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteFiveMember 2014-12-31 0001307140 lmnk:ConsultingAgreementsMember 2014-12-31 0001307140 lmnk:SecuredPromissoryNoteOneMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSixMember 2014-12-31 0001307140 us-gaap:WarrantMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteSevenMember 2014-12-31 0001307140 lmnk:UnsecuredPromissoryNoteEightMember 2014-12-31 0001307140 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2015-03-27 2015-04-01 0001307140 us-gaap:SubsequentEventMember 2015-04-10 0001307140 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2015-04-17 0001307140 lmnk:UnsecuredPromissoryNoteFourMember us-gaap:SubsequentEventMember 2015-04-17 0001307140 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2015-04-02 2015-04-17 0001307140 us-gaap:SubsequentEventMember 2015-04-02 2015-04-17 0001307140 lmnk:UnsecuredPromissoryNoteFourMember us-gaap:SubsequentEventMember 2015-04-03 2015-04-17 0001307140 us-gaap:SubsequentEventMember 2015-04-28 0001307140 us-gaap:SubsequentEventMember 2015-04-27 2015-04-28 0001307140 2015-05-28 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure LIFESTYLE MEDICAL NETWORK, INC. 0001307140 false --12-31 10-K 2014-12-31 2014 FY Smaller Reporting Company 31835101 38 19974 163 3750 16000 23724 116163 2667 1767 5800000 100000 94448 94448 88893 88893 100000 6000 126839 206823 779133 200000 75000 60000 75000 347200 21933 1050905 200000 75000 60000 75000 347200 193705 100000 176000 251000 88310 127944 1043443 1429849 25835 26085 7112725 7295255 -8045927 -8535129 9237 9237 -672709 25205 6934025 -7622702 -9237 -916604 25835 7112725 -8045927 -9237 -1223026 26085 7295255 -8535129 -9237 126839 206823 42500 42500 0.001 0.001 200000000 200000000 25835101 26085101 25834983 26084983 118 118 405725 429952 405725 429952 -405725 -429952 17500 7500 59250 7500 -17500 -59250 -423225 -489202 -0.02 -0.02 25333238 26061813 25205101 25835101 26085101 10000 500 9500 25000 250 24750 500000 250000 11550 130 11420 130000 157780 157780 157780 157780 5552 5555 38 900 179330 182780 1284 12250 -6000 -21933 -173359 -266583 100000 -2705 -100000 170000 271772 30000 75000 196000 346772 19936 -19811 <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">2.</font></td> <td><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">INTANGIBLES</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><i><u>The MPL License Agreement</u></i></font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men&#8217;s health within the territory of the continental United States (the &#8220;Licensed Rights&#8221;). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"></font><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The components of intangible assets are as follows:</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">License Agreements</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance January 1, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Acquisition of license</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="width: 112px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">6,000,000</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the period May 8, 2011 through December 31, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(200,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">5,800,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Amortization for the year ended December 31, 2012</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(307,692</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 1.5pt;">Impairment charge</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,392,308</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2012</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">100,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the year ended December 31, 2013</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,552</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2013</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">94,448</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the year ended December 31, 2014</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,555</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt; padding-left: 1.5pt;">Balance December 31, 2014</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">88,893</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font>&#160;</p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Amortization expense for the years ended December 31, 2014 and 2013 amounted to $5,555 and $5,552, respectively.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Estimated amortization expense for intangible assets for the next five years is as follows:</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: left;">Year Ending</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Amortization</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">December 31,</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expense</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt;">2015</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">$</td> <td style="width: 112px; font-size: 10pt; text-align: right;">5,555</td> <td style="width: 12px; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt;">2016</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">5,555</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt;">2017</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">5,555</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt;">2018</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">5,555</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt;">2019</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">5,555</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> <div>&#160;</div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0px;"></td> <td style="width: 0.5in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">4.</font></td> <td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">DEBT</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Short-term debt as of December 31, 2014 and 2013 were as follows:</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><u>Short-term Debt to Related Parties</u></td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 939.671875px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory note, interest free, due June 15, 2015 (1)</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 113px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">200,000</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 112px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">200,000</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory note, interest free, due June 15, 2015 (2)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">75,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">75,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory note, interest free, due June 15, 2015 (2)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">60,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">60,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">75,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">75,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory notes, interest free due June 15, 2015 (4)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">347,200</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">347,200</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 10pt;">Unsecured promissory note, interest free, due June 30, 2015 (5)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">193,705</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">21,933</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 10pt;">Unsecured promissory note, interest free, due June 15, 2015 (9)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">100,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">1,050,905</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">779,133</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Less: Current portion</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">1,050,905</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">779,133</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><u>Short-term Debt</u></td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 939.671875px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;">Unsecured promissory note, interest free, due on demand (6)</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 113px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">26,000</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 112px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">26,000</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;">Secured promissory note, interest @ 12%&#160; &#160;per annum, due December 15, 2015 (7)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">150,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">150,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Unsecured promissory note, interest @ 10%,&#160; &#160;due December 15, 2015 (8)</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">75,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">251,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">176,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Less: Current portion</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">251,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">176,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(1)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On January 5, 2012, LMC borrowed $200,000 from the Dellinger Fund, a shareholder of the Company. The note is interest free and has been extended to June 15, 2015. In the event of default, the Dellinger Fund has the right to request and will be granted the issuance of two million shares of the Company's common stock.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 58.5pt; text-align: justify; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(2)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On February 3, 2012 and March 1, 2012, LMC borrowed $75,000 and $60,000, respectively, from the Dellinger Fund, a shareholder of the Company. The unsecured notes are interest free and are due June 15, 2015. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 58.5pt; text-align: justify; text-indent: -19.5pt; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(3)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On April 3, 2012, LMC borrowed $75,000 from the Dellinger Fund, a shareholder of the Company. The unsecured note bears interest @ 10% per annum and is due June 15, 2015. In the event of default, interest on the outstanding balance shall continue to accrue at a rate of ten percent (10%) per annum from the date of the default.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.25in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(4)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On various dates from March 23, 2012 through November 26, 2012, LMC borrowed $327,200 from the Dellinger Fund, a shareholder of the Company. In February 2013, LMC borrowed an additional $20,000. The unsecured notes are interest free and are due June 15, 2015. In the event of a default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.75in; text-align: justify; text-indent: -0.25in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On April 17, 2015, the Dellinger Fund notes in the amount of $757,200 plus accrued interest were converted into 6,000,000 shares of the Company&#8217;s common stock. See Note 11.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(5)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the year ended December 31, 2013 and 2014, Saddleworth Ventures LLC, a related party, paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advances are unsecured, interest free and are due June 30, 2015.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(6)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On May 13, 2013, LMC borrowed $30,000 from Forbes Investment, LLP. The unsecured note is interest free and payable upon demand. In December 2013, LMC repaid $4,000 against the outstanding balance.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(7)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On October 16, 2013, LMC borrowed $150,000 from Edmund Malits, a shareholder of the Company. The secured note bears interest @ 12% per annum and interest and principal are payable in full on or before February 16, 2014. LMC provided the Corporation&#8217;s shell on the OTCBB as collateral for the loan. In addition, LMC issued Edmund Malits 500,000 shares of the Company&#8217;s common stock with a fair value of $10,000. The note has been extended to December 15, 2015.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(8)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On February 4, 2014, the Company executed an unsecured promissory note with Curt Maes and received $75,000. The promissory note bears interest @ 10% per annum and both principal and interest are payable on or before December 15, 2015. As additional consideration, the Company issued Curt Maes 250,000 shares of the Company&#8217;s common stock valued @ $25,000.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(9)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; background-color: white;">In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015.&#160;&#160;Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company&#8217;s common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Interest expense for the years ended December 31, 2014 and 2013 amounted to $59,250 and $17,500, respectively.</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">5.</font></td> <td><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: center; text-indent: 0.5in;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 953px; font-size: 10pt;">Interest</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; font-size: 10pt; text-align: left;">$</td> <td style="width: 113px; font-size: 10pt; text-align: right;">47,150</td> <td style="width: 13px; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">$</td> <td style="width: 112px; font-size: 10pt; text-align: right;">16,650</td> <td style="width: 12px; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Salaries - Officer</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">20,000</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">13,250</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Rent</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">22,418</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">Other</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">60,794</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">35,992</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">127,944</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">88,310</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="text-align: justify; vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in; text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">6.</font></td> <td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">INCOME TAXES</font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company adopted the provisions of ASC 740, "Income Taxes", ("ASC 740").&#160;&#160;As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits.&#160;&#160;The Company believes there are no potential uncertain tax positions and all tax returns are correct as filed.&#160;&#160;Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet.&#160;&#160;Included in any liability for uncertain tax positions, the Company will also setup a liability for interest and penalties.&#160;&#160;The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current provision for income taxes.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">There is no U.S. tax provision due to losses from U.S. operations during the nine months ended September 30, 2014 and 2013.&#160;&#160;Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company's assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S.&#160;&#160;Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&#160;&#160;The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The provision for income taxes consist of the following:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p> <p style="font: 13.33px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: center; font-size: 10pt; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;" colspan="5">Years Ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;" colspan="5">December 31,</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;">2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal; background-color: white;">2013</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Current</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 926.34px; padding-left: 20pt; font-stretch: normal;">Federal</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 13px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 13px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 113px; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 13px; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 112px; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 12px; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Foreign</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Deferred</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 20pt; font-stretch: normal;">Federal</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Foreign</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="6">Years Ended</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 953px; text-align: left; font-size: 10pt;">Book income (loss) from operations</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; text-align: left; font-size: 10pt;">$</td> <td style="width: 113px; text-align: right; font-size: 10pt;">(166,329</td> <td style="width: 13px; text-align: left; font-size: 10pt;">)</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; text-align: left; font-size: 10pt;">$</td> <td style="width: 112px; text-align: right; font-size: 10pt;">(143,897</td> <td style="width: 12px; text-align: left; font-size: 10pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 10pt;">Common stock issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">8,415</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">7,113</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-size: 10pt;">Warrants issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">53,645</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">53,645</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Change in valuation allowance</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">104,269</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">83,139</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Income tax expense</td> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of December 31, 2014, the Company recorded a deferred tax asset associated with a net operating loss (&#8220;NOL&#8221;) carryforward of approximately $2.7 million that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company&#8217;s NOL expires in 2032. The valuation allowance increased by $104,269 during the year ended December 31, 2014.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 878px; text-align: left; font-size: 10pt;">Net operating loss carry forwards (expire&#160;through 2032)</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; text-align: left; font-size: 10pt;">$</td> <td style="width: 151px; text-align: right; font-size: 10pt;">(2,712,745</td> <td style="width: 12px; text-align: left; font-size: 10pt;">)</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; text-align: left; font-size: 10pt;">$</td> <td style="width: 150px; text-align: right; font-size: 10pt;">(2,546,416</td> <td style="width: 12px; text-align: left; font-size: 10pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-size: 10pt;">Common stock issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">17,395</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">8,980</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-size: 10pt;">Warrants issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">156,316</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">102,671</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Impairment expense</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,833,385</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,833,385</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-size: 10pt;">Total gross deferred tax asset/liabilities</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">(705,649</td> <td style="text-align: left; font-size: 10pt;">)</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">(601,380</td> <td style="text-align: left; font-size: 10pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Valuation allowance</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">705,649</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">601,380</td> <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">Net deferred taxes</td> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td> <td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td> <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Section 382 of the U.S. Internal Revenue Code imposes an annual limitation on the availability of NOL carryforwards to offset taxable income when an ownership change occurs.&#160;&#160;The Company's reverse capitalization meets the definition of an ownership change and some of the NOL's will be limited.</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">7.</font></td> <td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">STOCKHOLDERS' EQUITY</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On February 4, 2014, the Company issued Curt Maes 250,000 shares of the Company&#8217;s common stock with a fair value of $25,000 as incentive for debt financing.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the year ended December 31, 2013, the Company issued 130,000 shares and recorded compensation expense of $11,550.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In October 2013, the Company issued Edmund Malits 500,000 shares of the Company&#8217;s common stock with a fair value of $10,000 as incentive for debt financing.</font></p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font: 10pt times new roman, times, serif;">8.</font></td> <td style="text-align: justify;"><font style="font: 10pt times new roman, times, serif;">WARRANTS</font></td> </tr> </table> <p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p> <p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px 0px 0px 0.5in;"><font style="font: 10pt times new roman, times, serif;">On February 6, 2012, the Company issued warrants as compensation to a third party to purchase 2,400,000 shares of the Company's common stock for services performed. The warrants expire February 6, 2017. The estimated value of the compensatory warrants was determined using the Black Scholes pricing model using the following assumptions: Expected term of 3 years, a risk free interest rate of 0.32%, a dividend yield of -0-% and volatility of 432%. The fair value of the warrant amounted to $479,912 to be amortized over 3 years. The Company recorded an expense of $157,780 and $157,780 on the Company&#8217;s consolidated statement of operations for the years ended December 31, 2014 and 2013, respectively.</font></p> <p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px 0px 0px 0.5in;"><font style="font: 10pt times new roman, times, serif;"><br /></font></p> <p style="text-align: left; font: 10pt times new roman, times, serif; margin: 0px 0px 0px 0.5in;"><font style="font: 10pt times new roman, times, serif;">The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.</font></p> <p style="text-align: justify; font: 10pt times new roman, times, serif; margin: 0px 0px 0px 0.5in;"><font style="font: 10pt times new roman, times, serif;">&#160;</font></p> <table align="center" style="width: 80%; border-collapse: collapse;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Weighted Average</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Exercise</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Remaining</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Intrinsic</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Shares</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Price</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Life</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Value</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Outstanding, January 1, 2014</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">2,400,000</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">$0.20</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">Granted</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Expired/Cancelled</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: left;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: left;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: right;">-</td> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: left;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 1.5pt solid; text-align: right;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; width: 40%; padding-bottom: 4pt;">Outstanding - period ending December 31, 2014</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; width: 1%; border-bottom: black 4pt double; text-align: left;">&#160;</td> <td style="font-size: 10pt; width: 12%; border-bottom: black 4pt double; text-align: right;">2,400,000</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; width: 1%; border-bottom: black 4pt double; text-align: left;">$</td> <td style="font-size: 10pt; width: 12%; border-bottom: black 4pt double; text-align: right;">0.20</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; width: 1%; text-align: left;">&#160;</td> <td style="font-size: 10pt; width: 12%; padding-bottom: 4pt; text-align: center;">2.1 years</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; width: 1%; border-bottom: black 4pt double; text-align: left;">$</td> <td style="font-size: 10pt; width: 12%; border-bottom: black 4pt double; text-align: right;">-</td> <td style="font-size: 10pt; width: 1%; padding-bottom: 4pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 4pt;">Exercisable - period ending December 31, 2014</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: left;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: right;">2,400,000</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: left;">$</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: right;">0.20</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: center;">2.1 years</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: left;">$</td> <td style="font-size: 10pt; border-bottom: black 4pt double; text-align: right;">-</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: left;"></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">9.</font></td> <td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">RELATED PARTY TRANSACTIONS</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">a)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the years ended December 31, 2014 and 2013, Saddleworth Ventures LLC paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advance are unsecured, interest free and due June 30, 2015. As of December 31, 2014, no repayments have been made.</font></td> </tr> <tr style="vertical-align: top;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: top;"> <td style="width: 0.5in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td> <td style="width: 0.25in; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">b)</font></td> <td> <p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During the year ended December 31, 2012, the Company received $737,200 in advances from the Dellinger Fund, a shareholder of the Company. During the year ended December 31, 2013, the Dellinger Fund advanced an additional $20,000.&#160;&#160;The majority of these advances are interest free.&#160;&#160;The Company recorded interest expense for the years ended December 31, 2014 and 2013 in the amount of $7,500 and $7,500, respectively, on the advances that were not interest free.&#160;&#160;See Note 4 for further information.</font></p> </td> </tr> <tr style="vertical-align: top;"> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td>&#160;</td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">c)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due June 15, 2015.&#160;&#160;Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company&#8217;s common stock at a price of $0.10 per share. See Note 4 for further information.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">10.</font></td> <td><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">COMMITMENTS AND CONTINGENCIES</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Leases</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Company formerly leased its offices in Orlando, Florida. The lease expired during 2014. In connection with the transaction with MedCure, the Company entered into a lease agreement with the former owner of MedCure. The Company will lease the clinics from the former owner of MedCure for five years with a five year renewal option at a monthly rental of $22,631.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Company also entered into a lease agreement with MedCure whereby MedCure will sublease the clinics from the Company at a monthly rental of $25,500. The term of the lease will be for five years with a renewal option for an additional five years.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Future minimum lease payments and rental income under these agreements are as follows:</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table align="center" style="width: 1000px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Rental Income</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;" colspan="2">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Years Ended December 31,</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;" colspan="2">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2015</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="width: 89.5999984741211px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">229,500</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2016</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">324,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2017</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">348,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2018</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">372,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2019</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">382,500</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 1.5pt 10pt; text-align: left; text-indent: 0px;">Thereafter</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">96,000</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 4pt 20pt; text-align: left; text-indent: 0px;">Total</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">1,752,000</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Rental Expense</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Years Ended December 31,</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2015</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">203,679</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2016</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2017</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2018</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2019</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 1.5pt 10pt; text-align: left; text-indent: 0px;">Thereafter</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">67,893</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 4pt 20pt; text-align: left; text-indent: 0px;">Total</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">1,357,860</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;">&#160;</p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Rent expense was $33,500 and $41,500 for the years ending December 31, 2014 and 2013, respectively.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Consulting Agreements</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">a)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In January 2012, Lifestyle entered into a consulting agreement with Saddleworth Ventures LLC ("Consultant"). The Consultant will provide services for management consulting, business advisory, shareholder information and public relations. The term of the agreement is for three years. Upon execution of the agreement, Lifestyle issued a payment to the Consultant in the amount of $25,000. Additional cash fees or reimbursement of expenses shall be agreed upon by Lifestyle and the Consultant from time to time during the term of the agreement. Consulting fees for the years ended December 31, 2014 and 2013 amounted to $-0- and $-0-, respectively.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">b)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During 2014, 2013 and 2012, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the years ended December 31, 2014 and 2013, consulting services amounted to $67,500 and $38,176, respectively.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">c)</font></td> <td style="text-align: left;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith ("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Lifestyle will pay Smith minimum compensation of $60K per year. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the years ended December 31, 2014, and 2013, payroll-officer amounted to $60,000 and $60,000, respectively.</font></td> </tr> </table> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">11.</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">SUBSEQUENT EVENTS</font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Material Agreements</u></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of two medical practices in Houston, Texas, has purchased the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the &#8220;MED-CURE Companies&#8221;), effective April 1, 2015. The MED-CURE Companies were purchased by Dr. Moomaw directly from the owner, Dr. Nazmudin Keshwani, for a purchase price of $2,500,000, utilizing local bank financing.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Dr. Keshwani has entered into employment contracts extending through December 31, 2015, with the MED-CURE Companies as a &#8220;physician employee&#8221;, pursuant to which he will perform medical services as are required for operations of the clinics. The MED-CURE Companies have agreed to enter into management agreements with the Company which will be effective as of April 1, 2015, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (&#8220;Lifestyle Management&#8221;), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the remaining amounts distributed to the doctors are no less than a specified floor percentage of gross revenues.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Through our subsidiary, Regional Professional Alliance, Inc. , a physician&#8217;s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have agreed to enter into a Regional Medical Director Agreement, which will be effective as of April 1, 2015, with Dr. Moomaw, pursuant to which Lifestyle Professional Alliance would provide the services of Dr. Moomaw for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Through Lifestyle Texas Licensing, LLC (&#8220;Lifestyle Licensing&#8221;), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men&#8217;s health.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Issuance of Warrants</u></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In connection with the engagement of our director, Dr. Ronald Moomaw, under a Regional Medical Director Agreement with RPA, at a Board of Directors meeting, held on April 17, 2015, the Board authorized the issuance Dr. Moomaw of a seven year stock purchase warrant, expiring April 17, 2022, to purchase 5,000,000 shares of our common stock, at an exercise price of $.09 per share, valued at $465,000.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Conversion of Debt</u></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">At the Board meeting held on April 17, 2015, our Board approved the conversion by the Company of $757,200 principal amount plus accrued interest of Company debt held by The Dellinger Fund, into an aggregate of 6,000,000 shares of common stock.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Refund of Deposit</u></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 10, 2015, the Company received from Dr. Nazmudin Keshwani a refund of the $100,000 deposit made by the Company in February 14, 2014, in connection with the Company&#8217;s previous negotiations to acquire the MED-CURE Companies.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Convertible Promissory Note</u></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.25in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 28, 2015, the Company issued a convertible promissory note to Ray Meadow and received proceeds of $250,000. The promissory note bears interest @ 12% per anum and matures one year from the date of issuance. At any time, the holder of the note, at his sale option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company at a conversion price of $0.15 per share, the fair value of the common stock at the date of the advance.</font></p> </div> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance January 1, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 1101px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Acquisition of license</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="width: 112px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">6,000,000</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the period May 8, 2011 through December 31, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(200,000</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2011</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">5,800,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Amortization for the year ended December 31, 2012</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(307,692</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 1.5pt;">Impairment charge</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,392,308</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2012</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">100,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the year ended December 31, 2013</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,552</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 1.5pt;">Balance December 31, 2013</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">94,448</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 1.5pt;">Amortization for the year ended December 31, 2014</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">(5,555</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-left: 1.5pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt; padding-left: 1.5pt;">Balance December 31, 2014</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">88,893</td> <td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> </table> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-size: 10pt;">Year Ending</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">Amortization</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">December 31,</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expense</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-left: 10pt; font-size: 10pt;">2015</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; text-align: left; font-size: 10pt;">$</td> <td style="width: 112px; text-align: right; font-size: 10pt;">5,555</td> <td style="width: 12px; text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-left: 10pt; font-size: 10pt;">2016</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,555</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-left: 10pt; font-size: 10pt;">2017</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,555</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-left: 10pt; font-size: 10pt;">2018</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,555</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; padding-left: 10pt; font-size: 10pt;">2019</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,555</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> </table> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <table align="center" style="width: 1000px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">December 31,</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Short-term Debt to Related Parties</u></td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 747.47px; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due June 15, 2015 (1)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 10.39px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 10.39px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 90.4px; text-align: right; font-stretch: normal;">200,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 89.59px; text-align: right; font-stretch: normal;">200,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due June 15, 2015 (2)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due June 15, 2015 (2)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">60,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">60,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;">Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;">Unsecured promissory notes, interest free due June 15, 2015 (4)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">347,200</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">347,200</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due June 30, 2015 (5)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">193,705</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">21,933</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due June 15, 2015 (9)</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">100,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,050,905</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">779,133</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Less: Current portion</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">1,050,905</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">779,133</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> <table align="center" style="width: 1000px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">December 31,</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2013</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Short-term Debt</u></td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 747.47px; text-align: left; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest free, due on demand (6)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 10.39px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 10.39px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 90.4px; text-align: right; font-stretch: normal;">26,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 89.59px; text-align: right; font-stretch: normal;">26,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 9.6px; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 10pt; font-stretch: normal;">Secured promissory note, interest @ 12%&#160; &#160;per annum, due December 15, 2015 (7)</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">150,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">150,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Unsecured promissory note, interest @ 10%,&#160; &#160;due December 15, 2015 (8)</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">75,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">251,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">176,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Less: Current portion</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">251,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">176,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p> </div> <div> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;"></td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Weighted Average</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Exercise</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Remaining</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="2">Intrinsic</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; text-align: center;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Shares</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Price</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Life</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Value</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Outstanding, January 1, 2014</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">2,400,000</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">$0.20</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: right;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">Granted</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Expired/Cancelled</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">Exercised</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 502px; font-size: 10pt; padding-bottom: 4pt;">Outstanding - period ending December 31, 2014</td> <td style="width: 13px; font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="width: 13px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 151px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">2,400,000</td> <td style="width: 13px; padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 13px; font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="width: 13px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="width: 151px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">0.20</td> <td style="width: 12px; padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 12px; font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt; width: 150px; text-align: center;">2.1 years</td> <td style="width: 12px; padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 12px; font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="width: 12px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="width: 150px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="width: 12px; padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 4pt;">Exercisable - period ending December 31, 2014</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">2,400,000</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">0.20</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt; text-align: center;">2.1 years</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;"></td> </tr> </table> </div> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.25in; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;&#160;</font></p> 2500000 6000000 6000000 -200000 -307692 5552 -5552 5555 -5555 -5392308 5555 5555 5555 5555 5555 0.06 P20Y P19Y6M 32000 10500 0.10 779133 1050905 176000 26000 150000 251000 26000 150000 75000 176000 251000 0.10 0.10 0.10 0.10 0.10 0.12 0.10 0.12 2015-06-15 2015-06-15 2015-06-15 2015-06-15 2015-06-15 2015-06-15 2014-02-16 2015-06-30 2015-12-15 2015-04-15 2015-12-15 2015-06-30 200000 75000 60000 75000 327200 737200 20000 30000 150000 20000 21933 75000 100000 100000 25000 171772 757200 10000 25000 10000 25000 2000000 500000 250000 500000 250000 6000000 0.10 4000 16650 47150 13250 20000 22418 35992 60794 757200 130000 11550 2400000 2400000 2400000 0.20 0.20 0.20 2400000 2017-02-06 P3Y 0.0032 0.00 4.32 479912 Over 3 years 38176 0 67500 0 171772 21933 P3Y P5Y 25000 60000 60000 60000 5000000 2022-04-17 0.09 2400000 2400000 <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;" colspan="5">Years Ended</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;" colspan="5">December 31,</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">2014</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">2013</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; background-color: white;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Current</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 926.34375px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 20pt;">Federal</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 113px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="width: 13px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="width: 112px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="width: 12px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 20pt;">Foreign</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Deferred</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-left: 20pt;">Federal</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 20pt;">Foreign</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;">-</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; background-color: white;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: center;" colspan="6">Years Ended</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 953px; font-size: 10pt; text-align: left;">Book income (loss) from operations</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; font-size: 10pt; text-align: left;">$</td> <td style="width: 113px; font-size: 10pt; text-align: right;">(166,329</td> <td style="width: 13px; font-size: 10pt; text-align: left;">)</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">$</td> <td style="width: 112px; font-size: 10pt; text-align: right;">(143,897</td> <td style="width: 12px; font-size: 10pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Common stock issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">8,415</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">7,113</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left;">Warrants issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">53,645</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">53,645</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt;">Change in valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">104,269</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">83,139</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt;">Income tax expense</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Principles of Consolidation</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Use of Estimates</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of the consolidated financial statements in conformity with accepted accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure of contingent assets and liabilities.&#160;&#160;On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.&#160;&#160;The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.&#160;&#160;Actual results could differ from those estimates.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Business Combinations</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company recognizes the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the literature.&#160;&#160;In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred.&#160;&#160;That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Evaluation of Long-lived Assets</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Licenses represent an important component of the Company&#8217;s total assets.&#160;&#160;The Company amortizes its license on a straight-line basis over the estimated useful lives of the assets.&#160;&#160;Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.&#160;&#160;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.&#160;&#160;If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Income Taxes</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Taxes are calculated in accordance with taxation principles currently effective in the United States of America.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.&#160;&#160;Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&#160;&#160;The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.&#160;&#160;In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.&#160;&#160;In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Concentration of Credit Risk</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company's cash and cash equivalents are concentrated primarily in banks in the United States of America.&#160;&#160;At times, such deposits could be in excess of insured limits.&#160;&#160;Management believes that the financial institutions that hold the Company&#8217;s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to these financial instruments.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Earnings Per Share</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period.&#160;&#160;Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period.&#160;&#160;Potential common shares consist of outstanding common stock purchase warrants.&#160;&#160;For the years ended December 31, 2014 and 2013, there were 2,400,000&#160;and 2,400,000 potential common shares, respectively, that were not included in the calculation of diluted earnings per share as their effect would be anti-dilutive.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>New Financial Accounting Standards</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In June 2014, the FASB issued ASC 2014-10, &#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consideration&#8221;. The guidance eliminates the definition of a development stage entity thereby remaining the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of September 30, 2014.</font></p> </div> <div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Fair Value Measurements</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">FASB ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&#160;&#160;ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&#160;&#160;ASC 820 describes three levels of inputs that may be used to measure fair value.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.&#160;&#160;The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date.&#160;&#160;The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability.&#160;&#160;ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.&#160;&#160;These tiers are defined as follows:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td style="width: 87.19px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 1&#160;</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Observable inputs such as quoted market prices in active markets</font></td> </tr> <tr style="vertical-align: top;"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Inputs other than quoted prices in active markets that are either directly or indirectly observable</font></td> </tr> <tr style="vertical-align: top;"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions</font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of December 31, 2014, there were no financial assets or liabilities that required disclosure.</font></p> </div> 203679 271572 271572 271572 100000 67893 1357860 No No Yes 3378296 229500 324000 348000 271572 372000 382500 96000 1752000 44297 39634 2705 -4000 P2Y1M6D P2Y1M6D 41500 33500 22631 25500 465000 -143897 -166329 83139 104269 250000 0.15 P1Y 7113 8415 53645 53645 <table align="center" style="width: 1000px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Rental Income</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;" colspan="2">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Years Ended December 31,</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;" colspan="2">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2015</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="width: 89.5999984741211px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">229,500</td> <td style="width: 9.60000038146973px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2016</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">324,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2017</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">348,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2018</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">372,000</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2019</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">382,500</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 1.5pt 10pt; text-align: left; text-indent: 0px;">Thereafter</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">96,000</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 4pt 20pt; text-align: left; text-indent: 0px;">Total</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">1,752,000</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Rental Expense</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left;">Years Ended December 31,</td> <td style="font-size: 10pt; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: right; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-size: 10pt; text-align: left; padding: 0px; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2015</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">203,679</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2016</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2017</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2018</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px;">2019</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">271,572</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 1.5pt 10pt; text-align: left; text-indent: 0px;">Thereafter</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">67,893</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px 0px 4pt 20pt; text-align: left; text-indent: 0px;">Total</td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-indent: 0px;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: left; text-indent: 0px;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding: 0px; text-align: right; text-indent: 0px;">1,357,860</td> <td style="padding: 0px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; text-indent: 0px;">&#160;</td> </tr> </table> -2546416 -2712745 -601380 -705649 1833385 1833385 8980 17395 102671 156316 -601380 -705649 <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31,</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 953px; font-size: 10pt;">Interest</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; font-size: 10pt; text-align: left;">$</td> <td style="width: 113px; font-size: 10pt; text-align: right;">47,150</td> <td style="width: 13px; font-size: 10pt; text-align: left;">&#160;</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">$</td> <td style="width: 112px; font-size: 10pt; text-align: right;">16,650</td> <td style="width: 12px; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Salaries - Officer</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">20,000</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">13,250</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt;">Rent</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">-</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">22,418</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; padding-bottom: 1.5pt;">Other</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">60,794</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">35,992</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">127,944</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">$</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">88,310</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> <div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">1.</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Organization</u></i></font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Lifestyle Medical Network Inc. and Subsidiaries (the &#8220;Company&#8221; or &#8220;Lifestyle&#8221;) was incorporated in the State of Nevada.&#160;&#160;The Company directs its operations through its subsidiaries.&#160;&#160;The Company operates its business under a License related to patent rights used in connection with the operations of medical clinics that provide medical services related to men's health, with proprietary trade names and logo designs.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Going Concern</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The consolidated financial statements for the year ended December 31, 2014 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.&#160;&#160;The Company has a past history of recurring losses from operations and is a development stage company.&#160;&#160;The Company will require additional funding to execute its future strategic business plan.&#160;&#160;Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure.&#160;&#160;These factors raise substantial doubt about the Company's ability to continue as a going concern.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has agreed to enter into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2015.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Significant Accounting Policies</b></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Principles of Consolidation</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Use of Estimates</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The preparation of the consolidated financial statements in conformity with accepted accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related&#160;disclosure of contingent assets and liabilities.&#160;&#160;On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.&#160;&#160;The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.&#160;&#160;Actual results could differ from those estimates.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Business Combinations</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company recognizes the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the literature.&#160;&#160;In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred.&#160;&#160;That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values.&#160;&#160;&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"></font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Evaluation of Long-lived Assets</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Licenses represent an important component of the Company&#8217;s total assets.&#160;&#160;The Company amortizes its license on a straight-line basis over the estimated useful lives of the assets.&#160;&#160;Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.&#160;&#160;The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.&#160;&#160;If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Income Taxes</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Taxes are calculated in accordance with taxation principles currently effective in the United States of America.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.&#160;&#160;Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&#160;&#160;The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.&#160;&#160;In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.&#160;&#160;In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Concentration of Credit Risk</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company's cash and cash equivalents are concentrated primarily in banks in the United States of America.&#160;&#160;At times, such deposits could be in excess of insured limits.&#160;&#160;Management believes that the financial institutions that hold the Company&#8217;s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to these financial instruments.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Earnings Per Share</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period.&#160;&#160;Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period.&#160;&#160;Potential common shares consist of outstanding common stock purchase warrants.&#160;&#160;For the years ended December 31, 2014 and 2013, there were 2,400,000&#160;and 2,400,000 potential common shares, respectively, that were not included in the calculation of diluted earnings per share as their effect would be anti-dilutive.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"></font><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>New Financial Accounting Standards</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In June 2014, the FASB issued ASC 2014-10, &#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consideration&#8221;. The guidance eliminates the definition of a development stage entity thereby remaining the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of September 30, 2014.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">&#160;&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Fair Value Measurements</u></i></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">FASB ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&#160;&#160;ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&#160;&#160;ASC 820 describes three levels of inputs that may be used to measure fair value.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.&#160;&#160;The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date.&#160;&#160;The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability.&#160;&#160;ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.&#160;&#160;These tiers are defined as follows:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td style="width: 99.09px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 1&#160;</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Observable inputs such as quoted market prices in active markets</font></td> </tr> <tr style="vertical-align: top;"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Inputs other than quoted prices in active markets that are either directly or indirectly observable</font></td> </tr> <tr style="vertical-align: top;"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: top;"> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></td> <td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3</font></td> <td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">- Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions</font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of December 31, 2014, there were no financial assets or liabilities that required disclosure.</font></p> </div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">3.</font></td> <td><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">LOAN RECEIVABLE</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: left; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On February 3, 2012, LMC loaned $32,000 to Health Clinics of Florida, LLC. On April 9, 2012 and August 10, 2012, LMC advanced an additional $10,500. The unsecured notes are interest free and due June 15, 2013. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. The manager of Health Clinics of Florida, LLC is a shareholder of the Company. As of December 31, 2012, the Company recorded a reserve for the full amount of the receivable reducing the balance to $-0-.</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; background-color: white;"></p> <table align="center" style="width: 1253px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="font-size: 10pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td> <td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 878px; font-size: 10pt; text-align: left;">Net operating loss carry forwards (expire&#160;through 2032)</td> <td style="width: 13px; font-size: 10pt;">&#160;</td> <td style="width: 13px; font-size: 10pt; text-align: left;">$</td> <td style="width: 151px; font-size: 10pt; text-align: right;">(2,712,745</td> <td style="width: 12px; font-size: 10pt; text-align: left;">)</td> <td style="width: 12px; font-size: 10pt;">&#160;</td> <td style="width: 12px; font-size: 10pt; text-align: left;">$</td> <td style="width: 150px; font-size: 10pt; text-align: right;">(2,546,416</td> <td style="width: 12px; font-size: 10pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left;">Common stock issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">17,395</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">8,980</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left;">Warrants issued for services</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">156,316</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">102,671</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt;">Impairment expense</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">1,833,385</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">1,833,385</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left;">Total gross deferred tax asset/liabilities</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">(705,649</td> <td style="font-size: 10pt; text-align: left;">)</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">(601,380</td> <td style="font-size: 10pt; text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; text-align: right;">&#160;</td> <td style="font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">705,649</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 1.5pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size: 10pt; text-align: right;">601,380</td> <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt;">Net deferred taxes</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> <td style="font-size: 10pt; padding-bottom: 4pt;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: left;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size: 10pt; text-align: right;">-</td> <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left;">&#160;</td> </tr> </table> 2032-12-31 -423225 -423225 -489202 -489202 On January 5, 2012, LMC borrowed $200,000 from the Dellinger Fund, a shareholder of the Company. The note is interest free and has been extended to June 15, 2015. In the event of default, the Dellinger Fund has the right to request and will be granted the issuance of two million shares of the Company's common stock. On February 3, 2012 and March 1, 2012, LMC borrowed $75,000 and $60,000, respectively, from the Dellinger Fund, a shareholder of the Company. The unsecured notes are interest free and are due June 15, 2015. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. On April 3, 2012, LMC borrowed $75,000 from the Dellinger Fund, a shareholder of the Company. The unsecured note bears interest @ 10% per annum and is due June 15, 2015. In the event of default, interest on the outstanding balance shall continue to accrue at a rate of ten percent (10%) per annum from the date of the default. On various dates from March 23, 2012 through November 26, 2012, LMC borrowed $327,200 from the Dellinger Fund, a shareholder of the Company. In February 2013, LMC borrowed an additional $20,000. The unsecured notes are interest free and are due June 15, 2015. In the event of a default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. On April 17, 2015, the Dellinger Fund notes in the amount of $757,200 plus accrued interest were converted into 6,000,000 shares of the Company's common stock. See Note 11. During the year ended December 31, 2013 and 2014, Saddleworth Ventures LLC, a related party, paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advances are unsecured, interest free and are due June 30, 2015. In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015. Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company's common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11. On May 13, 2013, LMC borrowed $30,000 from Forbes Investment, LLP. The unsecured note is interest free and payable upon demand. In December 2013, LMC repaid $4,000 against the outstanding balance. On October 16, 2013, LMC borrowed $150,000 from Edmund Malits, a shareholder of the Company. The secured note bears interest @ 12% per annum and interest and principal are payable in full on or before February 16, 2014. LMC provided the Corporation's shell on the OTCBB as collateral for the loan. In addition, LMC issued Edmund Malits 500,000 shares of the Company's common stock with a fair value of $10,000. The note has been extended to December 15, 2015. On February 4, 2014, the Company executed an unsecured promissory note with Curt Maes and received $75,000. The promissory note bears interest @ 10% per annum and both principal and interest are payable on or before December 15, 2015. As additional consideration, the Company issued Curt Maes 250,000 shares of the Company's common stock valued @ $25,000. EX-101.SCH 7 lmnk-20141231.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statement of Stockholders' Deficiency Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Intangibles link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Loan Receivable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Organization (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Intangibles (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Organization (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Intangibles (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Intangibles (Details 1) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Intangibles (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Loan Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Debt (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Debt (Details 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Debt (Details Textual) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Income Taxes (Details 2) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 lmnk-20141231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 lmnk-20141231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 lmnk-20141231_lab.xml XBRL LABEL FILE EX-101.PRE 11 lmnk-20141231_pre.xml XBRL PRESENTATION FILE XML 12 R39.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants (Details) (Warrant [Member], USD $)
12 Months Ended
Dec. 31, 2014
Warrant [Member]
 
Shares  
Outstanding, Beginning Balance 2,400,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Granted   
Expired/Cancelled   
Exercised   
Outstanding, Ending Balance 2,400,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Exercisable 2,400,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Weighted Average Exercise Price  
Outstanding, Beginning Balance $ 0.20us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Granted   
Expired/Cancelled   
Exercised   
Outstanding, Ending Balance $ 0.20us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Exercisable $ 0.20us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_AwardTypeAxis
= us-gaap_WarrantMember
Remaining Life  
Outstanding 2 years 1 month 6 days
Exercisable 2 years 1 month 6 days
Intrinsic Value  
Outstanding   
Exercisable   
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#WK3(D"P(```L<```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%NVC`8A>\G[1TBWT[$ MV,[:;B+THNTNMTIK'\!+?DA$8ENVV\';SPDMJBH&0D/:N2$BL?_S8:'O(F=V MO>Z[[)E\:*TIF:S6UKHIRYF=^MT>TOBJ0LLN]DN'+)*IIWKVDK'1,J?3?TN9?*2D*>=XYK0 MM"Y\2AB,[TT8GOP]X&7?CW0TOJTIN]<^?M=]PN#KCO^V?O7+VE5^>,@>2KM8 MM!75MGKJTPGDP7G2=6B(8M_EXS7O=6M>N0_DCXL#'R_BS"##[QL'G\@A03@4 M"$8HH"@&%6@*%6@.%6@2%6@6%6@:%6@>%6@ MB%6@F%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6AF%6AF%6AF%6A MF%6AF%6AF%6AF%6AF%6AF%6AF+5`,6N!8M8"Q:P%BEF+_V76F*H.XN/GO_\[ MQC%'WK6'N.DHG/G]V';HL>1&>ZI_1I]*H;,#O)U]A*/27773I';DS(>PFWLH M/U4V]]ZZD,HK3Z<#O+93P^Z)2X/(QY9V_=2^GF>7F(JOTP/?%4TT5&LUU7NR M^5CES?\```#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E M;',O+G)E;',@H@0"**```@`````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````C)+/3L,P#,;O2+Q# MY/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\< M8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+ M&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^ M^CSYLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]4 M7P```/__`P!02P,$%``&``@````A`$P5M)8V`@``.!L``!H`"`%X;"]?CKUGT`82MQ M:&('2_N3;S\1@KW`=OIBSHM!,I9_2+KG'-E/S[\/^^)G&.*N[RIC%TM3A*[N MFUVWK-W_==J,PI1/.\OOGP]#7L?I8N5:5,Z M?BS+6+?AX..B/X8NW]GTP\&GW!RVY='7;WX;2EDN5^7P]QAF?35F\=)49GAI MK)KB]73,KWY_\'ZSV=7A,=Y:]^>(MM""D/ZH=M2)49NV)YOF-U MD9E-^1^$(RLRCJP0CCZ20(6W($ M2@Y;<:#@L%<*+I2E3PV<&V&+L4`Q5G:-*RQR9>N?0@%T.9924Y=;(CUV=W/B MI!R6P^0,YV9YOL(-/"O#:$<3Q]AU<:@[-".636,ACK`/#0(/#<(^-`@\-"C; M%Q0;`[NX+2QNRPX4%@8*9=NF0M5Q;-MTT#;I-$@$V1L'[AO+GAH+%TK8^49@ MOA%VOA&8;Y0M@0HE4-ENKM#-'=O-'71S-ZN;UWY??VK]KIN2U]B%Q&96B#'K M31!CUR7^X421GV-^HX7K8]E28Z'46+;46"@UPJYM@;6M[-I6N'>4758*Z\K- MFM1C.NWS[YOI8^BYC41&V+XDT)<<.PN[,0N75_^[UG\```#__P,`4$L#!!0` M!@`(````(0#BO1FXJP,``-D,```/````>&PO=V]R:V)O;VLN>&ULE)?;;M-` M$(;OD7@'R_?@^)#05DT1M$%$0A#10"]76WN3K&KO!GO=I#P]LX[B_O::4*[2 ML3W_SN&;L7OY?E_DWJ,H*ZG5U`_?CGQ/J%1G4JVG_H_EIS=GOE<9KC*>:R6F M_I.H_/=7KU]=[G3Y<*_U@T<"JIKZ&V.V%T%0I1M1\.JMW@I%=U:Z++@ALUP' MU;84/*LV0I@B#Z+1:!(47"K_H'!1OD1#KU8R%3WV*R\H[GWN>SFOS"R31F13?TRFWHG.A;+>?JQE3G?/XU'L M!U=MDHO2R\2*U[E94GI'=:I7E$31Q#YI2_%3BEWU[&1-;W\G5:9W]E$J[5-K MQ13`KKEU)S.SH?NCT:B]]EG(]<8<+Y)\`/I-!>FZ3$"E80(S^E:NN9*_&U#AY`2/?M<_>JYH\M;R/J>A>VYA@@>= M]7V^:*[8=Y$*^08#G?;\;<6_P89K[MB;AJ/_TAS35M>W(@C_98QKN MZ&)9$SDSU#E''8>X.>V:0K`EWW=2'-.L/)_N0&;;][#1>493SF:_:J(=CAQW M&'?8NN-ER2ET]$"D0X>C[W;!4%X+7M)8+H1-)Z-71.S:@#.V_/`>PYTUX,RP M[A%VG8Q_G\V68F]J3N_BMGE1AP('N]XZ8P-)=+H_S)[K%6/;R>C%;K?A\:Q. MSC%VG8Q3?FZR,?::C)[W:>3)MZU:C-N&C)X0KM5C&NB-2R9VD!OR[A8!H:,O MF1>QL^0&SQ\H)N(7._@-O"2&2H'XQ0Y^[?@/$(3&?_^VK%Y0#L39)*,GL[I380#G2">9/R7$#8X03S)Z`DY;[&!QB3(*!DD M$33XTY=ORO.4/LGM3_--FXPGA[4?'/\KN?H#``#__P,`4$L#!!0`!@`(```` M(0"3>]4NUP,``(X-```8````>&PO=V]R:W-H965T&ULE%?! MCJ,X$+VOM/^`N`R<-ZHD(Q7:Y=X@>O0*N,YJXYK][]_7R9SUY$JK?*T MX!5=NQ]4NE\VO_^VNG#Q*D^4*@<8*KEV3TK52]^7V8F6J?1X32OXYL!%F2IX M%$=?UH*F>?-26?AA$,S\,F65JQF68@P'/QQ81I]Y=BYII32)H$6J0+\\L5I> MVGA_1]!6-C8!F_,8*APOH;6U9O-01JKS,ELK3M M!B&&.*`9+P[!EBM6/K8:TG.EMV!L/#,WQMJ-X&P/%PB^9+D366G1D'E3Q]-P ML8@MA3L#$,1)&'<,AL#$%#@L#,&6L&E'J^M%0P:$&8`!87@Q]4[]L#`$6\)N M\6IA&J*%33ZUS$0,2(,F,EX:@JUJNAU=+4U#>M746S"21:!TQN_+N5;^?!$&=K.P(&$4 M/FH7Y)?:?(.VY-E]OL4\2&`3PFX88R89.W'/Q^&^@1.2[9]ESK;%)$VOG4P_ M]4_37"%#_ED7PD_DW=\$B7T3$(V!8XHSS23P[K,[@#"]LRZ#D35X?RLD]JT` MDR_ZK&LPG`4S,B=6(#@=]S!Q%$5A=.L(6J@>?_5T6%)QI#M:%-+)^!E'VQ`L MZ%:[L?LIQ$G+6M_B.([K?O<%3,-U>J3?4G%DE70*>@#*P$L@MT+/T_I!\;J9 M2?=&UL MC%7+;MLP$+P7Z#\0O$?OAVU8#F(':0NT0%'T<:8I2B(BB0))Q\G?=RG:BB2G MJ2^V1`YG9W:7J_7M)6EJSK) M2-X?:FHW\+S$;0AOL658R6LX1%%PRNX%/32LU99$LIIHT*\JWJDS6T.OH6N( M?#QT-U0T'5#L>S'Q%ZYNY?+N@;3J50HM`.T+E6 MZ*7GI;MT@6FSSCDX,&E'DA49OO-7NP2[FW6?G]^<'=7H&:E*'#])GG_E+8-D M0YE,`?9"/!KHE]PLP6'WXO1#7X#O$N6L((=:_Q#'SXR7E89JQV#(^%KE+_=, M44@HT#A!;)BHJ$$`_**&F\Z`A)#G_O_(:+)92W%$T#004W7$M*"_ M`N:S,ZMC\/HOJ^#1D-P9E@PO,0(7"LKSM(G\9.T^04[I";.]Q/A3Q.Z,,*4` M>8-&<#[6^';6SU(,V$@Q53#:MG8!N`=MP2SN&XA7\1,ED*'KE1APAJ-1X,A/ MIZ&W%F-[QJC=C18FD8'F^L@&##TVB;R81;:8M"_639#Z01K%4\AN"HFC9%S4 MB3KHXK$ZTT4AW++W*V4.S54NIQ*V%I/8EEK$Z6Q_9_?[_$T$)5-![PLQX*F0 M()RGRV)LNGPO"I*YDC%@$?KAZ[X59H>+O7L-DR7;L;I6B(J#&1P!.!Q6AYEV M%Y@VGJUO8=;UD\$=-F#6=*1DWX@L>:M0S0J@])P4LB/MM+(O6G3]C=\+#5.F M?ZS@H\*@\3P'P(40^OQB+N'PF=K\!0``__\#`%!+`P04``8`"````"$`#ORZ M?^H"``"6"```&0```'AL+W=O,Z:78I__[J?S3&2BC0YJ7A#4_Q");Y9 M??ZT/'#Q*$M*%0*'1J:X5*I=V+;,2EH3:?&6-O"DX*(F"B[%SI:MH"3OBNK* M]APGLFO"&FP<%N(:#UX4+*-W/-O7M%'&1-"**."7)6OER:W.KK&KB7CT[L MQ`:GU3)GT(&.'0E:I/C676P2;*^673Y_&#W(P6\D2W[X(EC^C344PH8QZ0%L M.7_4TH=:%VRG@%`/"):J97!@1"GKOO`\M5F6(_LL+8\5V0HRV5ZIYI2XRRO52\_FM$ M[M'*F'A'$Q_HC\\]RYN';AC]W\4V1%V#=T21U5+P`X)%`^^4+=%+T%V`\]L= M02M:>ZO%70G`2IC"TRIP_:7]!-%E1\WZ7..-%9LW%%$OL8&KAX.6AW`Z=A^& M=QE2%Z4XP&@`&?3^72-KHS&CTIUM!C=&!!#)QPET$9".",()@='$78@S+W:] M.)A(-F-)&$2!^TY.T.R0\G(^6CRF\_Q77Y./TD9C9 MFJ/%[+PMV='O1.Q8(U%%"_!UK!BJA3E8S(7B;;?3;KF"`Z'[6<+Y3V&SF12<=$DF#@>1JQ)1<:;(L&_?]U=Q1@I39N,5J)A"7YF"E^O/W]:'81\4"5C M&H%#HQ)<:MTN75>E):NIAES`MWX8+3>I5QB,"D M'4F6)_B&++K+C]_.#NHP3-2I3A\D3S[QAL&R88RF0+LA'@PTOO,3,%F M]V+W75>`'Q)E+*?[2O\4AZ^,%Z6&:L\@(!/7,GN^92J%A(*-X\^,4RHJ`(!? M5'-S,B`A]*G[/_!,EPD.(FH"O*6:KE=2'!`<&GBG:JDY@F0)SJ?(+$+,?!'UD-CU6,^^*=D6B*/`78\5VK`B#>#'O%2,V M.,OO9S/B*=LYZY;-:N*.+0[)K']MM[P=+L\).4XC'C*%8_3L;$:RT6\T(^FA1P*XH`$Y_41F+FT!BWA[2-F MQ%.PLZ]-F-5`M?HO,/#&[-"\C7TX)/UL M?RG<^*8/3.8W<%ETK=7M%Z!9M[1@WZDL>*-0Q7*P])PY`$G;[NU`B[9KF3NA MH4UWCR7;V:4&,O*A.6J%#%] M$X;>K3Y^6!Z4?C:9$):`0VEBFEE;+7S?\$P4S'BJ$B4\294NF(5;O?--I05+ MZI>*W(^"8.H73);4.2ST)1XJ3247#XKO"U%:9Z)%SBSPFTQ6YN16\$OL"J:? M]]4-5T4%%EN92_M6FU)2\,73KE2:;7.(^S4<,W[RKF_.[`O)M3(JM1[8^0[T M/.:Y/_?!:;5,)$2`:2=:I#&]#Q>;,*#^:EDGZ)<4!].Z)B93AT]:)E]D*2#; ML$ZX`ENEGE'ZE.`0O.R?O?U8K\`W31*1LGUNOZO#9R%WF87EGD!$&-@B>7L0 MAD-&P<:+)NC$50X`\$L*B:4!&6&O]?]!)C:+:33S)K?!*`0YV0IC'R5:4L+W MQJKBMQ.%1RMG$AU-1D!_?!YYT6P23J;_=_$=41W@`[-LM=3J0*!J8$Y3,:S! M<`'.I\@<1Q/KOT*%&-'D'EUB.J<$HC"P/B^K<3!;^B^04W[4K,\U85>Q.2EP M*0"O883(VXSO9_V$@F)$P55`MK4;`.^&+>K-^XYBVD@Z))"ARTE0'--Q>^*H MGQ2G<36#M)O60&=FL+E\9A3'%*S^AAS-FXA<6IP&RJ_1C(*N9#,HZ="!S>5T M*.[1]:=>.\T@W:"D0S>]A@[%7;IQT,^=TPS2#4HZ=+?7T*&X5U.CWC9:.TVK MIEH#G9FQ/;7V_O"^0G$W+]%933G-8%X&)1TZ.$TNIT-QC^ZLIIQFD&Y0TJ&# M=G,%7JWN\HW#WG9;'T6#@,,:1^C:F#OE"Z%W8B/RW!"N]MBB(CB>F]&F?=Y' M>&#VQM?85G'<;QY`5ZO83GQE>B=+0W*1@F7@W0*T=GW1W5A5U;UEJRSTL_HR M@^\7`4=;G""YHMH]0<``/__`P!02P,$%``&``@````A`(C/6O:U M`@``4P<``!D```!X;"]W;W)K&ULE%5=;YLP%'V? MM/]@^;V`(4`2A51-JFZ5-FF:]O'L&!.L`D:VT[3_?M(%&/&&R5PTVPS__/%P,\5(&]KDM)(-S_`KU_AV^?'# M8B_5DRXY-P@8&IWATIAV[ON:E;RFVI,M;R!22%53`TNU]76K.,V[I+KRPR!( M_)J*!CN&N;J&0Q:%8/Q>LEW-&^-(%*^H`?VZ%*T^LM7L&KJ:JJ==>\-DW0+% M1E3"O':D&-5L_KAMI**;"NI^(1/*CMS=XH*^%DQ)+0OC`9WOA%[6//-G/C`M M%[F`"JSM2/$BPW=DODZQOUQT_OP2?*][STB7$0L7X#<2;Q0=])))3^?I$V*<,3 MC$XB0W+F[PI9.8QKF:ULW7LQ4`#6]!7\VQX+!AL'.T^'Q:\<)G7FI20.AO%U M/TZ2I!9=KI@R`1C7?TXB<*_Z8)C?;TN"Q[I"D?[ MKAP&KJ=N1B/(VD$.TL,).5L^L"QYCS0+'DLC(\L_H= M+O\```#__P,`4$L#!!0`!@`(````(0`[F7'=#1```(-J```9````>&PO=V]R M:W-H965T-V.]`\+Y`Z^`*XXU!?=_= ML<>S#+)-#"`"R>.9;[]5JA*JRK\XVCL/'OPCJ]3J[*,R)4N?_OGGP_W!'XOG MU=WR\>HP.#HY/%@\WBQO[QZ_71W^^U_Q/\X/#U;K^>/M_'[YN+@Z_&NQ.OSG MY[__[=//Y?/OJ^^+Q?I`S?"XNCK\OEX_71X?KVZ^+Q[FJZ/ET^)1_>;K\OEA MOE9_??YVO'IZ7LQO-X,>[H]')R>GQP_SN\=#,\/E\T?F6'[]>G>S")TVL[V/K'S?+A24WQY>[^;OW79M+# M@X>;R^S;X_)Y_N5>/>\_@\G\9COWYB^8_N'NYGFY6GY='ZGICLV&\CE?'%\< MJYD^?[J]4\]`[_:#Y\77J\/?@LO^-#@\_OQILX/^<[?XN7)^/EA]7_Y,GN]N MR[O'A=K;*D\Z`U^6R]]U:':K20T^QNAXDX'V^>!V\77^XW[=+W^FB[MOW]5=,?!PYT^--0>F?^Y^?_/N]OU M]ZO#\>G1].QD'*CP@R^+U3J^TU,>'MS\6*V7#_\U09MG]#+)R$XR5EMO?S\] MFHRF9^=#9IG86=3C;F<9'8W.I\'T=,"VG-I9U/^WLP1'Y]/IY/3\[.//Z,S. MHOZ_G>47MD6=9)N=>[&;Y1?V2Z`."I,C?738_?L+6Q.\Y%K]L)MG:+*#;;;U M#[MI@LG)D#0%ZE@Q3\HY:-2$'SSB@NW!HG_8;L2O[%MU2)C-^/^.NF![V.D? MMMLS.AJZ4[:'7?#_'7?!]L#3/VRW1ET`/G@N'9MKQ.:2$\[7\\^?GI<_#]1U M7!TWJZ>YOBL$EWKJ[<7&7!I>+C^O77W494?/\IN>YNI0G13JPK)2E\P_/H_/ M@T_'?ZC+W(V-N38QZD\G9N3'S/;%C/V8D(\E'BG:1NAKH]Z\>`MO/'2RC=D. M2@VH/YWM%=N2[8N9^-N;;R=^8YYB&[-]\'(+[B"QLZIMS'90;4#]^?H6-]N8 M[:!60B>A=^!8'38OQXXZM[UC9_\-:GN(Z&A]B&P?^-J`FMS9VJF_[V;[8D[] MF)`Q8D=%>R+$)#%#QN=G_@,E>V*F(B;=$W-^[L^3[8NY\&/R/3$7)WY,L2]& MG`KEOABQ>ZI],>)`K_?%B`.]V1,S%L^KW1-S(9+>[8F1^[DW,:/-I6:BKLF[ M/'B'J+H3#3A$=?35H;K][([("W&@7)L8L^[2UY:9A%!")"&6D$A()602<@F% MA%)"):&6T$AH)702>@>\/:_VXH`]KZ/5.M7;\[N4;B[BUR;&V?,20@-GFX,B M.-'_^6=,Y`:HJD;^/I8S)A)2"9F$7$(AH9102:@E-`;,,SL;GZEM]Y]9*T=T M$GH'O$2I5=*`1.EH/U&G,D\FQ,F3A-#`^29/TXO15#R9R/U]<#:53S:6$R82 M4@F9A%Q"(:&44$FH)3026@F=A-X!+RUJT3D@+3K:3\OX0MQVKDV,V>MJG\N] M.G-_OSE[_$,L-+_?Y362$$M()*02,@FYA$)"*:&24$MH)+02.@F]`UY>U#)^ M0%YTM,R+N"5>FQ@G+^)TF+D!.F\R1W]WBK+Q#A[7D(H(9(02T@DI!(R";F$0D(I MH9)02V@DM!(Z";T#WI[7C:0!NWX3+H]Z43)>$!)!8D@"22$9)(<4D!)206I(`VDA':1WQ4^&KB0'),,4 MGNZ9,3E!V>)4IS894D+]"J>7G@@20Q)(:F57)OBML@PCWMWA)\H77@.2)2I4_U$887F%+,V45+"0$H$B2&)E5?7;.E[`1GFS"$% MI(14D!K20%I(!^E=\5(U&M8*V(3[K0`NV&R04]E`0D@$B2$))+5BU@VG[')F M&))#"D@)J2`UI(&TD,Z*V6#]*H58YO3N$#]5O]89&+$S,#F1G0$;Y*8,G0'$ M1)`8DD!22`;)(06DA%20&M)`6D@'Z5WQDS*L,S#Z2&?`!KG)D+V"$#$1)(8D MD!2207)(`2DA%:2&-)`6TD%Z5_QDJ%O(@/O.2(?[%S,N$&R0FPPS;"(`E)"*D@-:2`MI(/TKOBIT27[QY<$(U/AO[TDL$&[1,P@ M(22"Q)`$DD(R*Z\N&W(,*2`EI(+4D`;20CI([XJ?&UU8#\B-JO_UA48[>L* MR#_7:<].7 M%?]L)"6$1)`8DD!22`;)K;RV#"C>^7V)&2M(#6D@+:2#]*[XB=+5^8!$F6+> M3Y3L"HQDQ3^#A)`($D,22`K)(+F55Q<%Q7L!)>:L(#6D@;20#M*[XJ5*MYT' MI&H3[B^DN2*P0KQOK:`?-W`!KDY0UL`,1$DAB20%))!%3\9ZAXRY&JFP]^]FID@-QE2PK&4"!)#$D@*R2`YI("45K95$2]H%<;4 MD`;20CI([XJ?G&&-@3$;`^,+^:*T#7*38X;M)$1,!(DA"22%9)`<4D!**R8Y MFT:V[`Q7&%1#&D@+Z2"]*WYV=-'NKMD^]J+TV-3ZZOA_>1TTP/LZ;-`N)S-( M"(D@,22!I)`,DD,*2`FI(#6D@;20#M*[XB=%]@3>N=.;HEZ=`2_)&/,?*,G* M?S:6$D(B2`Q)("DD@^20`E)"*D@-:2`MI(/TKOC)&-8+&)NBWCTS^&XT&^2> M&>@%V)B72N-<_'NXZ+V`&(^20%)(!LDA!:2$5)`:TD!:2`?I7?%3-:Q3,&:G M8$]5(_L",SMLE[S0BKFT!V?!V9DH8R,O8J3>N"M>GXLQ:0))(1DDAQ20$E)! M:D@#:2$=I'?%SY5L%GSPQL.FP0CO^1BC:0`)(1$DAB20%))!\N"H)`O"_DV@:YN4'YCYC(BMEB]6_5Q*PQ1B20 M%))!Z*@ M]+BS<_U!C20%I(!^E=\5,U MK#$P86-@S_I,M@%F=M@N>2$D@L20!))",D@.*2`EI+)BZ^'-9Q/X+[W5&--` M6D@'Z5WQDS.L%3#9UPJ0GY1A@W:IF$%"*_:I>PO(S9O:(PR)(0DDA620'%)` M2D@%J2$-I(5TD-X5/S>R]'_G_L.2GZ\(3%#R0T(K)C?[/C$CPI@8DD!22`;) M(06DA%20&M)`6D@'Z5WQDC.5+8"/]64VP^3R69Y`-L@Y@2`A)(+$D`220C)( M#BD@):2"U)`&TD(Z2.^*GY1AK8"IJ>G?7C[;(#<9:`4@)H+$D`220C)(#BD@ M):2"U)`&TD(Z2.^*GXQAM?^4M3^7SS9HM_#T[Y M,V3/YYU%&!)#$D@*R2`YI("4D`I20QI("^D@O2M^JH8U"*9L$/!CYFS0+A,S M2&CEC=S(+D.,21)("LD@.:2`E)`*4D,:2`OI(+TK?FZ&-0BF;!!P\6R#W-R@ M06!CG-R(3G.$66)(`DDA&22'%)`24D%J2`-I(1VD=\5/CFP)?'#QS-9`@,]I MG*(U``DA$22&))`4DD%R2`$I(16DAC20%M)!>E?\I`QK!4Q-*^"=Q;,)7N(RJ3'?U6.^..-A\?QM,5O39?(F3^LEX^;;[VX\MRK;[\9_/C=_5E3POU M6?8G1RKXZW*YWOY%/\#+UT=]_A\```#__P(```#__P,`4$L#!!0`!@`(```` M(0"BFUUVM`0``,X1```9````>&PO=V]R:W-H965TWJ^WN>66^\E*DHUC8;N;;%BT3LT^*XMO_^Z_G;W+9D%1?[ M.!,%7]L?7-K?-S__M+J(\D6>.*\LB%#(M7VJJO/2<61RXGDL1^+,"[AS$&4> M5_"S/#KR7/)X7SOEF3-VW9F3QVEA4X1E^4@,<3BD"0]%\IKSHJ(@)<_B"OC+ M4WJ6;;0\>21<'IUK3Q9_C@6HHQW&>3]SB9QTL:N M?_3"YVE2"BD.U0C".42TG_/"63@0:;/:IY`!EMTJ^6%M/[%EQ.:VLUG5!?HG MY1>I?+?D25Q^*=/];VG!H=K0)^S`3H@7A/[8HPFTGUU M6MO>;#3U78\!W-IQ63VG&-*VDE=9B?Q?`K$F%`49-T'@>B/('4>O<81KX\C@ MZQV'2>,`UZ\]"9*I\X3KW2,$H="VHJ02UO&\^?K)PWZ'#28+:$6=A6AQGKB*!%8#LQ;-@: M%)>9[A.U$!03I-3E!3U3\[JMFY8^@MILL3"X$V;^.7<"*-Q5CYO<%0^-.\C[<>X(UKE[OJ&]+6'@\RH;L_(MI)-T M:_C<)VHAIJ1G.G]\53U86.]+&YWT/,8N,WI`F&N)`],0FH9(,6@U]G6.][DA M>.BU(XS"S32$IB%2#!HWW!N82YV/XV.@A.BGE[#W!A*D47'_=0KHO@\+PE4J M,T-.X4"0:""(EBLLLV:ND\%$T4E/U/-]0RN$4?IA&D+3$"D&C2,#\:HD[XNE M1@^II0$I]'J6L&>)5(O.$*?+_Y$,H[$$JVC7[YYF&@R)ADUA#387CP9AR,;H M2#@8)QJ*H^>,4\O(>7B9833KU(0]?VYHIP&IW5%&9#/R34ND>NE,<4@I3`?T M0R,-AD/7DOZ0QVT:O`(J0],2]C"1:M$9XBA2&-:[JT>6'$8S#)[=D>WKAS`T M]GW4CU[NH`EBR,=H2MB@8''H'N49D:*A2'K2.+^4I`?:@FC8.EY+OL5]OFX* M^J:P;XHTD\X)YY7"J9V=7]WFTMA3V^*9R_B6$0@O747'S"AI<$5U6X.^*=), M>D8XY8R,?"C<5S.B8:EG9*PP6T8@+2//-W9RP15US:AS;$V1AM(SPOEF9#2# M$?'5C&A,ZAD9HM_"T;66F-HC;][K48=JZ8=7Q]:$Q^`F%I@H(SK6TCDKY^61 M!SS+I)6(5SRRSF"SVUGI.+UE2SC]@+]A#_&8?&ULK%E- MCYM($+VOM/\!<8]M8&P&:V:B,=W9C;0KK5;[<68PME&,L8#))/]^JRDP5=4> M8T>;0SQ^O"ZJNA[]VO3#QV_%WOF:575>'AY=;S)SG>R0ENO\L'UT__[KTX=[ MUZF;Y+!.]N4A>W2_9[7[\>GGGQ[>RNI+O9*M/7 M(CLT&*3*]DD#^=>[_%CWT8KTFG!%4GUY/7Y(R^(((5[R?=Y\;X.Z3I$N/V\/ M996\[*'N;]Y=DO:QVR]6^")/J[(N-\T$PDTQ4;OF:!I-(=+3PSJ'"LRT.U6V M>72?O:4.`G?Z]-!.T#]Y]E:3OYUZ5[[]4N7KW_)#!K,-?3(=>"G++X;Z>6T@ M&#RU1G]J._!'Y:RS3?*Z;_XLWW[-\NVN@7;/H2)3V'+]765U"C,*82;^W$1* MRSTD`/\[16ZD`3.2?&L_W_)ULWMT@\5D'LX"#^C.2U8WGW(3TG72U[HIBW^1 MY'6A,(C?!8'/,T$N#`RZ@?#9#?3\B7\_]^8+<_L+(^^ZD?!YVRTA;%LP?%YW MRRG.6-L`E33)TT-5OCF@:IB3^IB89\1;0K1^YC'I4R_>:P7TP`1Y-E':6##+ M->CGZU.P"!ZF7Z'G:<=9(2=RG1/'YXRX9Y@&F["J!\B0!1^C>XJ1%Y1TJ@NZ M2.LZKZ0^?4-^=*$+I]0"?\YOM$(.JL\D%TM`24`3@.4&0J&YF3D/X)FYG*,9 M!#R:X^).Y(B>3<7T@>&21Y.N1L\F0$2QZ4?GWRALR3#Q9B7E?(@?\'!"YW^=@LP@7H<7B6ZOD#-,<2P!)0%-`#;'(<_QLD`,>>P)1`[) M30)*`IH`+#>S<1"KWO@3:`;Q^0NL)Q`Y*&+81,`_H0(DA+`T#$I9B$5-C471 M(U%8K;#BWEZK&<1K]2*YVB"']$,"2@*:`"Q'#Y8_FN1EL;3L,;5T))*>A2@+ MT13A&1JCN5DR'MH3K*&DVW(>.Q**)IS;FND(0C0A5Y8:"Z/'PO!ZC7G=7B]: M'JW7UHU'?+'U^=A"E(5HBO!,C4.13$>T@WX&QC!TQ/)Z#TE4.Q)1%D=3A&=H M;(AD>-UR[:%YP8V'3*WUIB.A=A9GUIN.,*8=O->[8?18&%ZOL2U1[QU@(YU! MLZ/U>I'T6?.K`!8FVAF)*(NC*<(S->9%,AW)$*UN1#O$#SMU2T1Y$M$4X1D: M"R,97JD=-#XZE[97>4BZL.X@06CG7JX[(V%T=Y]WP_!ZC;7=7B\:(JW7BX2K MKCPD4>U(1%D<31&>J3$SDNF(=M#Z1K1#_+'3CD24)Q%-$9:A+USU.NVTH[CW MV]KI2*B=X"Z$O0Z71=PQ1-?%IE^-QM%C<7C%/^32ONW27B3L==61B'HL1%F( MI@C/5/CK9?7X:)F7U=.1:(;2:97%T13A&<+31/5]I7K,J%'U(`G5`S]"0NMW MJH\,KIY0:$QU+(SC0R#Q$%&Q,D#_25!9M1O&`O$FODRD<2;8U$E,71 M%.&9&L\CF8Z(!QT2;CAL)*PMCWE3Q8W50I2%:(KP#(W#D0ROG$OT1>C]D*FU MY?&1U+_E.+/GZ1F@_B%.Z/$%2G4LJ'L@"8'IL4B\9F.$I.:1KJ!MPM:D?R&P M\BTHMB%E0YI!/*^W_-M?PWDK]951S);F=.,^C/Q:R<>6'W=RH8T M@WA%QO_(+!ME+<#H;JT(;91+S5KSD20J$GO2V#^QAHHL2#,6J\B\>?@?*FK# M\(4H6,B%J".)BL1.*1Y8IXIL2#.(5W3&AJ/;>Q38OAPLQ`YBU9%814$H7RT/ MK*$BC`X#>T@S%J](V+51W0\\1P$:,E.==+551V(5^3-1=SRP^O25#6D&\8J, MPXKG*+Q]98!C(6E_@5QJ5QV)512$PJSC@354A-%9CRB$%>&Y$AYK%%FUS>)L MOZ^=M'PU9T81O%$^H7B>!:*!`ZWV^,>ZXL,5WTC"NA+TAV#RBK>,S\52<)-S M^+,?+LV2?>8>_CUK3_\! M``#__P,`4$L#!!0`!@`(````(0!PB,$:!0,``)X(```9````>&PO=V]R:W-H M965T;@DAB4*J)J1;I4V:IEV> M'3!@%3"RG:;]]_N,`P&G6[(7`H?CX_-=S)?5_6M56B^$"\KJ"'FVBRQ2)RRE M=1ZAGS\>[^;($A+7*2Y932+T1@2Z7W_\L#HR_BP*0J0%"K6(4"%ELW0.[[LRI,*V15ECR6S18EM&$Q"PY5*26 M6H23$DOP+PK:B$ZM2FZ1JS!_/C1W":L:D-C3DLJW5A195;)\RFO&\;Z$N%^] M*4XZ[?;A0KZB"6>"9=(&.4<;O8QYX2P<4%JO4@H1J+1;G&01>O"6NQ`YZU6; MGU^4',7@WA(%.W[B-/U":P+)AC*I`NP9>U;4IU1!L-BY6/W8%N`;MU*2X4,I MO[/C9T+S0D*U`PA(Q;5,WV(B$D@HR-A^H)025H(!N%H559T!"<&O[>^1IK*( MT&1F!Z$[\8!N[8F0CU1)(BLY",FJWYKDG:2TB'\2@=^3B!?84S\(Y_^C,CFI MP+Z=BF_[\\`+9M>].#JN-DTQEGB]XNQH0>N!<]%@U\J]Y@80H[H,B1VB! M+`A90"U?UI-@NG)>H`#)B;/1'+@..,&8L^TX*M]*.#:!W0!PP&EO%U)XNUU% M5G:[;38:&'N;&=XN.?Z8$;_#,$1VEY1)$/8RHXB@K+='I,@1FHZ2.^]UVUQN M-$"1S!]P]/UR1J$?!&'A>&1\T9>#2!V`1V M&@AUU\%'U.TE1Y:AATW+TZM]K189EF=G?9U6S9FW^WMN,-B_?;_5[\\AQ2:P M&P`CR[-+R]>SK!:9EKT^)=JRYIPM;4T@-H&=!D*O#=.USXHCQ^'8\;_[09%- MI\:1VFC.P&D'#+XB1D'BZQ08+&KK5E;[UW-"?P`KPG.R)64IK(0=U`Q04?=H M/YX>_';"]"]@/#0X)U\QSVDMK))DL-2U0R@OUP-&/TC6M)_7/9,P&-K;`OX' M$#B2K@WDC#'9/:@1UO^S6/\!``#__P,`4$L#!!0`!@`(````(0!?C)52[0(` M`#<(```9````>&PO=V]R:W-H965T0FT*J)JA;I4V:IEV>'3!@%3"RG:;]]CO&"8FAJE@>N-@___,_Y]B' MS?UK7:$7*B3C38Q]Q\.(-BG/6%/$^/>OQ[LE1E*1)B,5;VB,WZC$]]O/GS8G M+IYE2:E"H-#(&)=*M6O7E6E):R(=WM(&9G(N:J+@512N;`4E6;>HKMS`\^9N M35B#C<):3-'@>I;QN0>+` M*J;>.E&,ZG3]5#1M+N7D7S-4L$ESY4#F=`0LAK=S^Q3)4Q#N=.M/!"'W!TH%(],BV)47J4BM=_#>2?I8Q( M8&$:/9!PS%>800A2ZCERW86>!OW!0J0GIF=8>#:,^$RL)G]>TQH,\F8 M\7O"!?-]!)#=Z1%H6$>@*ZU#VID!VV[4_U''[-]CYC:3C)G@BEA^81=,]ZOA M&$-A^FS.@FL>3`B&,;M7Q[0?#B0W`Y85T)UN1<.P_6^LA*N5G86=89;=U@@B M#WXVL+\%NOD!D!B@"\:R"J=MNE4-#ZTN;2<[PRRN5NWY_>V\/XXD,?-CHW/; MJ&XX(;2MCP^67F0;G@6#0[,SS$V9AP.)&3#9]T/+LY7+A6WQ8VL:'EH;G-6= M86ZL#0>@Q6L5DVW?CZ)KV8TST\!-9ZJI*.B>5I5$*3_JYNQ#E?K1_KOQ$'2M MOY^`OMV2@GXGHF"-1!7-8:GG+*!2PG1^\Z)XV_6]`U?0L;O'$C[0%(Z.YP"< M&PO=V]R:W-H965T?/ZT/@KYJ/:, MZ0`82A6CO=;5*@Q5LF<%51-1L1)^R80LJ(9;N0M5)1E-[:(B#\ET.@\+RDOD M&%9R"(?(,IZP.Y$<"E9J1R)93C7$K_:\4B>V(AE"5U#Y>*@N$E%40+'E.=3_CB"8G;GO3HR]X(H42F9X`7>@"[>>\#)#5+9FA<+.V!?K+V5&U/@=J+XY?)4^_\Y)!M:%/I@-;(1X-]"$U M7\'BL+?ZWG;@IPQ2EM%#KG^)XS?&=WL-[;Z$C$QBJ_3ECJD$*@HT$W)IF!*1 M0P!P#0INM@94A#[;]R-/]3Y&L_GD4*$@.2HOBGP/AFLJ1 MD)H$WFL2`@O>7QRZ0&Q>=U33S5J*8P";!5:JBIJMAU=`>$K(R34P M`UJ-P32'2UNTKWWE5;P$W)C*XY-A93GN8(K+TQ1VH/TUXE`]9M)^H/T\U M"/(U%@G_$4TLG6G"HZS)HKO*_7FJ04.V%C;V,KS&SHS:SD@6_DA9RA@-4@?0 M"'6#]G/WI\K\00-HD/HH(\-])^L/5@WZL.>C?`SWC2PBO;%RH`^51]D8=A[5 MF:F6-3L+K4%G9FJ4;^$SQC5[/3346@[4[FXT>V.PR"COLNCNYNH7N08-DQ_E M7N90!]NV6VE_LFI0O])DE'M9M)=JK](UJ)UJJ_,=!X,S^(@IMFA/O;>;:]"[ MZN[<[LZW!9,[]H7EN0H2<3!G<@RNVWS;/"_<$'OB;WZ`XWI%=^P'E3M>JB!G M&2R=3A8@+-V!W]UH4=G3\U9H.*C;CWMX,&-P!IU.`)P)H4\WYI&B>=3;_`<` M`/__`P!02P,$%``&``@````A`+4#]=:D`P``=@L``!D```!X;"]W;W)K&ULE);=CJ,X$(7O5YIW0+YO"'\AB4)&'9C>'6E7&HUF M=J\=N#0B1P=I>Q7 M02"J(VFQ\%E/.CBS9[S%$@[Y(1`])[@>+FJ;()K-YD&+:8>TPXK?X\'V>UJ1 MDE6GEG12FW#28`G\XDA[<7%KJWOL6LR?3_U#Q=H>+':TH?)M,$5>6ZV^'CK& M\:Z!O%_#!%<7[^'@QKZE%6>"[:4/=H$&OU.(2.5V*I^*XFHH*)@XT>I=5)2-;^HT7A:*5-HM$$?D>3,/63 M*,T6'W&)1Y?DZA+YT2(-T_G_LP0ZKZ%,)99XL^;L[,':`W+18[62PQ4X7^JC MLYDJ]E\%@THIDT?EDJ,E\J`6`KK\LDGB9!V\0&>J4;/5&OB>-/$BLC7%K4]H M*\J+0C4=4ICR@-J:>?RZOQ=<)5:XJM^*?ZL#)EL2I_:=BUN-0U_^0C&?3"Q: MZ.7]M$J<(VC.5+@DOOKJ!+1&KV"54>$&2B-@H8"OB:(60`R/V?L%5!>!SD+* MIE0UDM8LAM40)3/UL16%5ERA2R-@,<*C9C*^SZ;$+MO"OO-6:^9ZI499YG2R MT.<-,B-@DOJW6 M9.%0N-B'EYGYB;X\Q'8ZA;[`**01L%#5"]?8A]YOL1*[J$X+MUHSHKH5U"<- M+"-@8<&6=C^6$KM83D&V6C-B)7[L8!?ZO$%F!"RR$![2^]$&M#N*[(?$V1&+230])6;$ M1E4;MX'Z_N*#<>6VS>[F-XJNA2K&B"YNF&;9PEF4:@ZZEM]1:%X]YNCW=TOX M@12D:817L9,:82+HVQ2=QJO'8;IRXH4:NX;!:3H!4T^/#^0OS`^T$UY#]F`Y M\S.H,M=SDSZ0K!^FAAV3,.\,?X\PWQ)XZ)N;-OP```/__ M`P!02P,$%``&``@````A`.,.1T23!```BQ$``!@```!X;"]W;W)K'YMK^H.GK4]R.ORLO:Q0CSYIX88K*UQT&:?@Q[T!_>RA/[4>TJK@G7)4WSR^GAT)4)PBQ*8]E]]X'=9VJ MF/_8UZ+)-T=8]QMA>?$1NS\8A:_*HA&MV'4S".>AT/&:4R_U(-)JL2UA!3+M M3L-W2_<[F6>4N=YJT2?HWY*?6^V[TQ[$^;>FW/Y1UARR#762%=@(\2S1'UMY M"B[V1E<_]17XLW&V?)>_'+N_Q/EW7NX/'90[A!7)AY:M%(\X.=`W,V9YRV8-D#I&OKPB6 M(MGO$NXO`;$ME.%U1<.%]PJ9*Q2ROH*81':%B"Z(![(NVF#%]VN3\-)EKC-H MBR]A>_EK1+!`(*&G16)D^'L3A(-Q0%4]1)6%+ ME=5,:T24*A*-NTT':!#33[I-/KKN]@4)6[J&L-AEB"A=<63=FID^3"-MV$A6 M.D64A"U1MEDA@J*2)$FM9&;Z>,H8&^YK0Q:!V_#^9/6T)6PP0,R68CYIZY[) M%(/JC?XSQ4US>'1GW#(+0*`D&TS'%3;)X,O;X8"B) MRISFZ2I/VAES=Z;N9021)0(9UF@F<9/AD[/C,=GS%*&V,I@FS.B`S$9\%C'U6WTG.3\;6 MKP56]47FMFG<9,S\37H$$'1P:+'+@]BNW%HQV@N8?L:P,WY4WR?3KV?6;[OF)0WD,2!B&A=O];C,_"E`YQ3(&6]\L21U^6F**;ZS:L M/9;Q1E",$IK"6XYE(3<`4Z+T<\WF;GLP1?D;<9\.P4[9M6'L[52E$!K;IWS/?^;- MOJQ;Y\AW4&I_%H-3-;B9QH-.G/K=Y49TL`GNOQ[@1P\.6S5_!O!.B.[C0&[7 M+S^CK/X'``#__P,`4$L#!!0`!@`(````(0`']5:CPP(``-\'```8````>&PO M=V]R:W-H965T&ULE)5=;]HP%(;O)^T_6+YOOB"0(D)5TG6K MU$G3M(]KDSC$:AQ'MBGMO]^Q#12'MJ-<0()?OW[..?;Q_.J)M^B12L5$E^,X MB#"B72DJUJUS_/O7[46&D=*DJT@K.IKC9ZKPU>+SI_E6R`?54*H1.'0JQXW6 M_2P,5=E03E0@>MK!2"TD)QI>Y3I4O:2DLI-X&R91-`DY81UV#C-YCH>H:U;2 M&U%N..VT,Y&T)1KX5<-ZM7?CY3EVG,B'37]1"MZ#Q8JU3#];4XQX.;M;=T*2 M50MQ/\5C4NZ][E%$K4.@"[T(&>QGP97H;@M)A7#"(P:4>2UCF^CF=% MAL/%W.;G#Z-;=?2,5".V7R6K[EE'(=E0)E.`E1`/1GI7F;]@M&0[53",C$-:N>;Z@J(:%@$R2I<2I%"P#PC3@S.P,20I[L M[Y95NLGQ:!*DTV@4@QRMJ-*WS%AB5&Z4%ORO$\4[*V>2[$Q&0+\;3X(D2^-T M\G^7T!'9`&^()HNY%%L$FP;65#TQ6S">@;.);`3Y>3TR",G,N3:3[%10*ZC& MXR*-Y^$C9+#<29:GDL17%*\H)@=)"'@'1HC\F/%]-B/.\1BC%[;!RDLG<84R M\11'?W@+0T+.7]B((7G'"X\.\=B\+9UD:C,V3M(H\L>+M\<]+`CN?"PC'F"- M_6673A)'EBO^][!@*Y^/9<0#K'2`Y229I8)^YSZ^IGA?X^%-/H)G MQ`.\E\WIBNDD.[Q)!`'#3C\`9\0!NZN=EZ20O<./+;%A5 M3P)PGL2#,[?848]X__P9\0`N&\`Y2>JV6SP8A3YN#$Y''9+KT:Z%]61-OQ.Y M9IU"+:WAP$?!%':$=!W:O6C1VU:U$AHZJWULX"*E<.ZC`,2U$'K_8NZ`P]6\ M^`<``/__`P!02P,$%``&``@````A`)\>QA-].0``>/ MBL5R,!T-)K-I^:M'M^7BT3__^K__MV\6BV7!N]/%KQY=+9 M+#9G-^64)^]G\^O!DG_./WR]N)F7@]'BJBR7UY.O=[:VGGY]/1A/'Q7#V6JZ M9-WM%RR\FH[_N"H/_*>]YT\?_?J;Q?C7WRQ_?3@;KJ[+Z;)@'\71=#E>WA;' M4U^`?1=/WIT?%H^_^N;KY:^_^5JO^&O;.\6;V71YM>"=43G*'Q^6P\UB=[M7 M[&QM[^4/_W4UY>%6]\/[]O/[_N5B.1\,E_^>3QLV?U9^&&L$1WH[N"[S4:^/ M7QV=7WS_^JAX+X[<%F/CQ,>@"$YH,)D!F5GXO? ME;?YN#XP'!D<7TT&'_*G!ZOYG!F*5^/%D%F^+P=SP:TX'"Q;&TP`N+B]:3W< MWMKX73YY>N&TG(]G0N(]$X==A.&O((!%/N>K[_-?TBKU,W2^&T#V73F9;/PP MG7V:%N?E8`&%CXKCQ6)5SO.IW\[R7\(4W\XFJ^ER,+\%+,5-,B\&0=?D;*92/.IV7-X/QJ"@_(P\7;;1>S):P6:2+ M_F(!G-IS($SGR]M><0,X7?[II#?&Q7:0_)5CB''Z8:R##FQ./V\^[&1Y!;7X MB/S9Q?SZ^.+XJ(V9\RM(?&-9SJ^+47FY+)8SP#\Q MLK@90/QM6&1OY(OVAZ8G%L7-X-90*#TP&`[G*RCM8?!]/1YO#X\.CO_I^+PZ-7QP?'1VX/OV^3IW+-P M[GF\N;6US?;G!42Z*J56MGI;_K]BX:PU6"T!W/A/Y>A_%#M/>UO/]WO;O*2S M[NSWGN_Z/\/@L:040-!#C=WKO7B^6XWU?X:QLXIGB\&R@.G*ZTNP'W6?O[:U MO=L#3XN;+HQ'-R,H>(.?*VN5X[Q4?E^/!RW M9,SK@OG5Z9XH:V1?]MX?%.G+((7*G;#Q%LF*FE,LQBO>K=;*R M*5'S!?I1EBT*[*+BX3:3"-2ZJX2+Z]U[,%9#"?71=2'W[D M?(PK@#&V_G59/`DS?=7:+NJD1"@LXY[R:6PI"*K\+)F)+KPRU02T)?KSTI>>;:P':>Z[SY=ZB2\T MG4(\P,5M1M=1R3?;N?>-9)W>]Z9L^VCP-73.8"$J0@J+_4137=3[96_'3>6[ M7SN+EEV4\X_C89N,'_32NA7[UW(Y_F1R0$3T:3"7Z\F1W8BX:V$:NT7NMF*[CS/<2-#X$S]&FM:K`1[VU$7;)"MOCY MXX]F6;:D9W_TA]4BF)9F!0]G6)68YO)`)&QD&^MO\V%6"P0(UD\0VO=,74-J M#A\<%/R=L2$\?_9V)K.-TT+_#L7O MI5YF&W?Z0%AL:>SL#H^D/B=VOR)$7^8,'`4GS"Q7.6Z7Y=5@\EZH9UF#18>O M+)5@>'\GS"`#@P4!9OH)Z3F`#V+K,A'=*T M.:&\XE+AEKCI]0?5B\AUI[$GHT!M7XDTQ0/Y1@QUHF\]K(<44-J5F@)%MP3' MON1EA;O6O'8R_S"8!N&<3UE_5JP/*KX>OX?";A$K;\J1?(B"#0>S'%IBRXBL2',9#*P;%:]0CX90444"`WK`[@B-SF6`,#%(443N5 M*PNS?QHOKVSKM>VP_^L`K2$&^7B(++["?H#[/HY'97H8-7)]06CUGQ;%53F8 M+*]Z/KN8%N!:()`H+!-,">RZF3Z9?9AA4"S&'Z:+5O#V-S/Q':II6,Y;,22! ME7-48;7`J:!X4;DVTM]"C*B2Z+WX(W>%]XHK+%.D7AF$\IQ!0&90?+#UI9=8 MWTS31?'I:CR4@L#VOR;PM.0$GGI*?&KY<2<+=%&34,8`ZWI9 M3IYV-M:;(]RUR#*8@TK3'0<_T%Y8K3%^//B7TC;T-SOYUAB\VFO>*B_$R:JJ@O8WB/K)]8 MGF5$V3Z'D5.@#\62.0K\XUM#7\MY$&5!F!_FLNSF(4:@7S3+C1)"""\]7MUL MU@_`@4"I&8/7@Q^`]6K.&TB[*KIL5JJ;2+G8&JV,"V-E58LWO9&&_7*-C>+:<6E]4Y(^8`GKC&SEX;'J#1 MD&H&D6*&ZVRCIP03BN6G<@*,"5:1P#-DS$[54Q#V$GL4\IR0WND+"IX!_.+Z9`%H.=Y#$=4=.X$+4E`9` MTYT'"""*@&3VR0J%4@=N%!N?B%Q.;C=(8#&9?KP>_($8\C+^U%"T!4%"!L!" M8EL1W7SH)D!TO5UFFBP2L4J(5GH#^B%*Q>NC%L2PCW7V(^QC<-_(% M/!@56>)^4,A0FUFF5]$-XV[L__*&34#!Y@BXE$PH"&&U"<(R#@SZYMUTK-?, M?#%4D0^=@^4H[UW)1:A#/,:+LMWM3`9>=-[J^L8A8^;"X/U[C`S##>=#BFIC MU^Z@`!'7D;VZ.E20W:.'-F.,X=D_@E7]TX\CDK!H-2D79@$$ M06I*&Y!T`HO)+?8G)\XF])F8V=FPIM@*Y:)[V`)*)HDQ;<28DP[XC\'72!@8 M&S!]N$F9R`#E9TD;DX3*C*$6F">L3#I1T?5H)QU#HXBD^<@BC,'GP/XD*FX_ MB2DXM%MY&Y&?9'!!.(D'A9I@?NFTX?'UB@,;#09@CK"W39R2J(N(`P35`@8^ MT\V51&2"(&Z`A7&N:CY&@9^`#B)L,H!4#+!:>D-<-_3((>81CQ8P-!;GQ,%P M@RPS-@I,JRU78,$W,D\B&-0PDND_CB*J%K@2/`*/A>5,\MCH,78W_IAH-J,< M.V`'X"+RM8# M$`N3S]-B?"T](.-AB':EIH2_C,(23_S7?_XO&7O*__NA6A(-%:*0;9!JV!WF M\TH*FK,A3Y>=39%1$O.5Z50=MBYJX_*UQ6J&H5!8$OBDP"L>-X!:CN7-3,ZU M&0Q$"\9SL[@_79&\DKDFGS::2M)J$GMD2JKP84,^0N6*3^`\&;L9-41IYTHS M$H;`C?X5\R>Z5V8%)>)BS,` M5Z#+/+Q$,PE'24#7MOR@NHA5`C"Z'!2C MH7?!!(*'XAD>LD./8*`W<258I2ZK:W1%W"\0EN#6M0<#HXX5!.!:*TGFR@>B M8O@S`7:*U4CY!0C`>IR"N25";.&(-Q139S6=_`?,`A;/QXH?< MOWCE\4WTW'@J:SD$_\S83`8+LIWPAQ#:`#>'@,JJI0PNI(BTUIRU3%!B3[!W M0#N^X8P6;I8F;FWZ@C,&/!+O-&4M6K`_%$4&5)S)I4>U*G!GS^X)[*_D17*>* M=@76\7+ECH^K"$KDZG`T&[;Y0L2#1&5Z(BP0#I$K)Y_.'"18<4)MGVJ>+`-0 M`S[RK^YV&^=ZW`>31_9/($+$4%JB3@0M#!T-YN+617&*N7K>5;OSTLIQR)WX M.$0LX/0J.0UW`P-+7I4Z2CR:0R)I(D9*K_%`V/N4%P)-5U9K">_5)X7H:D69 M(8)K#&,"W@3&H1<'54O\C78F`DY,],6[/DW^0O.\)MG=\ZL?/0Y2F6QQ$[/@ ML4+%X/"JEMY:K,UO:=>$P'=-E(&U3R7_V>GM>8WM3S_:\_C/=>=K%L!J*CC# M9I):B MKE_%.XEA?:)5K!#`+3"J2E/6T3 M0RI%BDF[%8121*9$!=*5^$,:*Y(,J\U+6';.C25/M(GY0#`_,`1H5]+%X[HZ M3HACN+:Q`-N[S?/-XC?]_FDH&JO@24@0>-IRP%.V113X-QXJ2'J.53W$9%:` MO.-J[7%UR\E/GA2JJ2UMFC2SW^H)-FIR9^0,A#Q)=00W("5D8]7=X#VHJ!+& MV_M^YPE9#4C?CO[)".X)PF%F!^,9A8IDUO-6`+(",Q- M(]NYDJ<2^9KO(.0<++6G=^"H);%:I;2-JK%C9*N<*\SOA>KA'E:+05[)._]6 M%?7%&P_R&6YRKC`>$/$_WW'"7_.>'?DPA=X7JHQX`I^$5U45H7@VZ(%#S.5U M7U<&'`?#S++`AW!M]H^$1U3,,@\ME.1H<5M-P1(KD))EI0PP+IZ2M*&\BGI. M.`@=:,;(L+3"%:V43!--<*V4[6#TD8@3)*>8=G#$HS?H?B80YBC"0ML8(LM.,F;(BG"M06834I'6"$W;X@1PXJN5_$A3^(L@XI M$M&8W<,K?_JC4@@E1]K\@E MRE6`0!68BG<";>/H#88.+#2R$!HTFKHYQ+.97%CK1>6`?5C?C:2TC`I8EK M\[^4]%;1@?W>,JY\J58Y^@8&CTD'3R7"0M.XP+J9(5:0KA.6%*P`3*^90Q2# M3@7)817%)BM!EHL4W\MN_O,&[F/U$E.YI+3:')>X9&NV^&)WD3UDC!JT M4A*I$H`M>P"S,EQ^;"&O]NB.4LKCMQ?]M[\Y?OGZZ#P_BSCQS>GK5(#8CU5' M#Q[8"['@*L`8.)O00:.0(U5M8#%A>RN'B7D$H0`5RP1A`5`TQU6&Z`XK044J MQE2R&:;?O>E;/$L1,M<3M=>E3V,542QVZE4U/5B_B]N%\OOXZ`,5VO#',!C] MW66-IHR=_I6?Y2JRYYDQ5S$%,;@1.FB)]069]2W%FBU#NQF\5+_$?4*5$]0* M)J-4[]3"$%Z):6&"H)&P6)$_H5!0)V=Q2BC8"D#TZ2_TWUC\A;5W@Y'"+^%]D!BOK_YQA54ER\L7 MX,^4!FHO!N;-D/O$YC$(=[:^LD@UO^J"E\Y693`4^^U1679;O#`K?ML7B`I$ MH4OHJ&:?$0T/,,K@%9-B]I$$3NR`$A(258D1!F"O!XY MSNP:+&J>#.)W<;/)2IW5#6Z@JG^('2?.$?@9H>H&<00G.(&86P%!QAO1YLJG M0*M%1K%0SY3#+1XJT"-MV%P] M-U@1[JE^DUH-55/"7HZF:J.N_2Y+34"$UE+!&&(X6\7VB\U])P#WIB84?XO* M!(\(BRZ)-(RYZ&#/)IB8_O<%[U*S(06=F*`E8./]U'^5Q""R[HTUMO.]/,Y_ MV,A_Z->J`CA8.%1K5.W^BS,(`'`7U1C@N3,`]IR]:OQ]7F5L\SOF'UG7$)_N]W1<[ MO=VMYP_=?&N-+]U\RQ1A#_O[K6G7`:_U^I>NW[KM9>OO/_3\K=<;ZX>JF41G M0N+]H%W%.H.D3]U,JKOI)(7LL%H'Y'V9Q6T M[V7*^D[1(7?P]O><1AU9D#8YN.HTGC\[\CM5^<_6;N/,HAWRUN]Y?('=''1:D[GY+ MWHRZ\(-PSP.APE6_.559O/#Z8+-@JCZF^B1HS1W#4G_U887KIB`DT=0PMX59 MAE(*V+W5]8#'C*)YB(OQ%7EV'%T&3?$R7++**+)XYWO%%(K_8L]H-4J&T*60U0C85T_C>O'N9[=#4:9J%0G*=[M[13B=,'Z M0$-W>@-`5F>*-HH"#X2EI'85)YU#PU%T4AS*"4W-Q[D9'=NZ`/!5E"NQ0O M6B)[A5W1[CB4$4].K%^&6D3-B.0(<<,G3UO;.0\";CW)@=.=7_ST8_'3CTG8 M.%X3\SUOS(NBC>;I?%^N7L_F<9`9*(QB!E6`\ MQ-E!,2(Q7Y'%QO^Y4\1=(,G$?!*&26HGF:^,QZ7*Y:RV1D(._JXK@?T[E("$ M9',SW,WPJ(#=?-1EK`T^?NHMD"3G4].AWI\# M^562A<+!.LUK@<5<%MX!^(1'`"7P_(VT;\Z^@-N-E(:QTX)LB@HT:>4AA-L$ M'Y0J(S>=/I/2AFJHO"5<_R*0]'`-2(*H_Z(V30=4XTT0F4`AJN(DO!,@#=;= MAWR+!VX)25INU8S""@>[.\]Z2)"?2\,8@(FCO)9!]FR:/K,YR65BWWZ)S?E` MRE?>_.]K>79@R6E_^YD!'N'=(0Z=Z4,$L+(3'S_;=ZS<3%;(A-`V+M&UQ82@ M-X(K$I/\/BOHJ-;LS28S&M8/1JH%'1NRD61U6;R5X-_>;@G*PY4%T37!'=[_ M;K02*=PXQ[>8E%SAQVOY%F\`;V(A5T5<'..?-]B#Q('F4D()`&1V42V\P9Q M1=.H!0NDF,*3JM/IH/#'O">?S838J]G\DF-[0PL%Z.2MG7;1>[>VC=%62\6Y M+6.R*5D*U09()*K+T>,]5TX?J`E!BZX1]EUG.N%RM%KJ;;M@X'0-SGV\O5\[ MV-'H6@5Q;RCFU-6?^RV*NC_9(99W:L:SB^7H+TK-XMAZ&:.A,`(%+C%W"OP3 M[@UMM9+P"OI07-"1;ASB= M#\A-,[^>R2TW^$>_V6$4>A`U8%+@2QLF.NV2%O>%>Z'U7#'\*I\\R4>)!C.7 M6N97HH9HCW:A-P$&WH1J^*].%%@%:\XZ`EA0(+&(D@1U=\PW>;#BGOV;`60M MU+CW*K/3S2*G[?S%!^CA2U(O=40S=Y)OXLN(]0:VVR>7AQZQ`^9B#-S"U\TC M!ZQ5Q]D)!/Y`C%D8?U3\"S+*#,(6T#-5F$$\`T-&5)3:I@M&,G",1ND2-C*"@J]R_V+9?> MN<%HO(>B*>1U4$)&6T:PK?J&L+C$KV4,.9ORQ>!WCG0TU?5`!%B$R-+3BE@\ MWMKJO^,HC>JQ2_'/SXJBONA!:L8] MJ#0%W9H:K45(?:^:I/ZWUCN6'ZUW;`AAMG(9#WKICEA1_^#@Y-W;B_/BM/^] M8I?6*Y0?S]X='19'_W9Z]/:\G6". MN'E47_)1KWCR*#QZ])67F<"!,DETFRT86=Q+\SXRJ4(RS5:7N@H4A@HE*AEJ MMQ0@2HU3=78L(N"*+(RRFM;>02F&.UIHORDU?;2J5X5]_7RA$MV<;*2H)"E+ M5;71*Z2+E\+:Q1`UA38`2+8K&JM?YR76FYK1\#*137:`>XZ;H1NT+ARNK$2P M\VC`)C]"YXI-X6R>?^UZ<#JUZ^%47.@PZ9Q0"EUW16(C%"UR'#H89 MA1X$%+/+4#"%W^P4758E?G06KM!A.00K.TM;B"?AJ18(;J546;R+ M>VFM(:K;;A<,BZ:AE+RN,AN5IU*`:E.&A$@$X",R8_UL$C^H:XJ`DSQJW(RV M.V'MGBS:QGIZ=>,.)R<(72^O`P^M`CME!]=\00/S3VR1D_ZKU]9E>1<7E(FQ))@ MX,[Q1F%ZI'XX4V)X357A2]U(#HL\$7Z^Z\:/^^M]M[ M_N)9_CL4DAIQ0^36S5TN!EZ"C"#I++-W)<*<)@H.4C^MU9 MK:;2$;)"WJ[.P:W**V[0T04E,C)U,>CFTNJKW7AQWR86$KN-;P#(P4`)J):D[6[L[/J@#ER)1+H6JK);SXN3L]7:>OJAKCCL" M3GM=.JM8\D47SP3-1[9T;:4:G9AZ\MHXE_UW\/M;*":C1J-`R6?I%RY$.4Y^^C$&@X685H+I MR4[O&;4"S_9:A2<\V=][VMO;?IJS5ZV:9PT#>MMTKRQLG_[K"!X4;#[WDV=; M^[VG>VVI]'1KN[?[O/6YDPZ]F4\I4-4WT5Z4[*!=P=I]OA/5B]DVYN!@S15G MU&RK%^#!;(2)A/6Q@.3D;'M7-[NN&HQ_YYMP$5P?\+"[N.*1NH0P\R\P/F9# MN"6"=N`>H)0\7MN';`)M MUF^9=<&>X+$KUWE`"PA\",EC!##BI`$D`(LAQ'W^_@X2^ZY^=]8EEY*_6R2:EPSJ`@/A4 M!MK,K0:0996A%<=8[XI?F0&>;@"GF[L/RDT;X43+27$L"(D"=]>;:0,NP:L4 MF^_ZF8_",3#K8M0L,4X[EC&99I*)$(T'=*_W&-'97](^ZX?B?`@7(](47Y-K MQX#>.$?&/0UP@GQ_=J5 MLG213&>J3'##NEY\6"#QGD#A!1-5B-']1>O/Q!69=(UI:':UF66)%.K5`.83 M,TV,,PC_20<$H1,T0H!35F,1'0'@S&V]#2RPR>RV#/88$X>W'-1I"Y;!C&4> M6)KT>5T)4M:%(A&PZCPD7SO8)&?M]#63/DE1JN/SYT>?*2?$6,M_/XNWJ?,' M:'YB&7SU)']PKG+!EM5R*KCE0]6N!)R4&4L(E?G@KGW5G<]MI.7\0 M`&XT^<6SGM4*"&^+"UTS#LU=\V76C[Q#/YP=O>Y?$-8^[9]=?%],W_71/;4>HJ$(MBT[51) MLF?B.O8"KW>"R/EVV*(,K-.4LVXGK%'.H1>!KI!U9B?EC?F.!>^_8?JT60XI MY'?N[__I[.G/0"&$FKZ/(#/B(+9\5L?Q.Z0OB;HWQQ=OCI1LU`<)#T[>7AR_ M_0V?I.3+G#F=O%:HJ*5MZWQB=K-:0DP\JJ0<$'XUZMBLGI,Y-PA'](0.]R?< M$+&Q(69%>,;3%J(Z*_<@AMNZ]EEO.&'>X9MR1#"Y;'IM.(7D4*R40:Z"+V,= M]RU#'SKLFM=()V_W\$6M8;*F06K.MT\A=H\W$I.\\Y.W)G$>K&[21%\V_H+\ MY@HE,8V0QK>\NC6M!X@*CNN1O-V=WM/==FE8'?;>.>,!9P[G4VC#FMBD?RN^ MP-WA.TX9Y>':;7)+*=84`OQT+=6GC`$,R>JGP#B(E!J(%['OC?*=.3X\XITS1RW/ MT;#4\G&@C)"KFN;D3\+T-0!ZSG53K>@BA")MW+7W]M$5<2:>*94P7;ZG%#&@'!RG"[!W,/YG2*:>D72 M_6$/1`#(^(=O;M@T_.(1L9"2J1P3`:&ZEFN9*K];K/[T"S7?`=,C/@")3TXC MO-J-HYJ2-!C=^%>NS1]39MXW4"?LZB`DA!SZV`]NA6\6[T@#@S.5=\E]@I$E M.]([=5B%D(\^4^,%1/AP&ER=O\-V",5/1;^Z2F9.&S?*D;MS!,CX^I(HI=U/ MUO+!:B&I:->]Y(S[%TBLR)$<0(6\Z(S6-N#"COZ!IUQ/H+&.NXM,%7RE M1*Z*-DFK8O)7SYITGIV-"Q2[)YW:[,415GM9,Q]WGO>UG M!*3NY.<3=7=#K[@SNQX2BKE8Z,#T9")7A\'!%7F6Y>P&,5:<8W-W5+"&@,=<)Y$CGG MI.D-._9%)C4/FE&D2RY3=Z0(C4*GDCLN1CVNR)OA,R;Q2:U"4TG0^F#A7;>< MPG?>Z+9`8BJ8LLVO0?6L.#A&GPEZ2B`V7IWQC3V5MP$==F;);&D4NFT<'6X< MO#L[*HA:$2R\Y8N14-%I/"LC3C?[FP:+-+1/NF.C3P<^KZ,YIS>RO1;&QI8D M:;Q3+C++6]!5#3]"L:E?BG"^;+_DMTZKPP$EH='Q5[4>2J:PI_*Q=4G/E3(_2SP#'?%5ITIQOF8!*<7V=+GQIJKYCD3GE;9QBSAU3A+J:N'S(!:#*[26>JPY?#`SL!L,$G`P M?]:,M*1DDJ:M@B^^V^@\5,3+@=E"@X2[CEGC:"DHAZT!;Z5B50]=;YR:'J%$.97]6%.2+CV#4%$7FK%BN!8`0;I;?_* MCO2^%27AGI3#*SXLR.!!VZ_"*&^NZ6ZHN2^K#%<4!MBUEI7PH M1H]4.Q?*N*JNK*X]60)50&=&J_62[VB-\%BP'PT2&0GZ..D#I8G)VTK9=8F7:J>=B`T=7`.& M[.0)"1R]FCOY[C7`5'._28*HCAIU=()WKB@)!_8-M$1$I,6&4#*:.!7%"P<1 MX!$!02\(Q`V%52.1-%\NL;OVNI8YJL$N;U^;C6<"JRUFTT.7LC5Y;A]3L.(= M."W8B>:;,"7@0.==YX#V`R-_UN7B#1Q`IN/?_LU>1+/78)I8YIF^W\O_+?A_5,O?*2CK4?0R>]2DXK!]'ND.>?+[:K/3!\PRNM7!5C49&2=$4DD8C] MNBA)#RM\3T=?2Q;.9_1)L;`NLDIR%8?'BF^&!%*P9'`+M0H]ZE0N8/M1><9X MN.(:BA.O%C]"$4CN3ARW77`AN9Q^"$W9)%XDB;TEYFSN M9FGF@7@T\$'RPRVPL],^U`+7%2]GJAX7(P=1H\_9F"I&LUL51;QVO_VL?O78 MWQNLJ/-4?8![#(H!F3-:DPI,C4)2P9L%E2A-[NITCV97REF`#?:0K4;46(!. MQK;=E'/KA?G5%C+K>:$+:;E[8L>`EI'&YT^_`@*'4`!EFM!J1"4K=66&5J9]H)=-E.1X0J=628H'+XR8W#KN@U>AW@+ M2&=\Y1(6,@#9!SIRLB>0$]#,%2GB!G@&@EG<9C,_)V)J^6$0%=_##:OHW92B MH[^@+B(AO"BNS*"'GY/2@KK%ZN$U>3^9Q*GM)E@QX3M_?'MGQM?@_)X3I!D; M1>J%ML1N0<;)9SE6<Q!CA]JJ[0/DD[?NWZ<(UJ0J7R$OL)PQF;NE8P75R MI=530G00)0--L*3K,?N(OCK2F\VRID#".-@:X@_4J?=&P$;]6,37S".J?%X/G9S M,N71S1$T@6(.0YTOXJ21K$W@^G9-@%2"B>NG^W7)I`.V2],:Q,\XMW+F%TP1MPJ9_..CI>[7U.)K__AHJ51#=2-^':S8E6,0"EJXI* MF-"J2F)QPU7QZ;Y'O7+FWOED(:S=V_GJVB*F")\%=M1RPW)04M+Y21]V(7L= M#.J'"J$;7.W:??`HU6)Z+5\>WUXY@0N[?O:05=`AY">1V^85(E-32B&?NKXW M29V_Q(6WN];HNNUITIV$1_P\40QP0]'F0->O>RCZK5:C4@CQXLEMOF`T]]=B M'JJ\H]QE'82_L$H@WU53#QS:9XS;#-,/UO\5,>J M+1EQNF[AZB7H=PW^7U$D@-B*L<2JVWN(8F#$G:;X:@Z(BU!9$R,>*123#]S9 MZJX'[M MV&+J,=PNI:;/[F;JLINOA;>R66SMFJ?2XH361M8AJQZ),!<0O;VVF6V^A5IM M1C`PI?;7OJYZ3_?M7OBN35)FS83S-:`X[&S=QL82K\K78_L%PI86E:%C;_ZF MP<"=FE`=;KEM@@[QWGO^AFOD^T10UDM41ZY7AQ-B)O35??V[]FH$=HQ&6R`) M1XD]YMOZ_79+7OQ^I_W3;ONGO?9/^^V?GK9^.M'U:%AG17H!,?./UG](D+]_ MZ[^J&7Q+#S063,G_^+O4G8=PE$$612.XI14XKUOR0SH@EV+P>W(W=_.'%(YCGKO2:)GG;U2\29L):9360_3->L/>-A3" M_JTU:<*\6<0&S/F&;-IH..0/[2A1;N4/ZVONY0]MVIB'R!\Z&B/Z\J?J&E^U M<#;-GUG#^1MU;R7&%)0T?.@X2Q7@3>3CS[-:TK5^NAU('7#]@^ZJ]7+O1`5X M^:PV^#@-UM?'2(:H3\=AQ^AWJ4-[EF5QQ=:X_%4\^8M_]*'XC^+!4%"("DD2 M\K660Y479JF.'`@/#$_>YW2E::(D4Y"-'RWC$F.3/3Z/S:VB?`O-$.5]*X71 MBOD%+^[N:34P1@'O'AEBI/>'=\[N#7:2XNENZ/6@LQ<[:P,2,LBKF/AA;#C' MUM$-*;KY.C1*5#G5[_N7L`/5$2TO4NUPJOJ,JC&=`K_TROK8W!\E MZGYKW9EL=&R7$`4J00ICSW`-`.&IFUBVT=8>%:7M&)=NV.0O5"'MBK?";TF0 M]HKN>&X^+I^[UC2@5[Q,7V9_2>-72D7O'$U(344C:X;6^@;DL^0]'G3-P^M% M3KNZ+Z36#E9JFT]6.T#^:"=$'+<]XDCD<32X;>DF`F!DGKD=X%]SSR=I`?]> MSG";QCN\M(R/B(^UT=VW*_O,`_;UI]B])MB"U"S?159IHP2N70MV,0C\$[I' M$@C.SQK:J>0_GW4W@,F''=),SQ&# MU^%Q,SA/*3!?4+>*A?R]$RIZBC6'"V!;RWSUT&.SA<7]K)N&_LZ62S"11MK`3`V2!\6Y9%0.1IDEXZ5*P#T'QR94 M.%Z2-T1/Q;3*6M77O*/:XL.'S7XO]YE?L"Z!Q16V]7[!/1M8IPXLP9!N7.

*X2-&Z MR"0Q:?$L;%Q=E*-+3K@JEQ\MM]0;U)T_O%<'N\/IWNA^OI2[C:$6+W_86FJM MVH!U6R57X-UNI7D`%Q=6G:*(+%EVZ8/#D.SP,)7\#BX/G M3T]CI9LYG_7]9#Y8_F++M1,'Y(.\8U'^ZT%5P-EI3L1JVX2V?(+3%1\1XS*G M\4T*S^2CDKJM^"S5RD)SR7];\YX7W:XW9"NU%$RCFR[3*&U"WII7<=>3>-7: M7R\6RU__7P$```#__P,`4$L#!!0`!@`(````(0!OWLQ&9`P``$IR```-```` M>&POKI- MU4J]JG+`)+[X"S5F-[E3__>^-_[V!K`]AC&3[:';@&'>^[PO\YDWX[%]]?V+ M[VF?G6CMAL%$[YUW=O?7__V M-U?K^-5S/CTY3JR!B&`]T9_B>'79Z:SG3XYOK\_#E1/`-\LP\NT8/D:/G?4J MB+ATI^+"/'MZ'FS.IN'_LJ.W0?7<^-7)DO7_/GE MA\<@C.P'#Z"^]$Q[GLEF'W;$^^X\"M?A,CX'<9UPN73GSB[*<6?<`4G75\'& MM_QXKA0L`\8?_;,+XN]\E?][]\=V[[K^_ M_>Z?/SJ+?_WTS>YW/WVK=S(U1";$H%KF>;=2+'R=2.ZD%EQ?+<.`&`*@F8,N MGX/P2V#A=Y`,8![^[/IJ_8OVV?;@2`_AS4,OC+08H@SVL2.![3O)+V:VYSY$ M+OYL:?NN]YH<-O``2XST=[X+8<*#G43#:?4\()K,IA'"X&SJXQ%JDP\FV7BP MVB;[YSTV<;H&];J.\1^GBUE1;9/#8W3EL2)ZHL>'B6Y9P"&];A?= M2@/6DK+QK`OZ3J;L8G`RR_I6WQI*M8S+Q=VXH<*^)=.5-0JM]\.;D[E3OK(R MZU(:/E4/P`XGUXLN=-V*_CVT\'6*/#GQ@-9.Q)A4CO19UY/%C1BL#0U8R_JX MK&]9UXYMA+3:R`W.CRWKRCM8K0_O7=]9:W?.%^W'T+<#['BTZ&$XN9J-,Z-6 M_''U(>^Q@D5>5ZLX*)RSQR5S'BS(ULS9G,\#5XQ/6\?!;0'V"=#$>N MKV!"$CM18,$'+7U__[J"*CF`N1-"["2_J_GU8V2_]@Q6*XHU6(>>NT`4CS-6 MFZ>UT>SBUIK=,KT$F2B*$J&6-1NV(/1V.I[)1SH;CV4+-2QX21;Z?H`OR4(M M^&\FS:CT>]B]%H-#;[/=-D3GY(,]H-%LZ+@]-K M:6[:13``!./^:'QA`)"N.6*J3HJ@#P"&@\%HT!L;)OS/F*Q]!+)].M!51Y4@ M4!15@D!15-ETKB.!^=.>`HM$BOLJ0:`HJ@2!HJ@.)3/P4'E4"0)%424(%$65 M+4)*[*NP8JRXKQ($BJ)*$"B*JK3B,V7@L?*H$@2*HDH0G#JJV;1J=GMKL26I MW>I#&"U@AIR=K^KA3#4Y=GWE.KM`%O6J-M-%ME$]50+),#W9,Q^$*3-KC]KF^SQ:&V;IK8"O^ST MC:F!+U8=[[&TIL6NG34-]EA9TT+41CYOLNARPO.E"Z3G/4BV_,W]_#`8H"AI M2/`0AD_I"<\-)6>'A-F.MW9'S98ELO2(6K''MQ"(%@P_`!#XJMDHG>FH]:ED MJ],"`NJ1N>-YG[!"^,_ZZF5)=KO`%B3<#H*;:?`M+*:G;Y,")/D` MUI;?P')[+8OB2F@AW%1?OBTY153L5G=M;!=]A*I9Z(^2$* M8V<>LWU3[+Q'&9Y^"9Y>*D@$SS'ZS1+]X"=A?QRC'U;"]@81_*)4/R27L'Z9 M^0!K2)D_(`0TJ:OPR$0`ZQT9`@B""@2XHRWMV)">*A#`/#)#``E:(``X%5EQ M3#_H$3:#'"A4@OZV5`+'9%9R*ENTLHQ^07^%E19'OT>YF?`M)'KA9OA0`>`H ME644JXIB2-BAIQ4N@`\5+K!@U)4SY,%*0YYWX(,"@#*'$-+E``$-5'E$7E82 MS@6=HAZ92JQ#2%(@%:F&`'"40""!Z"D:?WL4@Z(1F&:#HB&80N#&X&J6D-HG M:"2X$5(1!L"CI%<4?-WC1HP3NH%`4,60)!L,511),:CBR"(4ABJ*)!!4,22- MA"J*I!A4<20)A2J*)!#`(TH8DD9"%452#*HXL@A%7Q5%$@BJ&))$HM\R17;H MLFFRB$K63X?]@]9/M9=E[4)JKVS2!''/FB>SIV3F"+%@W/E\-!8&>J/:VQ%7O9&'!I3#6&-M-0$L'`\/ZFW(1XA+I( M^[VU!V7'F\$BVR^U1$)S5[9RFKNX@8$.C8T)7ICE#N,>`+"8NMZF<5H)0>0).PO[U6 ML*4=!F`L;=/*^>O#0@.5$%63,+7M*8J.[>H2J(SWET4U6;2_-FLYMR#)*RID MP>&?NNB0GD9#*!V0:,RPNV=SP#:IZ+@,Y]R#9]VJN&":GNS+N*&4F6@`C\-7 MD^-\0@GF=C4Z#2_E3!@0]G!U=B;W)7%M`^C!M%4SO!Q"\-5.V^LIPEJT1]9X MJH2VCL5\9+=M8\RL=FE='I9YMWIP?YO>;9^%#AE&#."Y_\_R]>?-.G:7KT?- MX/#$FS+O(`FG"PYU/5-2_4JZF[CRDMXF"=()1R)*55*9M*[DX(?T-@L0$F!N MM.+X=!=N28@KAJN#C#C6Z6!=49?#;1(KZSSU3J^!^W4XG1_5@"ZEU]:'C&KE MR0UXJQ#R62%4^Q^-C\L#.?CD%-4GZ$)RNWPCYQU$48(3O3*>Y4+]U?(L/UJ\ M&9Z%Z.];C.!KI[>9TP8F3%KK@1G%*%:3T:4$=<12OG0LM*Z24927D_MNCZI: M.SF(`*025DUTVQR,RABJIF^_L:*DS`J>9^$3/^:_,2MPY73/*BJ_AM1[ZU:4 MT6]-+-Y"#ST-Y34IREI%M%O$Y.MPR4WHJM:##6`(J4-5([><7#ED;WW?W.'Q MY@13.I+7NJ<,(=#_`4FB^"BLHHX(O$166!R4UE%'"%P5!:8 MW%16$4=`2&29H*2IK"*.$`4J"]*MJ:P\CB8$CL@:"/K^8F\<^5S%3?DBN*BL M(HY\KO8%02OQEPA=-915QY'G"%.0):F,11][W`T'? M;S,JG_&&8,8G4HK8P3OB(YS)B/@HD5)$C<_ROF"6)U**>/'Y;0KF=R*EB!3( M(Q:9\(6X17F,^KQW34'O3NU%QKI\PN`X(P(#[O@_WWCPI*X0G_/%+CK!A3!B M$)[I%)+TY,R?M1G<0R@7Q/<''$9%!-V^K#P[L.,P>M7P0I-<'!_T@:"X/X5A M[B->@@$?10#]&9Z*!@](B(]N\.PL^,SA60)GEB*2[IQ-'-EY M_O%=RA!TS!W>>2J7P5-$\@"-[#99:?UY!S>:RIR(E[*0OH,%O`CPOVYBXD9L M183@1@P1(?=N#'*O7,06HPC*^+L=!=A;N*Z[E:,E%A67 MTD'UOW@I[D+&_![C

!^ M#F,F8J(7[S_B35:A%\,V+J";CVNX<2?\U3:1.]%_O9T.QS>WEG$VZDY'9V;? M&9R-!].;LX$YF][<6..NT9W]%UR&#UF\A*?T'?$00_:P1;B8KF=>KCUXU&&4 M&IN"_U0&UL[%E/;]LV M%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L# M/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=: MZ]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'- M)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J M6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^ M`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q M-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I M(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0 MWEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK M//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A M5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+ MDXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O M2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6& M`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RF MB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W M4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]< MQ+P]6.RJ=KU9GNV]147TQ*+-JF=9`2!=(.SB" MQLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K M.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]V56JFJ[FV?"7$2M(`C3#:[_[XS#!#;;+=T'[+AY/AP9CS,X.W7M[*P7GDM MI`WXEY?\*GNU,ILB5Z;UR^WZ)1/E%20. M>9$W[ZVH;979YMNY$G5Z*"#N-^:E6:_=7HSDRSRKA12G9@9R#AD=Q[QVU@XH M[;?''"+`M%LU/^WL)[9)6&`[^VV;H+]R?I?*=TM>Q/V7.C_^EE<7Z^-+#=2X@(`]L'M(X[A/QYSO,#5 M=9*/.&S@:$$M_D]02-[9GA*#%QC^0N)0@6)^(Q.(32!1`,T;W&AZPI$,):]Y M6PPQMUL=$D?Q1D#0EE.P#*#CZ2MBS%1*'#,R7Z$`G1$1X!!6;0*(`FF</AB^AWQ:H))`J@687&.MTJD@VK0:!G+20.5-[0[[Q@I7.B MGM,WR=@$$@70[#)XMJ;[;=FFX='P0$F846Z?7*.XHTY%R>X(251$-XQ397(M M,)I!6C=;&749=J2'GVB$Q",D41'=(4Z-Z0YIQD`[5/;7*,>0$4EU:"+QB).H MB.X0!\5TAS16]!R:#Q0CDNK01.*.HW8(8RL254:WC/-"L3RM;3&:,KKU47*5 M4=1VAZA;1D;;3F;VLKBC/.)-5$2WCE-#L?YY]\(W5;,GK,SYVY$>=X\ZQ&^? M.<_S?:-%Q*,EB8KHAG&43#=,@T?/L3E\F3FNH@X9NH1KM)%XM"11$=TPSHWI MAFG*Z(:-'A7"`06W0%%( M*Q,W/)',8?L&=#@M/$'.,126M@I]`TIT% M4%$U'8/HHA'7]C!Q$`T<7]JO%SBN&PO=V]R:W-H965T:JJ\\*R MRO@DLJ@0@BRRJX&MQM,IS(:)]/2E++6<\]JTL2G*3%!;%/1KR<$AB M$GY%RV:EE\CUP6%2^OYR^QS,X@L4O2I/JH14TCBQ?? MCKDLHET*<;_;DRANM>LO`_DLB0M9RD,U`CF+C`YCGEMS"Y36RWT"$6#:C4(< M5N:3O0CMN6FMEW6"?B;B4K+_C?(D+W\4R?Y[D@O(-JP3KL!.RA>D?MLC!).M MP>SG>@7^+HR].$2O:?6/O/PIDN.I@N7V("(,;+'_"$090T9!9N1XJ!3+%`S` MIY$E6!J0D>B]_GM)]M5I9;K^R)N.71OHQDZ4U7."DJ81OY:5S/XCDMU(D8C3 MB+C@OAEW1L[,LSW_`95)HP+/;56\T<3QIK,[O%@45YVF(*JB];*0%P-J#YR7 MYP@KV5Z`$(AI2)I[&"3_C3#L=)2*H*!X1KIX+>^1Z9#AI94(Y=5F=>+-. MO_:Y(0[M"%R*K0X$.A`R0/$(#^(>KWM#,L2@>)MKWH@SKM9NG&M!6P:$G,^0((&:;?B6-^*(9^B&L<.PXKA M>J)MZD?*">9/M&.A(7GUN:`E<'MM,.@&V[84-PI-1W(6)_QP;N-S3H3O;@-D&"`A!Q1G6(384YOU`2U M'#67^DELL[[4.-218,`).X0%[__BQ='&KL),WUD(U(M4\X/3F#6LQKR.!/7C M>;&$#=)L`SB>^V-1S3;VE\>-4U=2C>OOO'`/Q0JF%TM?L=#$<8,0-`K]'L"[ M;;#2%K5G0W9>^5/)JS_!P``__\#`%!+`P04``8`"````"$`>1,VCRP#``#_"@`` M&0```'AL+W=OB)%6KJENE3:JF?5P[8()5P,AVFO;?[_@C&2%+"C=)R'EY'Y]C^]C+V[>F M=EX)%Y2U*Q=Y@>N0-F<%;;[O^_&FY9_Q% M5(1(!QQ:L7(K*;N%[XN\(@T6'NM("Y&2\09+>.1;7W2F#GFX&>YSSWYSXXK9<% MA0Q4V1U.RI5[AQ;W*'7]]5(7Z#]'[[8B*[;]P6GRC+8%JPSRI&=@P]J*D M3X7Z"U[VS]Y^U#/PS)V"E'A7RQ]L_Y70;25ANF/(2"6V*-X?B,BAHF#CA;%R MRED-`X!/IZ%J:4!%\)O^WM-"5BLW2KPX#2($1L[\"J`:;HL%J#:`'.*K,(ZO/_ MS"`E]DF_"FH!T_&ZGL71TG^%$N96N3/7 M.9+#^9!L-'H>3D#1%)`20RET!\%1<,*$D8Y/3HE[ MS.1H:9@FG&EF%,Z"2TQ84N.92MQCI@.F"5OF++O(3*8PE;C'S`9,$[;,%%K= MA=JF4YA*W&/.!TP3MLPLO#B?JJ/WMLOUQ:K$BME?K,.%9#0&/$\NYCJ?PE7B M4VXZ7$M&8K`HC2\7&4$S&)^Q5I_NSUD\&]3:BLXW*!HTH^O5U>K>E`XK:^,F MQS"(DO3?I)_L432I`VEU#SNLK(U;;(KB]$+?0Y/ZD5;WL,.-:N,CL)-:$AKT MI.%>M?$1V$E=21VNU[:KC8_`3FI,Z-"9KNU8*S+L),UZY\_ILIK4G^#Z\N&F MM1ISZJ`H3K-DV!K-%<:<\!W>DN^8;VDKG)J4<&(&7@J%Y>8"8QXDZ_1)OF$2 M+A[Z9P4730+'?."!N&1,'A[4%>EX=5W_!0``__\#`%!+`P04``8`"````"$` M.'Y7K4\%``#=%```&0```'AL+W=OC%=:-P6K=B99V*9!JYP=BNJT,W]\3[X\F$;39M4A MN["*[LQWVIA?][_^LKVQ^KDY4]H:X*%J=N:Y;:\;RVKR,RVS9L&NM()?CJPN MLQ:^UB>KN=8T.W1&Y<5:VO;:*K.B,KF'33W'!SL>BYQ&+'\I:=5R)S6]9"W$ MWYR+:S-X*_,Y[LJL?GZY?LE9>0473\6E:-\[IZ91YIMOIXK5V=,%=+\1-\L' MW]T7S7U9Y#5KV+%=@#N+!ZIK]BW?`D_[[:$`!9AVHZ;'G?E(-BGQ36N_[1+T M=T%OC?#9:,[LEM;%X?>BHI!MJ!-6X(FQ9Z1^.R`$QI9FG705^+,V#O28O5S: MO]CM-UJP6*4-CF\![1)H>,@IO%

]Z9SGJQ\FR'`-UXHDV;%.C2-/*7IF7E/YQ$>E?:"!F13>T>%:[(D59 MF^VW-;L9T/F0M^::X7-$-N!LJ`[W,-;KO\H%=4(GC^AE9T)NH!(-]-CKWG4? MMM8K]$7>L?W MQJQT;19PCM?U+;'Q3R:$G##)BT0+F">J0:P:)**!YWA@(]\B%2PDL;`BS!>+ M9%GL6M7**0^=UI6_7"EQA/QW0:IH0+R5&GBL&B0JD`J`)`W6L/G2D"Q+4Q^` M@%.X-&*O;-]>R4D..4,0)YIXGD\<1[:(58M$!5(!D-3!8CI?'9)E=:Y:F8!S MIN!#%8A4(%:!1`52`9"BQ]V7,!;NKQ!(_FR%X!PA>A6(5"!6@40%4@&0HH=! M-#]Z),NYUQX:3N&=I3\"(?]YTA;=Y\)0_GFQ?)1+8GUM?\A)DY:0J$BD(;&&)!J2BHBL!J>NH.:3QXC/ MZ$\:D)-$%2H2$16)-231D%1$9!4X8.>KX.-8K(6^(\(7-%@4114J$FF<6$,2 M#4E[9)C2TMY)5H6#55#5O9EX^([XV6K')[(L4![K`>&<.UN^@0&/T[C<.&ME MHQ[U+(AI(BD[JGB6IV3T-.SY4Q&1,X-#6\C,)UW+1[R8#G>EK`D!$?8!W9XX MU)!(0V(-230D[1&8`?A6:"^FL2-KPE$^7Q,?_-!+0[8"HD&A#D4Z%.M0HD.I M!,F1XZP6(L<^=:$A?O8-FH]\L4Q:NP5P3H./)7;&U&^>LF<-)]:0G4B'8AU* M=`A/AOH[@B^NFY_T\$.$DM8G&M++I3%R]H*G.&NH\XB.)TR/2ZR4@@=D`R_T M'^#+3?@1/UINX,U8YS^2!SC">OC@%TC8<+AEC3>'PZ5K=J)_9/6IJ!KC0H\0 MMKWPH&8U/Y[B7UIV[8Y'GE@+QTK=QS,<(U)XO;470#XRU@Y?,#GCP>3^7P`` M`/__`P!02P,$%``&``@````A`$]-7DQ+!```NPX``!@```!X;"]W;W)K/NG+>:M^^_MULG0=WF7-(:M80[?N)^7NE]W//VVNK'WC)TH[!QP:OG5/77=> M>Q[/3[3.^)2=:0-G"M;660>'[='CYY9FA_ZBNO("WY][=58VKG!8MV,\6%&4 M.4U9?JEITPF3EE99!_S\5)ZY=*OS,79UUKY=SI.PV)=5V7WVIJY3Y^NO MQX:UV;Z"^_X@LRR7WOW!G7U=YBWCK.BF8.<)T/M[7GDK#YQVFT,)=X"Q.RTM MMNX+6:=DX7J[31_0]Y)>N?;;X2=V_:4M#[^5#86T89ZZ;/\7K6C>T0/,G.O@ MC.P9>\-+OT+)AT%X+\!!^+]RF)<`1_'4,/IO.>1K/VU_M,Z!%MFEZOYDUU]I M>3QU,%($,6`:Z\-G2GD.TP!C38,(77-6@05\.G6)SQ/$F'T(NO+0G;9N.)]& M"S\D('?VE'>O)5JZ3G[A':O_$2(R6`F38#"![^M@$DQG0;18/N,2#B[P/;@0 M@%Y&))H_P3(;7.!;N@#6XQOQ1"A]WFG69;M-RZX./.UPV_R.TQJ/BABH8!/I2"F(I$*G$$T3;6" M![0*&6Y61_[Q4(L;2*UBE$K&(SXSZVUE\=/'(I-1F)-6RPD(C[1:(C=1Z1$L6D%@PW:U7@V M%%ML5E^(A60^]`W?M]9M(L[?UFVJ%0PP`DUB/%FOMM!N#4FTC$%CY&;C*8T* M3J^8@-B:1T\K$8U<[R3$;B6#1JS8P"=W<,)#"T]=`;@F'/;G\7"BFQMP5A>+ MB=`8Z5D=)U&:6WKRJCM`;,_C`5%M3:_=5(C0/`:4FAN@5C$3Q"X]'E#T=#!3 M?P-VOXB)[/LW36`M[41I;H#RJKL$X4Z?`$2UF6!@-8T87RA!HR<86.L[49H; MH+SJ#A![]O@$18?7$PSN5K#V+]"OZ838E72H+/H.%(:+9;"Z/H$[`+.V9'^GK7'LN%.10NXU)\N8-9:L8\0!QT[]R_" M>];!^W__\P2;1`KO5OX4Q`5CG3Q`0+7MW/T'``#__P,`4$L#!!0`!@`(```` M(0!#(22KX`(``+('```9````>&PO=V]R:W-H965T'3!@%6-D.TW[[W=M!QI(UX4' MP/;Q\;GG7B[KVV?>H"4TY49[H:`LKI9"<:!C*RE>=I*2P MFWCC1T&0^IRP%CN&E;R&0Y0ER^F]R`^VX[N*#G+)="B5)[0.<[H9E1G[TC5XOA)LN(K:RF8#6DR M"=@+\6B@7PHS!9O]B]T/-@'?)2IH20Z-_B&.GRFK:@W93B`@$]>J>+FG*@=# M@<:+$L.4BP8$P!UQ9BH##"'/]GEDA:XS'*=>,@_B$.!H3Y5^8(82H_R@M.!_ M'"@\43F2Z$0"SQ-)F'J+))FEB_GU+/&)!9X]2^1%BR1,TO]K\5UF!XD)QXA=CS`)!7F#1O#M7./;N>NE&+"18G)IM&W=!'`/VJ+)N6\@7L6/ ME(!#URLQX`S/S@Z.9_/QT5N'<95GU.[.)D8G`\WYR29/,7P-[WMA-@%NI&`Q M4>`P\]!F+?""U\BM?3NW;A6.!$'AG@MZ7X@!3X4L)T(E8S'7NF$T34,Q4U'XMZWR$#GHJ)Q]%O'69N,Y7`-5Z& M-FHHAN57F2YOKD>ZCY]36=$=;1J%ZFW1-UPVTZ&S+V0L-S=*^UO!OI%#Y@0?@4@C= M#XR=P]]V\Q<``/__`P!02P,$%``&``@````A`-^O0PSC`P``&PT``!D```!X M;"]W;W)K&ULE%?;;MLX$'U?H/\@Z#W6S3<9MHO8 M4G8+M$"QV+;/M$3;1"11$.DX^?N=$6V9I-34\4-B#8\.S^$,R?'R\VM9."^T M$8Q7*S<8^:Y#JXSGK#JLW!__/3W,74=(4N6DX!5=N6]4N)_7G_Y:GGGS+(Z4 M2@<8*K%RCU+6"\\3V9&61(QX32L8V?.F)!(>FX,GZH:2O'VI++S0]Z=>25CE M*H9%G4I:2472T()(T"^.K!97MC*[AZXDS?.I?LAX60/%CA5, MOK6DKE-FBR^'BC=D5X#OUV!,LBMW^]"C+UG6<,'W<@1TGA+:]QQ[L0=,ZV7. MP`$NN]/0_>MDNT$]&ST+[[H@C/__=L/PKJRBL-N0),[#C_!FA M7W(,P[^VG-@/?&R>G>W(JY+_\_`]EAZ.$=$_`$1I;Y&\)%1FL*-",P@DR M9;P``?#7*1F6!JP(>6W_GUDNCRLWFHXF,S\*`.[LJ)!/#"E=)SL)R"&!-RXD03@*YY-@,OTSBZ<4M083(LEZV?"S`U4#D>01659N[#K@0D!^7M91-%]Z+["FV06SZ6,"$[&](G`!D3:Q`ZD6 M\,!`YP+61GK6`2CV.LT&Q4`[DY]:"D;0$Q-2-*'1%%L8M(!S-CO,(:C MZ"..$+QRQYJ!*+0L;!1&529MW8@L0.I%C"TX;6LG7GO%P."_[2W%$;39@<2 M.Y!J`4,;G*&ZMOOV%KYDKY^]MQ1&97X@LUM]//#Q8Y9&H@,F\P%$JA!0R]TY M&MU(#)ZS?=3T*)-?\'4KH\+2$M"+Y+T(NDEHI9EVIKZG62\>^ZNFD#= M5/IQUSM#+A@U]\/`*=(#6+LY,0&1/YO&%B0U(=`WPJ=+K)D3O)WN-ZCN,MU@ M,+LQJU,R4"`])W8DN6"NJQ#%8>1;YWZJ\YB:\8JZ7S.BS3KJGY#01R)(74)# M1Z0!&-A)B0$8VDK8J][FL/>2,JAZ4=6JE;0YT"TM"N%D_(1]9@@73Q?M>N#' M$'L:*[[!WACC7C<`K6E-#O0;:0ZL$DY!]T#ICV:PNV0=QQ"4UI M^_4(/T(H=`_^",![SN7U`2?H?M:L_P<``/__`P!02P,$%``&``@````A`"8D MP4?)`P```PT``!D```!X;"]W;W)K&ULK%?;CMHP M$'VOU'^(\EZ"N2X14$%6VU9JI:KJY=F;&+`VB2/;++M_W_$M:X=T"U5?@,R, MSSF>L2?#\OU354:/A`O*ZE6,!L,X(G7."EKO5_&/[W?O;N)(2%P7N&0U6<7/ M1,3OUV_?+$^,/X@#(3("A%JLXH.439HD(C^0"HL!:T@-GAWC%9;PR/>):#C! MA5Y4EUXDBP20ULN"P@Y4VB-.=JMX@](,S>)DO=0)^DG)27B_(W%@IP^<%I]I M32#;4"=5@7O&'E3HIT*98'%RMOI.5^`KCPJRP\=2?F.GCX3N#Q+*/84=J8VE MQ?,M$3ED%&`&HZE"RED)`N`SJJ@Z&I`1_*2_3[20AU4\NAG,T7`QG@/*/1'R MCBK(.,J/0K+JEPE"%LJ`C"P(?%N0R0O&*^O&=AU\VW7CV6`Z'XX1:.TA3(QX MG8M;+/%ZR=DI@@,&\D2#U7%%*8"Y)!CJ-BU_R@JD0X%L%,HJ7L01;%A`*1_7 MH^EHF3Q"^G,;LSV/06%$YB)4U4!>JQ&2\Q\T*A2E4552B=XZ@R>Z(\A%=`5! MHGQ!_2?&Y48%K^))D)MQ2+0U,7#ZG+C,MP3)`*#+N54P5'86D$\ZY#8(Z;K- M0V=FG&-H>EYI7Q`":7#R+I>F@K4TM^6MM7A)\"T!$VSH-M4_O"OUEQJKZ,Z)LB:?S3>%->XT)?4J_8<+K)IU M5T;;G?PKW.W4;J&7!S/[F/=]1?B>9*0L192SHYIKT!PZ?FLV0]<6S=S4=>89 M@D>/5&<>-:GIN>;,,P+/2+W5SCQC\(Q[/1/P3'H]4_#H[7708%3<]+/`@CXD MD-4;#Z+Z-&TFZ<9)^@FS6[Z[(LTTQ-+T@+! M"-K@/?F"^9[6(BK)#DHY'*B9DYLAUCQ(UD")81!E$H9/_?,`?S8(3#[#`03O M&)/N037]]N_+^C<```#__P,`4$L#!!0`!@`(````(0`!T%JCD`\``)Y4```9 M````>&PO=V]R:W-H965T3[:KM;;YX_G!;OSD]/5L^WF[OU\Y_KW:G?_OXU[^\_['9?MT]K%;[$_+PO/MP^K#?OUR?G>UN'U9/ MR]V[SVWI]7S?G"R73TN]]3_WGF[?XNYIN?WZ[>67V\W3"[GX MO'Y<[W_OG9Z>/-U>NR_/F^WR\R/%_5LQ6]ZR[_X/W*WNE]\>]__:_+"K M]9>'/0WWG"(*@5W?_=ZL=K>447+SKIP'3[>;1^H`_7ORM`ZE01E9_M9__EC? M[1\^G);EN_G%>560^Q'7WR"=\8 M8D&%.-1%J,AAS(\&>3;455^FS7*__/A^N_EQ0G.?*F?WL@PK27$=O'*!#N$> M2O9G%4NE&KQ\"FX^G%(@5(P[FF;?/Q95\?[L.TV-VVAS,V*C+6JV"/,@N&UR MT.:@RX')@$&BPUH%&87 MHCFMS!,O1,&-SD`D=.)D3L[T)*L/1CP5&B`MD`Z(`6*!."`^)2HI=$%523F^ M\`9K'7LDR>@#:8"T0#H@!H@%XH#XE*A`@_28$&EOKD-EE$QI1`VB%E&'R""R MB!PBKY"..>B.M.2/CVXQR!2ZN'"-WC!*QA=1@ZA%U"$RB"PBA\@KI&,.$B.- M.>C-ZC+<_$R=Z<6@5E0^(M)S?9[-=6XHE=(@:A%UB`PBB\@A\@KI%`4MDJ;H ME;*(TB4MBU3-]$*Z+@`UB%I$'2*#R")RB+Q".N8@B<"3%'693&?%!*Z>4\T\QU4.`A9JF&!E&+J$-D$%E$#I%72*],R'F*(_2F%/%%&,&U!2`6D0=(H/((G*(O$(JYG*: MDNO-M9*+:);<($=4#?N:_=80HI8;4C82J7^A+_^=6+&.,H@L(H?(1S3T2Z=A MFK@K4=Q%I-(P6*DT`&JY89J&XC+;@>G$2M(P^)K)5I5%*X?(1S26AESO'1[Y.#"0#X,:BE1,4/6<[/%X,R+,NBVGB MKD1Q%U$X15+DE[K(:['BV!I&U>'^H64T.Z".D5@91N7!RC(2*\=(?'E&O95. MPS2]5Z+>BXA&-TW#59Z&H:&JE`.2AL4BVZMNQ]P7"YA#!U^<92,-&5E!1\[H MQJVR,WJQ@LH*,N_MUYIPPY5M%D2D*ZLZSU,Z-"0K#K"1AHQ:06G,632=6'%# M@\@BM\G5:K`[)0F0%'3FC&[?*SNC%"O(71.K;BRW,O^PZ MQRBY=T;4(&H1=8@,(HO((?(*Z9H)LG1"S(.*I?T''JZ;*B+9$*D1-8A:1!TB M@\@BX.JFQVU=7!B@ND0=0BZA`91!:10^05TFF8)F4KE+*,9)QK1`VB%E&' MR""RB!PBKY".>9HBK5"1,DJG>+02U*!5BZA#9!!91`Z15TC'/$UK5J@U&4F` M-:(&48NH0V00640.D5=(QQQ4U(0I/H@N-<4C$FE;T[,D_45.4!-1$/JR$)39 M7E@K5KP0=(@,(HO((?(1T?<^&C`Q:640.D8]H M)#NS7"/VV:&'$6-R?MV\],EY>Z9ZCUI&,I*TU(B:B&87/]E%:\6`,]*A&X/( M2L/Q730G!NS9*S=J7LUR69@7%.=LI*!HGX`KJG>3Y6E0D$&I'&JEK+(MOSHV M)`W'G6T8I0UQIRE:S5*KLLKW*L=]95][&;:23EA&J7OHA!OO1/;%N1_W)9W0 M`T)G5#/\E<0'\RSQ`PJ[B$GBY73#UR$A<=0PW8]B))7=1D37WU!LE[,BBZW# M-H91LJW`2#P[[?FB*++*\*J-3M$TB3M#B1M15IO9*E^SE91%PTAB:QF%Y?7[ MQWFUF$&.A@[0V;C<2UY:16#E&/W7MV:)OI).4:^)\8K_I2C%#J1Q15E[Y M1CI;231-1-1E3D/+:'B"LSB?E8ML*[IC1]+*,!+?EAV)E6,T^+ZLBBIS[=E/ MWT@G+U?2?_Y"@F)[-J"L"+-.UFPEE=)$%#X.$QS6IC9:S>F:F%AEMS0=NY=< M&D9R1AM1^$A\99LB+EH=/Z-G]R,E&V3W,7'SQFM15.^B-6YF$27W-8@:1"VB M#I%!9!$Y1%XA78'3-#[I#+@,1)1H?+82U"!J$76(#"*+R"'R"NF8IVE\^FH3 M8HXH'6=`#3<4JQ91A\@@LH@<(J^0CGE,T/^Q!_OH^V?(1T14"H=Y6\[R_6%N MF);%H:&LU8`Z;&@0640.D5=(I2BL)VI9.*Z(>G.MB!C)@->(&D0MH@Z10601 M.41>(1US+LM?B7G0VND-77@&/`A#&=0:48.H1=0A,H@L(H?(*Z1CGJ9\YZA\ M&:7C'*T$-6C5(NH0&406D4/D%=(QYU(V"(UR'NY8)S[`/T>5RTC/_NRJ78L5 M3_4&48NH0V00640.D5=(9RC7L:_,!!2L\XBD!&I$#:(648?((+*('"*OD(XY M*,-4"+T249]58Z%T&%Y253+OH?@KPR8Z)^2\MD0/H.=);=(M;S M:"7W@PTCNK@>="7>@4:KL)%SL"IGV3Y/-^XKVZXR;"6=L(Q2]]`)-]Z)K-+] MN"_IA!J#Q31!VIOKY3FB;`]%3C=LT;&5E$_#2,JGC2ANT147U56^_X2-#"-Q M;1F):Z==7UY=9G<.7K71.9HF8!W1L)771,)+86D;#1EHQ7U1% MENR.3:25822^+2.Q=FGHW60)/&S:IHM75C5U;)A^?<%(2J2-*%L(LU+N MI*&S=^QFR3UK,O&H+#`IV>49?J-"&^0"$>45)M-:*& MD=1(RTBND!TCL3*,)/&6D5@Y1N++,QHIKR"0__STC#([N?(N!J07MUF^]\M6 M,M9-1'07S6/=,BK[&71Q/E_DCCIV)*DQC,2194>"'*/!]^*\J/`:<`B%>J0K M)I?T?WH7?8&J/R*]T,VS"U7-5I*`)B*Z\Y1,#N[#C5DR'S(]U+$O:6@8B7N+ M[AVCH^X]^QJIQM=N%]ZXV.']PB*BY!8948.H1=0A,H@L(H?(*Z1K*[\G."Y^ M%ZC]&26WBX@:1"VB#I%!9!$Y1%XA'7.N_5^)&07_(J)TG`$U:-4BZA`91!:1 M0^054C'32\9P!?Y#&V2])WV-9T35?YCOY3Q3;[58\4+1(&H1=8@,(HO((0HO M6Y/MW"%#P\O3AK=2/:VV7U;UZO%Q=W*[^19>C$9[RQ_?'_#PUK:;^?PZ;,%0 M''!D04?Z"U1^9'%Q'>;A2)O%)1WI?VT(;:[H2/]SN/S(Q3F_."X_,J,V]"7` MR'GFU(;"&3M"KZ$;+H6YMWE)1_KE&(Y4=*1?7.'(C([TNB`_4E'>Z`9KI`<5 MY6UXJ@G:4-[H>;:1-C-J0]_\C1VA-O3]V-@1RC5]BS1RI*!>TZ_EQXY0K^DW MY6-'J`?#EP5YKPOJP?"=`1RA'M!/=L>\T"IHI.GU&&-':*3IK1!C1VBDAZ?$LEAHY^LZ;&YA&]JYNG:C1^B-AY_&ST(G M&?%T0]T:M:=.C57?I]GU)YKDV*6;,&?'.(WA:!'1"(Z%1C_SO0Z_Q<4ST"]? MZ/JGA;)\_Y& M>SN\7W+X8Q^?$?R\V=-[(>EZ0>_VH_>`KNBU>N?A:YG[S6;/?X03'-XL^O%_ M````__\#`%!+`P04``8`"````"$`MC\_^X@%``"?%```&0```'AL+W=O5F: M9#0V#7K)RGU^.2[-/[Z%7V:F43?I99^>RPM=FM]I;7Y=_?S3XE96;_6)TL8` MA4N]-$]-<_4MJ\Y.M$CK47FE%_CF4%9%VL#'ZFC5UXJF^[91<;;L\=BSBC2_ MF%S!KQ[1*`^'/*-!F;T7]-)PD8J>TP;Z7Y_R:RW5BNP1N2*MWMZO7[*RN(+$ M:W[.F^^MJ&D4F9\<+V65OIXA[T_BIIG4;C\@^2+/JK(N#\T(Y"S>49SSW)I; MH+1:['/(@-EN5/2P-%^(OR.N::T6K4%_YO16#_XVZE-YBZI\_TM^H>`VC!,; M@=>R?&.AR9XA:&RAUF$[`K]5QIX>TO=S\WMYBVE^/#4PW!/(B"7F[[\'M,[` M49`9V1.FE)5GZ`#\;Q0Y*PUP)/ULG[=\WYR6IN.-)M.Q0R#<>*5U$^9,TC2R M][HIB[]X$!%27,06(O`4(L0=N?9D.GM&Q1$J\.R[0MRQ]T1/7*$!3Z$!?7HP M"\BWM0*>HNWT^21@7K4B\'RZ`W/1%IZBK?=P!RP^KFV9!&F3KA95>3-@[L'( MU=>4S63B$R@O62!\.+N2^:>*@5)A*B],9FE"SZ`8:BCSCY5-)@OK`THS$S%K M'$/4B(V,8'7(9`,=;'40ZB#20:R#1`>[`;#`ELX;J(W_PQLFP[R16:TE&)BE M&2$C9)-`!UL=A#J(=!#K(-'!;@`4(V#*(2,<*);[JXBL"=9J:<)4&]2$IR:Z MYC&P(LE,-X@$B&P1"1&)$(D121#9#8EB`:2A6/#CU%DTS"A/R7VJY2Z"2#M= MM,FRZ;XF)OK'HMF_2\K4@@T%`)$!DBTB(2(1(C$B"R&Y(E$3! MSR<29=%JHH(,$D4D0&2+2(A(A$B,2(+(;DB41*=/)?D93*('FE&=OZY*?+NY,-P?F#=]\F(B:OR!.OZP@ M$G#BP!ATZQ.9V>H=,T@C0B3N6K5'A#%Q5-6D^UZJ[H8: MBD_LM(*-FO2U(YVZ4SMP9)3%T\JH]@CD,)?[X\Q,[>JFCY)]#22"?;1K2#SM ME+.54:R`/U;NE$S&JG0H(^RN?B.)^,F:'8YBB7[XMD1&\;<1S]/?MI,1[=M4 MB]G):#@]_\5*?I"";4\ZLB8*).JE8XEZZ425)HZ-3>H2@=Q4D]BIZ0F3^"%+,8DCM=YL+;D-Z:*D MNX%$?7);@5P([@PGGK:LA;AA)-&PP,0;>_E$1O%JLFV7:--B)R/:1JI1['`U M-(K_UN@G[$.+/:R8^G(FD#W,V;:U:;?IHWK_N);;5\)61+EN6V3>>#K7%KY0 MZO2-(HEZHV*ITTO=?=@6X=4`^<@1U*!W: MB*@!"@1RV88D5\<[BQS7M0B_+G[H=8F,XJ^;S1RB31]V MR\+R=09UR6]-^,_A@E9'NJ'GR;.0']H+N:G'U-P```/__`P!02P,$%``& M``@````A`"WQ!6S2$```>EX``!D```!X;"]W;W)K&ULK)S;;ARY$8;O`^0=!-VOI3E+@NW`ZF;S@`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`>"`A)RI0RO"(0*.U#C21 M+%`@+1`#I`-B@3@@'DC(B0IT-2K0:*T#320+%$@+Q`#I@%@@#H@'$G*B`HV: M\4_8B*(;G8%$J)3D?'0YT8NL.1CQ4FB!&"`=$`O$`?%`0DY44FA#54EY_<0; MK77LB62S#Z0%8H!T0"P0!\0#"3E1@4;IH2+]61T2_>@<]*X)Y04P*\[)C1@= M"@"10=0ALH@<(H\H**33$R5*OCI>+X3)H&AH'^)HKAEEI8"H1600=8@L(H?( M(PH*Z9BC&LEC_MF2&%2-2D9"LT-^FLF`)#UM(JIN)A>%4C-BQ:GN$%E$#I%' M%!+JAZ6S$Q7+GY&=I'SR4DDHS\Z`\NPDHT6O6:;GDT*VF,G!0!)3>K')2/PZ MZ18O(LCO3)^IO1BPWY![T4F*VBE/TI%EDW18GHNDONC$E>T>11$TD]11,M8F M-!5?!E&''2TBAQT]HJ`ZZC1$&34B#4EUR="OXR*@TZK,4Y,(I9ZGH4U(A3ST MRU"''2TBA[X\HJ`ZZI"CH,I#CB>/&6T.1RH@Z;`\]`%-Z92:54!1E4V4_)0@ MLI)T'%#6<5D(#\,=>1V=T_]TQ7=L(KXM(B?HE<-YMGKY<(%-^L/II$;QEB?U M2#*3ULN3.:#I])"F9@*H922U91C-#QT[1F)E&8E[QTBL/"/Q%1CU5CKFJ,WR MF-]82$G2Y;$/J"BDXK393`Y64DB`#%L-T[A:5(H&.EGN)'7D$'E&+[H.;%$I MD*CO\F0=*9`D!_,D#6C>WY?L[P$UDP%E-=,RDDDUC&12.T9B91GE!9+9&D0=IFU=`DJPRUC&12#2.9U(Z16%E&68$P$BO/2'P%1I4" MJ>G8.6V,KR\."J>\DDDH'BK;BA9ZNVC$2@ID\$4=&1FV>G&9=VPAG2PBA\@S M>M%U8(M*@42)^/8SR#2)S.P,DA`=@F-M$+6,9%(-(YG4CI%864;BWC$2*\]( M?`5&E0(I5>K;MI@IJM6$B@)9E@4R=,RJH96.G#3#:)C%V7Q%S]ZTHXY-\@H! MWPZM/*.7?02.[`%I4*&:=3IZA3$U(5@CHU666S M:AC)K':,9.XMH[Q"DGNQ\FPEO@*C2H5$O?<3%3+(1%4A!^68[S+%P[QF>K#B MBFX1&4:I0J(,@9,(.++<2XK&(?*"LG$NBTOS(%8T3J7LIU'XY1D[LA\/.E%E M"I1ITSM5IY86D6$T&9Z4GB_.+W'E#,ZS$K3<3<2Q0^09#4,@FJVS*6T%YD9I6Q5+HQ(IS;A$Y0:\MBB,&L2H7WZP4 MQ:\OOMZ\R%_2Q]D]*;82U"(RB#I$%I%#Y!$%A?3:*K5MW,3C+:R1[UK,4/0R MDMVC22C/1>I'1Y3+![BAS:ZD8X?((G*(/**04.]=9Z>F@G\F.RB+9PGEV1F0 M!-FR41(<>$-;#'CY=`F)%PO$2;<7;FB+`?L-N1>=I*@CW[YGS0;9F>]9"92U+[M$F"&XC8AM4/3@Y;B$D"LN"Q; M05([$[BCS59I(<5[3]IUQQ;YEIWDKR`G5J\CXOFB>*Z>4%%&A01HQ$K*:/"5W7\P;#7,XB3>SX:B@5Z6>^5%`U:>K5[V M'=@$2X2TF$[7ZSJE-]4;B*S#" M$IF7VO9M9YJ^6Q%[TKCT)]MLB@OY)G7,ZJ%%9!@-TUA[Y,$64@X6D4/D!>C( MR+!5VDNJF8->EGM)V3E$GE$Z"U73E/O6:2JU\9$TH02>#TB=A0:D"NR`7IEQ MDWS%$\AA5<-RZ<2*\VL1.4&YKZ*D?=VJV&J"6-$1=?[&R>:X'1:;'2.1^@VB M%I%!U"&RB!PBCR@HI&,N-7)_M7E.)YHCQ8-B>9Z05'@C*%[5_%),6,O-5$^' M$IF>R[-N/=)2V1X9("K:>4+Y[`!JT4Q`VJY MHU@91!TBB\@A\HB"0CKF*#3>OA`7@RY1,200>41!(1WS.-6S1-7#*(\9A%"+5@91A\@B MU=7,8O:!RY(ERB[$DH MWP/9*NV!N@E4'4(;*( M'"*/*"BD8EZ56N?->V#?4Y]Z$\K7(5NE=2A7>\,ZE.9L'4[DJ:<>ZSB-LD*- MPBB;'T0M(H.H0V01.40>45!(QUQJE-?7X0J%":,\YF0EJ$4K@ZA#9!$Y1!Y1 M4$C'/$[WK%#W,)(`&T0M(H.H0V01.40>45!(QQSU2*Y[^FO">"?GR(0G'9.] MV+\:D%J%R2JM0KG62ZOPT)RO0GF00>41!(1USJ7KZ5?BF!Q4K5$`)J868K-)"E`N_M!`/S?E"E,<9 M>K#CY,H*Y0HCF8T&48O((.H0640.D4<4%%(Q7Y1RY?6%V)MKC<(HBQE1B\@@ MZA!91`Z11Q04TC&/DST7*'L8Y3$G*T$M6AE$'2*+R"'RB()".N92]O0+<=Y_ M8?'(CGB!$BBA?"&R55J(B/-'0@QVG5RY0KS"2V6@0M8@,H@Z1 M1>00>41!(1USE`RY7CFR$)/"R&3*14)YS(!:M#*(.D06D4/D$06%=,SCE,\% M*A]&>@:A#()+>2-]&^MA;R12JRUK*BE?Y,?O%U22_^MS[+EXIS&UK\"6;8L M:01TO[!RG"4=A^Y4U5HNJ*5_#P2\T0CHKD>ESXIF@:ZW:RU3:NE?/BV]+6@$ M]#ROTF=!QZ')KK0L*5)ZWE)KH1'04XE:"\T/W1NOM5`=T!WD2LN<1D"OWE1: M%G0<>N>CUD*1TIL1M18:`5UUUEIH?NC9=:V%*H2>\%9:)I0#^IY;K87&1E\] MJ[3,:&ST\[%*RYQ&0*_ZU5IH?N@ULUH+50B]C(4M]-7H3]6CQ(%5[*]I6%5[ M2E@M7Y_F5Y_JBS#FL78`RF(UB7&5U>PILEI@UU0/M7)H9[.K^%LT3`7]ZNO* MT*^ML(5^MT5]:BWT2RCJ4XN#?M=$?6HM]$LBZE.+D7X71'UJ+?0!NJOX23@< M6SN97<7OJV$+?3Z-^M1:Z(-DU*<6CZ.6^#TQ]$9?]*(^M7CH^US4IV\Y.YPQ MZ,O?3^NOFW^LG[_>/>Y.[C=?:#LX[Y\I/@_?#A_^L=\^T84)??5ZNZ=O?O?_ M^8V^\;ZA#SZ?QQ_X'#>KL\-7XC_\7````__\#`%!+`P04``8`"``` M`"$`IFCJ42H#```Y"0``&````'AL+W=OI;&=TMF_/Q%L/@;*RD4 M&]JD&W#@_*A-'V,-@3,>>3_4#?@AK)@FY)2KG_S\E;(T4]!M#Q+2>?GQ2TAE M!`4%&MOU-%/$F.9$5 MG:3BQ=_&RFFY&A:W98%GQ[(R6-[QG+:>\&P]Y_;,]19+!^2^%W+6.L*S=9S. M;6\QF;[AB)O$ZSJ&1)'-6O"S!;,)FGO14.C_(%JS:-%= MN%T'O&;A7BCL+#J7T``&"J&AIL+K\]A53QL'"*IO5,\;1MXU-C#;7>C]"`E- M9*`&J&]7HXUA&N8#.?,+.:U1+U<:U MV*XLNQ8Q"C5"0A,9Q(:D;X^MC8>Q6\2(/4)"$QG$7GPDMC8>QFX1(_8("4UD M$%NOP\M;8`)5^N`UH&F&JEH$J(S97@RG8]\;=4V$E5$3USX?Y&MOOYC[T_@J^\*$O5_!ENSEQ'P`V5T52^IV(E)72RFD"J4]LO:E$ ML_N:%\4KZ`*L+ZY@9=5?,_B+0N&83FPP3CA7W0L$QOV?GLT_````__\#`%!+ M`P04``8`"````"$`+OOZ#?T*``"2-P``&````'AL+W=OT`)%<7=]]CI*8JQM M!;9WL_O?=T@.Q1D.G96VW8?+Y:,A-;_(+ZW(M[]^V^]&7YOC:=L>[L;%U70\ M:@Z;]FE[>+D;__&[^64U'IW.Z\/3>M<>FKOQ]^8T_O7^KW^Y?6^/GT^O37,> MP0R'T]WX]7Q^NYE,3IO79K\^7;5OS0&N/+?'_?H,OQY?)J>W8[-^QGN#GVF:-]?MYN&M5NONR;P]E/C_>;FMY=#>UQ_VD'VN?S%4PW\8[*F*\GUQ.8Z?[V:0L1V+2/CLWSW?BAN#&+:CRYOW4)^G/; MO)_(_X].K^W[WX[;IW]L#PUD&^ID*_"I;3];T]^>+(+!$S':N`K\ZSAZ:I[7 M7W;G?[?O?V^V+Z]G*'<%$=G`;IZ^J^:T@8S"-%#N)0Z$GR&&\FI55>5BM808/A@) M5UWT\#.,G$6_/QBXP('P,P1\M2RFU_/\#2<^ZZZ(:GU>W]\>V_<1K`Q(Z^EM M;==9<0-SA>KY.W?UO%1.J("=Y,'.^'H^@4"?HP:_W136[G7R%OMF@S6/& MAEO4P<(6UDZK4J!38`B80$1=6-`'_X>P["PVK.#08P`QSB3*.EB$(2H%.@6& M`!8#M"&-(;^@0@6L\=T8&I!48,[S^^AM8'$&YVI!E"!:$$,)\QANW]]C:PQ= M!TU'7"X3E]'(+W;;$W5';)D'J4>)H:FGJN..!W4AD))(2V08XFY:!>GO)NH-=1-1;(>Z$$A)I"4R M#'$WK6KT=Q,UAKJ)B+HID++G>+N51"LMD6&(NVG%@[AI&WD!6\70/D8-HOYW MLD3[>)GV<6<5^U@@;8\@/$K#$`_)Z@T)Z0=]C.I$/:>"A7TLD"H$TA(9AKB; M5DKZN^F%AVT4B&+IZT(@)9&6R##$W;2*TM]-U!^:32I)F$V!5"&0EL@PQ-R< M)?+VDY^2W#1<]P*"A4;VXU72Q]&JZV.)M$2&(1[2("F<22D,B#2(1$HB+9%A MB+N92.''RVTF!2\@ZJ94-VFE)3(,<3<'J=M,JEM`U$VI;M)*2V08XFX.4K>9 M5#=$O%NOTV[%D`HK%T@&5W4`34*9;!HG?3(H? MHJ0,R>.4.EJ%8)1$.J#*/19;3-T_7A<3;-QC#IYQJUS],XXZ1S/N$"N"5+"B MY4`K6@Y$F7)8.>R];-*//XAX&9:I$$>K6(9.B`/2T8J489EHL\E:+2Z5 M89`0VV>5:1F$ZM9HQ=*(AV0 MWX>*[#;D/?`;&H_$2E__AO)"R1H*M3,><^JY0"H@FG"TH@E')/N^_"D==J/X MKHDH27QZ`HI67>(ETA'1_D\TW62M+O5_.4B'G742GY=FTNPU6A&D`B+E"(B4 M(Z!,.0;I<.FUDW8-HJ0,R1&FCE:Q#%*'@Y7O_^NR+!-5,<%"JG!IA:]W^SOK M)-]"YNA@1?--K=@J+7]*A=VHQ-V<"B_C9NR?-.%`OUTXI"32 M$='V3\Y2)FMUL?VM\/4OAY=)UE>HG&0W*@52`='V1RM:#D29]A^DPJ54841) M^R=M6T>KV/Z="I.<+Q+)U6&@7Q&KU>HZV>!,L,BL""MZ_4O@)9*5`!%YXE,* MI"32$AF&^(I(%/@GGUR64IH#@NIWCRKFZ0$I&L72X%0Q;BVM#$,\(BM^_1/O MI9(E'E%TH"X%4A)IB0Q#S,WJ@A(/_-.'FX;O30'1Q!?+Y%1?1ZLN\Q)IB0Q# M/*1!HEO)#[\!D2HAL0=1.M(E+22DMD&.)N#I+4RFL> M[>.`HD^U1$HB+9%AB+N9D53[![^A?>P%E?F/B/7Q*MU!JLXJ]K%`6EH9AGA( M<,?^.TAEK9,5B(AF7B`5!D8K+9%AB+N9J.=/;MV5E-6`P.?+6WZ77Z+57+ZJ,/` M>+I282`DM1MXG9SV=30*A3%L*AY+HI:^B:[L2Z+GU^WF\V,+-X*=.A/C'!Y8 MNT/M0R5%%)%];MQY6JS2#^9A(`W1SV6?=I"!R;E+XT"PBC&B$_*8:=\HH.LY MC?'W]NU2C/"GG!"DFX6OPNR$=$L0KI&308T"KX:5@5$%VN M`AW#0["JVS\$U&@:`B(B*/!=":?W$2F)M$3V2Q9QH'?3?VG"OV^_;XXO3=WL M=J?1IOUBOQ`!3[SN;SOLOZWQ6,UO[&D,>E1<*>&*^]PMKE1PQ?DKKBS@BHM7 M7%G"%?=W[O3*`F:#6#(>E#`&/FKFKJS@RBI[Y1JNN#?HT_M44_#`?;=$7(&O MK,#Y/G.?:@97W`I.QQ3@`;QGE!E3@`?P:D_FR@P\@#=D*6`,O!F9N4\!8^!EQ-P5J#:\_Y>[`O7Q;^2)^T"U_0E;7('* MPK2ESW$H8JZ&#^7-0WXAV?5J M)YIT=8)O1+VM7YI_KH\OV\-IM&N>88.8NG/:T7^GRO]RQK/,I_8,7X5RQYI7 M^.Y;`]^,F%[!!O3&PO=V]R:W-H965T&ULK)S=;^O& M$<7?"_1_$/0>2]2W#-O!M19I`[1`4?3C65>6;2&694BZN_ M?OIAT>^=SNO7A_7+X75[V_]]>^K_>/?G/]U\/QQ_.3UOM^<>MO!ZNNT_G\]O MUX/!:?.\W:]/5X>W[2LBCX?C?GW&/X]/@]/;<;M^J`?M7P:CX7`VV*]WK_UF M"]?'+MLX/#[N-EMWV'S;;U_/S4:.VY?U&?Y/S[NW4]S:?M-E<_OU\9=O;S]L M#OLW;.+K[F5W_KW>:+^WWUS__/1Z.*Z_ON"X?ZLFZTW<=OT/M?G];G,\G`Z/ MYRML;M`8U<>\'"P'V-+=S<,.1^#+WCMN'V_[7ZIK5XV6_<'=35VA_^RVWT_B M_WNGY\/WOQQW#W_;O6Y1;IPH?PJ^'@Z_^-2?'[R$P0,U^J?Z%/SCV'O8/JZ_ MO9S_>?C^U^WNZ?F,\SW%(?DCNW[XW6U/&Y04F[D:3?V6-H<7&,!_>_N=[PV4 M9/U;_??[[N'\?-L?55>+Z70R6\RQF:_;T_FGG=]FO[?Y=CH?]O]MLJJPK68K MH[`5_(U;N9J,IO-%A9U>&C@.`_$W#*RF5_-JN!S[O5_8XR0,Q-\P<#R[FLZ' MXWJ/EVT/FAK4)77K\_KNYGCXWD.CXB!/;VO?]M4U-AQKV=AHJ_M><5%5OY$O M?BNW_66_A[*=T!*_WE75]&;P*\[B)N3<&SF3HE2G%2H7W/2_;MDWG?01''K10G%=JW_R3, MKOG%TK,RT*?S9>\WQ+Z"@EV+4S_/^J--BJ?1286L`BG2ZN7KR">SG:"(,BG% M287V7>&3J?O.ZVS>>Y1$AVC)D<0&//_$B;I\]%5#2URXL:SW41+'KR5'$AOP M>.MNH($A&0@2SJ_HAT76#U6;%9WC!J(YEPM_,.S)4ZZ[I\!$612)R?IS9E4I MR9'$!HIH6K4XC<=V'R79%B$K28ZRV(`'6O<*!/S)"D@BA@HHR?E;*G\YURW"+PC#=XH"?!J MR9'$!CS^.I^Q48"E.&-12D!9:R9:J\9=JLU#)28K^>EMT+%M@J"R9QVUQC_HZL)7`M.9+8@`=@=P,! ME])`D-(#T6JD)$<2&_``[&X@X%(:D`0-%5"2&TF)#7@`=C<0<"D-!`D<$R11 MSX!M5FH+*;$GS\3NG@)!I2<)U5`4)3E,MZ1.(0/C#+V7/_WJ;,9KE`1)M.1( M8@-%+!UKED9)L%1+CB0V4,32L69IE'"215N,,UJDK+8M2&)/17@=:[Q&219% MXY6RV(`'6>>^'`?LB;Z,DFP+"<<&5Y3%!HIX.=:\C)*L@.8E9;&!C)?^`V:* M[BN\AQUKD$8)H!+],LG[)0Q,!71I(%J(S7KH=3]=`9'R=$EJ-A@9*\F1Q`8\ MX;H;"#R4!H*4#G"- MDJR8!B]EL8$,O)?O2"::KU&2/:-A2EELP(.O,THF`9,")5&2%=`PI2PVX,'7 MW4#`I#00)$9)/LTZ:;-26TB)/7GP=?<4,"D]27(&EBG)3:1$!J9%?*VSF:]1 M$FVA)4<2&RB"J;]5R":;HR3:0DN.)#:0P;1&R:3^$K/TKF2J21LE1DD^%9NR MVIXAB0T7P7>JX1LE63$-7\IB`QE\+Z-DJOD:)=DSDIQU'SO*8@-%,)UJF$9) M5D##E++80!%,IQJF46*4Y!.N*2NU1=B6GJ&?%O&USLZN9`735+K3/,U2K(M0E:2'&6Q@2*8S@(Y!4JBE`YWI25' M$AO(8.I1,II>?0(DFK.S%JKB\6:<3[BFK-0Q[4!(;+<(O3.-WBC)>FGT4A89 MF&?HO0R2.IM;-DJI/59:FK-0R[<"<,O,B*M?9V44> M0"T+IB07!]997+",RA]01J-W+@G:W&%JR9'$!HHX.]>2F+#63D_:!C-%T7$I(-2+3D2&(#12A=!$B*&]PHR0IHE%(6&\A0 MZCMFCA?KBY^4%YJR4>*.R2=J4U;J&(EGMEL$WH4&;Y1DO31X*8L,+(O`6V*,D&*,E1Q(;**+L4E,V2J("6G(DL8$BRBXU9:/$'SWY7&S*:MN")/94!-ZE M!F^49%$T>"F+#63@O0R2I:9KE&1;2&XV<[&4Q0:*4+K4*(V2K(!&*66Q@0RE M]4WLY^;OEYJS46*4Y!.U*2OUC`0T&_:8[#Q-N0Q0%>B-DJQ8R$J2HRPVD*'W M@Y[1?%U*3#8?/EIR)+&!(I@N-4RCE`YWI25'$AFHAD4T;=(9IZU&-)GDT[$B MK6T-UC)C192MAAJSK2:*8VA8`!'&UGF9BR+45D/-VE837#$TN`ACZ[S,11%< MJZ&F:ZM1+31?.2]SD1&VYHO_BC311)+2F>4B)E=# M#>56H\)I+'->YB(#\V7,5$,-WU:3Y5'?>(@L49UW\5L-/2L[\[=)SZ]]A=M5 MFY5EUBB!<#36%6XT)E,_CBC11GK`Y/?>/%;%EY=%T;C:!DJ52H#PA M+VDHC]2X//7RK.XG*:[F$I^25=0D@;2&=5C^LP!N#0+5:[0*7!@TIF5>S6=E MI36X>)_&]:HLX:(FT*=F=JNXP(OJU!)8S,A,\KG==F@J)TRW0]%:V0DL@W=< M^$7&%*A75?`_/["JDB8;*9LBQEK5P&U<=VDF>9+F!3/7GJ_" M]4=>#92'A6/C=J4OK#9I28(M(646/"V%!7\!CA?U.ZL?N0FY0&5R$S2J7*O) MRF7/^;`8TO`G]=PT/?1EMLNX'U>9D5?)\W"]QCSY&4A:YB+C_D>]%EA,+B2? MHPNEH3Q2RUR4<3RN-R,7DL_1A=+@0FJ9BXSC_A+\U&L5U2A@F@RVZ);=H9[F MXM#T20#/[5#U"5BO,A/-_]'Y"^0F8Y+FL7)*@PNI-95K?@^H^?&:_?;XM%UM M7UY.OC1O-?*P^8AV;^UA=:QWS7E!Z:W_5"#'GBV?0S\.#Z%FS!\['BO-F#\/>#JS8M40 M,3PSF3'_(U1XDK%B0S\.\VYFS(_#?)09\^,.=BQOQY MP+2'$5MB&&:[K0@&81K:BN`48`K8BN`$8"+6BJ#\F"&U(B@^IBZ-R`)C\*V5 M%<$8?'=D1)8H.[[4L2(H.KYML2(H.;[SL"(H.+Z,,"(+C,$7U%8$8_#-L15! MK?&]K15!K?'MJ15!K?&UIA5!K?%]HQ&98PQ>-+$B&(/7/:P(:HWW,*P(:HT7 M)(S(`K7&:PI6!+7&^P-&9(XQ>*O,BF`,7O>R(J@U7JRR(J@UWGBR(J@U7D6R M(J@UWA$R(C.,P8NC5@1C\/JF%4&M\5ZE%4&M\<*C%4&M\;JA%4&M\=*?$9EB M#%X%MR(8@W>TC<@,M<;+T%8$M<9;RE8$M<;KPU8$M<9[O49DBC%8OV%%,`9S MQU8$M<:*!RN"6F,I@A5!K;%&P(J@UGA3WXA,,`:+M*P(QF#UE!5!K;&LR8J@ MUEA<9$2FJ#56_5@1U!K+<8S(!&.P[-**8`S60UH1U!H+%:T(:HT5A%8$M<;J M/2N"6F,-G1$98PS655L1C,&"9RN"6F-UL15!K;'LUXJ@UEB/:T50:RR4-2(C MC+'O8OR-&&[JC#%CU!H_'V!%4&NLZ[U[0'\+:-\!CE#K=^[_,.:=.RZ,>>=^"[5^Y^X5M;;O74>H M-68KK.-!K3%A8$3JVRQS3(4Q[]QCH=;OW+&BUN_4:],>M8?`M8NF\:0_\RN?X2?LHTO]N%)?-*PXDTKS.<1O,JPTDTKS&R_81CSW#>DG/L?D1U.8?Y\,;'H?P.Z:',WZ[ MM/[?9_Q:[18S6D/_5M/CX7"._\#I'K2_?WOW/P```/__`P!02P,$%``&``@` M```A`&,>7)L!!0``RA(``!@```!X;"]W;W)K,4V]@=K[&_;WW];GWG]TAP9:RV(4#4;^]BVIY7C--F1E6DSYR=60<^> MUV7:PF-]<)I3S=)=]U)9.-1U`Z=,\\K&"*MZ2@R^W^<9>^39:\FJ%H/4K$A; MX-\<\U-SB59F4\*5:?WR>IIEO#Q!B.>\R-N/+JAME=GJ^Z'B=?I['&8@9+=JMM_8#V25T,!VMNM. MH)\Y.S?*_U9SY.<_ZGSW5UXQ4!O62:S`,^B_8>?_V3YX=C"[CD349*`IAYM07D3)>``'X;96Y2`U0)'WO M_I[S77O=M&=.V\@:29A,1C"-$1R04A5@+8]11AXBK%ZZ)?F`BP8"(605"+ ML0%B]]0,9LD51-!3TYB`0-.9"/#&7B@#1UX?%KDA!#-&D$V4!FU@B#)]8`&& M#%,&#HTIQP@)NY6:+981=0U$HB.H1ZG?D]>H00*KU$0">5!@MU=)O&1HL^C# MHS8(4;11&C0"@4[@]L`"K&L3#?/"@1&R[+3QX4?GE1C=@VX:J?`>4@)LD!H2 M$$DAQ,?2 M`-"(@6NHQ*8ED'C)2*!AWD@0(4H"*0T:`0+IJC*X+4V'-K2)#&TD!L69$:B= M8>X=N<1$+(?TU[D)4YR\;`0M5"U]8B9++$%(+G#-_D3V0[GUCOG9TA'#FJ>M M7?>6KB!QC9/!F[O#?*+]7'9U`E M5PH!(1T_G8WA[A-3:FSSQ#5VEYA2J6T:-K0NSR_0YN.9>XW M$H3:T)"$YE=7HB%(J*6(O@R@)C&$20 M2-M<=99WN3V]XO;$W(PD2`I$HB4Q^"<:@D21-U2W3LZP^HD2HIOK$AK[32P. MJF#Y%X&BT-@3$@G`#]W//F7AJ*^M\1(O+!<%; M=D-5;`]A'3G(6A9XUT$/K3\U)WGGWD+=PC=OT>X,V)PL'3G M`-YSWEX>Q!F[OX7:_@\``/__`P!02P,$%``&``@````A`*,WR1@'!0``*!0` M`!@```!X;"]W;W)K=7.@ M,W"B8Y\#(S"`:;W<%N"!D%UK\MU*_\X6"?-T8[WL!?JGR,^M]%MK#_7YEZ;8 M_E94.:@-<1(1>*GK5P']L15#8&R,K),^`G\TVC;?I6_'[L_Z_&M>[`\=A-L! MCX1CB^UGE+<9*`HT<^X(IJP^P@3@OU86(C5`D?2COYZ+;7=8Z98[=SS38@#7 M7O*V2PI!J6O96]O5Y;\(8@,5DO"!!*X#"6-/DU@#"5PO)/:<^PYSW">F8@\L MMG49PU6$L2A/:5B7;(%,(MH6Y`SMZ,-818VWX51;PKH%E+T?>TY2^,= MLBH;(.$-B*M"-C<@G@J);D!\%1+?@`0J)!E#?/,*,4"(JQJ0;[(:TRH(,*BE M:U<5?':E[84*$>+U$LUE=YJ91+F(VL1T()$& M%"]@H3[OA3`B7EBJB"%"<-+,A#_U^0:?.[U3#GT:R=;!Z'%\,?[*)8OP)Y,0 M10&H,L\K((R(`K;J88@0*8XX@)*`3R--(FH1TX%$&E!\@%HD^S"]$@68S)VL MDA`A0_28XQ!U-_@H]I%J;7-B'5^L)\(W"5%<]U37'UN&PHA(0.IMB!`I M?#@P:&+="!^UB.E`(@TH/HAN\.EM11@1'[XJ%194A`Q3=CQ/*N0]8(,`R*IK M41X%\QY'?)\CF80H2@2J$M.)+,"J`AXMI@A!!68VMSC=$#:(F)3@/B2^^YYD MDD31@$%'(:?#M`@]6E7!)[M^.&`&&0+FNB:I5AL%PAW?(B4A4@`>8]RC4L8* M9.:;MA-PDI*)BOG_W96)-D1:$W=$P*8%-KEK(OND=PA[QI4NK>AA!&7I?1[O MK".K>#22R"-J)$4K(3GQ6'%BV(`HSM#M=41U1;06 MS[N"#8GB"ED;(4,,3IS=JM<#8K):W66)'V!)IC&J(*(KD02YLU0%6JU7HZHM MOJ`!@T+,;#_@M$G?#)!I)9!F"A/??U4R_2I5"M&W/"X%=CER3@0D54.&F.&C MB'%NF9RT*AL%PUW3']5NF<3C@<,=`HD5CIGO6`[CI((F*F:B=HL^YW$5L"M2 M5"#?-R$9BSL7Q08,G/7C3U:?^\_ZE[N"$IO]Y@!.Y'+[=S#F`=W7=76[$6=+U MC&_]'P```/__`P!02P,$%``&``@````A`+9+VC!F`@``308``!D```!X;"]W M;W)K&ULE)5=;]HP%(;O)^T_6+YOG`0"%)%4156W M2IM43?NX-HZ36,1Q9)O2_OL=VX!2V(!R06+\^GW.AVT6=Z^R12]<&Z&Z'"=1 MC!'OF"I%5^?XU\_'FQE&QM*NI*WJ>([?N,%WQ>=/BZW2:]-P;A$X=";'C;7] MG!##&BZIB53/.YBIE);4PE#7Q/2:T](ODBU)XWA")!4=#@YS?8V'JBK!^(-B M&\D[&TPT;ZF%^$TC>K-WD^P:.TGU>M/?,"5[L%B)5M@W;XJ19/.GNE.:KEK( M^S494[;W]H,3>RF85D95-@([$@(]S?F6W!)P*A:E@`QK'WT#GC4J>44W MK?VAME^YJ!L+WR?V2R!8`UUX*4;C\8*\0.G8 M3K,\U:0'!0'H@0RT(=G5=`2=.1^!6Y3C,4:#"+*#OX]R&32^#^^`H_?`\R`G MAH!\DFF<'#/"]-1/9_`YA/"."'$.4SQ/=.(!<7*P#%F%Z=D%(FRGZXE./"!. MCXAA^A)Q\A&B$P^(LR-BF+Y$G'Z$Z,0#XNT1,4S_MX_A1@@'IJ&ULK)I=<^*X$H;OMVK_`\7]`N8S<279"E^VP0;CVG/. M-0$GN`9P"CN3F7^_+4OMMM0>-IS:N1C(X^Y7WQ^9__IK_<==L9/GVO-\>TW/\V/P99\T_GW[_[>$SO7S+ M#G&<-T#AG#TV#WG^;K?;V>X0G[99*WV/SW#E-;V7EK9^^7>+LOG$[' M=K?3&;9/V^3MKLHNGZ>[C%)]S*7*)C]L<^I\=DO<,U4Z[K\B= MMI=O'^]_[-+3.TB\),V]G=/+]N4(]_W#ZF]WJ%W\P>1/R>Z2 M9NEKW@*YMNPHO^?[]GT;E)X>]@G<@0A[XQ*_/C:?+3NR[IKMIX0<0[0A3R(#+VGZ39AZ>X'`NH0/P?^.4B*$!$=G^*#X_DWU^ M@&]WK<&HT[/`O/$29_D\$9+-QNXCR]/3_Y21DI(B724"GTJD-[Q9I*=$X!-% M>JV[P:`_O!M!5ZXTWU>>\*D\NZ.K#B!7W#1\HL.P9?4[0W'/5QH:*C]01[_K M#<$L*QJ"3^4P^-HMW2M'^%2.EM4:69W[WC_$PH(1)!-*R?B':%@8>?$%[PMB M>240%H9<##5TN1X*"X,GOMP6#`N4Y3U1X/LTOJ[U$Q,`4Q`;K8]&6\Z+8II- MM_GVZ>&2?C;@V04C/WO?BB>A90L5G&"RU7+*_6K&P503*L]"YK$)Z83)E,%C MXOM3=W#WT/X.4WNG;,;-Q@I">,3!F9,3)GQ&'$9<1C9,'(DA&?D8"1%2-K1D)&-HQ$5:*E M`L)Z0RJ$-3SIX!%-N1AVC%Q(H\&@>(P9#[&)NO@K!:UOL'C+ M6G?0`OL;ES4AI.=$DB$,@\H(,M>QT@A3.65DQLB<$8<1EQ&/D04C2T9\1@)& M5HRL&0D9V3`258F6)MCN:&FZ_A@5UGHN%*D\-!F9,C)C9,Z(PXC+B,?(@I$E M(SXC`2,K1M:,A(QL&(FJ1`L\[/-N"+RPU@,OB3$)NOIC=%(:E9.`D1DCEY`V1+\SUT"O4+8XPBH)E M@E:T9D_1:E@NXS..YMS1X<@EQ^KRT]-GGD=6./467&O)D<\=`XY6W''-4<@= M-QQ%FJ.>'E$-52O3ZZN#)8LGV-KA/8\5TM*CK*KID:A+CC-T)#1'>7)T.'+) ML9J>OID>UN*":RTY\NOE![I\0%88B1776G,4DF.U]T-=?D-6*!]I6GH21055 M3:(\7FB)4Y[\D.R^C5/81D$\:I+;@_VW.ER0=9B66XFTW"HK2M'4DJ@'.Y#* M;FVDW]&,K/".Y@K!B1$BAR.7'*OR1L7@D15J+;C6DB.?'*OR1N48D!7*K[C6 MFJ.0'"OR(Z,8VI`5RD>:EIYN4:9=2_=?Z?NOT@UGDV6^5;5'\V\LSNY@X>O! M4*%,CLQ]-UEA9Z<*#3OR4*K?$?_,`2#%P0;=YES)X;S' M%;=:(R*M$!%I;;A6I%GI2125=#6)_]]J*NMQ+;<2&1/4V+=,P(--4(GZ-"QG MRFH`Q>>U":JTR-'A\JY"%7GO2_(+U"+Y)2(*OH^(K`)$-*E6B,AJC8BT0H4J M7=TH!)'`<1*A8Z&EYU84ZV9NNR/:*>'2><.V2=7_U654(F,2&SO(B?A!RIS$ M$O7IK&6FK/K#7Z^LD!4Z3A4:T(R9(;J_-EA4>^3F M<'$7E6#/5HF=$6$/K?KU.[,%"E-;2T0T,GQ$9!4HU(>^ELW7#!9V*VO4(OE0 M(8@3:=4,%JDUN+HE$2]A%,DJNBH'BWRI0O[:>XHO;_$D/AZSQB[]$"],0,'[ M]%#B\FV.YZ)_!A^+MSS$P#!YUX;?R&IXSX9?;#A_[MO/T%%^83RPX32_A@]M M.#ZNX2,;3C=K^)T-)VTU_-Z&@R#.H4*T1?W'KT!Q9XO2C5^!NLP651>_`B65 M+0HF?@7*$&BG+B100T`[=5>@"(!VZJ[`EA[:J;L"ATW03E''&*F"HR-HI^X* MG/I`.W57X`P'VJF[,K4L:*=N2,`9"+13=P6.+Z"=NBMP\@#M%%?:9;?A+9[W M[5L<;"]OR3EK'.-7&+2=8CV\R/>`Y!^Y*BE?TAS>WRFJRP.\KQ7#ZP,=\8O/ M:YKF^`&ULK)O;;B.Y$8;O`^0=!-VO MI3[I8-A>C$4R62`!@F`WN=;(;5L826VH->.9MT_Q4,TJ5D?NGN1F//Y8I/[B MZ6?3K;M?OQ\/DV_UN=TWI_MI=C.?3NK3KGG:GU[NIW_\;GY932?M97MZVAZ: M4WT__5&WTU\?_ORGN_?F_*5]K>O+!%HXM??3U\OE[78V:W>O]7';WC1O]0E* MGIOS<7N!7\\OL_;M7&^?7*7C89;/YXO9<;L_37T+M^P'][>O^K<76CKLAS1VWYR]?WW[9-<UO M+Z?FO/U\@+R_9^5VAVV[7T3SQ_WNW+3-\^4&FIMYH3+G]6P]@Y8>[I[VD('M M]LFY?KZ??LINS2*?SA[N7`?]:U^_M^3_D_:U>?_+>?_TM_VIAMZ&<;(C\+EI MOMC0WYXL@LHS4=NX$?C'>?)4/V^_'B[_;-[_6N]?7B\PW!5D9!.[??JAZG8' M/0K-W.25;6G7'$``_#LY[NW4@![9?G<_W_=/E]?[:;&XJ9;S(H/PR>>ZO9B] M;7(ZV7UM+\WQWSXH"TWY1O+0"/P,C>3ES3*;KXLE-'*E8A$JPD_\]/E-F5?+ ME?OX*S7+4!-^8LW!NF>^#UR7JNUE^W!W;MXG,$\AR_9M:V=]=KN83K`OO8RN M=_];YT*OVD8^V5;NI^OI!/JMA1GQ[:$L[F;?8!!W(>11AF0\8H,1=L1LJRH% M.@6&@!DDU&4%H_)_R,JV8K-"08\(8IIYD@-&8!65`IT"0P#+`29(FD,!:Z5_ MEN-`V$KW4Y@AW4#DJR77^.AC8,6@R(T@2A`MB*&$*8>/I\JO*[;!,/E@[A') MJT1R",KV%2X\$!@W M,DW7R43L@G"^*$&T((82E@OLIS27Z^O(!G/)@9"^%D0)H@4QE#!]&6Q'PP6Z M:*X0$9$HD9)(2V08XC*M2Y`Y<;T?,^\IL"'A(#XBHC)#5$1*1FF)#$-*P5>S]A^@-BDW>=[J)9%X6)*XFT1(8AGI*U")+2!ST?#(7V//48 M=RC89`(IB;1$AB$N>)N/_EHY)KAMH<(%D4\ M3*S%HX3]?+8.5:R(4UM+9!CB*8URPEPZ(:*X-VPD4A)IB0Q#7&;BA->76RX- M#Q&5*=U-1FF)#$-)^S=37(`#H@++Y,S.]:CPD-35+A`AE7DPJVW M#!<>G(AL<+E'L$+L54H^SZI4=!>`&X&*=>*FDBT2<]085?F6\W4U3\Z!!D/< M?1?/R_K3\+R"F]&\/"KGF-3F72=!:/`GK7L.3"%Y' MD_`H#DYRO[+)NX"8A$`:H_Q(%.6J)PE:BR=AO6UX$L$):1(>Q9%(;EPV>1<0 MDQ!(8U08B27F1:C M3-=%)XEXA[6VWIUJEND"#_4@"$6KB&(]N7%AE!^D;%GU3#6,Z1FE459=2*L. M"%P6=6\0N;]TN%.H0A2C-**RJV@02<+^DMT9%9Z'A$"*F M41<0IY%`&IL)9YEE5BV3)QV#(3V;DG7`X4EXOV1)=!8:DDC-NN@"8A(":8P* M(]&;!*W%1\(ZX/`DO%^R)#H+#4FD9EUT`3$)@31&71L)6HLE81?F\"1<--^: M`HK+))G*FQC0)2&11G1E)#!$VD`YRJQ==))$Y[EQW4JS#A5!1\RDJXA(8Y0? MCL5RM4Z>J0Q&R'51CC)K%YTD,L2L0SUJUA'%#I!FC5'!K`OXX_8B/1=B3,\H MC3+K4IHU(O)<+9&22$MD&.(K8I19E]XZZ;)&1&6&J(B4C-(2&8:X3.M\@WU&;/$4CBIHV$BF)M$2&(2XSL>&?O&TKI3\C@LRZ42DYR52$FF)#$-W6$!61DE%:(L,0EYG8W`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`"+H!G'5C"U_0>-N^U'_?GE_VIW9RJ)]ANYF[+?+L MO^+A?[DT;^`T\#6-Y@)?S7#_?86OXM3P?8'Y#>RGSTUSP5]`Z*S[&ULC)1=;]HP%(;O)^T_6+YOG`]H`1&JEHJMTB9-TSZN MC7.26(WCR#;0_OL=QY!!81IK_X^&&^T^;%U@".(*&U.:V=ZV:,65 2 M';3XI-1&<8=+4S';&>!%_Y)J6!K'MTQQV=)`F)EK&+HLI8`G+38*6A<@!AKN MT+^M96U2`I'M(AN[WS],HG8R3\>W_*2PXZ@-\XHXOYD;O M"#8-GFD[[ELPF2'Y$%GP,<3ZKU`Q1@]Y\)2<3BG!*"R69[O(LO&<;3&G8J]Y M/-%+@?8&CQCYLWL,&\@>O*7OSKV@N!TD)TXP M0]<[\>*+?+HXV3DQ%S_C#UVQ_IPH<*$^YK`C>PL"$?E)@*EA"TU@B],8/0XKL87>8TX?4E^;=_B/.;]_M M;'B`\]/Q"KYR4\G6D@9*1,;1'0Z,"1,8%DYW?1>OM[-U_?F]IY M0UU?X7;K!C/?=5!;XF/5GK?N7W_F7Y:NTP]%>RQJW**M^X%Z]^ONYY\V-]R] M]!>$!@UY?7E!3='/\!6U\,L)=TTQP-?N[/77#A5'.JBIO=#W M%UY35*W+(JR[*3'PZ525*,7E:X/:@07I4%T,H+^_5-=>1&O**>&:HGMYO7XI M<7.%$,]570T?-*CK-.7ZV[G%7?%<@^_W("Y*$9M^L<(W5=GA'I^&&83SF%#; M\\I;>1!IMSE6X("DW>G0:>L^!>L\#%UOMZ$)^KM"MU[YW^DO^/9+5QV_5RV" M;$.=2`6>,7XAU&]'`L%@SQJ=TPK\WCE'="I>Z^$/?/L55>?+`.6>@R-B;'W\ M2%%?0D8AS"R!3QXDC&=)X*^B9'J0F`>!3Q'DOP1XS`S-35H, MQ6[3X9L#$P[D]M>"3-]@O7`=D11F0:;I1UF"])`@3R3*UEVY#B2@A]*^[:(H MVGAO4(Z2<_8V)]`9!\$@N2=A4Q/(3"!7``\<25N0W__!%HE";`E!>P&,/D/# M@V"((:D)9":0*X#F(;(]1##K[\]740DR:.O"S)"5")>)KG'/.##WA!40LJZ>(6,YC%5\D+]+ M]1:2<83E/HJ7MGIUC*8>-O/IZ@E95\^0,?=+(_?R=ZG>0C*.\-PG<%XR9XXZ M1E,?P$8Y73YEZ_HY-*9_91@8"=*!#64"XA58AO;L%Q1Z4-!-D.XV>08%K!?" M1BH$[3D$51@7*"Q`TPD;""PQ,!T'"B@3$*O&:F$70S#8,4SMQ@%I<=.-L(:H M&6$05&,TDIC+F3YEZP))B$Y':!QG[U""Q8H4)/,[,TUP[E2)M,'IYGC35*O$ MH'!L`X>`0_0XS,]"%BL3K%@:S@5$8^F3B32ZZ3)Y6U1E,LB83%81&(L=Y+ER M#HW^LH!#JG*5I2LG#6^Z5>4,,I2;S9B\"\`FIBGGD*J<0ZIRE:4K)YUM MNG+6![5Y+ULC.5/?Z0@_G/&?QMNQ'B\38X7(MMNZ+]+SIOEB' MU'S)ILE]6=-($L:U;$%9P"%^9$F">6*Z:4$?IE2`=<+H)UB\U$[*%DT8C5K$?26)$[3=YNUF(@;];1 M/%DNS&.AX"A58M="[.JC0=T9'5!=]TZ)7\F53P*O"!)EUU%IO(:W11!GXO-U M1M^<#1RNKYYHNS;P/5QK41TF'L)UUYWX^V@-+];V#(27$]=BS/Z MK>C.5=L[-3J!%W]&KI(Z=L'%O@SX"G,-[HCP`!=3]-\+7$0BN&/Q9T`^83R( M+_!D3UYM[OX%``#__P,`4$L#!!0`!@`(````(0"]&Q40:0<``'P?```9```` M>&PO=V]R:W-H965T M))V``0,V&*:[>^V`"9X`9FRG:?_]'MDZLJ1#*=EI+PH\.>>UI%>2]?'PY?OQ MT/@69WF2GAZ;1JO3;,2G3;I-3J^/S;^_CO^Z:S;R(CIMHT-ZBA^;/^*\^>7I MSS\>/M+L+=_'<=$`A5/^V-P7Q=EIM_/-/CY&>2L]QR?XRR[-CE$!/[/7=G[. MXFA;)AT/[6ZG8[>/47)J5@I.=HM&NMLEF]A--^_'^%14(EE\B`HH?[Y/SCFJ M'3>WR!VC[.W]_-LIS:*7`]3[NV%&&]0N?Q#Y M8[+)TCS=%2V0:U<%I76^;]^W0>GI89M`#5BS-[)X]]A\-IRU83;;3P]E`_V3 MQ!^Y]+V1[]./299L_>040VN#3\R!ES1]8Z'3+4.0W";9X]*!,&MLXUWT?BC6 MZ8<7)Z_[`NRVH$:L8L[VAQOG&VA1D&EU+::T20]0`/B_<4Q8UX`6B;Z7GQ_) MMMC#M[N6U>_T#`AOO,1Y,4Z89+.Q><^+]/@O#^)2E4B7B\`G%^G9GQ:!QY4E M@4\NZLRS3ONO?7A+HUJ4(?'(1R+U2\GL>#Y\\W@`+KB08/9[!OHAR&F;' M_D1[&3:*P!MV']C?H MLAL>,Z`QAAHQQ`C6/YFLJX.1#L8ZF.C`T\%4!S,=S'7@ZR#0P4('2QV$.ECI M8"V!-M@C/(+Q]#L\8C+,(VS=`8+:-,VR(49@BJN#D0[&.ICHP-/!5`(5-"9H3,"?$)"0A9$+(D)"1D1NY^PAT67]F!%!Q61O>`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`P,RH.==^HN)=W_: MPUW;@>,,FN'9#IQ%4.[;#APD4![:#IP"4.[V'=A`4^[U'=@#4^[W'=C34A[V M'=BC4NZ:#AQ[4NZ9#IQ94NZ;#IQ!4AZ:SNH2=RUG5`X5K=T\RYE>XK[EP"': M!7W+@1,PX&TA!'>?Y^@U#J+L-3GEC4.\@P[5*2?KK+H]K7X4_$3D)2W@UA.6 M\W!#!K?<,5Q.=5HPUG=I6N`/]@!Q;_[T'P```/__`P!02P,$%``&``@````A M`--K^Z*D`P``B`L``!D```!X;"]W;W)K&ULK%9= M;YLP%'V?M/^`>%\(^2Y*,B5!W29MTC3MX]D%)[$*&-E.T_[['6/#[-"UF;27 M$DZOSST^OK[J)",5ZLP'@S#@%89SUEU6(4_OM^^6X2!5*3*2<$K MN@J?J`S?K]^^69ZYN)='2E4`ADJNPJ-2=1)%,CO2DL@!KVF%_^RY*(G"JSA$ MLA:4Y,VBLHA&P^$L*@FK0L.0B&LX^'[/,IKR[%322AD200NBH%\>62U;MC*[ MAJXDXOY4O\MX68/BCA5,/36D85!FR:=#Q06Y*[#OQWA"LI:[>>G1ERP37/*] M&H`N,D+[>[Z);B(PK9MD8])/1LW1^!_+(SQ\$ MRS^SBL)MG),^@3O.[W7HIUQ#6!SU5M\V)_!5!#G=DU.AOO'S1\H.1X7CGF)' M>F-)_I12F<%1T`Q&4\V4\0("\#F^>9Y>JX"L>3P6@QC:7:L5V+9[OV^L03NQC/5OYL,)T/ MQ_'KZB-C1>-L2A19+P4_!RA7[%761!=_G("XM=3LOS/Y;Q[#7$VRT2RK\"8, MX)Y$83RL1_/%,GK`868V9MN/B?V(71NA3T[3I@X006\G&H;_!]&:18MNTVU; MP-G%A<(VHEV2.H"G$`?L*GR^0EOW=/`JA/N.>S=^YJV)0;6WJ7<])'413PVH MKU>C@U$-,U?.8G@AQP;%S5E?:-V9?X[1=O]LR&'PI*'\KY>F@QMIK0E;BSBV M])#41;SDKJ(EWO^+[EUL)_;(D[N'I*ZB)=;?P\O[_P0 ME?QRE>I5O@B+F/:H+^RN0]R3O[CFJ0U"E3CE,>H*S).*EN)*?5FA#O856L11 MV$-2BTSTS?)RQ_A`N%-"M])1;"I6AK=_<'3)[4&JC\.AYIANB(Z#Q;-)\ MCU_SS+123XR%G./#>/&,&]/.#>N9C?)+;-9%&<_,G&&^AB45![JC12&#C)_T M#+%`:^O0;K[9-./-!;[5X_<"CC@AS4$T.]`L1!U;)H*![[''8U+(PDY1Y4;Q&L6&@X0H# M4//SB(F7XG8/!RC\/>>J?=$)NAEZ_1L``/__`P!02P,$%``&``@````A`.!& M"(@#"@``["T``!D```!X;"]W;W)K&ULK)I;;^.X M#L??%]CO$.1]F_B22X.VB\9W8Q]?=]O!>W5H-O7^=NA=C8>#:K^N'S?[Y]OAWW^EO\V' M@^:XVC^NMO6^NAU^JYKA[W>__G+S41^^-"]5=1R`PKZY';X!XUKX=J]=@VVFU'_G@\'>U6F_U0*RP.YVC43T^; M=177Z[==M3]JD4.U71VA_\W+YK5!M=WZ'+G=ZO#E[?6W=;U[!8F'S79S_-:* M#@>[]:)XWM>'U<,6_/[JA:LU:K=?A/QNLS[43?UTO`*YD>ZH]/EZ=#T"I;N; MQPUXH,(^.%1/M\-[;U$&X7!T=],&Z)]-]=%8_Q\T+_5'=M@\_K'95Q!M&".1:)VV(_"?P^"Q>EJ];8__K3_R:O/\X M:M8049"Y\B=*:5UOH0/P[V"W4:D!$5E]O1WZ\.#-X_'E=AA,KR:S<>"!^>"A M:H[I1DD.!^NWYECO_J>-/".E14(C`I]&!.3.;`M/:3L`GZ;M]57H3V;S2SHP M-2+P:42\BYV`&=%V!#XO=N+:M(7/'W?"@\%O>Z#^.Y%A%:J#Q4LC$'"0D$*2TB>,[K+D7^*ZL6]]Q2)>&6(X*$@N2")(*D@F2 M"U((4MK$<13&RW'T!Q=!)>-&0)-P3FFNB:\WR':-$R319&JOIKX_<[,H[8PP MW)D@N2"%(*4FND-.4&8_)RA*Q@V*)G90-+&#(DBBB1,4;\Z6E;0SZH(B2"Y( M(4BI24]05%UL;Y>GEP-E[?JNB>V[)K;O@B0=41NK/_9"E@O=[YW;@N2"%!TQ MJH&K6G:_@ZJ3&9"8%P1!6;M!T"2$:J-;)7U>+43:R/>[J1,;$G0D,:2MG]N" M(14VF=#)A4TA=$K;QO%=U4@7.-^:N]X;!"-NN\\VB8BL<$QC0M30F[(:*NFW MXA.%K%`^DR@G=.*)1;\5>V))5CR=/%5_G3^I6G,64EW!N1D5C-U\CDQ#L$*? M8XD20K;/S)N4K%`KDRB7J"!T0KXD*Q$L5:-=$"Q=TD%%@OU<>AH%M`5%!MF+ MD$0)H1-=3\D*GYA)E$M4$#HA7Y*5B(RJX2Z(C"GY[,AHQ-*(3;#(TU;VRH3( M6IH066L3(K+*$-$JER,BJP(1:96(6BMW@5+EW`5A,-6?'0:-/EN@.BL).2%6IE$N42%81.R)=D)8*E2L4+@J4K2V?ITNSZTQSZ.V3W MDTW#1!VR('Y.EGI3L4YW5A0L@?)^+?;$HM^*/;$D*Q$_555>$#]=A"J]KDP* M^*:V](P5+1>11+%!OJTECA0)66&P4HDRB7*)"HE*@V#I$I%1I:8=&7T`NYK! M'#F^;-9?EC6$`#;YGG([@+=-YAV4+E@A8-C]I6>0'1V!8F,5V-$19XN$K%`^ ME2B3*)>HD*@TJ"\ZJA@5T8'7L"8X?]6O;7`NB)0N;YU(&61'2J#8TRB>(2+EPE6>>QS*C=-JX(8)!<:;Y)[FIS%EN:L1RD[TX MBJ!P50VM33A&1+XEB-3R^GXW"::AB%'W-)R0&3:R,TY8%6CU7>D2+=K^N$%2 MQ;=8"R<7[A0JB7CL3%7OIA?[$T9D&D+_T.?8H)"2($$4MK'SQJ$_9!U[`I$O4:1NYP5/UN0C>_[.1^+KBMS<2@U@2LDY&:$69 M$AL4JFT-_X@DUJ;$6$WLET>R[$-YBF6&B)Z8G_7$XJPGEBC?D[*JT/^Y45>* M[=2G2`4!*U>7Z@^TRHJ2)Y(H-F@V;G.U9TE(U-/U5_P^RIDP%U!TYTI,.1+7R-WOH;L5!.A%&!$L M\*?FJY9W"YJ0[8IIOQ;;W#.THD[DB$YVHC!6K!.LJBK[M:@3[ACP(\LGN[4\ MF_@:J>6ZBY\?T.-,06.L*'UB:HB#F!AD"AIO%ER+W;I[&C;*4(>D%- MIH''@IVB"44D0T3:.2*R*A`9[;$_G;'EN$23MI43IN"SP\I9I]]6Q5W9#'(S MC-=Q$5J1.[%!=DV#R-0T\R`(YCS'4(FR)T-$XCDJD56!Z(1XB4IR.81*UDVS M'SOLM3(L@/H8XJ9?R+(F,@WM@AH1N9T8Q-8@ELHI-:1%P9NR)V9H924E(GIB MT?]$5M*6U+#_B6ZJJFK^_!FM`L=V6X.LK362*$9$.9(@HATR1416&2(*0XZ( MK`I$I%4BZDDO=3*P?>;I==[TU.<+NU(.-%)/I@T@Y)4R6M%8QP9-""6(_+:, MFXTG4RZ4HA"%)D-$0CD*$2H0:>WIV`O$'H!"K;:;,3_]S`'7)452:>0N=!.V M446FH95ZL4$3RHT$$4AVHR(/&*A%#3-$%-\L:TUK"#=8V63CW%W"?3#YA&<"-UQY^'R[N]>S@0N$"KBCU"$T6 M<*-'\GMO!CWM:Y%,%W`!1K9(9@NX`R(YO#9?J!?9?;_,X9?V6@_K+;PB7:BW MH+(-O.*$-NTOHZX1W+5]73U7?ZX.SYM],]A63S"8X_9UQD'?UM5?CN8=[T-] MA%NV,-YP4Q-N55=P27*L7@0_U?41O\"C1]T][;M_`0``__\#`%!+`P04``8` M"````"$`2(1;7^<)``!L,```&0```'AL+W=O'X3__S'Z[&PX.Q^7N9;FI=]7#\%=U&/[^^->_W'_5^^^']ZHZ#DAA=W@8 MOA^/'XO1Z+!ZK[;+PTW]4>UHRVN]WRZ/]'7_-CI\[*OE2S-HNQF%X_%TM%VN M=\-68;&_1*-^?5VOJJ1>?6ZKW;$5V5>;Y9&.__"^_CBPVG9UB=QVN?_^^?'; MJMY^D,2W]69]_-6(#@?;U4*][>K]\MN&\OX9W"Y7K-U\`?GM>K6O#_7K\8;D M1NV!8L[ST7Q$2H_W+VO*0)=]L*]>'X9/P:*,YL/1XWU3H'^MJZ^#]>_!X;W^ MRO?KE[^M=Q55F^9)S\"WNOZN0]6+1C1X!*.S9@;^L1^\5*_+S\WQC_JKJ-9O M[T>:[@EEI!-;O/Q*JL.**DHR-^%$*ZWJ#1T`_3W8KK4UJ"++G\WGU_KE^/XP M#*VG8ENMO_;9-,L M:Y4G+?,PI".C>3R00W\\1N'M_>@'N6IE8IXQ)G`C8H[0%M*RB0]2'V0^R'U0 M^$#YH+3`B,K2U8:L]O^HC9;1M>&LGAE(L4*O$!S!0Q(?I#[(?)#[H/"!\D%I M`:<0D5>(_A.?O:"C'X9TBG5>".[F;H+/;0Q=1#C#&$@")`62`0.)#%D9@D%=YY+TBZ(BY@!R8$40!20 MTI#F$)URT,7OBG+HZ*8->1M-O.JAEHY$"*;I2^ M.)%JY,Z*ZK:S:FEK.$6@Z;VB"#K:+4)+IJ0O9\CZ.;_Z+NR#V7](1:]C4NV6F;="43Y8Q_7&- MG74R+)P#*3IR8E?J[*[*3H9VY123&@.GF*#;&\@2AA9[F!DV8.1 M1.6,Q'H%(XE2C$2K9-1$N3GK-LO.^7*/M`V:DWZ+SGFDB^*Z)0&@U"#CD6G/ MM00'Y8@*1.JL=.D,P2T%$>)5LFHQR.Z`[-SOMPCIG>STV^1YQ&O+8V#+DH\`B@U4:>N(S`H1^D" MD3HK73J#7(_H9LVNUQF/F-[.+E*+'(\`2O1K#[HWA3+[*2.9UXR11.6,;(^` MEN(HT2H9]7A$-VEVSI=[Q+1W=OHM\CPR=7N)6#_94/H4)1X!E)HHXY'H=D;O MZURA#(5R1`4B=5Z[=$:Y+M'=GEVQ,RXQS:%=)M-!RC3&`:"$D>222J M,PFBU"`VB6Y)_$L)CLH1%8B4(,O,4^\YO)0H.D['*.%UO6L3[E6J;6?M>XZ) MLE""*#5H>M>\(PG&D_$<3AXKLTULG&):C>(%(N>+]=;*UW3KI!O&*.K7]I'V5H1ZD M:47D,A`C2@39)O??(O1'>:=")E%<\QQ1(>C$'E5_E+?'4J+@Y--=YA7U:YM2 MIWX&6>^@0T`)HA11ABA'5"!2B$H'N9[1#>,5.;?]I9.S0;/NEA[K%UKZ;8N@ M!%&**$.4(RH0*42E@]R<=7MY1M"E02PG+V6\V+'^)T&^6]3#?(:;#H!S&O/YP"\2)LKT7*%^C>A*9Z+#TCFB0M")O:FS>RM%A_;F7&K3"6*#[D!%%JD'%)W\]8."A'5"!2@L3,`;P.D"@Z3--4O10@J M=UV_&V&_:Y!CL6#NOS.0*,XN090:Q/>OWLJU1T"[8Z$-I?Y1W[<\D2BH%>RPDZL0>57^4M\=2HL!FU_7/ MM*(6.B>#I(V+.4I0@BA%E"'*$16(%"*]^%>>9UO/M(MYVZ6>VVK_5L759G,8 MK.I/O5"7;@R/]QWN5A$_-;<0CS_3ZN+&Z#X/%[1@D(KL\XA6(_?PI]O%$QUH MSX#PEI2:^Y(O%4YH2_."!K9,:4MS[?2W1'->#>UMH>?=A7X"Q2.@1\!%2@]> MN(4>X6A,WQ9Z)J(Q??G0$PZ-Z=M"SQ0+_1#1LQ_:HA\)<$MRNZ`%>CU\LJ"5 M<,B+R8+6LB%/I@M:+X:\F"YH_1?R9+9(^VI54!$;/NK*2VN]/Y9OU=^7^[?U M[C#85*]DL?&-7A:];U>+MU^.]0>US[3@NC[2*N_FG^^TJK^BE;[C&PI^K>LC M?Z$#&G7_3^#Q/P```/__`P!02P,$%``&``@````A`.5'W$9T!P``+B0``!D` M``!X;"]W;W)K&ULK%K;;MLX$'U?8/_!T'MMZQ8G M09PB<='=`KO`8K&79\668Z&V94A*T_[]'E*D-!Q.7!/=EZ:>.1R29SA'(JF[ M]U\/^\F7LFFK^KB,XND\FI3'=;VICL_+Z.^_/KZ[CB9M5QPWQ;X^ELOH6]E& M[^]__NGNM6X^M[NR[":(<&R7T:[K3K>S6;O>E8>BG=:G\@C/MFX.18>?S?.L M/35EL=&-#OM9,I]?S0Y%=8SZ"+?-)3'J[;9:EQ_J]>7T[MU?3@AQ%.UK[IO.F@T.:QO/ST?ZZ9XVF/>7^.L6-O8 M^H<7_E"MF[JMM]T4X6;]0/TYW\QN9HAT?[>I,`-%^Z0IM\OH(;Y=Y8MH=G^G M"?JG*E];\O])NZM??VFJS6_5L03;R)/*P%-=?U;03QME0N.9U_JCSL`?S613 M;HN7??=G_?IK63WO.J0[QXS4Q&XWWSZ4[1J,(LPTR56D=;W'`/#OY%"II0%& MBJ_Z[VNUZ7;+*%E,\\4\C0&?/)5M][%2(:/)^J7MZL._/2@VH?H@B0F"OR;( M8KJ(YS?I`C'.M$M-._PU[=*KL7._X:P?O.;B0]$5]W=-_3K!`L/PVE.AEFM\ MBV"6A#["0,M;K(`.%>1!15E&-]$$$VZ1RB_WZ3RYFWT!_6N#>?0QL8M8683* M&H8WC!'D_`]C5%'4&%4FU:`?K6$<-!ORRB+X@$`4'9"\8BPW"KR,,H>;U)WY M8X_!ZK.#6U&+0P8"7=ZW`B.S5T[G&>O<@&*=MY@G9?".-*7S,80S-JS9R\>F MP'IL=LZ/QD)8H!:G)\SH\IX4V.W)6+2ZZ,6PHA:GIT5(3PKL]F0L9$[4XO2D M'BRD%,^O*@5V>^HM5Y@(*<+(()F*!YT::3\#0/*"_-2EXN3[,1 M(SH`JD\FS=3D$A^D6;$O6M9$TVQ0VN3V%B12L:]2UD33_*9.)4RG=)KG6(.! M2=9QW%*R)O!*:OF:)7E$\20G0:*FT6P`1N<($1;EUW+"1.V\A&HTZXV*4K^D M+,I/O-URJ*$N2E-(>6BWW\S_<8?G&)X'E)?G M(%U3VPZF:]9$\_RFKB5,U[Z39U^[=``D@Q2S8W**.5&B0IC_3F]&@BBY5)7, MJJ(FM[<@H4I\H3(F]_4JGO-4]@V!\E(9I%V)KUW61%/YIG:E3+O.DZO1;A%9 M$TFE8W+(38/D2*-9;[X<691?LBF3(UVR,8A(K4J[8+E$4)0&"53F"Y0UD8IU3&YO06J4^6ID M371N!B6DDJG1#U2LKU39($NT8OG1QHCRTAPD7IDO7M9$J7A3O'(F7N#)1$\.CQZ0%^T*'OVH\3P+>/3RX9X, M;?!$$,:6H0T$7?)F[@T?=AO)]\CA'HVU//HRYE]14F]V1H@Y<`U7BPD#[C&$U_R@&L\G05/BC;8QD@>M,&60_*`:^P%)`^X MQGN[Y`'7>.V6/.`:K\B")T$;'"Y('K3!KE_PI.`:VW')`ZZQ=98\X!H[5\D# MKK'+%#P)VN"D3O*@#4[5)`^XQKF7Y`'7.)"2/.`:)T62!USCI$CPQ&C3WX_P ME1BC37\&Y7G`-4ZF@B=&&UQ)21ZTP?61Y`'7 MN+V1/.`:-RV2!USC[D3R@.O^.IEQ@*\J'N1>T$"*I):`9%>+1K`_9+&PO=V]R:W-H965T8"_N>7W>O9]7;87M/= M87/Z\O7UMVU_>$47GW?[W>6'Z70Z.6R7?SP?^]/F\Q[S_IZ5FZWKV_PANC_L MMJ?^W#]=;M#=;"`JYWP[NYVAIX>[QQUFH,,^.75/]]-5ME2+:CI[N#,!^L^N M>SN3_T_.+_W;7TZ[Q[_MCAVBC772*_"Y[[]HUS\>-83&,]'ZDUF!?YPFC]W3 MYNO^\L_^[:_=[OGE@N6N,",]L>7C#]6=MX@HNKG)#8UMOP;F?%L5-UM>WFE9V);XM2V;FR:;WQ;-^^U*VPZ_CG9]+>W9$`(34;6Y;![N M3OW;!&F*29Y?-SKILR4Z=J$ MS;YA$;?69RU],N[1.@\=9MVM(L`,?$?2B/G_@;3N19-VPZT=X&>1!PR=AVNB M",`88FTIPWAFNNAIY_LIHC]&+\MJ/O)Z\$&6NZ%;@2B*,#;H^GHVVAG94%,Z M>1'0L4Y05,\Y=&I')\=9480Q1.9?SU`[&X:NW[5%2'0$HBC"QL9,KQ];._.Q M+=+XE1&(H@@;NTD96SOSL2U"YBT011$VMKX(22U_WPDE9!..2W"AY M`K6CDUM#11'&$[)">;Y?2]J9T[$(B9%`%$78V!DN3M@)5*&@&JGN;RTV8"4@SB!+2V$0+F2GJ;Z3N0U)+*K$Q2 M=A;B115<)%K7T`=1,8@3UH)("/\B9ZQ\4DY446W$!*3TC9FN2)-9G(!6Q>L) M6`W%#ZF:)JPMZ\5K*_!J]<5-II5;&B<+T=H2D,HHQ`EH M9;R>@-512L!"/BU:3-U$P$.*09R`EL?K"5@QI02HOMI,$9#**,0(Y($*F]HJ MS=U]:FV9KO@%PD%8@#&SBGS.,ZOU7DXT%8,XX20]SJ4>.XCDC(04@SB!)#W. M1SWV$>2%UQC@)K]9[^3C9[DVY<9I)JIU+U780C9-4;>;%"02J_;X( MYE*8'>0+J9608A`GH.7QZMK2%Y/@]L9!-`)4;%"6@M)`1,;=75C7\8 MO?HI,+>R2BK?0;2VLD+4EFWH@ZA\0Z01)ZR%DA#^Q9)96:6<+$0C)B"54X@3 MT-IY/0&KM)BBKYHB>/1=Y]:+U5;HU7HO7UMC0Q$G+:?7T[3B2^-$]7A0[5Q` MBD$L3D6@VN\OE/'FPNP@GQ:MA!2#.($D%2ZD"CN(9(J$%(,X@4"%=6WEU0W* M,_$AJQ@%VBW\VD%(4Y)7X8:%]W(-%8,XW20U+J0:.XC&2ZHQ\^($DM2XD&KL M()HQULM#BGEQ`DEJ7$@U=A"-@%1CYL4)Q-0X;SZ2,E*,BU%F:,"T_EU/P*HE4;G"0CX_6@DI!G$" M23);2)EUD)]N*R'%($:@#&367,`_E#*F)[X\#N(J$V[F>*\Q91C$^2:I/`J_5>/DZV>WEO7":IL?$. MUDY(;^N\?.@4@WB_DXV>[E?4Z5I-G&.XB3E7$?E-9Y>4@QB,6I#C3[_?M!X\T) M.(C4EH04@SB!)!6NI0H[R$^WE9!B$"<0J+!YA-!BE+A-48_Z[-9][2!66&6P M_=5Z+]=0,8BS31+CVBHO>>1S$`V7T&?%O#B!)#&N1S&FA15LU*R=%R^LP*OU M7CY.MGM96'629!OO(*^MBM,X"4BYAL:+QRF0[%\4EE3EFHKKL#D@(<4@3B!) M@FNKMS13I`0[+Q\4Q2!.0*L>V9WX^+-Y;?63DK,0+ZUP.\^?'>2CTTI(,8@1:)*TV'CSG'60GVXK(<4@3B!)BQNIQ0XB$9"08A`G$-/B MC[V/::0<.XCG3+B?X[U&F6$0)YPDQXV48P?1B$DY9EZ<0)(<-Z,`IRD$T`E)HF1':+R"9R_EO%B\*O]\PADGJ?A"JKB#2$5*2#&($PA4_/V\ M6DBA=I`7H%9"BD&<0)(J+Z0J.XA&0*HR\^($M(*2$O>:E/A0L=`=!4ED(785 MJ\*'"M?0AU`QB---TG!\W2`X"<%NG9,X_0@/WU>L%R4^L"BU]@E+Y3Z]""U-L52XAD;:-.@-%[>8 M!;WAJA.Q+/0G'J:&PW$6.2QYM`T8(%]D;ZNZ7*Z&#T;"WF!1>.B1;=8UN.'1 M(V:I83'7"M%;`XM)!V%9P&(>H83E%A;SD4!H:>:(COE215@0'=SA1;@UB`YN MI:1E52V6*SQR2@OV7)8*.RHQ"[AA7R-BJ<$-&PXQ"[AA)R!F`3<\=<O4G+*D M<,EVKM_-/O7]Q?V!4,_& M#X(?_@<``/__`P!02P,$%``&``@````A`#]/PE/.!```HA```!D```!X;"]W M;W)K&ULK%C;;JLX%'T?:?X!\7Y"#.2&DAPU(5RB M&6DT.C/S3(F3H`*.@#;MWY]M?`FV,U6JF3Z49F7O9>^U+]A=?G^O2NL--VU! MZI6-1F/;PG5.#D5]6ME__8B^S6VK[;+ZD)6DQBO[`[?V]_6OORROI'EISQAW M%C#4[ON6DN@#% M5_82"/1K;SGK9"_1W@:_MX&^K/9-KW!2'WXH:@]J0)YJ! M9T)>J&EZH!`X.X9WU&?@C\8ZX&/V6G9_DFN"B].Y@W1/("(:6'#X"'&;@Z)` M,W(GE"DG)6P`?EM504L#%,G>^^>U.'3GE>U-1Y/9V$-@;CWCMHL*2FE;^6O; MD>H?9H0X%2-Q.0D\.0GR1[X[FPUSX,>'+?V=@>GO):!>B`(K($LEEJ9#I M_K=L0YHIRQ.E6=FP,TAD"R7ZMO;2>.Y, MS?V&&WDW20PD9(@W)$)SK8AVTDAH&QE(;"")@:0&LF<(ZK>HJ`1JF"K!L.L.Z''(I.D#A3I\FMFH10=ZH)WIFBG"B+*@Y#/!AH@YZ;J_O<2B.Q MSY`CT/[2#4VUX;SC1K2:W];^#$W&*F\D601O;*R42)M/5DJ5E=!TJJ^TERRP MDJ+K3-/U<_VHM:H?0UR8`E((%RW4.+?(D-Y?8H$T,VE2A]2:+A9:'_9!6 M$8P>%4W%_LND[QE5^3@$12>DV9I0R"$?AJUL6G-Z":MI+R%R04)=0\%]*]98 M0+<=)(+HT^528<66F\\]I/4*O;'1#N#.#H^">`=9^+))("WE(G##?*IWX?&LZ$WRSOV&S>`LZ+) ML_$".$&9^),?/$&\\(4C5X`;XB4[X=^SYE34K57B(\0X[ENN87=,]J'C9X9G MTL'=$`H$[BCPOP`,UX,Q/5@<">G$![J`_._"^B<```#__P,`4$L#!!0`!@`( M````(0#V'K'XW08``'`<```9````>&PO=V]R:W-H965T:WT[5N MLJ<+Z/[NS[):_6.&K,F_JMCYV$PCGB41MS6MO[4&DW<.A!`6L[$Y3'+?N MH[])0]_U=@^\0/^4Q5N+_M]IS_7;+TUY^+V\%E!MZ!/KP%-=/S/J;P<&P6'/ M.IWR#OS9.(?BF+UB[=*2A72=_*7MZNI?0>** M=)"9#`(_91`(-_(L7(4G`#_EV?5D-9_/%JOE^`06,@C\E$'\R=*?KL./8WBB M(+R^<=9ENX>F?G-@:$%R>\O8+>!O(*XJK"B#+O6]2D.)69!'%F7KKET'BMC" M>+SNPL!_\%ZAI;GD[&V.P8@4@_6/A8U-(#&!%`$>*-*RH#/_@RP6AT5 MT.L,J,I(,=21V`02$T@10#2$5,/PK*L.,/+6A='4'?#G(X$$0=\+"XDE$FI.(I&91E+,(?E!7(AN5G-#`RU2`07&,+B26" M:BP15&/,(?FQQPMC>8;@;>_//3M$\Q2(4>L9+5*D2;K6%I)H!(_]G`9*!TD+ M32("8:-C@>\+8V0J3""X`1822P0U0"*H`9A#\O.AVN,3Y&R:H82,VB]U-;@/ M13U+%]^&$@6)49^OAD9=TEA*MM0[&"4+T5 MA`JN(,ZB:3*W0FFR!X:/9]X7'D?2%9!1^959>)V"(BTPX)B?AEX+L7MD"S<#@D-M(/YT_@TA9N1-FB# M0Z5;F@[K:Y:J>6Q#20_A6(;MIH.LQ;TV,'\;KT^X(=$G#1(9+?O@`(L*=296 M$&Z#9.$V2&B@# MW\SLQBL1UDB42+?$!;>@V)<0+KB$<,$QBZ;)7`RE.7(-">\CZ0[9X=)\T/$U MJY]_"TIZ%FZB8>3I(.ON_#/K0SH_6$/"*(D^Z9VX'184^Q+"[9`0;@=FD78$ MG_)ASJ8^+"'J!DOCT27J6;H--I0H2,S_>C:;&:Z2*H;MPBR!\?7F;$.(,&:T M7"+)0E"L(%1O!:%Z*\C>-Q"+I#EN_/DI(UWMKWAD^V4LGG_D0@.QK]/$ MAX`^GS`PKK:7K`!6:"]W960=J5A]5V)U$.Q+'UP;6R+I2:I,*0E%6\><$,D3 M7X!-V#=JW;G,G_Q1!$K MQ!+]E5'!1!X$5J]1)C&P+9B-OJ/Q6WV[IQ$*IT4*,R8B!03/_^PKOV#J&ZV( M`DG`BT-"L#_ZPM@3*UFLQJ^[.?PS'N959'X7TXXR8T9J!SJ'50D;)ZH$%,Z4 M*FL="@+9(!+J&YFPZ89;(10WW9`$?(9*8$8[7H*P92)!0'UCC"T'& M2*C?BXEBW>\"/D,DL,^$XR5P-MW<$NJ[8&Y#2L7]I9D!0EI5+S!@=6Z89L3DK?^LH"_\$5C_`7>^CSR:QKX'MX&<4DF'FS@ MRV[["OL0WAX-X(\SB,^?AXQ`CY#L(ZB&4)[^$[SON66GXH^L.977UKD41U`Z MY9N\$6^,Q"^=W'9/=0=O>OCB.\.;O0)>.$PGL/:/==VI7]@%]+O"W7\```#_ M_P,`4$L#!!0`!@`(````(0`PNR%^]0(``$D*```0``@!9&]C4')O<',O87!P M+GAM;""B!`$HH``!```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````````)Q6 MT4[;,!1]G[1_J/(.*:R:)I0&L;832$Q4),"CY3JWK45J!]NI6KY^U\F:)N!X ML+?$]_CZ^)SK:T>7NTT^V(+27(IQ<'8Z#`8@F,RX6(V#A_37R8]@H`T5&!B%[=\H832'"2:.ES37$(7' M@>@:J!5M3KG2<;0U%UM@1JJ!YJ\HVWDP6%`-ELXXV%+%J3!(R\+JG^H[+[11 M\9-4SWH-8'04(J`>K#[;V/8W'\6C487`KR[29JB98*#+,>4F!WVWG%-E')1' MHS;GBD7-N"9T<)%@;9"9,*@7N1&UVURVF3=[F$BA92(=5,\7.2(QDGYA2K3*A'=>:5>[4 MB@K^6E6@,^>-P%.VX@NTQ!F_E520>V#`MQ1!3LP4%L89N&),EE:'.=W;V95I M.*A*=&+FG'*#76`#)*6['D)6G>>US#-L'F3V4F(!.!,]4:6PVMV[NH>\J@9; M@WN2(E!39D^I&SZ1FPTWM:6V[M`[@X<..Q;V(>?J2;G0\%)B$9#9UI:"$]5V MA\RQ1GOSM6Q";7K=LD[XXGY#SIPDVX[XZ3=GY3#'B:V<\M%L`WKX=2`^8G[;SYT$ M.[;[B+J`/82=T(\O[Q7?T1>\!C3EZMO;6Y"707]3L42<(OO/@[LJ_7/<:KYK M1RYI.G?VFUOZEHMG_5"D&UL/(Y!"@(Q$`3O M@G\8YNYF]:`B2184?($^(&1'$T@F2R:(_MYX\=)0-%2WGMXYP8NJQ,(&M\.( M0.S+'/EI\'Z[;HX(TAS/+A4F@Q\2G.QZI;U+_A)<9.@&%H.AM>6DE/A`V/$K-KG6L3R5+)3=+(&HYJ=TX[E7N`K3:0S5X/B#$_@$A_5)9K?XC]@L` M`/__`P!02P,$%``&``@````A`!V&FCLQ`0``0`(``!$`"`%D;V-0C78R.81SD#HP(16K8%&Y:;T1,1[_%3LAW ML04\(62*A1!3X",S=2$0#4LD1Z3Y\TP.4Q-"``1L#I@7%W]T(WH0_+_3) M1=/H>'!IID'WDJWD*1S;^Z#'8M=U15?V&LF?XM?EPU,_:J[M<5<2$#_NIQ$A M+M,J-QK4[8'OWWR3A;"K\.^L4K*W8]*#B*"R]!X[V9V3E_+N?K5`?$+H-">S MG-(5G3)2LI*L*WQN#??Y"#2#P+^)9P#OO7_^.?\"``#__P,`4$L!`BT`%``& M``@````A`/>M,B0+`@``"QP``!,``````````````````````%M#;VYT96YT M7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P`````` M``````````!$!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`3!6TEC8" M```X&P``&@````````````````!J!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"+0`4``8`"````"$`XKT9N*L#``#9#```#P`````````````` M``#@"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`)-[U2[7`P`` MC@T``!@`````````````````N`X``'AL+W=O&UL4$L!`BT`%``&``@````A``[\ MNG_J`@``E@@``!D`````````````````NQ4``'AL+W=O&PO=V]R:W-H965T\_G[@(``%8)```9`````````````````!(<``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`(C/6O:U`@``4P<``!D` M````````````````-Q\``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*4D*^**!@``G1T``!D````````````````` M4C<``'AL+W=O"```&0`````````````````3/@``>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`+G_NZ&:`P``+PX``!D`````````````````&UL4$L!`BT`%``&``@````A`&_>S$9D M#```2G(```T`````````````````D(T``'AL+W-T>6QE&PO=&AE M;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#<&Y]T3@0``$4/```9```` M`````````````.2@``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`+(EHFV;!```.A$``!D`````````````````::4``'AL+W=O M1,VCRP#``#_ M"@``&0`````````````````[J@``>&PO=V]R:W-H965TM3P4``-T4```9`````````````````)ZM M``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`$]- M7DQ+!```NPX``!@`````````````````)+,``'AL+W=O&UL4$L!`BT`%``&``@` M```A`-^O0PSC`P``&PT``!D`````````````````O+H``'AL+W=O&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`''"V(^A#P``1%<``!@`````````````````^/<``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`+9+VC!F`@``308` M`!D`````````````````0Q(!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'9+[E!W`@``OP4``!D````````````` M````-B@!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`--K^Z*D`P``B`L``!D`````````````````(S@!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.5' MW$9T!P``+B0``!D`````````````````5E`!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/8>L?C=!@``:__E0```*D````0```` M`````````````!=T`0!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A M`!V&FCLQ`0``0`(``!$`````````````````VG0!`&1O8U!R;W!S+V-O&UL4$L%!@`````V`#8`HPX``$)W`0`````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses (Details) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]    
Interest $ 47,150us-gaap_InterestPayableCurrent $ 16,650us-gaap_InterestPayableCurrent
Salaries - Officer 20,000us-gaap_AccruedSalariesCurrent 13,250us-gaap_AccruedSalariesCurrent
Rent    22,418us-gaap_AccruedRentCurrent
Other 60,794us-gaap_OtherAccruedLiabilitiesCurrent 35,992us-gaap_OtherAccruedLiabilitiesCurrent
Accounts payable and Accrued expenses, Total $ 127,944us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent $ 88,310us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization (Details)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Organization (Textual)    
Dilutive potential common shares 2,400,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 2,400,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
XML 17 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details) (USD $)
Dec. 31, 2014
Rental Income  
2015 $ 229,500us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent
2016 324,000us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
2017 348,000us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
2018 372,000us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
2019 382,500us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
Thereafter 96,000us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableThereafter
Total 1,752,000us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable
Rental Expenses  
2015 203,679us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent
2016 271,572us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2017 271,572us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2018 271,572us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears
2019 271,572us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears
Thereafter 67,893us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter
Total $ 1,357,860us-gaap_OperatingLeasesFutureMinimumPaymentsDue
XML 18 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details Textual) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Income Taxes (Textual)    
Net operating loss carryforward $ (2,712,745)us-gaap_DeferredTaxAssetsOperatingLossCarryforwards $ (2,546,416)us-gaap_DeferredTaxAssetsOperatingLossCarryforwards
Net operating loss carryforwards, Expiration date Dec. 31, 2032  
Change in valuation allowance $ 104,269us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance $ 83,139us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Loan Receivable
12 Months Ended
Dec. 31, 2014
Loan Receivable [Abstract]  
LOAN RECEIVABLE
3. LOAN RECEIVABLE

 

On February 3, 2012, LMC loaned $32,000 to Health Clinics of Florida, LLC. On April 9, 2012 and August 10, 2012, LMC advanced an additional $10,500. The unsecured notes are interest free and due June 15, 2013. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. The manager of Health Clinics of Florida, LLC is a shareholder of the Company. As of December 31, 2012, the Company recorded a reserve for the full amount of the receivable reducing the balance to $-0-.

EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V M-#$Q93@R,#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O3PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E=A#I%>&-E;%=O5]4#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E M;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=OF%T:6]N7U!O;&EC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O&5S7U1A8FQE#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E=A#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]$971A:6QS/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DQO86Y?4F5C96EV86)L95]$ M971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I% M>&-E;%=O#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%C8V]U;G1S7U!A>6%B;&5? M86YD7T%C8W)U961?13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN8V]M95]487AE#I7;W)K#I%>&-E;%=O&5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I%>&-E;%=O#I.86UE/E=A#I7;W)K M'1U86P\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W M8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V M83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA2`R."P@,C`Q-3QB M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^+2TQ,BTS M,3QS<&%N/CPO'0^,3`M2SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS<&%N/CPO2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^4VUA;&QE3QS<&%N/CPO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^)FYB'0^)FYBF5D.R`R-BPP M.#4L,3`Q(&%N9"`R-2PX,S4L,3`Q('-H87)E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S M7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W M8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V M83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'!E;G-E*3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2`H55-$("0I/&)R/CPO'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)FYB'0^ M)FYB'0^)FYB'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B M,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAAF%T:6]N(%M!8G-TF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV/@T*/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=V]R9"US<&%C:6YG.B`P<'@[('=I9&]W'0M6QE/3-$)W9E"`P<'@@,'!X(#`N M-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE6QE($UE9&EC86P@3F5T=V]R:R!);F,N(&%N M9"!3=6)S:61I87)I97,@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@ M)B,X,C(P.TQI9F5S='EL928C.#(R,3LI('=A2!D M:7)E8W1S(&ET2!O<&5R871E"`P+C5I;CL@=&5X="UA;&EG M;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E"`P+C5I;CL@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UEF%T:6]N(&]F(&%S2!O9B!R96-U2!T;R!C;VYT:6YU92!A6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I M;F'0M"`P<'@@,'!X(#`N-6EN.R!C;VQO2!H87,@86=R965D('1O(&5N=&5R(&EN M=&\@36%N86=E;65N="!A9W)E96UE;G1S('=I=&@@"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU M:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P<'@@,'!X M(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P M+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M"`P M<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M2!A;F0@ M:71S('=H;VQL>2UO=VYE9"!A;F0@;6%J;W)I='DM;W=N960@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[ M('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO M'0M:6YD96YT M.B`P<'@[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[ M('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M'!E;G-E"!E>'!O'!E6EN9R!V86QU92!O9B!A M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M"`P M<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE M='1E"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE2!N;VYC;VYT2!F M"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@ M;&5T=&5R+7-P86-I;F'0M M"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E"`P+C5I;CL@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UEF5S(&ET#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M&5S/"]U/CPO:3X\+V9O;G0^/"]P/@T* M/'`@"`P+C5I;CL@ M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN M9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU M:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I M;F'0M&5S(&%R92!C86QC=6QA=&5D(&EN(&%C8V]R9&%N8V4@=VET M:"!T87AA=&EO;B!P2!E9F9E8W1I=F4@:6X@ M=&AE(%5N:71E9"!3=&%T97,@;V8@06UE"`P+C5I;CL@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M'!E M8W1E9"!F=71U"!B87-I'!E8W1E9"!T;R!R M979E"!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E'0M"!A&ES=&EN9R!T87AA8FQE('1E;7!O2!D M:69F97)E;F-E"!A&5S+CPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E"`P+C5I;CL@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E2!T;R!C;VYC96YT6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E&-E28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T2P@ M;6EN:6UA;"!C&ES="!W:71H M(')E"`P<'@@,'!X M(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M2!T:&4@=V5I9VAT960@879E2!T:&4@=V5I9VAT960@ M879E"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E"`P+C5I;CL@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z#0H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B"`P M+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M"`P M<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M2!T:&5R96)Y(')E;6%I;FEN9R!T:&4@:6YC2P@=&AE($-O;7!A;GD@:&%S(&%D;W!T960@=&AI M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU M:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P+C5I;CL@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E M"`P+C5I;CL@=&5X="UA;&EG;CH@ M;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE&-H86YG92!P&ET('!R:6-E*2!I;B!T:&4@<')I;F-I<&%L M(&]R(&UO2!I;B!A;B!O2!W:&EC:"!R97%U:7)EF4@=&AE('5S92!O9B!O8G-EF4@=&AE('5S92!O9B!U;F]B2!B92!U"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@ M,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P M86-I;F'0MF5S('1H92!A8V-O=6YT:6YG M(&=U:61A;F-E(&9O&ET('!R:6-E M+"!R97!R97-E;G1I;F<@=&AE('!R:6-E('1H870@=V]U;&0@8F4@F5S('1H92!I;G!U=',@ M=7-E9"!I;B!M96%S=7)I;F<@9F%I"`P<'@@,'!X(#`N-6EN.R!T M97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E6QE/3-$)W=I9'1H.B`Q M-#(R+C'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M3H@)W1I M;65S(&YE=R!R;VUA;B#L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Y.2XP.7!X.R<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!T;R!D979E;&]P(&ET"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M'1087)T7S1B-F$P8F,T7S9B M8S-?-&(R-5]A86,R7S=C,C8T,3%E.#(P.0T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R M,#DO5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M#L@;&5T=&5R+7-P M86-I;F6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&9O;G0MF4Z(#$P<'0[(&9O;G0M3L@=&5X="UI;F1E M;G0Z(#`N-6EN.R<^/&9O;G0@F4Z(#$P<'0[(&9O;G0M3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E&ES=&EN9R!C;&EN:6-S+"!A6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT M('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B"`P+C5I;CL@ M=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E2!M86YA9V5M96YT+B!-86YA9V5M96YT(&-O;G-I9&5R960@82!N=6UB M97(@;V8@9F%C=&]R65A#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M M86P[(&UA"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&IU M6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(#$[('=O'0M#L@ M=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[ M(&UA"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&IU6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T M3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P M<'@@,"XU:6X[('1E>'0M86QI9VXZ(&IU#L@=&5X="UT M'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA M<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT.R<@8V]L6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M86QI9VXZ M(')I9VAT.R<^+3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/"]T6QE/3-$ M)V9O;G0M'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W=I9'1H.B`Q,W!X M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-TF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[ M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT M+79A'0M86QI9VXZ(')I9VAT.R<^*#(P,"PP,#`\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXI M/"]T9#X-"CPO='(^#0H\='(@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/"]T3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M3H@)W1I M;65S(&YE=R!R;VUA;B'0M86QI9VXZ(')I9VAT.R<^-2PX,#`L M,#`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF%T:6]N(&9O65A6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXI M/"]T9#X-"CPO='(^#0H\='(@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`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`P+#`P,#PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/"]T6QE/3-$)V9O M;G0M'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;BF%T:6]N(&9O65A6QE M.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ(')I9VAT M.R<^*#4L-34R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W9E M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/"]T'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V)O6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X- M"CPO='(^#0H\='(@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/"]T3H@)W1I;65S M(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V)O'0M86QI9VXZ M(')I9VAT.R<^.#@L.#DS/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@-'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI M="UT97AT+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S M=&EF>3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US=')E=&-H M.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[)SX\9F]N="!S M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'!E;G-E(&9O65A2X\+V9O;G0^/"]P/@T*/'`@F4Z(#$P<'0[(&9O;G0M"`P<'@@,'!X(#`N-6EN.R<^/&9O;G0@F4Z(#$P<'0[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O'0M"`P<'@@,'!X(#`N-6EN.R<^/&9O;G0@F4Z(#$P<'0[(&9O;G0M#L@=&5X="UT'0M:6YD M96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q M.R`M=V5B:VET+71E>'0M6QE/3-$)W9EF4Z(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY996%R($5N9&EN9SPO=&0^#0H\=&0@ M'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]TF4Z(#$P<'0[('1E>'0M M86QI9VXZ(')I9VAT.R<^-2PU-34\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H M.B`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`Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M M:6YD96YT.B`P<'@[(&QE='1E#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D+7-P86-I;F#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)V9O;G0M MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V-O M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M M86P[(&UA"`P<'@@,"XU:6X[)SX\9F]N="!S='EL93TS M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#L@=&5X="UT#L@9F]N="US=')E=&-H M.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[('1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG2`S+"`R,#$R+"!,34,@;&]A;F5D("0S,BPP,#`@=&\@2&5A;'1H M($-L:6YI8W,@;V8@1FQO2!R96-O3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W M8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V M83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;BF4Z(#$P<'0[(&9O;G0M"`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL M>3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P M<'@@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@ M)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P<'@@ M,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M#LG/CPO<#X-"CQT86)L92!A;&EG M;CTS1&-E;G1E#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$ M)W9EF4Z(#$P<'0[('!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0V/D1E8V5M8F5R(#,Q+#PO=&0^ M#0H\=&0@6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S M(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)W!A9&1I;FF4Z(#$P<'0[#0H@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E M>'0M86QI9VXZ(&-E;G1EF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T#L@9F]N="US M='EL93H@;F]R;6%L.R!F;VYT+79AF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3$S<'@[(&9O;G0M6QE/3-$)W=I9'1H.B`Q,W!X.R!F;VYT M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I M;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT M9"!S='EL93TS1"=W:61T:#H@,3$R<'@[(&9O;G0M6QE/3-$)W=I9'1H.B`Q,G!X.R!F;VYT+7-T>6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA M;B6QE/3-$)W9E6QE/3-$)V9O M;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E2!N;W1E+"!I;G1E6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI M9VXZ(')I9VAT.R<^-S4L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$)V9O;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`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`[/"]T9#X- M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[ M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T3H@)W1I;65S(&YE=R!R;VUA;B6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE M=R!R;VUA;B6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M'0M86QI9VXZ(')I9VAT.R<^,3`P+#`P,#PO=&0^#0H\=&0@ M6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R M;VUA;B6QE M.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M6QE.B!S M;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(')I9VAT.R<^ M,2PP-3`L.3`U/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`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`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE.B!D;W5B M;&4[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[ M(&UA6QE/3-$)W=I9'1H.B`Q,C4S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B3H@ M)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O M;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-EF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Y,SDN-C'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T M:#H@,3$S<'@[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A6QE/3-$)W=I9'1H.B`Q,G!X.R!F M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W=I9'1H.B`Q,3)P>#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ(')I M9VAT.R<^,C8L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3)P>#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.PT*(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V)O6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-TF4Z M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X- M"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$ M)W9E3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`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`G=&EM97,@ M;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&9O;G0M#L@=&5X="UT'0M M:6YD96YT.B`P<'@[(&QE='1E#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D+7-P86-I;F#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M M86P[(&)A8VMG'0M6QE/3-$)W9E6QE/3-$ M)W=I9'1H.B`P+C(U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I M;65S(&YE=R!R;VUA;B'1E;F1E9"!T;R!* M=6YE(#$U+"`R,#$U+B!);B!T:&4@979E;G0@;V8@9&5F875L="P@=&AE($1E M;&QI;F=E6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B"`U."XU M<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R9"US<&%C:6YG M.B`P<'@[(&9O;G0M2`S+"`R M,#$R(&%N9"!-87)C:"`Q+"`R,#$R+"!,34,@8F]R2X@5&AE('5NF4Z M(#$P<'0[(&9O;G0M'0M M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z M(&%U=&\[('=O'0M"`P<'@@,'!X(#4X+C5P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI M;F1E;G0Z("TQ.2XU<'0[(&)A8VMG6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=V]R9"US<&%C:6YG.B`P<'@[(&9O M;G0M2X@5&AE('5N#L@9F]N="US=')E=&-H.B!N;W)M86P[ M(&UA"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`M,"XR-6EN.R!B86-K9W)O=6YD+6-O;&]R.B!W M:&ET93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R9"US<&%C M:6YG.B`P<'@[(&9O;G0M2`R,#$S+"!,34,@8F]R6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B"`P+C'0M86QI9VXZ(&IU M'0M:6YD96YT.B`M,"XR-6EN.R!B86-K9W)O=6YD+6-O;&]R M.B!W:&ET93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M#L@;&5T=&5R+7-P86-I;FF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^#0H\=&0@ M6QE/3-$)V9O;G0M#L@=&5X="UT#L@9F]N="US=')E=&-H M.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[('1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@=V]R9"US<&%C:6YG.B`P<'@[(&9O;G0MF4Z(#$P<'0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R M9"US<&%C:6YG.B`P<'@[(&9O;G0M6%B;&4@=7!O;B!D96UA;F0N($EN($1E8V5M8F5R(#(P M,3,L($Q-0R!R97!A:60@)#0L,#`P(&%G86EN6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE M=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT M+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8F%C M:V=R;W5N9"UC;VQO6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T#L@;&5T=&5R+7-P M86-I;FF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@3LG/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^#0H\=&0@6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E2X@5&AE('-E8W5R960@;F]T92!B96%R6%B M;&4@:6X@9G5L;"!O;B!O6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@=&5X="UA M;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT'0M:6YD96YT.B`P M<'@[(&QE='1E#L@ M;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D+7-P86-I;F#L@9F]N="US M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[(&)A8VMG M'0M6QE/3-$)W9E'0M86QI9VXZ(&IU M6QE/3-$)W=I9'1H.B`P+C(U:6X[('1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6%B;&4@;VX@;W(@ M8F5F;W)E($1E8V5M8F5R(#$U+"`R,#$U+B!!F4Z(#$P M<'0[(&9O;G0M'0M:6YD M96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@ M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L M969T.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQF;VYT('-T>6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E#L@;&5T M=&5R+7-P86-I;FF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@3LG M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^#0H\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A('!R M:6-E(&]F("0P+C$P('!E6QE/3-$)V-O;&]R.B`C M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT M#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&IU3H@)W1I;65S(&YE=R!R;VUA;B'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'!E;G-E M'0^/'1A8FQE('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA M;B6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UTF4Z(#$P<'0[(&9O;G0M#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL M87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$)W9EF4Z(#$P<'0[('!A9&1I;F6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/@T*/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W9EF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I M9VAT.R<^-#F4Z(#$P<'0[('1E>'0M M86QI9VXZ(')I9VAT.R<^,38L-C4P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T M:#H@,3)P>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY3 M86QA6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT.R<^ M,C`L,#`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`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`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`@("`\=&%B;&4@8VQA&5S/&)R M/CPO'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=V]R9"US<&%C:6YG.B`P<'@[('=I M9&]W#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/@T* M/'1D('-T>6QE/3-$)W=I9'1H.B`P<'@[)SX\+W1D/@T*/'1D('-T>6QE/3-$ M)W=I9'1H.B`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I M;F#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[ M('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M2!R96-O9VYI>F5D(&YO(&%D:G5S=&UE;G0@:6X@=&AE M(&YE="!L:6%B:6QI='D@9F]R('5N"!P;W-I=&EO;G,@86YD M(&%L;"!T87@@"!P;W-I=&EO;G,@87,@82!C;VUP;VYE;G0@;V8@=&AE(&-U6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F"`P<'@@ M,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E M"!P"!B87-I2=S(&%S2!T;R!R961U8V4@9&5F97)R960@=&%X(&%SF5D+B8C,38P.R8C M,38P.U1H92!#;VUP86YY(&AA2!N;W0@8F4@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[ M('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO M'0M:6YD96YT M.B`P<'@[(&QE='1E"`P<'@@,'!X(#`N M-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"]N;W)M M86P@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W=I9'1H.B`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`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`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`Q,'!T+VYO6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[(&9O;G0M M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M"`P+C5I;CL@ M=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I M;F'0M2!R871E('1O(&%M;W5N M=',@<')O=FED960@:7,@87,@9F]L;&]W"`P+C5I;CL@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M#L@=&5X="UT'0M:6YD96YT.B`P M<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B M:VET+71E>'0M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)R!C;VQS<&%N/3-$-CY996%R6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W9EF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE M.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;FF4Z(#$P<'0[(&)O6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I M9'1H.B`Q,W!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`Q,W!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3$S M<'@[('1E>'0M86QI9VXZ#0H@'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$)W=I M9'1H.B`Q,3)P>#L@=&5X="UA;&EG;CH@#L@ M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`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`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CPO<#X-"CQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ M(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@ M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N M-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E&EM871E;'D@)#(N-R!M:6QL:6]N('1H870@ M=V%S(&9U;&QY(&]F9G-E="!B>2!A('9A;'5A=&EO;B!A;&QO=V%N8V4@9'5E M('1O('1H92!D971EF4@=&AO"`P<'@@ M,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E M"`P+C5I;CL@=&5X="UA;&EG;CH@ M;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2!D:69F97)E;F-E"!B87-I"!L:6%B:6QI='D@86YD(&1E9F5R"!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!C96YT97([(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M#L-"B!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@ M6QE M/3-$)V9O;G0MF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#LG(&-O;'-P86X],T0R M/C(P,3,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;FF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[)SY.970@;W!E6QE/3-$)W=I9'1H.B`Q,W!X.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,W!X.R!T M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT M9"!S='EL93TS1"=W:61T:#H@,34Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F M;VYT+7-I>F4Z(#$P<'0[)SXH,BPW,3(L-S0U/"]T9#X-"CQT9"!S='EL93TS M1"=W:61T:#H@,3)P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q M,'!T.R<^*3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-3!P>#L@=&5X="UA;&EG;CH@ M6QE/3-$)W=I9'1H.B`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`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;FF4Z(#$P<'0[)SY.970@9&5F97)R960@=&%X97,\+W1D/@T*/'1D M('-T>6QE/3-$)W!A9&1I;F6QE.B!D;W5B;&4[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[(&)OF4Z(#$P<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE M.B!D;W5B;&4[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+W1D/@T*/"]T"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!C96YT M97([(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!C96YT97([(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E69O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$)W9E6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3LG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M3LG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!W:71H(&$@9F%I6QE M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R M;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!L971T97(M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF;VYT M('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V-O;&]R.B`C,#`P,#`P M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B"`P+C5I;CL@ M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M2!I'!E;G-E(&]F M("0Q,2PU-3`N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ M(&IU6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X M="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B M,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O M'0O:'1M M;#L@8VAA#L@;6%R M9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT M+7-T6QE/3-$)W=I9'1H.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE"`P<'@@,"XU M:6X[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2`V+"`R,#$W+B!4:&4@ M97-T:6UA=&5D('9A;'5E(&]F('1H92!C;VUP96YS871O'!E M8W1E9"!T97)M(&]F(#,@>65A6EE;&0@;V8@+3`M)2!A;F0@=F]L M871I;&ET>2!O9B`T,S(E+B!4:&4@9F%I2!R96-O'!E;G-E(&]F("0Q M-328C.#(Q-SMS(&-O M;G-O;&ED871E9"!S=&%T96UE;G0@;V8@;W!E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE"`P<'@@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE"`P<'@@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-EF5S('1H92!C:&%N9V5S(&EN('=A3L@9F]N=#H@,3!P="!T:6UE"`P+C5I;CLG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE6QE/3-$)W=I9'1H.B`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`Q,B4[(&)O'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('=I9'1H.B`Q,B4[(&)O'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O M;G0M65A6QE/3-$)V9O;G0M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R9"US<&%C:6YG.B`P M<'@[('=I9&]W#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W=I M9'1H.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M#L@ M9F]N="US=')E=&-H.B!N;W)M86P[(&UA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=V]R9"US M<&%C:6YG.B`P<'@[('=I9&]W6QE/3-$)W=I9'1H.B`P+C(U:6X[)SX\9F]N="!S M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M2X@5&AE6QE/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(&IU6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E M:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I M;65S(&YE=R!R;VUA;B6QE/3-$)W=I9'1H.B`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`P<'@[('=I9&]W6QE/3-$)W=I9'1H.B`P+C(U:6X[)SX\9F]N="!S='EL M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6UE;G0@9F]R M(&%N(&%C<75I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'1A8FQE('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I;F'0M6QE/3-$)W9E6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R M;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US M=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M:6YD96YT.B`P M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(#$[('=O'0M M"`P<'@@,'!X(#`N-6EN.R<^/&9O;G0@F4Z(#$P M<'0[(&9O;G0M'0M86QI M9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'!I2!W:6QL(&QE87-E('1H92!C;&EN:6-S(&9R;VT@=&AE M(&9O'0M:6YD96YT M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R M;6%L.R!W:61O=W,Z(#$[('=O'0M"`P<'@@,'!X(#`N-6EN.R<^/&9O;G0@F4Z M(#$P<'0[(&9O;G0M'0M M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P M+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4Z(#$P M<'0[(&9O;G0M'0M86QI M9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE/3-$)V-O;&]R M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[ M(&UA"`P<'@@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6UE;G1S(&%N9"!R96YT86P@:6YC;VUE('5N9&5R('1H M97-E(&%G6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S M(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US M=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#L-"B!T97AT+71R86YS9F]R;3H@;F]N M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[)SY296YT86P@26YC;VUE/"]T9#X-"CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F#L@=&5X="UI M;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[)R!C M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M#L@=&5X="UI;F1E;G0Z(#!P>#LG(&-O;'-P86X] M,T0R/B8C,38P.SPO=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D M/@T*/"]T"`P<'@@,'!X(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'@[)SXR,#$U/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@.2XV,#`P M,#`S.#$T-CDW,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@ M=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[)SXR,CDL-3`P M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@.2XV,#`P,#`S.#$T-CDW,W!X M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T"`P<'@@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI M;F1E;G0Z(#!P>#LG/C(P,38\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M86QI9VXZ(')I9VAT.R!T97AT+6EN M9&5N=#H@,'!X.R<^,S(T+#`P,#PO=&0^#0H\=&0@#L@=&5X M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^ M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E3H@ M)W1I;65S(&YE=R!R;VUA;B"`P<'@@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z M(#!P>#LG/C(P,3<\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[ M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W M(')O;6%N)RP@=&EM97,L('-E'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@ M,'!X.R<^,S0X+#`P,#PO=&0^#0H\=&0@#L@=&5X="UA;&EG M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R M/@T*/'1R('-T>6QE/3-$)W9E"`P<'@@,'!X M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR M,#$X/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#LG/C,W M,BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M"`P<'@@,'!X(#$P<'0[ M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR,#$Y/"]T M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R<^,S@R+#4P M,#PO=&0^#0H\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X M="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE M/3-$)W9E"`P<'@@,2XU<'0@,3!P=#L@=&5X M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/E1H97)E869T97(\ M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V)O#L@ M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B0\+W1D/@T* M/'1D('-T>6QE/3-$)V)O#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[ M)SXQ+#6QE/3-$)W!A9&1I;F#L@ M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[('!A9&1I;F#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C M,38P.SPO=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M#L@=&5X="UI;F1E;G0Z M(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@'0M:6YD M96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'0M86QI9VXZ(&QE9G0[)SY296YT M86P@17AP96YS93PO=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI M9VXZ(')I9VAT.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO M=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M#L@=&5X="UI;F1E;G0Z(#!P>#LG M/B8C,38P.SPO=&0^#0H\=&0@'0M:6YD96YT.B`P M<'@[)SXF(S$V,#L\+W1D/@T*/"]T"`P<'@@,'!X(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR,#$U/"]T9#X-"CQT9"!S='EL93TS M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P<'@[)SXR,#,L-C3H@ M)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T"`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN M9&5N=#H@,'!X.R<^,C`Q-CPO=&0^#0H\=&0@#L@=&5X="UI M;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@#L@=&5X M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^ M#0H\=&0@#L@=&5X="UA;&EG;CH@'0M:6YD M96YT.B`P<'@[)SXR-S$L-33H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E"`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@ M,'!X.R<^,C`Q-SPO=&0^#0H\=&0@#L@=&5X="UI;F1E;G0Z M(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@#L@=&5X="UA;&EG M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@ M#L@=&5X="UA;&EG;CH@'0M:6YD96YT.B`P M<'@[)SXR-S$L-33H@)W1I;65S(&YE=R!R M;VUA;B6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE M=R!R;VUA;B"`P<'@@ M,3!P=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/C(P M,3@\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@ M=&EM97,L('-E'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R<^,C#L@=&5X="UA;&EG;CH@;&5F=#L@ M=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T M>6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA M;B"`P<'@@,3!P=#L@ M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/C(P,3D\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R<^,C#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI M;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$ M)W9E"`P<'@@,2XU<'0@,3!P=#L@=&5X="UA M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/E1H97)E869T97(\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V)O3H@)W1I M;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#LG M/C$L,S4W+#@V,#PO=&0^#0H\=&0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B#LG/B8C,38P.SPO=&0^#0H\+W1R/@T* M/"]T86)L93X-"CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M#L@=&5X="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UAF4Z(#$P M<'0[(&9O;G0M'0M86QI M9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I M;CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X M="UT#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R M;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R M;VUA;B'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O'0M"`P<'@@,'!X(#`N-6EN.R<^ M/&9O;G0@F4Z(#$P<'0[(&9O;G0M"`P+C5I;CL@8F%C:V=R;W5N9"UC;VQO6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T M3H@)W1I;65S(&YE=R!R;VUA;B'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O'0M"`P<'@@,'!X(#`N-6EN.R!B M86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M MF4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM M97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@=V]R9"US<&%C:6YG.B`P<'@[('=I9&]W'0M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`P M+C(U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;BF4Z(#$P<'0[(&QI M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O M;6%N)RP@=&EM97,L('-E2`R,#$R+"!,:69E2P@6QE(&%N M9"!T:&4@0V]N65A#L@=&5X="UT#L@ M9F]N="US=')E=&-H.B!N;W)M86P[(&UA"`P<'@@,"XU M:6X[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D+7-P86-I;F#L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT M+7-T#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^ M#0H\=&0@6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T65A#L@=&5X="UT#L@ M9F]N="US=')E=&-H.B!N;W)M86P[(&UA6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=V]R9"US<&%C:6YG.B`P<'@[('=I9&]W M'0M M6QE/3-$)W9E6QE M/3-$)W=I9'1H.B`P+C(U:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E2`Q+"`R M,#$R+"!,:69E6UE;G0@86=R M965M96YT('=I=&@@0VAR:7-T;W!H97(@4VUI=&@@*")3;6ET:"(I+"!T:&4@ M0V]M<&%N>2=S($-H:65F($5X96-U=&EV92!/9F9I8V5R+B!4:&4@=&5R;2!O M9B!T:&4@86=R965M96YT(&ES(&9O65A2X\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A M8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@;&5T=&5R+7-P86-I;F6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L M969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T M.R!C;VQO'0M M:6YD96YT.B`P<'@[(&QE='1E"`P M+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE2!I;B!E=F%L=6%T:6YG('1H92!A8W%U:7-I=&EO;B!B>2!T:&4@0V]M<&%N M>2!O9B!T=V\@;65D:6-A;"!P"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C M;VQO'0M:6YD M96YT.B`P<'@[(&QE='1E"`P+C5I;CL@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'1E;F1I;F<@=&AR;W5G:"!$96-E;6)E7-I8VEA;B!E;7!L;WEE928C.#(R,3LL('!U&-E960@86X@86=R M965D(&-A<"P@;W(@=&AA="!T:&4@"`P<'@@,'!X M(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2P@4F5G:6]N86P@4')O9F5S"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.PT*('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6UB;VQS+"!O<&5R871I;VYA M;"!S>7-T96US+"!A;F0@;W1H97(@:6YT96QL96-T=6%L('!R;W!E2P@:6X@<&%R=&EC=6QA6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[ M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N M-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P+C5I M;CL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UEF5D('1H92!I65A'!I"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!J=7-T:69Y.R!C;VQO'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F'0M"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M"`P M<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO'0M:6YD96YT.B`P+C5I M;CL@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E2!T:&4@ M0V]M<&%N>2!I;B!&96)R=6%R>2`Q-"P@,C`Q-"P@:6X@8V]N;F5C=&EO;B!W M:71H('1H92!#;VUP86YY)B,X,C$W.W,@<')E=FEO=7,@;F5G;W1I871I;VYS M('1O(&%C<75I"`P+C(U M:6X[('1E>'0M86QI9VXZ(&IU"`P+C5I;CL@=&5X="UA;&EG;CH@ M;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2!.;W1E/"]U/CPO9F]N=#X\+W`^#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO"`P<'@@,'!X(#`N,C5I;CL@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M2!I2!P;W)T:6]N(&]F('1H92!P2!A8V-R=65D(&EN=&5R97-T(&EN=&\@ M2!A="!A(&-O M;G9E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$"`P<'@@,'!X(#`N-6EN.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE M='1E"`P<'@@,'!X(#`N-6EN.R!C;VQO"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F M=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2!I;F-L M=61E('1H92!#;VUP86YY(&%N9"!I=',@=VAO;&QY+6]W;F5D(&%N9"!M86IO M2UO=VYE9"!S=6)S:61I87)I97,N($%L;"!M871E"`P+C5I;CL@=&5X="UA M;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[ M(&QE='1E2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!E=F%L=6%T97,@:71S(&5S=&EM871E2!B87-E2!A<'!A'0^/&1I M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU M:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E2!F"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[ M(&QE='1E28C.#(Q-SMS('1O=&%L M(&%S2!A;6]R=&EZ97,@:71S M(&QI8V5N2!N;W0@8F4@&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@ M"`P+C5I;CL@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE&5S M/"]U/CPO:3X\+V9O;G0^/"]P/@T*/'`@"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M&5S(&%R92!C86QC=6QA M=&5D(&EN(&%C8V]R9&%N8V4@=VET:"!T87AA=&EO;B!P2!E9F9E8W1I=F4@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE M"`P+C5I;CL@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M#L@ M=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'!E8W1E9"!F=71U"!B87-I"!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E'1E;G0@=&AE>2!B96QI979E('1H97-E(&%SF5D+B8C,38P.R8C,38P.TEN M(&UA:VEN9R!S=6-H(&1E=&5R;6EN871I;VXL('1H92!#;VUP86YY(&-O;G-I M9&5R"!P;&%N;FEN9R!S=')A=&5G:65S(&%N M9"!R96-E;G0@9FEN86YC:6%L(&]P97)A=&EO;G,N)B,Q-C`[)B,Q-C`[26X@ M=&AE(&5V96YT('1H92!#;VUP86YY('=AF4@:71S(&1E9F5R2!W;W5L9"!M86ME(&%N M(&%D:G5S=&UE;G0@=&\@=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@=VAI8V@@ M=V]U;&0@"`P+C5I;CL@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT M+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E2!T;R!C;VYC96YT6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[('1E M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P M<'@[(&QE='1E&-E28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T2P@ M;6EN:6UA;"!C&ES="!W:71H M(')E'0^/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@ M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[ M(&QE='1E2!D:79I9&EN9R!N970@96%R;FEN9W,@ M8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R M97,@;W5T2!D:79I9&EN9R!N970@96%R;FEN9W,@8GD@=&AE('=E:6=H=&5D(&%V M97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@86YD('!O=&5N=&EA;"!C M;VUM;VX@65A"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C,#`P,#`P.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R M+7-P86-I;F'0M"`P<'@@,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L M969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E2!R96UA:6YI;F<@=&AE M(&EN8W)E;65N=&%L(&9I;F%N8VEA;"!R97!O"`P M+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,'!X(#`N-6EN.R!C;VQO M'0M:6YD96YT M.B`P<'@[(&QE='1E"`P+C5I;CL@ M=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE&-H86YG92!P&ET('!R:6-E*2!I;B!T M:&4@<')I;F-I<&%L(&]R(&UO2!I;B!A;B!O2!W:&EC:"!R97%U:7)EF4@=&AE('5S92!O9B!U;F]B2!B M92!U"`P+C5I;CL@=&5X M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M#LG M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE"`P<'@@,"XU:6X[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0MF5S('1H M92!A8V-O=6YT:6YG(&=U:61A;F-E(&9O&ET('!R:6-E+"!R97!R97-E;G1I;F<@=&AE('!R:6-E('1H870@=V]U M;&0@8F4@F5S M('1H92!I;G!U=',@=7-E9"!I;B!M96%S=7)I;F<@9F%I"`P<'@@ M,'!X(#`N-6EN.R!T97AT+6%L:6=N.B!L969T.R!C;VQO'0M:6YD96YT.B`P<'@[(&QE='1E M6QE M/3-$)W=I9'1H.B`Q,C4P+C1P>#L@=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1EF4Z(#$P<'0[('=O#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W=I9'1H.B`P+C5I;CLG/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!T;R!D979E;&]P(&ET"`P+C5I;CL@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"`P<'@@,"XU:6X[(&-O;&]R.B`C M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M'1087)T7S1B M-F$P8F,T7S9B8S-?-&(R-5]A86,R7S=C,C8T,3%E.#(P.0T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W M8S(V-#$Q93@R,#DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$#L@ M=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E M#L@8F]R9&5R M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M M6QE/3-$)W9E3H@ M)W1I;65S(&YE=R!R;VUA;B2`Q+"`R,#$Q/"]T9#X-"CQT9"!S M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`Q,3`Q<'@[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3)P>#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI9VXZ(')I M9VAT.R<^-BPP,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3)P M>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA M;BF%T:6]N(&9O2`X+"`R,#$Q('1H6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V)O6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA M;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(')I9VAT.R<^ M-2PX,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA M;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF%T:6]N(&9O65A M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E M3H@)W1I;65S(&YE=R!R;VUA;BF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE/3-$)V)O6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M3H@)W1I;65S(&YE=R!R;VUA M;B6QE.B!N;W)M86P[(&9O;G0M=F%R M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M86QI9VXZ M(')I9VAT.R<^*#4L-34R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,2XU<'0[(&9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE M/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`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`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE.B!D;W5B;&4[(&9O;G0M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W!A M9&1I;FF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'!E;G-E(&9O'0^/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE M/3-$)W=I9'1H.B`Q,C4S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P M<'0[)R!C;VQS<&%N/3-$,CY!;6]R=&EZ871I;VX\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0[(&)O6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/D5X M<&5N6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W=I9'1H.B`Q,3)P>#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T M.R<^)B,Q-C`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`Y+U=O M'0O:'1M M;#L@8VAA"`P+C5I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)W=I9'1H.B`Q,#`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`P<'@[(&QE='1E'0M#L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@=VAI=&4M#L@;&5T=&5R+7-P86-I;F#LG/CPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E#L@;&5T=&5R+7-P86-I;F#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@;&5F M=#L@<&%D9&EN9RUL969T.B`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`P/"]T M9#X-"CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M86QI9VXZ(')I9VAT M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW M:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[(&9O;G0M M6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE.B!D;W5B;&4[ M(&9O;G0M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'!E;G-E M'0^/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`Q M,C4S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X M.R!L971T97(M3H@)W1I;65S M(&YE=R!R;VUA;B6QE/3-$ M)V9O;G0M'0M M86QI9VXZ(&-E;G1E6QE M.B!S;VQI9#LG(&-O;'-P86X],T0V/D1E8V5M8F5R(#,Q+#PO=&0^#0H\=&0@ MF4Z(#$P M<'0[)SXF(S$V,#L\+W1D/@T*/"]TF4Z(#$P<'0[ M)SY);G1E6QE/3-$)W=I9'1H.B`Q,3-P>#L@9F]N="US:7IE M.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0W+#$U,#PO=&0^#0H\=&0@ M6QE/3-$)W=I9'1H.B`Q,3)P>#L@ M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$V+#8U,#PO M=&0^#0H\=&0@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE/3-$)V9O;G0MF4Z(#$P<'0[('!A9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^-C`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`Y+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'`@F4Z(#$S+C,S,S,S,S`Q-30T,3EP M>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O'0M6QE/3-$)W=I9'1H.B`Q,C4S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V9O M;G0M3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&-E;G1E6QE/3-$ M)V)O6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@ M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(&-E;G1E6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q,W!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`Q,G!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT M+7-T3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM M97,L('-E6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@ M;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE M=R!R;VUA;B6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A M'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)W9E6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E3H@)W1I;65S(&YE=R!R;VUA;B'0M86QI M9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M3H@)W1I;65S M(&YE=R!R;VUA;B'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\ M=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`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`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E6QE/3-$)V)O M6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M86QI9VXZ M(')I9VAT.R<^+3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E3H@)W1I;65S(&YE M=R!R;VUA;B6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E2!R871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO'0M:6YD96YT.B`P M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L M.R!W:61O=W,Z(#$[('=O'0M M"`P<'@@,'!X(#`N-6EN.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET M93LG/CPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E#L@;&5T=&5R+7-P86-I;F#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE M/3-$)V9O;G0MF4Z(#$P<'0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W=I9'1H.B`Y-3-P>#L@ M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^0F]O:R!I;F-O M;64@*&QO6QE/3-$)W=I M9'1H.B`Q,3)P>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H M=#LG/B@Q-#,L.#DW/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3)P>#L@ M9F]N="US:7IE.B`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`Q,'!T.R!T97AT+6%L:6=N.B!R M:6=H=#LG/C@S+#$S.3PO=&0^#0H\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/"]T"!E>'!E;G-E/"]T M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I M9VAT.R<^+3PO=&0^#0H\=&0@"!E9F9E8W0@87-S;V-I871E9"!W:71H(&1E M9F5R"!A3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'`@F4Z(#$P<'0[(&9O;G0M'0M86QI9VXZ('-T87)T.R!T97AT+6EN9&5N=#H@,'!X.R!T M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M#L@+7=E8FMI="UT97AT+7-T"`P+C5I;CL@8F%C:V=R;W5N9"UC;VQO#L@=&5X="UT'0M:6YD96YT.B`P<'@[ M(&QE='1E#L@ M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET M+71E>'0M6QE/3-$)W9E6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W=I M9'1H.B`X-SAP>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T M.R<^3F5T(&]P97)A=&EN9R!L;W-S(&-A'!I#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=W:61T:#H@,3-P>#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N M.B!L969T.R<^)#PO=&0^#0H\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^*#(L-S$R+#6QE/3-$ M)W=I9'1H.B`Q,G!X.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,G!X.R!F;VYT+7-I>F4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@ M,34P<'@[(&9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^,3'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M M'0M86QI9VXZ(')I9VAT M.R<^."PY.#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SY787)R86YT6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0M'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0M'!E;G-E/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('!A M9&1I;FF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^ M,2PX,S,L,S@U/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@ M,2XU<'0[(&9O;G0M6QE/3-$ M)V)O6QE.B!S M;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$L M.#,S+#,X-3PO=&0^#0H\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXI M/"]T9#X-"CPO='(^#0H\='(@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0M'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/"]T6QE.B!S;VQI9#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU M<'0[(&)OF4Z(#$P M<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^-S`U+#8T.3PO=&0^#0H\=&0@F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)OF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE.B!D;W5B;&4[(&9O;G0M'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W=I9'1H.B`Q,C4S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T6QE M/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI M9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<@8V]L6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O M;G0M'0M86QI9VXZ(')I M9VAT.R<^+3PO=&0^#0H\=&0@F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O M;G0MF4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M M6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0M'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/"]T6QE/3-$ M)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^ M+3PO=&0^#0H\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V)OF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T MF4Z(#$P<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q,W!X.R!F;VYT+7-I>F4Z M(#$P<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q,W!X.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M M+7-T>6QE.B!D;W5B;&4[(&9O;G0M6QE.B!D;W5B;&4[(&9O;G0M M6QE/3-$)W=I9'1H.B`Q,W!X.R!P861D:6YG+6)O='1O;3H@ M-'!T.R!F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,W!X.R!F;VYT+7-I>F4Z M(#$P<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q,W!X.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M M+7-T>6QE.B!D;W5B;&4[(&9O;G0M6QE/3-$)W=I9'1H.B`Q-3%P>#L@8F]R M9&5R+6)O='1O;2UC;VQOF4Z M(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^,"XR,#PO=&0^#0H\=&0@'0M86QI M9VXZ(&-E;G1E&5R8VES86)L92`M('!E6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O M'0M86QI9VXZ(')I9VAT.R<^,"XR,#PO=&0^#0H\ M=&0@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M65A6QE/3-$)W!A9&1I M;F6QE.B!D;W5B;&4[ M(&9O;G0M6QE/3-$)V)O6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O'0M"`P<'@@,'!X(#`N,C5I;CL@ M=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE M;G1S(&%N9"!R96YT86P@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\=&%B;&4@86QI9VX],T1C96YT97(@#L@=&5X="UT'0M:6YD96YT.B`P M<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B M:VET+71E>'0M6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^ M#0H\=&0@'0M:6YD96YT.B`P<'@[)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M#L@9F]N M="US='EL93H@;F]R;6%L.R!F;VYT+79A#L@ M=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A#L@=&5X="UA;&EG;CH@;&5F M=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I M9'1H.B`X.2XU.3DY.3@T-S0Q,C$Q<'@[(&9O;G0M#L@=&5X="UA;&EG;CH@ M;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)W9E"`P<'@@,'!X(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR,#$V M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T M3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B#LG/C,R-"PP M,#`\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M"`P<'@@,'!X(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR,#$W/"]T9#X- M"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H M=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S M(&YE=R!R;VUA;B#LG/C,T."PP,#`\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E"`Q,'!T.R!T97AT+6%L:6=N M.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R<^,C`Q.#PO=&0^#0H\=&0@#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@ M#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P M>#LG/B8C,38P.SPO=&0^#0H\=&0@#L@=&5X="UA;&EG;CH@ M'0M:6YD96YT.B`P<'@[)SXS-S(L,#`P/"]T9#X-"CQT9"!S M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E"`Q,'!T.R!T97AT+6%L:6=N.B!L969T M.R!T97AT+6EN9&5N=#H@,'!X.R<^,C`Q.3PO=&0^#0H\=&0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B#LG/C,X,BPU,#`\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXF M(S$V,#L\+W1D/@T*/"]T6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E M>'0M:6YD96YT.B`P<'@[)SY4:&5R96%F=&5R/"]T9#X-"CQT9"!S='EL93TS M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#LG/CDV+#`P,#PO=&0^#0H\=&0@6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T#LG/B8C,38P.SPO=&0^#0H\ M+W1R/@T*/'1R('-T>6QE/3-$)W9E3H@)W1I M;65S(&YE=R!R;VUA;B"`T<'0@,C!P=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P M>#LG/E1O=&%L/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L M.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA M;B6QE.B!D;W5B;&4[(&9O;G0M6QE.B!D;W5B;&4[(&9O;G0M'0M86QI9VXZ M(&QE9G0[('!A9&1I;F#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P M.SPO=&0^#0H\=&0@'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0M'0M86QI9VXZ(')I9VAT M.R!P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0M6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[('!A M9&1I;F#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\ M+W1R/@T*/'1R('-T>6QE/3-$)W9E#L@=&5X M="UA;&EG;CH@;&5F=#LG/EEE87)S($5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^ M#0H\=&0@'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R!P861D M:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E"`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@ M,'!X.R<^,C`Q-3PO=&0^#0H\=&0@#L@=&5X="UI;F1E;G0Z M(#!P>#LG/B8C,38P.SPO=&0^#0H\=&0@#L@=&5X="UA;&EG M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B0\+W1D/@T*/'1D('-T>6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R<^ M,C`S+#8W.3PO=&0^#0H\=&0@#L@=&5X="UA;&EG;CH@;&5F M=#L@=&5X="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R M('-T>6QE/3-$)W9E"`P<'@@,3!P M=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/C(P,38\ M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L M('-E'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R<^,C#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X M="UI;F1E;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE M/3-$)W9E3H@)W1I;65S(&YE=R!R;VUA;B"`P<'@@,3!P=#L@=&5X M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/C(P,3<\+W1D/@T* M/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[ M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M:6YD96YT.B`P<'@[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E M'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E M;G0Z(#!P>#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E M"`P<'@@,'!X(#$P<'0[('1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXR,#$X/"]T9#X-"CQT9"!S='EL M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B3H@)W1I;65S(&YE=R!R;VUA M;B#LG/C(W,2PU-S(\+W1D/@T*/'1D('-T M>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[ M)SXF(S$V,#L\+W1D/@T*/"]T"`P<'@@,'!X(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`P<'@[)SXR,#$Y/"]T9#X-"CQT9"!S='EL93TS1"=F M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@ M)W1I;65S(&YE=R!R;VUA;B6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B#LG/C(W,2PU-S(\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[)SXF(S$V M,#L\+W1D/@T*/"]T6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`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`T M<'0@,C!P=#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG M/E1O=&%L/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[ M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F M;VYT+7-T3H@)W1I;65S(&YE=R!R;VUA;B6QE.B!D;W5B;&4[#0H@9F]N="US='EL93H@;F]R;6%L.R!F M;VYT+79A#L@=&5X="UA;&EG;CH@;&5F=#L@ M=&5X="UI;F1E;G0Z(#!P>#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O#L@=&5X="UA;&EG M;CH@'0M:6YD96YT.B`P<'@[)SXQ+#,U-RPX-C`\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F#L@9F]N="US='EL93H@;F]R;6%L M.R!F;VYT+79A'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`P<'@[)SXF(S$V,#L\+W1D/@T*/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S M7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y M+U=O'0O M:'1M;#L@8VAA'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XU+#4U-3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'!E;G-E M(&9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T M8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&5X<&5N M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)? M-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!O9B!S:&]R="UT97)M(&1E8G0\+W-T2!O9B!S M:&]R="UT97)M(&1E8G0\+W-T2!O9B!S:&]R="UT97)M(&1E M8G0\+W-T2!O9B!S:&]R="UT97)M(&1E8G0\+W-T2!N;W1E+"!I;G1E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2!O9B!S:&]R="UT97)M(&1E8G0\+W-T'1E;F1E9"!T;R!*=6YE(#$U+"`R,#$U+B!);B!T:&4@ M979E;G0@;V8@9&5F875L="P@=&AE($1E;&QI;F=E2P@ M9G)O;2!T:&4@1&5L;&EN9V5R($9U;F0L(&$@2`R,#$S+"!,34,@8F]R2=S M(&-O;6UO;B!S=&]C:RX@4V5E($YO=&4@,3$N/"]T9#X-"B`@("`@(#PO='(^ M#0H@("`@("`\='(@8VQA2P@<&%I9"!E>'!E;G-E2P@;VX@8F5H M86QF(&]F('1H92!#;VUP86YY+B!4:&5S92!A9'9A;F-E6UE;G0@9F]R(&%N(&%C<75I2=S(&-O;6UO;B!S=&]C:R!A="!A('!R:6-E(&]F("0P+C$P('!E M'1087)T7S1B-F$P8F,T7S9B8S-?-&(R-5]A86,R7S=C,C8T,3%E.#(P.0T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T8C9A,&)C-%\V8F,S7S1B M,C5?86%C,E\W8S(V-#$Q93@R,#DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB2!N;W1E+"!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!N;W1E+"!I;G1E6%B;&4@;VX@;W(@ M8F5F;W)E($1E8V5M8F5R(#$U+"`R,#$U+B!!7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!N;W1E+"!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!$871E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\2!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\2!$871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!N;W1E+"!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1U86PI/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^1&5C(#$U+`T*"0DR,#$U/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1F5B(#$V+`T* M"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!$871E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,34L#0H)"3(P,34\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!N;W1E+"!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@86YD($%C8W)U960@17AP96YS97,@*$1E=&%I;',I("A54T0@ M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^ M1&5C+B`S,2P@,C`Q-#QB6%B;&4@86YD($%C8W)U960@ M17AP96YS97,@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD($%C M8W)U960@97AP96YS97,L(%1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#$R-RPY-#0\7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)FYB M'0^)FYB'0^ M)FYB'0^)FYB'0^)FYB'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V M8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X M,C`Y+U=O'0O:'1M;#L@8VAA&5S("A$971A:6QS(#$I M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"!!'!I M"!A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA&5S("A497AT=6%L*3PO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$69O'!I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B M,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A8S)?-V,R-C0Q,64X,C`Y+U=O M'0O:'1M M;#L@8VAA2`H5&5X='5A;"D\+W-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)FYB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,B!Y96%R65A7,\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'1U86PI/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT M,S(N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^3W9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U7V%A M8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5?86%C,E\W8S(V-#$Q93@R,#D-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&(V83!B8S1?-F)C,U\T8C(U M7V%A8S)?-V,R-C0Q,64X,C`Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\2!R96YT86P\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,R!Y96%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\6UE;G0@86=R965M M96YT('=I=&@@0VAR:7-T;W!H97(@4VUI=&@@6TUE;6)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R M'1087)T7S1B-F$P8F,T7S9B8S-?-&(R-5]A86,R7S=C,C8T,3%E.#(P M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T8C9A,&)C-%\V8F,S M7S1B,C5?86%C,E\W8S(V-#$Q93@R,#DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1U86PI M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES92!P'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&UL/@T*+2TM+2TM/5].97AT4&%R=%\T8C9A,&)C-%\V8F,S7S1B,C5? 586%C,E\W8S(V-#$Q93@R,#DM+0T* ` end XML 21 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details Textual) (USD $)
12 Months Ended 1 Months Ended 0 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Jan. 31, 2012
Jul. 01, 2012
Commitments and Contingencies (Textual)        
Monthly rental $ 22,631us-gaap_OperatingLeasesRentExpenseMinimumRentals      
Sublease monthly rental 25,500us-gaap_OperatingLeasesRentExpenseSubleaseRentals1      
Rental expenses 33,500us-gaap_OperatingLeasesRentExpenseNet 41,500us-gaap_OperatingLeasesRentExpenseNet    
Consulting agreement with Saddleworth Ventures [Member]        
Commitments and Contingencies (Textual)        
Term of consulting agreement     3 years  
Payment issued to consultant upon execution of agreement     25,000lmnk_PaymentIssuedToConsultantUponExecutionOfAgreement
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsMember
 
Consultation fees 0us-gaap_ProfessionalFees
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsMember
0us-gaap_ProfessionalFees
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsMember
   
Consulting agreements with third parties [Member]        
Commitments and Contingencies (Textual)        
Consultation fees 67,500us-gaap_ProfessionalFees
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsOneMember
38,176us-gaap_ProfessionalFees
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsOneMember
   
Employment agreement with Christopher Smith [Member]        
Commitments and Contingencies (Textual)        
Term of consulting agreement       5 years
Payment issued to consultant upon execution of agreement       60,000lmnk_PaymentIssuedToConsultantUponExecutionOfAgreement
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsTwoMember
Amount of compensation as per payroll - officer $ 60,000us-gaap_OfficersCompensation
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsTwoMember
$ 60,000us-gaap_OfficersCompensation
/ lmnk_ConsultingAgreementsAxis
= lmnk_ConsultingAgreementsTwoMember
   
XML 22 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Loan Receivable (Details) (USD $)
4 Months Ended
Aug. 10, 2012
Dec. 31, 2014
Dec. 31, 2013
Feb. 03, 2012
Loan Receivable (Textual)        
Issuance of debt to Health Clinics of Florida       $ 32,000lmnk_IssuanceOfDebtToAffiliates
Additional advance to Health Clinics of Florida on April 9, 2012 and August 10, 2012 10,500lmnk_AdditionalAdvanceToAffiliate      
Interest on outstanding balance, per annum       10.00%us-gaap_LongtermDebtWeightedAverageInterestRate
Loan receivable - net of allowance          
XML 23 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangibles (Details Textual) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Intangible (Textual)    
Fee of gross receipts of licensee, Percentage 6.00%lmnk_FiniteLivedLicenseAgreementsPercentage  
Term of license agreement 20 years  
Amortization period of license agreement 19 years 6 months  
Amortization expense $ 5,555us-gaap_AmortizationOfIntangibleAssets $ 5,552us-gaap_AmortizationOfIntangibleAssets
XML 24 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events (Details) (Subsequent Event [Member], USD $)
0 Months Ended
Apr. 28, 2015
Apr. 17, 2015
Apr. 01, 2015
Apr. 10, 2015
Subsequent Event (Textual)        
Principal amount of convertible debt   $ 757,200us-gaap_DebtConversionConvertedInstrumentAmount1    
Debt conversion, converted instrument, shares issued   6,000,000us-gaap_DebtConversionConvertedInstrumentSharesIssued1    
Deposit amount       100,000us-gaap_DepositsAssetsNoncurrent
Proceeds from convertible promissory note 250,000us-gaap_ProceedsFromConvertibleDebt      
Debt instrument interest rate 12.00%us-gaap_DebtInstrumentInterestRateStatedPercentage      
Debt Instrument, Term 1 year      
Conversion Price $ 0.15us-gaap_DebtInstrumentConvertibleConversionPrice1      
Director [Member]
       
Subsequent Event (Textual)        
Purchase consideration     2,500,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TitleOfIndividualAxis
= us-gaap_DirectorMember
 
Warrants issued to purchase common stock   5,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TitleOfIndividualAxis
= us-gaap_DirectorMember
   
Warrant expiration date   Apr. 17, 2022    
Warrant exercise price   $ 0.09us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TitleOfIndividualAxis
= us-gaap_DirectorMember
   
Warrants and rights outstanding   $ 465,000us-gaap_WarrantsAndRightsOutstanding
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
/ us-gaap_TitleOfIndividualAxis
= us-gaap_DirectorMember
   
XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt (Details) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Summary of short-term debt    
Short-term Debt to Related Parties, current $ 1,050,905us-gaap_DueToRelatedPartiesCurrent $ 779,133us-gaap_DueToRelatedPartiesCurrent
Less: Current portion 1,050,905lmnk_ShortTermDebtToRelatedPartyCurrentPortion 779,133lmnk_ShortTermDebtToRelatedPartyCurrentPortion
Short-term debt to related parties net      
Unsecured promissory note, interest free, due June 15, 2015 (1)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 200,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteMember
[1] 200,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteMember
[1]
Unsecured promissory note, interest free, due June 15, 2015 (2)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 75,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
[2] 75,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
[2]
Unsecured promissory note, interest free, due June 15, 2015 (2)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 60,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteTwoMember
[2] 60,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteTwoMember
[2]
Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 75,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteThreeMember
[3] 75,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteThreeMember
[3]
Unsecured promissory notes, interest free due June 15, 2015 (4)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 347,200us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
[4] 347,200us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
[4]
Unsecured promissory note, interest free, due June 30, 2015 (5)    
Summary of short-term debt    
Short-term Debt to Related Parties, current 193,705us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSevenMember
[5] 21,933us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSevenMember
[5]
Unsecured promissory note, interest free, due June 15, 2015 (9)    
Summary of short-term debt    
Short-term Debt to Related Parties, current $ 100,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
[6]    [6]
[1] On January 5, 2012, LMC borrowed $200,000 from the Dellinger Fund, a shareholder of the Company. The note is interest free and has been extended to June 15, 2015. In the event of default, the Dellinger Fund has the right to request and will be granted the issuance of two million shares of the Company's common stock.
[2] On February 3, 2012 and March 1, 2012, LMC borrowed $75,000 and $60,000, respectively, from the Dellinger Fund, a shareholder of the Company. The unsecured notes are interest free and are due June 15, 2015. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.
[3] On April 3, 2012, LMC borrowed $75,000 from the Dellinger Fund, a shareholder of the Company. The unsecured note bears interest @ 10% per annum and is due June 15, 2015. In the event of default, interest on the outstanding balance shall continue to accrue at a rate of ten percent (10%) per annum from the date of the default.
[4] On various dates from March 23, 2012 through November 26, 2012, LMC borrowed $327,200 from the Dellinger Fund, a shareholder of the Company. In February 2013, LMC borrowed an additional $20,000. The unsecured notes are interest free and are due June 15, 2015. In the event of a default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default. On April 17, 2015, the Dellinger Fund notes in the amount of $757,200 plus accrued interest were converted into 6,000,000 shares of the Company's common stock. See Note 11.
[5] During the year ended December 31, 2013 and 2014, Saddleworth Ventures LLC, a related party, paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advances are unsecured, interest free and are due June 30, 2015.
[6] In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015. Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company's common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11.
XML 26 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt (Details 1) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Short term debt    
Short-term debt $ 251,000us-gaap_ShortTermBorrowings $ 176,000us-gaap_ShortTermBorrowings
Less: Current portion 251,000lmnk_ShortTermDebtCurrentPortion 176,000lmnk_ShortTermDebtCurrentPortion
Short term debt net      
Unsecured promissory note, interest free, due on demand (6)    
Short term debt    
Short-term debt 26,000us-gaap_ShortTermBorrowings
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFiveMember
[1] 26,000us-gaap_ShortTermBorrowings
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFiveMember
[1]
Secured promissory note, interest @ 12% per annum, due December 15, 2015 (7)    
Short term debt    
Short-term debt 150,000us-gaap_ShortTermBorrowings
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
[2] 150,000us-gaap_ShortTermBorrowings
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
[2]
Unsecured promissory note, interest @ 10%, due December 15, 2015 (8)    
Short term debt    
Short-term debt $ 75,000us-gaap_ShortTermBorrowings
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
[3]    [3]
[1] On May 13, 2013, LMC borrowed $30,000 from Forbes Investment, LLP. The unsecured note is interest free and payable upon demand. In December 2013, LMC repaid $4,000 against the outstanding balance.
[2] On October 16, 2013, LMC borrowed $150,000 from Edmund Malits, a shareholder of the Company. The secured note bears interest @ 12% per annum and interest and principal are payable in full on or before February 16, 2014. LMC provided the Corporation's shell on the OTCBB as collateral for the loan. In addition, LMC issued Edmund Malits 500,000 shares of the Company's common stock with a fair value of $10,000. The note has been extended to December 15, 2015.
[3] On February 4, 2014, the Company executed an unsecured promissory note with Curt Maes and received $75,000. The promissory note bears interest @ 10% per annum and both principal and interest are payable on or before December 15, 2015. As additional consideration, the Company issued Curt Maes 250,000 shares of the Company's common stock valued @ $25,000.
XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangibles
12 Months Ended
Dec. 31, 2014
Intangibles [Abstract]  
INTANGIBLES
2. INTANGIBLES

 

The MPL License Agreement

 

The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States (the “Licensed Rights”). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.

 

Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.

 

The components of intangible assets are as follows:

 

License Agreements      
       
Balance January 1, 2011   $ -  
         
Acquisition of license     6,000,000  
         
Amortization for the period May 8, 2011 through December 31, 2011     (200,000 )
         
Balance December 31, 2011     5,800,000  
         
Amortization for the year ended December 31, 2012     (307,692 )
         
Impairment charge     (5,392,308 )
         
Balance December 31, 2012     100,000  
         
Amortization for the year ended December 31, 2013     (5,552 )
         
Balance December 31, 2013     94,448  
         
Amortization for the year ended December 31, 2014     (5,555 )
         
Balance December 31, 2014   $ 88,893  

  

Amortization expense for the years ended December 31, 2014 and 2013 amounted to $5,555 and $5,552, respectively.

 

Estimated amortization expense for intangible assets for the next five years is as follows:

  

Year Ending   Amortization  
December 31,   Expense  
2015   $ 5,555  
2016     5,555  
2017     5,555  
2018     5,555  
2019     5,555  
 
XML 28 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt (Details Textual) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 2 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended
Feb. 04, 2014
Oct. 31, 2013
Dec. 31, 2014
Dec. 31, 2013
Jan. 05, 2012
Feb. 03, 2012
Mar. 01, 2012
Apr. 03, 2012
Feb. 28, 2013
Nov. 26, 2012
Apr. 17, 2015
Oct. 16, 2013
Feb. 28, 2014
Dec. 31, 2012
Apr. 28, 2015
Feb. 03, 2012
May 13, 2013
Debt (Textual)                                  
Fund borrowed from related parties     $ 100,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent $ 20,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent                   $ 737,200us-gaap_NotesPayableRelatedPartiesClassifiedCurrent      
Interest expense     59,250us-gaap_InterestExpense 17,500us-gaap_InterestExpense                          
Issuance of common stock 25,000us-gaap_StockIssuedDuringPeriodValueNewIssues 10,000us-gaap_StockIssuedDuringPeriodValueNewIssues                              
Issuance of common stock, shares 250,000us-gaap_StockIssuedDuringPeriodSharesNewIssues 500,000us-gaap_StockIssuedDuringPeriodSharesNewIssues                              
Subsequent Event [Member]                                  
Debt (Textual)                                  
Debt instrument interest rate                             12.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
   
Unsecured promissory note, interest free, due June 15, 2015 (1)                                  
Debt (Textual)                                  
Debt Instrument, Maturity Date         Jun. 15, 2015                        
Fund borrowed from related parties         200,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteMember
                       
Issuance of common stock, shares         2,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteMember
                       
Unsecured promissory note, interest free, due June 15, 2015 (2)                                  
Debt (Textual)                                  
Debt instrument interest rate             10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
                10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
 
Debt Instrument, Maturity Date           Jun. 15, 2015 Jun. 15, 2015                    
Fund borrowed from related parties             60,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
                75,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteOneMember
 
Unsecured promissory note, due June 15, 2015 (3)                                  
Debt (Textual)                                  
Debt instrument interest rate               10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteThreeMember
                 
Debt Instrument, Maturity Date               Jun. 15, 2015                  
Fund borrowed from related parties               75,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteThreeMember
                 
Unsecured promissory notes, interest free due June 15, 2015 (4)                                  
Debt (Textual)                                  
Debt instrument interest rate                 10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
             
Debt Instrument, Maturity Date                 Jun. 15, 2015 Jun. 15, 2015              
Fund borrowed from related parties                 20,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
327,200us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
             
Unsecured promissory notes, interest free due June 15, 2015 (4) | Subsequent Event [Member]                                  
Debt (Textual)                                  
Fund borrowed from related parties                     757,200us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
           
Issuance of common stock, shares                     6,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFourMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
           
Unsecured promissory note, interest free, due June 30, 2015 (5)                                  
Debt (Textual)                                  
Debt Instrument, Maturity Date     Jun. 30, 2015 Jun. 30, 2015                          
Fund borrowed from related parties     171,772us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSevenMember
21,933us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSevenMember
                         
Unsecured promissory note, interest free, due on demand (6)                                  
Debt (Textual)                                  
Fund borrowed from related parties                                 30,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFiveMember
Repayment of debt       4,000us-gaap_RepaymentsOfShortTermDebt
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteFiveMember
                         
Secured promissory note, interest @ 12% per annum, due December 15, 2015 (7)                                  
Debt (Textual)                                  
Debt instrument interest rate                       12.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
         
Debt Instrument, Maturity Date     Dec. 15, 2015                 Feb. 16, 2014          
Fund borrowed from related parties                       150,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
         
Issuance of common stock     10,000us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
                           
Issuance of common stock, shares     500,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_SecuredPromissoryNoteOneMember
                           
Unsecured promissory note, interest @ 10%, due December 15, 2015 (8)                                  
Debt (Textual)                                  
Debt instrument interest rate 10.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
                               
Debt Instrument, Maturity Date Dec. 15, 2015                                
Fund borrowed from related parties 75,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
  25,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
                           
Issuance of common stock     25,000us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
                           
Issuance of common stock, shares     250,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteSixMember
                           
Unsecured promissory note, interest free, due June 15, 2015 (9)                                  
Debt (Textual)                                  
Debt Instrument, Maturity Date                         Apr. 15, 2015        
Fund borrowed from related parties                         $ 100,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
       
Common stock price per share                         $ 0.10us-gaap_SaleOfStockPricePerShare
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
       
XML 29 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants (Details Textual) (USD $)
0 Months Ended 12 Months Ended
Feb. 06, 2012
Dec. 31, 2014
Dec. 31, 2013
Warrant (Textual)      
Number of warrants issued as compensation 2,400,000lmnk_NumberOfWarrantsIssuedAsCompensation    
Warrants maturity date Feb. 06, 2017    
Expected term 3 years    
Risk free interest rate 0.32%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate    
Dividend yield 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate    
Volatility rate 432.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate    
Fair value of warrant $ 479,912us-gaap_ProceedsFromIssuanceOfWarrants    
Term of warrant amortization description Over 3 years    
Warrant expenses   $ 157,780lmnk_AmortizationOfWarrantsIssuedForServices $ 157,780lmnk_AmortizationOfWarrantsIssuedForServices
XML 30 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Balance Sheets (USD $)
Dec. 31, 2014
Dec. 31, 2013
CURRENT ASSETS:    
Cash and cash equivalents $ 163us-gaap_CashAndCashEquivalentsAtCarryingValue $ 19,974us-gaap_CashAndCashEquivalentsAtCarryingValue
Loan receivable - net of allowance of $42,500      
Deposit on acquisition 100,000lmnk_DepositOnAcquisitions   
Prepaid expenses 16,000us-gaap_PrepaidExpenseCurrent 3,750us-gaap_PrepaidExpenseCurrent
Total Current Assets 116,163us-gaap_AssetsCurrent 23,724us-gaap_AssetsCurrent
Property, plant and equipment - net 1,767us-gaap_PropertyPlantAndEquipmentNet 2,667us-gaap_PropertyPlantAndEquipmentNet
Intangible assets - net 88,893us-gaap_FiniteLivedIntangibleAssetsNet 94,448us-gaap_FiniteLivedIntangibleAssetsNet
Other assets    6,000us-gaap_OtherAssetsNoncurrent
TOTAL ASSETS 206,823us-gaap_Assets 126,839us-gaap_Assets
CURRENT LIABILITIES:    
Short-term debt to related parties 1,050,905us-gaap_DueToRelatedPartiesCurrent 779,133us-gaap_DueToRelatedPartiesCurrent
Short-term debt 251,000us-gaap_DebtCurrent 176,000us-gaap_DebtCurrent
Accounts payable and accrued expenses 127,944us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 88,310us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Total Current Liabilities 1,429,849us-gaap_LiabilitiesCurrent 1,043,443us-gaap_LiabilitiesCurrent
Commitments and Contingencies      
STOCKHOLDERS' DEFICIENCY:    
Common stock, $.001 par value, 200,000,000 shares authorized; 26,085,101 and 25,835,101 shares issued and 26,084,983 and 25,834,983 shares outstanding at December 31, 2014 and 2013, respectively 26,085us-gaap_CommonStockValue 25,835us-gaap_CommonStockValue
Additional paid-in-capital 7,295,255us-gaap_AdditionalPaidInCapital 7,112,725us-gaap_AdditionalPaidInCapital
Accumulated deficit (8,535,129)us-gaap_RetainedEarningsAccumulatedDeficit (8,045,927)us-gaap_RetainedEarningsAccumulatedDeficit
Less: Cost of common stock in treasury, 118 and 118 shares at December 31, 2014 and December 31, 2013, respectively (9,237)us-gaap_TreasuryStockValue (9,237)us-gaap_TreasuryStockValue
Total Stockholders' Deficiency (1,223,026)us-gaap_StockholdersEquity (916,604)us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY $ 206,823us-gaap_LiabilitiesAndStockholdersEquity $ 126,839us-gaap_LiabilitiesAndStockholdersEquity
XML 31 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Cash flows from operating activities:    
Net loss $ (489,202)us-gaap_NetIncomeLoss $ (423,225)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 5,555us-gaap_AdjustmentForAmortization 5,552us-gaap_AdjustmentForAmortization
Depreciation 900us-gaap_Depreciation 38us-gaap_Depreciation
Non-cash compensation 182,780us-gaap_ShareBasedCompensation 179,330us-gaap_ShareBasedCompensation
Changes in operating assets and liabilities:    
Increase in prepaid expenses (12,250)us-gaap_IncreaseDecreaseInPrepaidExpense (1,284)us-gaap_IncreaseDecreaseInPrepaidExpense
Decrease in other assets 6,000us-gaap_IncreaseDecreaseInOtherOperatingAssets   
Increase in accounts payable and accrued expenses 39,634us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 44,297us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Expenses paid on behalf of the company    21,933lmnk_IncreaseDecreaseInExpensePaid
Net Cash Used In Operating Activities (266,583)us-gaap_NetCashProvidedByUsedInOperatingActivities (173,359)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:    
Deposit on acquisition (100,000)lmnk_DepositOnAcquisition  
Purchase of property, plant and equipment    (2,705)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net Cash Used In Investing Activities (100,000)us-gaap_NetCashProvidedByUsedInInvestingActivities (2,705)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:    
Proceeds from related parties 271,772us-gaap_ProceedsFromRelatedPartyDebt 170,000us-gaap_ProceedsFromRelatedPartyDebt
Proceeds from short-term debt 75,000us-gaap_ProceedsFromShortTermDebt 30,000us-gaap_ProceedsFromShortTermDebt
Repayment of debt    (4,000)us-gaap_ProceedsFromRepaymentsOfDebt
Net Cash Provided by Financing Activities 346,772us-gaap_NetCashProvidedByUsedInFinancingActivities 196,000us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase (decrease) in cash (19,811)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 19,936us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents - Beginning of year 19,974us-gaap_CashAndCashEquivalentsAtCarryingValue 38us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents - End of year $ 163us-gaap_CashAndCashEquivalentsAtCarryingValue $ 19,974us-gaap_CashAndCashEquivalentsAtCarryingValue
XML 32 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details 1) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Reconciliation of taxes on income at federal statutory rate    
Book income (loss) from operations $ (166,329)us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate $ (143,897)us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
Common stock issued for services 8,415lmnk_IncomeTaxReconciliationCommonStockIssuedForServices 7,113lmnk_IncomeTaxReconciliationCommonStockIssuedForServices
Warrants issued for services 53,645lmnk_IncomeTaxReconciliationWarrantsIssuedForServices 53,645lmnk_IncomeTaxReconciliationWarrantsIssuedForServices
Change in valuation allowance 104,269us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance 83,139us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
Income tax expense      
XML 33 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2014
Income Taxes [Abstract]  
Schedule of provision for income taxes

 

      Years Ended  
      December 31,  
      2014       2013  
Current                
Federal   $ -     $ -  
Foreign     -       -  
      -       -  
Deferred                
Federal     -       -  
Foreign     -       -  
    $ -     $ -  
Schedule of reconciliation of taxes on income computed at the federal statutory rate

    Years Ended  
    December 31,  
    2014     2013  
Book income (loss) from operations   $ (166,329 )   $ (143,897 )
Common stock issued for services     8,415       7,113  
Warrants issued for services     53,645       53,645  
Change in valuation allowance     104,269       83,139  
Income tax expense   $ -     $ -  
Schedule of temporary difference and tax effect associated with deferred tax assets and liability

    2014     2013  
                 
Net operating loss carry forwards (expire through 2032)   $ (2,712,745 )   $ (2,546,416 )
Common stock issued for services     17,395       8,980  
Warrants issued for services     156,316       102,671  
Impairment expense     1,833,385       1,833,385  
Total gross deferred tax asset/liabilities     (705,649 )     (601,380 )
                 
Valuation allowance     705,649       601,380  
Net deferred taxes     -       -  
XML 34 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details 2) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Components of Deferred Tax Assets and Liabilities [Abstract]    
Net operating loss carry forwards (expire through 2032) $ (2,712,745)us-gaap_DeferredTaxAssetsOperatingLossCarryforwards $ (2,546,416)us-gaap_DeferredTaxAssetsOperatingLossCarryforwards
Common stock issued for services 17,395us-gaap_DeferredTaxAssetsOther 8,980us-gaap_DeferredTaxAssetsOther
Warrants issued for services 156,316lmnk_DeferredTaxAssetsWarrantsIssuedForServices 102,671lmnk_DeferredTaxAssetsWarrantsIssuedForServices
Impairment expense 1,833,385us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses 1,833,385us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
Total gross deferred tax asset/liabilities (705,649)us-gaap_DeferredTaxAssetsGross (601,380)us-gaap_DeferredTaxAssetsGross
Valuation allowance 705,649us-gaap_DeferredTaxAssetsValuationAllowance 601,380us-gaap_DeferredTaxAssetsValuationAllowance
Net deferred taxes      
XML 35 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2014
Commitments and Contingencies [Abstract]  
Future minimum lease payments and rental income
Rental Income      
Years Ended December 31,      
2015   $ 229,500  
2016     324,000  
2017     348,000  
2018     372,000  
2019     382,500  
Thereafter     96,000  
Total   $ 1,752,000  
         
Rental Expense        
Years Ended December 31,        
2015   $ 203,679  
2016     271,572  
2017     271,572  
2018     271,572  
2019     271,572  
Thereafter     67,893  
Total   $ 1,357,860  
XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization
12 Months Ended
Dec. 31, 2014
Organization [Abstract]  
Organization
1. Organization

 

Lifestyle Medical Network Inc. and Subsidiaries (the “Company” or “Lifestyle”) was incorporated in the State of Nevada.  The Company directs its operations through its subsidiaries.  The Company operates its business under a License related to patent rights used in connection with the operations of medical clinics that provide medical services related to men's health, with proprietary trade names and logo designs.

 

Going Concern

 

The consolidated financial statements for the year ended December 31, 2014 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.  The Company has a past history of recurring losses from operations and is a development stage company.  The Company will require additional funding to execute its future strategic business plan.  Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure.  These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

The Company has agreed to enter into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2015.

 

Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.

 

Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accepted accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.  On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results could differ from those estimates.

 

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the literature.  In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred.  That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values.   

 

Evaluation of Long-lived Assets

 

Licenses represent an important component of the Company’s total assets.  The Company amortizes its license on a straight-line basis over the estimated useful lives of the assets.  Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

 

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States of America.

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

 

Concentration of Credit Risk

 

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash.

 

The Company's cash and cash equivalents are concentrated primarily in banks in the United States of America.  At times, such deposits could be in excess of insured limits.  Management believes that the financial institutions that hold the Company’s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to these financial instruments.

 

Earnings Per Share

 

Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period.  Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period.  Potential common shares consist of outstanding common stock purchase warrants.  For the years ended December 31, 2014 and 2013, there were 2,400,000 and 2,400,000 potential common shares, respectively, that were not included in the calculation of diluted earnings per share as their effect would be anti-dilutive.

 

New Financial Accounting Standards

 

In June 2014, the FASB issued ASC 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consideration”. The guidance eliminates the definition of a development stage entity thereby remaining the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of September 30, 2014.

  

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  ASC 820 describes three levels of inputs that may be used to measure fair value.

 

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.  The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date.  The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability.  ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are defined as follows:

 

  Level 1  - Observable inputs such as quoted market prices in active markets
     
  Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable
     
  Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions

 

As of December 31, 2014, there were no financial assets or liabilities that required disclosure.

XML 38 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Balance Sheets (Parenthetical) (USD $)
Dec. 31, 2014
Dec. 31, 2013
Balance Sheets    
Allowances for bad debts $ 42,500us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent $ 42,500us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Common stock, par value $ 0.001us-gaap_CommonStockParOrStatedValuePerShare $ 0.001us-gaap_CommonStockParOrStatedValuePerShare
Common stock, shares authorized 200,000,000us-gaap_CommonStockSharesAuthorized 200,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued 26,085,101us-gaap_CommonStockSharesIssued 25,835,101us-gaap_CommonStockSharesIssued
Common stock, shares outstanding 26,084,983us-gaap_CommonStockSharesOutstanding 25,834,983us-gaap_CommonStockSharesOutstanding
Common stock in treasury, shares 118us-gaap_TreasuryStockShares 118us-gaap_TreasuryStockShares
XML 39 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events
12 Months Ended
Dec. 31, 2014
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
11. SUBSEQUENT EVENTS

 

Material Agreements

 

Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of two medical practices in Houston, Texas, has purchased the two medical professional associations, MED-CURE Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”), effective April 1, 2015. The MED-CURE Companies were purchased by Dr. Moomaw directly from the owner, Dr. Nazmudin Keshwani, for a purchase price of $2,500,000, utilizing local bank financing.

 

The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Dr. Keshwani has entered into employment contracts extending through December 31, 2015, with the MED-CURE Companies as a “physician employee”, pursuant to which he will perform medical services as are required for operations of the clinics. The MED-CURE Companies have agreed to enter into management agreements with the Company which will be effective as of April 1, 2015, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), will provide organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and will receive an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the remaining amounts distributed to the doctors are no less than a specified floor percentage of gross revenues.

 

Through our subsidiary, Regional Professional Alliance, Inc. , a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have agreed to enter into a Regional Medical Director Agreement, which will be effective as of April 1, 2015, with Dr. Moomaw, pursuant to which Lifestyle Professional Alliance would provide the services of Dr. Moomaw for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management.

 

Through Lifestyle Texas Licensing, LLC (“Lifestyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men’s health.

 

Issuance of Warrants

 

In connection with the engagement of our director, Dr. Ronald Moomaw, under a Regional Medical Director Agreement with RPA, at a Board of Directors meeting, held on April 17, 2015, the Board authorized the issuance Dr. Moomaw of a seven year stock purchase warrant, expiring April 17, 2022, to purchase 5,000,000 shares of our common stock, at an exercise price of $.09 per share, valued at $465,000.

.

Conversion of Debt

 

At the Board meeting held on April 17, 2015, our Board approved the conversion by the Company of $757,200 principal amount plus accrued interest of Company debt held by The Dellinger Fund, into an aggregate of 6,000,000 shares of common stock.

 

Refund of Deposit

 

On April 10, 2015, the Company received from Dr. Nazmudin Keshwani a refund of the $100,000 deposit made by the Company in February 14, 2014, in connection with the Company’s previous negotiations to acquire the MED-CURE Companies.

 

Convertible Promissory Note

 

On April 28, 2015, the Company issued a convertible promissory note to Ray Meadow and received proceeds of $250,000. The promissory note bears interest @ 12% per anum and matures one year from the date of issuance. At any time, the holder of the note, at his sale option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company at a conversion price of $0.15 per share, the fair value of the common stock at the date of the advance.

XML 40 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2014
May 28, 2015
Jun. 30, 2014
Document and Entity Information [Abstract]      
Entity Registrant Name LIFESTYLE MEDICAL NETWORK, INC.    
Entity Central Index Key 0001307140    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Type 10-K    
Document Period End Date Dec. 31, 2014    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2014    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 3,378,296dei_EntityPublicFloat
Entity Common Stock, Shares Outstanding   31,835,101dei_EntityCommonStockSharesOutstanding  
XML 41 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization (Policies)
12 Months Ended
Dec. 31, 2014
Organization [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All material intercompany balances and transactions have been eliminated.

Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accepted accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.  On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results could differ from those estimates.

Business Combinations

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the literature.  In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred.  That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values.

Evaluation of Long-lived Assets

Evaluation of Long-lived Assets

 

Licenses represent an important component of the Company’s total assets.  The Company amortizes its license on a straight-line basis over the estimated useful lives of the assets.  Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If an impairment exists, the resulting write-down would be the difference between fair market value of the long-lived asset and the related net book value.

Income Taxes

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States of America.

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash.

 

The Company's cash and cash equivalents are concentrated primarily in banks in the United States of America.  At times, such deposits could be in excess of insured limits.  Management believes that the financial institutions that hold the Company’s financial instruments are financially sound and, accordingly, minimal credit risk is believed to exist with respect to these financial instruments.

Earnings Per Share

Earnings Per Share

 

Basic earnings per common share are computed by dividing net earnings by the weighted average number of common shares outstanding during the period.  Diluted earnings per common share are computed by dividing net earnings by the weighted average number of common shares and potential common shares outstanding during the period.  Potential common shares consist of outstanding common stock purchase warrants.  For the years ended December 31, 2014 and 2013, there were 2,400,000 and 2,400,000 potential common shares, respectively, that were not included in the calculation of diluted earnings per share as their effect would be anti-dilutive.

New Financial Accounting Standards

New Financial Accounting Standards

 

In June 2014, the FASB issued ASC 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consideration”. The guidance eliminates the definition of a development stage entity thereby remaining the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard as of September 30, 2014.

Fair Value Measurements

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  ASC 820 describes three levels of inputs that may be used to measure fair value.

 

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period.  The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date.  The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability.  ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  These tiers are defined as follows:

 

  Level 1  - Observable inputs such as quoted market prices in active markets
     
  Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable
     
  Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions

 

As of December 31, 2014, there were no financial assets or liabilities that required disclosure.

XML 42 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Operations (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Statements of Operations    
Revenues      
Costs and expenses:    
Selling, general and administrative expenses 429,952us-gaap_SellingGeneralAndAdministrativeExpense 405,725us-gaap_SellingGeneralAndAdministrativeExpense
Total Costs and expenses 429,952us-gaap_CostsAndExpenses 405,725us-gaap_CostsAndExpenses
Loss from operations (429,952)us-gaap_OperatingIncomeLoss (405,725)us-gaap_OperatingIncomeLoss
Other income (expense):    
Interest expense (59,250)us-gaap_InterestExpense (17,500)us-gaap_InterestExpense
Loss on extinguishment of debt      
Total Other income (expense) (59,250)us-gaap_NonoperatingIncomeExpense (17,500)us-gaap_NonoperatingIncomeExpense
Loss from operations before provision for income taxes (489,202)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (423,225)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Provision for income taxes      
Net loss $ (489,202)us-gaap_NetIncomeLoss $ (423,225)us-gaap_NetIncomeLoss
Loss per common share $ (0.02)us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare $ (0.02)us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
Weighted average common shares outstanding - basic and diluted 26,061,813us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 25,333,238us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
XML 43 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes
12 Months Ended
Dec. 31, 2014
Income Taxes [Abstract]  
INCOME TAXES
6. INCOME TAXES

 

The Company adopted the provisions of ASC 740, "Income Taxes", ("ASC 740").  As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits.  The Company believes there are no potential uncertain tax positions and all tax returns are correct as filed.  Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet.  Included in any liability for uncertain tax positions, the Company will also setup a liability for interest and penalties.  The Company’s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current provision for income taxes.

 

There is no U.S. tax provision due to losses from U.S. operations during the nine months ended September 30, 2014 and 2013.  Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company's assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S.  Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.  The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.

 

The provision for income taxes consist of the following:

 

      Years Ended  
      December 31,  
      2014       2013  
Current                
Federal   $ -     $ -  
Foreign     -       -  
      -       -  
Deferred                
Federal     -       -  
Foreign     -       -  
    $ -     $ -  

 

A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:

 

    Years Ended  
    December 31,  
    2014     2013  
Book income (loss) from operations   $ (166,329 )   $ (143,897 )
Common stock issued for services     8,415       7,113  
Warrants issued for services     53,645       53,645  
Change in valuation allowance     104,269       83,139  
Income tax expense   $ -     $ -  

 

As of December 31, 2014, the Company recorded a deferred tax asset associated with a net operating loss (“NOL”) carryforward of approximately $2.7 million that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company’s NOL expires in 2032. The valuation allowance increased by $104,269 during the year ended December 31, 2014.

 

The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:

 

    2014     2013  
                 
Net operating loss carry forwards (expire through 2032)   $ (2,712,745 )   $ (2,546,416 )
Common stock issued for services     17,395       8,980  
Warrants issued for services     156,316       102,671  
Impairment expense     1,833,385       1,833,385  
Total gross deferred tax asset/liabilities     (705,649 )     (601,380 )
                 
Valuation allowance     705,649       601,380  
Net deferred taxes     -       -  

 

Section 382 of the U.S. Internal Revenue Code imposes an annual limitation on the availability of NOL carryforwards to offset taxable income when an ownership change occurs.  The Company's reverse capitalization meets the definition of an ownership change and some of the NOL's will be limited.

XML 44 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses
12 Months Ended
Dec. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

    December 31,  
    2014     2013  
Interest   $ 47,150     $ 16,650  
Salaries - Officer     20,000       13,250  
Rent     -       22,418  
Other     60,794       35,992  
    $ 127,944     $ 88,310  
XML 45 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants (Tables)
12 Months Ended
Dec. 31, 2014
Warrants [Abstract]  
WARRANTS
        Weighted Average              
          Exercise     Remaining     Intrinsic  
    Shares     Price     Life     Value  
Outstanding, January 1, 2014   2,400,000     $0.20              
Granted     -       -                  
Expired/Cancelled     -       -                  
Exercised     -       -                  
Outstanding - period ending December 31, 2014     2,400,000     $ 0.20       2.1 years     $ -  
Exercisable - period ending December 31, 2014     2,400,000     $ 0.20       2.1 years     $ -

  

XML 46 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangibles (Tables)
12 Months Ended
Dec. 31, 2014
Intangibles [Abstract]  
Components of intangible assets
Balance January 1, 2011   $ -  
         
Acquisition of license     6,000,000  
         
Amortization for the period May 8, 2011 through December 31, 2011     (200,000 )
         
Balance December 31, 2011     5,800,000  
         
Amortization for the year ended December 31, 2012     (307,692 )
         
Impairment charge     (5,392,308 )
         
Balance December 31, 2012     100,000  
         
Amortization for the year ended December 31, 2013     (5,552 )
         
Balance December 31, 2013     94,448  
         
Amortization for the year ended December 31, 2014     (5,555 )
         
Balance December 31, 2014   $ 88,893  
Schedule of estimated amortization expense for intangible assets
Year Ending   Amortization  
December 31,   Expense  
2015   $ 5,555  
2016     5,555  
2017     5,555  
2018     5,555  
2019     5,555  
XML 47 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Related Party Transactions
12 Months Ended
Dec. 31, 2014
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
9. RELATED PARTY TRANSACTIONS

 

a) During the years ended December 31, 2014 and 2013, Saddleworth Ventures LLC paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advance are unsecured, interest free and due June 30, 2015. As of December 31, 2014, no repayments have been made.
     
  b)

During the year ended December 31, 2012, the Company received $737,200 in advances from the Dellinger Fund, a shareholder of the Company. During the year ended December 31, 2013, the Dellinger Fund advanced an additional $20,000.  The majority of these advances are interest free.  The Company recorded interest expense for the years ended December 31, 2014 and 2013 in the amount of $7,500 and $7,500, respectively, on the advances that were not interest free.  See Note 4 for further information.

     
c) In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due June 15, 2015.  Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company’s common stock at a price of $0.10 per share. See Note 4 for further information.
XML 48 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity
12 Months Ended
Dec. 31, 2014
Stockholders' Equity [Abstract]  
STOCKHOLDERS' EQUITY
7. STOCKHOLDERS' EQUITY

 

On February 4, 2014, the Company issued Curt Maes 250,000 shares of the Company’s common stock with a fair value of $25,000 as incentive for debt financing.

 

During the year ended December 31, 2013, the Company issued 130,000 shares and recorded compensation expense of $11,550.

 

In October 2013, the Company issued Edmund Malits 500,000 shares of the Company’s common stock with a fair value of $10,000 as incentive for debt financing.

XML 49 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Warrants
12 Months Ended
Dec. 31, 2014
Warrants [Abstract]  
WARRANTS
8. WARRANTS

 

On February 6, 2012, the Company issued warrants as compensation to a third party to purchase 2,400,000 shares of the Company's common stock for services performed. The warrants expire February 6, 2017. The estimated value of the compensatory warrants was determined using the Black Scholes pricing model using the following assumptions: Expected term of 3 years, a risk free interest rate of 0.32%, a dividend yield of -0-% and volatility of 432%. The fair value of the warrant amounted to $479,912 to be amortized over 3 years. The Company recorded an expense of $157,780 and $157,780 on the Company’s consolidated statement of operations for the years ended December 31, 2014 and 2013, respectively.


The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.

 

        Weighted Average              
          Exercise     Remaining     Intrinsic  
    Shares     Price     Life     Value  
Outstanding, January 1, 2014   2,400,000     $0.20              
Granted     -       -                  
Expired/Cancelled     -       -                  
Exercised     -       -                  
Outstanding - period ending December 31, 2014     2,400,000     $ 0.20       2.1 years     $ -  
Exercisable - period ending December 31, 2014     2,400,000     $ 0.20       2.1 years     $ -
XML 50 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies
12 Months Ended
Dec. 31, 2014
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES
10. COMMITMENTS AND CONTINGENCIES

 

Leases

 

The Company formerly leased its offices in Orlando, Florida. The lease expired during 2014. In connection with the transaction with MedCure, the Company entered into a lease agreement with the former owner of MedCure. The Company will lease the clinics from the former owner of MedCure for five years with a five year renewal option at a monthly rental of $22,631.

 

The Company also entered into a lease agreement with MedCure whereby MedCure will sublease the clinics from the Company at a monthly rental of $25,500. The term of the lease will be for five years with a renewal option for an additional five years.

 

Future minimum lease payments and rental income under these agreements are as follows:

 

Rental Income      
Years Ended December 31,      
2015   $ 229,500  
2016     324,000  
2017     348,000  
2018     372,000  
2019     382,500  
Thereafter     96,000  
Total   $ 1,752,000  
         
Rental Expense        
Years Ended December 31,        
2015   $ 203,679  
2016     271,572  
2017     271,572  
2018     271,572  
2019     271,572  
Thereafter     67,893  
Total   $ 1,357,860  

 

Rent expense was $33,500 and $41,500 for the years ending December 31, 2014 and 2013, respectively.

 

Consulting Agreements

 

a) In January 2012, Lifestyle entered into a consulting agreement with Saddleworth Ventures LLC ("Consultant"). The Consultant will provide services for management consulting, business advisory, shareholder information and public relations. The term of the agreement is for three years. Upon execution of the agreement, Lifestyle issued a payment to the Consultant in the amount of $25,000. Additional cash fees or reimbursement of expenses shall be agreed upon by Lifestyle and the Consultant from time to time during the term of the agreement. Consulting fees for the years ended December 31, 2014 and 2013 amounted to $-0- and $-0-, respectively.

 

b) During 2014, 2013 and 2012, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the years ended December 31, 2014 and 2013, consulting services amounted to $67,500 and $38,176, respectively.

 

c) On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith ("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Lifestyle will pay Smith minimum compensation of $60K per year. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the years ended December 31, 2014, and 2013, payroll-officer amounted to $60,000 and $60,000, respectively.
XML 51 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Current    
Federal      
Foreign      
Income tax current, Total      
Deferred    
Federal      
Foreign      
Income tax deferred, Total      
XML 52 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]  
Schedule of accounts payable and accrued expenses
    December 31,  
    2014     2013  
Interest   $ 47,150     $ 16,650  
Salaries - Officer     20,000       13,250  
Rent     -       22,418  
Other     60,794       35,992  
    $ 127,944     $ 88,310  
XML 53 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangibles (Details) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Components of intangible assets        
Intangible assets - net beginning balance $ 94,448us-gaap_FiniteLivedIntangibleAssetsNet      
Amortization 5,555us-gaap_AmortizationOfIntangibleAssets 5,552us-gaap_AmortizationOfIntangibleAssets    
Intangible assets - net ending balance 88,893us-gaap_FiniteLivedIntangibleAssetsNet 94,448us-gaap_FiniteLivedIntangibleAssetsNet    
MPL License Agreement [Member]        
Components of intangible assets        
Intangible assets - net beginning balance 94,448us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
100,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
5,800,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
  
Acquisition of license       6,000,000us-gaap_LicenseCosts
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
Amortization (5,555)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
(5,552)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
(307,692)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
(200,000)us-gaap_AmortizationOfIntangibleAssets
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
Impairment charge     (5,392,308)us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
 
Intangible assets - net ending balance $ 88,893us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
$ 94,448us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
$ 100,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
$ 5,800,000us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicenseAgreementTermsMember
ZIP 54 0001213900-15-004383-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-15-004383-xbrl.zip M4$L#!!0````(`#)8RT8UHO(S[9@``')7"0`1`!P`;&UN:RTR,#$T,3(S,2YX M;6Q55`D``]"B>570HGE5=7@+``$$)0X```0Y`0``[%WY;^LVMOZ]0/\'C0?3 MS@!QK,7RDMQDX"QNTV9#DCN=XKV'0)%HFW-ER26E).X#WM_^2$JV)5ER+&NQ M[!#H[B>U1?:A\JA>-@2_DML-22Q M(8N2*HB=(U4Z$D7A_N9_A'I]UM29ADDSI`YK0#Z4O&?DZ?L+,N$1_:]`L%GX MR!Q;WTYJ(\>9'#4:)AP`[$Q-,`8&U#73`LZ;C;X=ZO:8]M>49$6J??_=K"H, M5'U[>SNDS1[::$C>%94&??Q"@-0$85Z%OF'`>:5@A5;#>QAZ?:F+-X6]+W6[ MW09[&GH=P[B72>-2X]\WUX_Z"(RU.K2PHUDZP16"!5>(LJBRJ`.QW92E]JI: MWAO!2I9M6>XXOH[AH(8SG8`&>:E.W@((ZJ&Z'U="<'CJWG/$J2S-*CC^'KL$:TF+5?#4(^O1!XD57$F**$. M>9)0R<7UH:9-YO4&&GYA=O8?)*B#/*7$P;'UV).$BN_F"M[_^SHR+ET');[> M;9"G="A2WT4']!%FP_0!#`0VP(\TI"/;!*O=0&."[`E`#B20%X[':X`*K\ZC/'=OB.C9K0F/G0<]MRP+LC/`+=H>[7=Z^>`]7]A]`X MJ?DO/O?P\]W@69&>+X#^3!H5GT3QV?OGZ2Z^O`\MZ(!K^`J,*XMXF"%\,4$/ M8^#@L^F-]A\;G9L:QKUWB)^OH0XL#'I#!(A[MIPG@,;X!HQ?`*HM@)$'T)DN M_@X-6C*```E,KV$USIAU?O5K[50D;E(1VU)3_-*(5EXTB,&0]CXK,$B7[Q,3 MZM#QL`@&),^]"<\GWU$*,6NGLTHKY/W2B.V:8FHLH6S$*X:0!=I&0%',Q=,: MU$1U22:,7]1>/)V5+.HW0I18S9'^[Y?/HO3\BV91)D@)#)$X0RK($,(`Y%R0 M!9K'$>:%Q0!'@L_GNC:"%2*D6CS-1JJHX^&TVB5:A1S/$D?R1T1UYGKD M$$=BRQ]'-F+"7X`7YXG,H8P-7XEJR&(.&/?('D.,;32]M1VP&WR(%:EV2IQ8X\#DPZW_-8M'YE)Y+0SR1)9\II)/B"+$E=.ZF+7 M=*`UG'M,;]Z(>U!MLC`V),GCDR59JLHRI;@UAZ@\]\%+C%>)*2_'Z!OZ7O*/ M4MBDFT))Z5SOG;6_WG[!M MS&!*:%F8][B2$\85MW^E9C`YE<<(4R;WC4%O$N9I1'9=>\N9@'1E M>(UFD>M>*6DVYAS8)@?B/(>4;JT1IDW.AT]R]_D7-^ZD4B+E9I;#IZ5N*KZT"YEI9HN33OQ4(XG//7>X4XM^,JXZJ13;J4N%;3GE MUO.M_;JLU]CR5.Z[;[NHV@,Q@_=>"%?"!"Y)=;G`[;3$&5`Y!BQY#2GMC4"$ M-'EYC7!HR]+%D1^#$"CG,0B5B4'(?LU44FC+Q[2JU!0?===%QG:D41(?>]49 M>Y7ER*-#1C`5YO(/ETAP;H\GMA788(W'MO7HV/JWW>#"2G$6UE^2B]M\;O.> M84`:"ZV9]QHD(^I7I.$/V8_O+F;EP97@-M2X5 M%K&`''E\01XW-N8C]62E6!Z^HUBH4?_W/;5L?W25$&LGVZJB-`E M_P]&8NFBQ)17ZH`V%\46<"F";1+T!]US*JS9C%.G9=Z7P:QV\:,N9F_TU# MB`#9#1N'H"_6>B$9/I4M>?!66<%;^T&!2S@<[EVG0)B65FL2C8ZM5 M5\3\QU;X>X)FPE:GHBI:IEZZ*/MF.5]I?*Q5'CY>G?#Q_2$5S\T#2L[-\UG( M4OD@Y5W(S;/#9.'AC)PD&4G"XQ\Y>38F#P^8Y'1)01<>8^^X MPF^>.%_B^<*#NCZQ\7D4V)92>.TP9W@*+[ZY68,F/(57!5)X58<_T?C4';NT MC=QKEQ3$R^]@=^D.MK(PFL/"0A+J2F\=H<+/"+E,UN?!YCLK=UY"J_R4WA5B0`\ MA5?E4GA5B1X\GHR?"?+PL/(R?E3'_#S::W]LR8.WMI+":VV/!5Q/QTG\_%4S-Y2`2E8?'NW$^P=5\X= MU2=R5#$L;%>#A9M=B>^9MRKH`GT_W&4!1)UE@Y.YO^3^EEU#A1IO&4F2IO+I?,Q(EJ1D&TE_J=>&K!1WA$;!/8`6A M7I^5?__=U?])_]W_U_W/X!U5+J_ZOTCJ<:OYY;C3:1[UNWX''A*7 M=DU-@T<:`H2D?OF818"!4Y\H[.$,_>S9[.^TC9@6OSY>+#4'L=V4I?81>9:^ MM><)7;]0*/-VV78#G`9>OG7'`&EDK[%AUTOU:>$%L,@:PHIK=ET%A9IHA-&O MEGSB!@0.=TL??:1'2J1+D\7JA#CVQ0#PZ)(Q_0$,(7;H-?"M-@:"S\X',,B2 M,OKZJG_Y^/3[]:5P_CU0+BZ/3_\TDCJGX)>/#LGN)%F MDITE>/\53',"%W0$B7W-@/2([@RJO[ZI#7,",-!,#+R^0\W/^CQW$:)%$.N: M^3O0T*7G>G/JON[=P'D`DOJ:8;FP=7?LSV0Y]2^)]5^]SH.-1SN\9WXS7\D7 MUX_A_D-]18$L5-,G)3A'*&$0D7[B87A(\P32_ST.1J"?\)#L0Q.@)/EH(!=$B`XY/:U6V_=JI('4651"GD4U8`HR+,O[G1\*AG&?1_ M-#C[53,!C@`U+GQ02WP/&=?D&V M>,?PR(+F247JLK(-TC,-&@*RU57%AW5@8^>#, M3$*R8$H!U`LB+U&1LM*6`\,]U'\V8%DU)[5"(S@1V3VRR?;&F=Z;9!E,A@<= MWQ,Z&9.!48H&6ZUVT,+):')%G56][4U0K_CP85W<8@+N0'E>J876]V,YR"4E MR"45+E?(KFI'%$,N9[5H.2OAXQ54*4J0MJF#C.ZDVVPV.Y6%7HKYMJF"C&ZU MT^ETED?KC8*#/M,XU^2D`>ENW-&`*40+3>' M$EZ!QL+(!V>N.PL/02D;7KG54;K1A>:&6#*Z#UEL=>2E16]HD+C@R0ZD^H2@ MS-U"N]V5E`"^9#2E8MXHT>`*.=GMP94#QL\2M4EDL.^BS(NO:=<26R&F5G=? MZD5JN;6D5CUGN?-2!S*JK25W:S^L'4@CMI;8G=JITFS+.R]W\`O+]9P:G6FD M[LX[\N!WA2M7%@'1Y?`R(Z-$60]A1%7LBFK)9B@H<>]ZU&MN:4(M+FGM>G*K MV_&QQ25K74_LUG:FU"*3E*XG>'L_[)UV3I6V-:D6F;9@/^\.U\Q MJ\9++L>=B*PG.8%3XNY5:KAT%"D`.@6Z(H7*NAZ3V]UF,[-4V[&()#:59C.PIB\$ M9%8--^5NI]E=%R2-`8*.]\M(ED$QT9^RL73R=OGQ%UG!Y'H^&HB.*BTT2%8[ M2F!VBT+(#"^K(VV)G37A)>3I+>4(52)>1@[@3,"2%]R,2FW+7556T\&-)L`E M3M,=NVPM<`$&]!.-,A1=[XA-M2L'HAP^QE6`%!GU7^^HBBK)W4VE"&6D+JLMM\6`X9=AE`(R=2K_U5.( M'-P@55.DU9GJ5]ZU=I6F*%=>P(3TZRO9V&[)A(YRU46+RRV^4JZP(RA$J*P3 M65=JM<3FUD'F[`A":\EJBK2Y(UA:Y553P$T'&\ MKVY[KC.R$?P3&/E;)>%K8"]`)'0IM@)6GNA3&:%X]%<8NV7J79U]A?T!HKQ` MYZ)NNGS,#'J]C][S5W>SVU%6($_ZY#TK_+P4OQG\T(+,>[,TI4M2)^'8UP.2 M!\X\M)L&YR,P3:+BGX`%D&;26VIC#"V6&,:!K\#_VGB-?!-9ESZB&C[S6`M7 M(9)D7NMTR:XMBR3G-F;7Q/ZC=1*.Y*S]*(*,Z'+6Z"IT=Q.:2(KH^\K2[3&X MMG$)ZJM']1>#(CO(K"=`435^`/**8"#.PBG-!4CMT"8ATG_1T)X#$6?3)Z19 M6&-IN_#9-/C$2U#M#6F`^JYEK'..4YQ@&4FA=F5U>]`JH?-;V[+#(Z$TQMK"XD0I>U\"Z\2Q_98R_TR245?/=#K0T&-@+>>T_:.\"7[V1RM!%9 M^VEH2N-$V>>DI":R&0EFUBS#L\N*'/3L!4I3':5EGFDZ73EXW5NJTDAUGX5G M9,DU2`BUR%UF\/(-WI2R M*WM%4>1@EKO-P)8B;L8]N']D],)%Y*&7M91=#+`<("5L%L.GY!\B*A]^ MKH$.ZFX+NWD(1'?')5\O-F+%,JX24JP1!E&P")D_E-NNNR@[+DK=:6$W=Q=R ML[W;HE?"7Y01-I5>!'])4H4).F$9I8IKK4H"@N0N]E96CVH!8C/">L5]&ST" M]`KU,J[")$E=UX,LH=NN6+G.()*RETK8?&:1I*:\ERHI=,;9BD0%SCZ5&[E) M(2!*"I<3=X#<-T9\+*D@)JT>?VFYWB#QI4&U%BJQ. M.(:859,A@P_=$RMN[#*K)LAFGC)G*;*F!:D&J8K?X5?!$OON&K:W?Z^:(-D6 M43WC/RYF^6X([*!4Q2\55#48Y)8()"^T60.PU'""E#707H`)(DV4I,[@G6VP MYPR(LJ;?B*3/CX7$5K9G&@8&Y36P<$GJDMI=);1UCL61"]*L\V9'9AYW?:17 MEDZ=`B#]L/]?6>'?I"I!NW*G&0J:6(DG9^R9$\1%0BVS@&>G:/,`WA4_,E!L MG%,^J+*&FX4S,ZX':S[E+K_N&X"N8$H(,/23:7^,)3?$N4:9T5\0U/#H'MGT M5Y6-L^E73'^L9:%MW8&O['/<4L)I%44-?,R\/KC"1,K*;;G54H/?2:43B?'% M_X69.ZNGDX4>AB5-+_Y=2"*$-51^9;T"7#J+Y%`>WO6A%290YM0?D6NIS40B MK^L`&"Q`,1B=3W/.EK&N"LNP"DV.J+.&';2E=EO.ACJ4@+F$]7ZRGD-(\H*; M-<>DFAYN`O_[T-(LO61O(W5;ZXS-&&R%2931(DJS%>+\9A+%_^BR=VL170"5 M8:6N$DB=E`9<@4)EGA>Z'4G*+M5/MFV\09-^VAK]E;X+B'73QBX"3P3^F6GK MW_*1Z_0'TSEV:)80`3M3$YS4!J2I(T$2)T[#LA$14OC1@6-">`N\"<0;:-:/ M!P(K.1`PD6EP++Q!PQG1.N+?C@6*H^[0;]`&I/J18-D6\$NA90#:N#AY/Q9, MX#@`U?%$H^2E[]'.CH6QAH;0JCOVQ'_1+WBQ'<<>^V5O-C(65;TB:-AOF*`X M%J@(=0S_!'6-G0/-0'CE#@*./EIT^*+IWX;(=BVCKMNFC8Z$MQ%TR.OU-_#R M#1)A*'92S?X&ZKZHM,>:H`/3]$&P;/ST[Q/-,/R__S!TCK__CBD8S;3["I`# M=S'8$7U.GS8<8]6KARJT%B]388,VK;,_+\1F9:\: M@IKE1$K?6(Q]I'!);W,M>VPA%H46J(_BZ@ZT,32G1Q\RB8&7#YFLM&*"X#LO MXM7M4^_VIZNSZ\O'U;(V'!3\"QVGB[]/9K+[M/VKE_(D):!E(3.J,FE@Q^K. M1I,1<15'@N8ZMN\F_*&!';*BB_,<\1ZK6:P!VP"G$N(P/!G@"*3Q_Y+^2 MY#QV?QC^H(TGQW^56N+Q,D4G^T_"BO`K."#H5`8'T^B0V!.W3\'#V1]<^H>G M$1!N[J\%_T>0A?FO(#,.NG,VSFM].I)6UBW&T78/*/JY76)%V;;XEWG"$/=, M,'#V@'B)GO"`[$L-@*C>]9'@D-?HG:-F37_$I,PVS6G=?K,`V2JX+Q@:4$/3 M`^'2)$8Z$"!F%4RO32!,7(1=(CG9D[`'9.=)=$A[$08$FO#;3>]`F'BG#Y@( M@8+5!7L@C(%!MS84.(NN.!#LV5?7M'2*:?:!`V(ZRR5;YP.R74(TQD.P-*H! MS3($TQ[:9&]-^_4*;!:M#\GFUC2![I!Z%`%IU9F24KH%M@#+=$)(YG@*F/<9 MA*030T"="JPY,QGF.`7DG2!2P8FXWBCOR%+[&`LCH)FD8=HZZ8^V3\80@HZ- MIK1]6D#WX9#&>Y!^OEJ0-L0B0K#P=_IXUIPL'OOF,X0'2@@\?R(=_^-0H#9> MLF]8WYHP`$S3K;_1_Y)U)Z;@=0`G#J8E?GUBW(GW:UG"'RY91`-D3KT.R!_' M,]S+G4'?K&_D+U/A[[+X#V$*-(0]^],Z8#"@^GX%@J%1#MUH4Z%[(,BB)'D= M^/03)B;Q#%2A`--="\0C1O&H/:A0]"8#D:;?(3LTGST[$#3"86)W^G_2T,QJ M1-W8-=F;4D3+)9WA/8ZT'2R&J!M MSIN9S3J::=JZEW6&++IXJ2"7`3G:6.+,LYRF-;OI:<<_-)-02& M(F(08+!(5G[]VSTSV$B`!$F`!,A)Q38)`H/>IK?IZ<$!""]H!$")Q_;XF41 MZW$^@THCN`0#@T199.8!<<-/*?+NHN:!5W+\E%GVT*C9O)!!\Y94:]62J'&$;!I=!AI((Z*(4U))^&<4%_Z/KE([' MS9X[BM`7)[@Z`\.>]D+2O246GF:E_(Y+!.Z3HO+4\DH.U!_G=66J_ACEK+.] M/#34A'Y`?$X.#;?$\FB%2BM1$;52,^>JAGV:B$)D6L_<[!"P:HU.Z.:J;37A M:]=_&N0*6G)SES,.$ZBKRV_53I/P+RZ`C41OF^D;2;366(P32J;?:K?;^*<` MQLU%6!HR:94FFLG,(RD&& M@L<>"N(&Y[I870@&>[UESJ`,!*4)EB:X,>*^=B!X"#;UP(.D(PL$A]U6M[LL M-]E(!&4<*(W0L1BA[1@+F1D>.R187V,,(L+>S(NE"99FN1#,,GS MT[6[5-SR@L6#-+/=:HUL-]=4&$XPLFCC=>:R/C"26@MZ[^RL=39"@WV>LNV0R MT>'E93I8)WE,W&-S^,`6I]F\9/$:^XU]U%J*2[T9/\+%>CK.KO`UD._GSXY5 MPO.TK)0]J5NKE;Q+<%2F[)@ODJ=E%QO&A[K7!C(J8SSWBFMATSOZ/O)2E.N@ M1*4Z;88,QE(G^\=7WS]^96KX3UPTO+3QK;M/G>>U;$]Z_R5"54'3]HRUW`J6 MRQ@HR4AG'8)ONVQ:A(.5(#TO%9?<0=ETT:U>S>F7BM#/Y@ES54LK0$7*YRY`\G'`YB- MJPLO)1>;,!N'DH_E+$$:YD/&X^+JSZ\#[^2>D-F;WQS'>#0MZ]PVXJ-KSUEN MZ9WIZ9;C!2Z]!6H[^[=?GSWX.G[R90#!P2]WI.SKRHSO88?/PY0L=__+B M@G^^>__GY5U;O?N=V'>X%'#;;M_Q_V^O[SKJ'7C0Z>LO?HUCSP2U.*%>\X"Q M0(@H/)%>?U!&?,ICY1/?F8D;Q870J677,L+2B,\GQ,#%R/#-V1'Y+L)30&') M&FF.0Y=.$2SU_3)681/RW.2\5C=C02J;%(>Y!/WN\NWM<@H<95E$!5D^/KI, M-LL5.RE\=18^Y@4!/=RI8H`?A(MNSGA9]<,CE4<\2YFMB\*4JK,Q8GC0"W2U M6Y4K9W6F_@KA>!#=_?)8?_WUP0;0<3.!J<'!W`=+VP8BNJ^UZA6;P1J^._0` M!47.B.IGQ#J[N@YL1I1FEII""@`]F,M;X/H-[L7X0BU6??P9HB&3>HP\P8HT M=T5^\YIU:85&+JD(Z9AQ/[K9(L5@/5"?/SM\[*NMGA"&?-@9GO8'ZMF@UZ@3 MS_,*.[[:'M4#%XS+#!XT/<]QG^`5/FWAEA;J4L]7QBZ%KT9`E=\#FRIJCV7. M>\HK=;&[R6*Y8:=)=%J_YK-1Z&U3B]I<1!.E/ZN/3SXDOFY:O%Q_A`\D`A^Z;500-4XHAKRQSQII#FP%/'1]9T>]`[ MVL.7FH?CX6%T#%R34V\/[G)SJ2;]5>G.2W=>NO/2IY`^Q=H^1?]XSU)M'H[[ MQ>CY,\DW.?D:X]#+_+=TF*7#7%^'V4MXS/^&!WY09M15B&T'TTSGN2.=YSIB M=,SV^X@3?F^H:2/-)UKMAUQF1SEKOYR'3$Z9IO= MZ0Y:VI$:[>;A>'@8'0/7Y-R3Q2.R>$0Z]-*A;Y)#GU\\TFF'#GU/.O2E8_3\ MF70KMG(KU&&G-6BO;KK>,`P/E(N'A]$Q<"UW+Z7:&G:6=1)J)(+2HY<>?3T` MJP<4TJ.OPUS+Z613297X\!`<_:V[$E70B4]I#/&VT!^2;AE1RLJN$PUONG@4 M;K#4*%*CU$6CG$A=THR"I/K3^_`P.@IKE.=JM-J]=FLH4Z(-P?'P,#H&KN56 M!0^&+57F1(\Y4Y-_]G'!W,T'ZGEOE(O`=:GM*S,'R.?8AR!1AQX_/7]6KPG9 M',K5U5$ZNDA*:I7CG1M2I^S`_3LZC;++W,R"+N@>9,)F2S37GKC=W&EK.,'( MHHT7WV7MSR6UMLH]=P];NTGE<:3302H/J3Q*=8U>LV.]X^_R`'9Y`/NZS)8' ML#=#4QP-HO(`]GT*C#R`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`+?L&"!\T6G/M!/,6KKKKGVJI>Y&?)MFQ1GPKU1>DX=/ MKD`]__#EQF)_;2N_$SL@[I/"BQ2UEO+AXP5:3]=YI(;R4N/G:"IC&$3Q)UC6 M:,'+[ZFKO`9J<2Q M7/IW@&_$ESV:E@5O4^Y!2_CXJ@E"Y07$UBF#^]%1@'26Z=@<)6\.FW]YBNY, MI_BS[^C?3I?+S5$:IOI:H>A/[XSGBY*S&36W.7Y:D3MI]$R?YP\\TLW4?BZA-%S3;HO%Z:W?>RSVQ[ M"\RD-Z.Z;SY0ZZFUC:D/HFT3:/0]!>[.,/MX%7=(%+7TT0@.O\,)?`A];)QE M,'T0@.?8\Y+L]D0 M(1/7F]ODF+"8:+\AEJ_&?.M`'M.&H2%TEZ;\R$PYUW=%+'FH[.IGR9\_D[9< MVG)IRW-M>??(;3F"Y00>,U(>MUD\6M?"`-Z?@&3?3Y1/S@-O'Z#ULRU_1QNT MM,U-_U4B>8#=\>>&)[:"\P*+YD&/O-18IJ""()_(,%_Z!@5\@T'SG0/I&AR! M:U#9"OM1F4D>\JH#;C4RUWJY[3&YJ2!38#FS)Q`0<[,XL\#,,+7L;0[$A6IK MV.'COE0':FLPT.:7D\%.L[+,'MMMXP-".QY%1;-E:%5)VVB*DE(:W M"?%;P?!-W"BMK[2^TOHV1ZK#8\".T_I"P/J1/"DJ3^'.9U)?=A(5U.\==P3C M74$`ZOE3F'AP\X?/F0NQF173,_+$-$,PB\Y@8SG5R-3'`+B4&>Z775[O=4], M&T;*2:Q**RK#USU,MK#QKC2ATH0>NPD='+D)O=9]A[5+[V>;47%`!;>CE\8T M8)7.ENE[1:J<5M0X:0LU3N&/S.I"=*V;,]`:&(*&-MBTE7%@61C@.BZ,"7J! MQFNJ`HWN*4-CYCH/IB%V'5V`M7%]!3D'?S"+>)%X/I@63%;#2;6!4-G/L1EV-PPSC]8H*(:)NHDZ66D')"$ MRY%R-1;-K'+N):NV=,?VP.G@GD8:9>$JQ.AHO8WD; MH16DI9>6_O!LW:OAD5KZY9IJKMAYSOY'9IRE%C)7QEDY]$/8*@3B8&XM_0GQ ME4>(@0,/W0=VGVF#_075`,K;1L.-67X6N>,8^M^!Z3'[S'V%<-#,9#^N=8M* MN"B0CK56]"D3X+`5BC/#EV%4+JK>V%7FE[AT!G=2L9@?`X-+[T`\!_T-%S]C M'4"+U\JMZ1ZP"FW`0)"M?:JVF>?#ACE5XDJ_=K+2C[M;@(!8PA")%EEO)QV- M9BFE=1P-*91U$LJ4S]%H\;L*S8JHX(J2R$\L+,VN%.N&E6(=4>_%$[LO>\,6 M!(IAN5>K-]\\)$,K,Q'_^77@G=P3,GMS,P$[=4O=Z3LZ@G^_^V\M,!2_/G_V M6+AJ";1Z&+U_H^)<7 M%_SSW?L_+^_:ZMWOQ+Y#K&[;[3O^_^WU74>]`[33UU_\6J;/WV[_L#^//YP_ MZKK.?PUW2C1V\JU:^>"?&XWB^<7%]==/MS?*Y_,_S]]^N%3./[U3X.*7KY?O ME,O_]_GRT\WEC736=M'#5:VZ@6MCA?3(?;!ZB%%*[G&?+G4SJW^7]`MF#P-[ MV,,OYHR&JO4Z9>38UF-V!JE$[W&V<#_S@,+AIQ2-=V%GQ9D@FQW]L>XQ0-4/ MF"5`%1RB\P(9!I0'2>OS[14)][AZ`JQWWDLAWAXW$S5^5ADX^DO@7'JLD*3D M'"4[U5.RVH,P!?9#;C(R80LCY]4+"FK^((4XNW28#8[,",/J`9,GF/5;_4)D7`?,NAP/E@W=#;'`D04WZ42Y M'H]-G;IKJ+&2%.!&1PVMYB9O?+,GH.I-&K6#R*SLU9'7>?4[)(XG+-T%Z_W;[B:GRP(N+)U9TIOR?=FK/KON=*W5NO^ MF0U?UBX&2)TAN:*R=\W"WC5YG$DY[MNM7.E?1I/JX;OZ='']\5*Y/?]_Y:S& M;P!<:BUP?H5UV^F2-1-6+')N-@TJY]2Z:]7;<6)U969M.;7Q+H7*67B;*"XG MAC,+CYMDN\`]T[%9!?7YS84RZ+9;R@MNX10P<=1[T5)>O1`_O?@QL^`;=WEA MV5U@^6$EMCF=610KS=E>K]3H@-K'0$UO%S52E_PR"81VW$O*35D-Z9(\<-16$>W-9 MCG(-$C8#C6)'HJT'P'#X&DT>`7\HB@CU#A1E3O>Z3;0CU[1'K!^EB6L\"V^9 M-H>Y#\K\Z^G-*9_*T10U^"%.$*UYX3D7["YG)K8CXQ%24<]2V[2I,H5W3<*" M]!L*1I.7W+3G*M(S==0[.J:NFS)1HJ-HU'DEK'N'<;'[BOND&.88GJ*L^>B( M^H_8QP3O&)LV*&@T3BZ%6]G^*'P[LWO$,S,.AB:`I\^-EA4'MN%^\'!?-[!N MJMR;#SB@:WJ,1$8(.0?9]")#+&@%]R(9%9VX[A,@\4A<([372-,LXORKH97#H33`]!H@2X&M3^,E#:C`E;@0Z38$48@:_)AJMXUX"76CS M$>XD@^GT3XXM3CH#N"L-AE.807I8!)(Q*10:^!C:B23N'M]U9_JQ:S$E;*M] M&A2I69JI6:1Q:#P+;Y.QSH*[QOM2>)&#-W9P^B,U),.K9?@R9I6M+JQ$+-\/7'3):4TUD0]9T:DHP=L*O+C2N,=` M_9/M4;W$D*!VL.YU!3X+_J+%!+41CJ4`UU:DJRLH.324GS\K$^EYW;#&IIRF MR*K4&?7@0UTFT!'JC+)17K'KZZBELIE0UT2PCA#E%?O^FB255=?GEY9*N^"K MGVN45A:7SL745SEC\;K$D@;;%K!Z0%$S\E1?'KY9\>10ZY]VNICE"K4`XO=& MT=JY*H!!\)YBFV.K7.64L=VUP'I%-:_/8WD60,M*E+>`8Q&0E"!G0;)J^]FN M*%(UB[3]2HA6%PE9`&1?$K(V19KC*N2X1VOJ2\>E`'6YQ%_'<=N9"RVZB^[* M@=X97F)F[1:QDF?K(I]J(T*U`43*LI3EO?1!J(KQ=9A"M1#W/8KF[O&77&\H MUVOF_>;C$%8`RU20S)0U-U/V_%EQWW2/J3&ISANJSB77CY'K-3/B,H4EPWX9 M]LL4EI3E(Y)EF<+:D1]0\N+>`;@_DME'Q.Q=M"\ZYCV$..P![ON5#%N;8>>L MZ8NMFY89=1WB&WRQT0W?\(O=7`)L%$#XP;-CGHT">(@?^([[I&`_'6PCP#L+ M>'&_!I,UA.&;@[V];`V6,M&P27Q,>EAN7][EX5B[7D7)VQ>]<#15\1VRU:UZ ME$S!TD]B*K;AO#[GB.WE`"7)Q)J>(W;0E#RP<\0*KC>_=9QOH8?\"MM=_=CYW?3\P+1U@^\S0=3I\MF3;.* M6\Y:7;6W(YB:19E!2UUJ-.I>\5,0OO\2%V(TWSMH*>]U6OVN%/,]D6:W^GP= M9^YB0NQ[;"2=U2)T7YYR-I$K\9/+E*;*`%3;W9;67^:V;2<$^X^-),?3`)YU M6FIG+PS?M4DN=%@2&^LJ/A$!>R+;WCKZ*7_8O.6))S/7+FMC:6A*WO:ODY.TDBN2K$CKI8/+/)Q8(( MDG$P`_[MZ"8[6>?1]"=P4\;1$:_"'X##C5U7#P^Z1N^#*[;[!P'=D/J-"-VG-.(*H'-EKKQ$"'?M/CQ2XY'H^.H MPH,Q`"'J43)>RQ[5V1^,W9R%EVKI+B0?D!KQ? MBB`H>9;)$R6N.,1D@;'R4(JFSE19U])X%N*,]I]FE)_>L_P0H.1!/]E'^_`# M@2;4=+./"Q+5;$R3W9L/-#KOAZO#A!Z/SV7#(;-4?/2FA&[F(2>`KOO\9!]9 M*]S@9G:]03?04%>]U^JZOV*Z>@+(G;G>I4!ZW.4!8+95<+#L_: M#38HLB8N(>:]?JNS5'4=KYRK;:W5'ZCUEO3*JN*NIC-BNE,JCM]>K]1$%D95 M60K7.NMT6IVS]:Q3L^)_R?,:\;P6YOC6\8FEP+@0RBVN6KQ.K)4C60:T=C#:-)OZW"/"C!_]QM?'4L3I/,R-6!//NN8%YF:/Z0FRSJZF5L M8F^D7]EDCF]B3>OB56X5^N97:./20=+!7.I0'DP9_BXD=>&`]KI7Y$L^RWT7 MLARJ<3LO#I^@1U`D*`N/-V3A#=59=-4YTUCI\80J7T]O3I4KG!0VC/V%/E`[ MP,T)!E7,Z`PL7I'T6[H<4)Q8,5YM*GK3F6XP4NO04FO[4<_=NOSY_]'-YW@XOC$\<" M0^==_AT`T3XY/LUX"*3;1C'Y0L>_O+C@G^_>_WEYUU;O?B?V'5;TW;;;=_S_ MV^N[CGKWCNKIZR]^94:2$7US<0JCAG;[A^TG&9_A)[XS$S>*"Z&5YM,N8R;. M3SJPX2?$^"OP_!"([,FXBW)4P"8[U@A?Q%18[O0.?9U4H>X#<4UB^W-7'RFZ M7',7%W!><,@LTZ8GDZQGB]8#\QQ`QD18[8XAC\SQTP'@?W-[??&__[G^\.[R MR\V_E,O_^_7J]L_E%"GF/\Y;LO4JM1>PW9*F>5,WDXB..P-%"A.3!+Z3I0BR M%<8JPYJA`59,Y!Q12'@4:1_B<*1R7;],2MLNI&VE_]I\P;NVE?=TY`:X=ZV; MM5]85$==!*ZO?"0PGM9KMT#F%&]"7+'[+6E:U< MZ[Z#"C17>5X:TP`4YD?`W/>47KM$+U=M;^/EQAG*PIE'3%=:4_O;&[')8:_) MR3D&+4U-%DHMKI4\K$-RD--C!2'XWIMJLG/%`?CO^9.3O8:_-NASVK4$1)(A>Y]Y@UJF0GL,-S@1+^W]X?%H\(#I&LJ, MN/X37I@%KCXAX!)JK>XRU?>O.867W#6ES*B+QHP:O.%5!`#?BCL/]8#?14$P MIJSC6*0P\7T1Q'BJ6S02]O@*NW_!$X$7^LIOL3)!N=%!.R(@KHG379DZ!K42 M=_&6-JRC#M!H.F.'8[Q1+L$=UA$"'!@!Z##?&\A.L-$.8.E27/*"GP%:?L8< MW-4^[6@_X#V&B6?,@?%X,JG%VIZ=M$]^8/[W@V,1/UI9Z\(#'.NTA?!C:HE> M/PB,H[SL#H:MH:KAYQ'%GT`O_0._.0\8"W`H4ZW($OW=YMS\WJ`U.&LSH*(O M8@$PVZS9K(Z,<0;/UZ-LKQ`,%1\KPK@?1BI>7ILR]DIN=H%\2&FP?]93P8BC MMM,0GQZYRNL(^N:B%,2C#?XB#?`) MG7B3M-++453KK'"+YL?8?*-! MYMOG6\E4O(5AQ]C\EP5:,)/.@6WD?EG=?F-P.BP.50)3!2?[Y4_=8R'JWK"Y M_$Y=W5RZG;LQN'RA4V+:8%X.`9DKVW=-VS/U8YJZ.;M)MA@P56(N2M+YJ&+C M2R%FW#"7=*^(U)0RG]%SEX19),P'QP%N2_F= MV"QY);(:N[')A+MO!FO+[`+AR6)=5?323Y M^3-)EP.!M5.5%WP>-2N:,F?6\AM+Y])>0[Z(V2+@8Q60I1K5DL5KI^9S MIR:S\CE?#TZL-;MW906;1ONJ02O7L#6-NG66[*UR',L(O]0LQ?O7?GZ]8M-D ML@W<%[[3X3/NH+K%?;R$]>7S9",XV0B.-F!/]/#(&\%]N?QP?GOY3OE\_N7V M3^7VR_FGF_.+VZOK3Z7L?3VPU@6U:%20W19C3E_Q'@9+`XE&B^U:V[VVMQ.] M_B"_6T6-+<7&_7OW8$)RU&YTLW88!H?\N(G!.9`.)'-MG8ILEKX!H;,H3`I_ MHOP!4RS`/;0?/ER`YVL:X=YN3^P79X,[RDM-;0T[';'+>Z"V!@,MO>VZA9N^ M1W1"K''6UEJ/*L1XP'(AA;A4">`5.KS8:,7;W]EF>'R!$5#E]\"F2J?-@.^= M*N=LO^X"5BV@'$`Q(T^XB=Q3)N2!`A#4!CU@T!6.2,$]`9M+1V M&SL9""WL@;IUINSV=^"(P.`PS'MP:[#O".NKP/M!+>CRM?H(IH<.W\UZB*#G M@WD-R<%YCD,'5L100+3(7B&/K? M@>DQ4\1[`(6#FMZRT$3MB=`D4U%GP3LAO..1,PN;I>F.C1.%7;51KT,D`W=2 M$77%L+18>R1L0:8XJ.]9>S46.3GK-I($XI"XB=++]JG:QH5K/LRILI&)*;0" MLL'R1G)5!!";FCZ+\LYM`]/ M5[?;J\^_7;YZ>+J4JY_+*Y_B"G@^:`.&]7-N?G3L>"" MAY0\*7DE2]X'2CS1(TA*G90ZJ>^DY!VTY"73KZP]KFL]`4,)!NAX)H(S'K/N MN1#87KL6A-E.2WD/PF<:A(?D[%[1[1MC<):!QE@-3Z?%6,\69]>R8Q(P#O;C MR))?_$B-"X@0TUD&5J/)4\'8NIR_AMQ#L,\R!-%H'&A^0"R&S6*P=(-L=BXL M'X(U-@;BF7HBS9XS"(^S\>0&GG<.3WH(KR@N!>I"I"GR!BR`AWC>GUB8)K%] M_`E//--:_8YZG,?MR+DMK8J4O".3O*3N)9;G%-+FH=)]G,"MHZ?X.RIO#XO( M<_5W]*X\!=S#-3]N$\+S'OS(>(6GAF=K^SD='Z:FXR72^!&IX>4\DQI>2MX1 M2-[[`%?.E"DHXFDP%8HTJO7CIU`R]6O:NC/%HD(L6!$5(J'>YS4B!,^4P8-( MO#=2BJ44UU!_%CA'105)!!H^?[;U.N)ZTIS!YOS37)+RL8O5P]4MZ.LO)^&> MPZ7UBU^XKKMBNFY)K<@"?!F#)X5D^RVDN2.7TO%W6_A+.\K@0.3H3Q9X7"Z4 M-TJ1JDBD-FOPU#!IB_[D[+7/(3*64*VN^!N>]ID;UCE3N_WAH)-P))I%I:WF MRH$2HX"4+&L2$)XQ-SSM#>&_L^Z@JVJJ>B!4X4T,\B:/-L24DQ29'6OOE;V# M&D;5S75W?Z71;1@I2G!FFHGQ=E/JH&BP5.=VM&ZA'E6-IL"^%*MTBV/5.CA0 M$3M:M2)5ZRK5VCV3JE7ZK%4KUK,#%;"C52I2L:Y2K`--*E;ILU:O6H<')V+A M6NO1*A:I7%]EBHN/G(N\0B0\H;A)B,+]>K';_DG4ZEF#<+,2GF!U':+@5>QHM[6)19 M5E_?2%(<^W+$IK'=`:"^O!R^W6GU!X>W!MF,,*S^5'W^3%:]2XTJ%[DW4:T# MM=4;:(=-`;FXL7]G55:]'PK&4K5*U;IWU7H`7JNL>I>*52I6J5CKI5BESWK( M5>]'KE:D:I6J5?JLLN:]G@I6UF;+FO>Z&(+^H'4V[,C"1^EBRYKW.IN`$JJT MGS^K,1EEU?NN-;_:ZO1`^?=EU?O:)]'+'O/[[C'_4]157O;^KQ-?XC^)WO_I M62;Y57=^60T^JP'W2>`Y@[A+0GDDGO*RT\'N#NRPD9==E7W&TYGP8"=^@A.U MT<:ERLT5/)J0/0(?.BW%I=X,#RA\H-:3/+Y)BO1.17I.?TK):XCD+<\,-UHD M+QS;"RP?U>9Y=$R3E$XIG;60SH(*DY_7E$"0@_&:O[C`H4HBB:SUVJ?=?%XO MRD2>T'%FG?C.3-PH+O#\A+B6(1H)P8E(>D*,OP+/#X'(9D">".SDV"=`,SLS M&KXH;;Z7GX_0/M4.P]B3'Q=E-AOS[`V4C4;^RE9^)W9`W"?TN[66\L$<4P;\ M_-&P>FR`YLZ'O0$IM"C,$OC\!UP-P'=7/GRX4%Z]$%8+L'[Q8WCR=WB%'^\Z MEX`I"+A28LPU<3YMQ&VILT?G\+D]\/#;]MX^.UY?&2M3KR),J9`!@GH\#U.(3PA`BR/,2:GXS+@#&4`"$=/24`0OSG`."'\H($,.#P7W$HO)]' ME5,EX74PJ!;"N+E-P^DH3B`+]\`;7YZT3WA("!]6QG='GQALB$NSF/>53HYT M6PZ/C MN03"Q<0U/1"N"5B^FRE>>?6"_?OBQY:(8J.S5M#_LM_^7V4&X.$`I^)F M]BRQ/`?,K$YQ>(+WL"2$K5-EY-C@/XR(!T3`E`3^B(?4DWL:0ADC9E,(\>$& MPBS\S'7&I@\1/@Q&@8)X?+GBD^^%'8=6PG,`]%S'LDX<3JLYKZ&-20CN-?#/ M97@-/[\.O)-[0F9O`$,@%G.:SFWC`L8!_*BM@\?TSO1TR_$"E]["Q'AK.?JW M7Y\_^SE\\B88>?3O`)Z\?,#'HYO0%<*I](6.?\$,$WZ^>__GY5U;O?N=V'>( M_VV[?_(L2&^5"^=6FW?Y"6I5++,J\NUV14)@%XA9ZZ M0M[YYTIAN/GZ]N;R_WZ]_'2K7/X!?]^4X;=O`.&2K,]\%+"ML&?)\0JWNV0A MKIRKZY84E,NPQ32=9.'Z+(3!`_SPD0`)3!AL;B4^B#@JV=M`]LH9VG06O@/? M_`LNI!G*1P>>?00W6#%,<,]]<)K3/C=S>0G$03JNJ1G*;/+DF3H$6.%*W8T/ MTQP?`L>3P-L?)XXR(08XY12<><^#D"5[A` ME[P9P7ETE"DUT!,"EY^`RZWS1.)_'/#7'+L5OGM"/&46N/J$!1-LP2[UJ`/Q MC,>7$`$R!]!@*YXMY>/ENY.+KU\NE<^N.<55W@L"`<7G$%>XX_/I^2FC173K M.?CH)^?W+.,)UV^^`4#XF+CW%;Z>3Y8S36O_%#W'$0/'/OI1_0D".#H>\V!" M.9^YIB5"Q1X/V18?5AXA:DP@"U1#MG)^"F9"P,E7,V$$Y]&F;HO=\XG\,PW` M[53^EWJ31QBMQ2(_$HT&E`(*\\573);R<`$83\+T$\\9162*EW<\AJ]+P88@,JC,1(X(E'MHSR(BY+!E0AZB0A$D!E*& MTR519K.XM!4;*@XM`W5$$^J<,!!22CT+S<10K8C6)KS("T:>:9C(ZS@AQPR> M\E&0XF,$88M7%"7H'3\3WY6V/*D"(\>]!WK\0T2EC4$?J.7,^-!$US$EQHJ, M)@&0!5-@((\Z3@?,!09(,Y_J$YMS*)C-'-=G/UDF)OM@UN@3:@06&P/D]QOU M0P-*#);N\-A//`FG,&4`MA$XRV!@0UI,K.`)Q\=4:((]L4C`KPRM*.5HA[Q= MS"Z"]O`\N/.!V@&-Y"5T-/#G8"9DG&>(N``8U`/]&$H+YN?@.>(GX6'%0(8# M6@&W?NCX^A@0G<"H+$D)#^$;73HE(*-(#I9ZA$?!>7+-42"RD'B3X:"3QB7> M=D"]`N@P`N9-,1MICDV<`98#`Z1J"A1/Z?=G821B(8)RRA' MU*:XS@-:+'1T."1&NIHS:08?Z1*+3F)2AR;T71C^GL>%JVM9=&8?XA`LR\3' MD&8R&$0_@)`\M,2(><0$>%\BO,L@3!85DJQQP+AZN(S):WZSF!^]3`?K`2X? M2=;SA@0/&2!\,R1QRHG,M,9S7E,6K-(@-56;U=P@/7\FF5C<),U'&!^8RF8N M>7Y@$=V4CBN2P=',`NJC'O+8;@.V"5IXM!FQ&%X&)IV`SVP%'JI$_3D6/!M2C*9!<]GTZ]5B(R`85(+0N,1L"S MCW"W_\11@?LR"B'CR@9F(%$YXI?YQ$#2D&>$P[;Q&KU_US$"C.!!@1,629@V M-U_ZA&!L@R4.\):_`3C3?V+PL!I-/;"(*[:#8-B/YC_M:$PHL?R)U-A-G>PU MU]B2A6LLLEYYZ&3R;/U_B0M$J],J:U23NPF+^7#'S&0Y3YO.PJM%(X^N"K7O MPR@)YBWF`<+E5[Y$-[X!@L?Q:T0.U,J M[2/<]D:1"W&8V[9U]4@]NZZ]<.#;+1/', MTCLZ\J6WH.6 M!N8=QK)U2:9@_9ES%#YM@*K@L,"PN(;_CEJXC`SF M_CV0LA5MH"'WX`O=BZ*T?H9#D70F]FY1I,Z1.N>X61AZ!E_H.+!YJ$)GCF?N MV#&0TU).2SDM(Q9>1P:_G4P+A-98U%49O,`XLZI8(7!7.*7QV9>J,,4&G]_` M0X/..PDPP'LZ&-20968^[2G#6G M73L"6IF>P/-G4NE(I7,`+$QG"7QSQ&MEIJ;'VL)\(/`NX%2NF/=$$LLV[ M0-Y.%@<9L18/4=+@WXJJ_<#6`8@=3$4I!6^W"4SDJQ31OBA#)`K"I8U3Y1Q7 M%YX8%3A"HF^F\&+PC6P)8F)ZBD<`)V>&/D9+M)MD)7&LG#LL61'X\VU8@>_Y MA&^H6,B!L#?`J/P5N"4+*V<<-UF'M_`0GF2(52^LA![WZ\WG4%A>)#O[L;#7 MSX_8Q1(X\#,,IDE^>:&S2L@7 M@?<:@4:!&+S#S00>&GE!;:11^+(SF9[@1-RQMQ MF"/#Z"VQV/IIV$R85P^K&?TSFH;S`9Y@G-V':MEA;XU$C9_%QG`[.33<$NW# M]GFL<@+!7-6PQMR)A]O\R?7)5'"LA#CM"+!JCT,-K;C:5AMUU&"NH)TG>BV` M7R8JJ)=P**1`ITGX%Q?`1J*WS?2-)%IK+,8))1.M\!;`N+D(2T,F#=FQ14]A M#T5*U MYUBF<HDT]FI3FX>*8 M4!B]UME*J]1('&5H*.W0T=NAS!B0K?1GG_R@U5\+/'\F+=116:A7G?:@U1\V M0#1E?"3MDK1+R\1][20F+UKBK?4FQ+U?MB#7&++(I*1,2M;&NO9:G:'6ZK3/ M9%I2FEUI=@_![*Z=ECP$W_K``Z(C"_I4F9245DA:H2;+?2GU*DMRE9U#4`XR M%)2A8%UL+H2"O=XR5U"&@=(`2P/<&'%?.PP\!(MZX"'2D86!PVZKVUV6F=P) M@L^?R3A0FB%IAO:U"+AN9-C=M\*0D6'=9$[2;>O(L"$$(XLV7FE:\GUE6&S1G_-ZTP01_P%YZ\T^^#[`=7C+:N/P^PRX@MPB' M[)-6LSYIF39X,=K,=(3^Q.CQDC4]6N&J8@FIDF;>3[B>T:/^S1UP5:6\"Y9YRS-MQO%^Y7MZ,8MEC;@U.(5#TJ(!D&_8B$3M@*2/VPK%EZ9';!M*[?/UJ]3D=I0&2%756 MN"(YAUD<>O;7B;WW3/`2\AM2V/8I;%KHG:Q:46HJH6L#2.TXOJKDM/EJ94T, MEH!JB5/`F%,(YMJ=LH/"V6%!U"(^-93/!("C'@,_/@RL1AG3!1DH-'+IH!X? M[K639LDFB?NNBW/6E%YA[P;=P6EW@`%5?J8E2\2_0I"O0^QOS)_,UHI/(1N[ M%+X:`55^#VRJX&%QN-JAO%(7B\_*P$5MGW:&B7;_._0]YB'(2]!DP;3J=*'- M0!FV3[M+UV:R0%G=Q'D+@$[[ZU*F8FX)B/;]_OW+RMGPM+<@M@L^4M([!ZP>4-2,/+5S(W;H-6@E>PW[S5#LR_:MI>('O?(U?!V((%G?9-97 M;E>9\ MUSJ]TQVTM)HJ=YZWO4'ZGEOE(O`=:GM*S/LP[6RO:[T+Z1_ ML1\U7AM1J@T@4J8K0FQ'QJDIGO.2DQ;VU!BLV]@)5_C@CNKW[Y1 MZ9ZDIB9@2.$]4N'-Z=;+OY?4V?;`>ME*JF3(E*2/[(`L.R#7(]R3'9"K"(OV MOF[P_)D4MWEQDSV0CY;CL@?RUCV0&:P[;WB\\.2!=HZM%9Y[MW7[I.'Q0%Z[ MUM6@/W&]+LM42(]OW^_8O*AIV! MFR(K]2U6D]7QDCR-=BFV]2!N5OH/_U94[8>8)$K\<:ZW4)3GBC<6#.3^PYT7 MB_;JVT!.\OYX>2]]@,88.4F>0_$!*M]2R)H,MC*]@QR7X&PG>PUK82UDC6DY M-:8[:9M7&SFJ#2!2H.5&PSK[;6^>/SND"*+ZLL\EF<2>6MO`X8"#QGVR7!U4 MD#VN2ZS8$`];;BN4WL36B.U(=]=&D&H#B)3HJC;*[L8T-<5+EIL*Y;ZLX]Z7 M)857"F]CA5=N*EQ[>]AKPWS`;S^_#KR3>T)F;V[T"34"BUZ/6=7V+76G6+-] M"X.^M1S]VZ_/G_V<<:\//TT<"R3,N_P[,/VG3XY/_TMLO?D4, M!`+%=[MIO8[<[;9Q]776AHQ8LJJN9LY\>V-KLPMA\U^*4X<:RCFPC=S30\#I ML#A4@XKZ+:?NL1!U;]AN;GH',7F_T"DQ;3`OAX#,E>V[INV9^C%-W9Q\ M3+FDKB*3M<"^FPEQJ;<$TLIWUQT.+3^[IKY,04E2%B;E!W,L*5D*)?\@5K`# M4E:_#+H`S77@>SZQ$?J6`C%O0-PG166U>ZN:"E1@'WEF:7&_>ZM;J/E\K6Q] M#BXOVZ?:(>#13,]XE\CLO)#J-\QR46/W5&49U'(YA,^MROE6!8^D2O.HLG?` MZ@'%GLFS!P?F\OO,=*GQ^H+8F'.6ZN_`)5E21:J_NI)GEQ[?LN`ZS/.NHPNW M#M:K*QDK1U9V#E]!I54P=U#J-)&\EKQNO+ZN`3%Q0Y*<.J5-G?VRO=K@15"K MU];B#EA+9FDW(T&KG"@SZIJ.H5#^/=EH>%7&-N169[W7%V)):NS*R@++D>\0 MUIZZ#V`3PEXDJ9TB;*&R\#)(<\`BLJPJMC:2L6*%(*H@W*E0K*FV2AB[2B>( MD2EB>'N^]5VRMD$[594G2MQEZ_L'RI*:S]/VGN?I,D]_%Q*QUW1#)%8BV6LQ= M:L+G]XJ]3FTJBG:.S>_\8N\NO`5H`5)^@=,IM:OH@;@FP0U(J:N/;"-(?#%O M8Y)EVO1D,G>SX\XFQ/;>*"3PG:QM3MG;H59M1,O8UK1BPU+.WK7$#KOXSZG6 M,^WE.XYPM/3V8`M<"V3O&M)PKQZ2"L*'"J26+93+W-OWGK[[9*;]CZ3 MIRE0T;MUSG5XTJ5O`P]P\CSJ_>8ZGI>Y-^\B\&#.W6F#NX_$Q6UXO=3VO+9Z M=SZ;OWX3C#SZ=P#ONGR`OVZ?9O3\N^G-7__('-6[6]-'Q*[`?WTPC8!8[-YW M`)_N.RZ_Z842V"8'[.O-NQ>*0743Z._A1K=?M1Z;EC&U5B&:),H'$R3+HQ>. MYV<3(+TY4@22)[]>E]!KKKH94DR/D46P#]0[`-$`I= MFD'-D8`3;8XDRQ$KE01:#@FT'9.@TQ[TA]I>2-#)(4%\?2GHO5ZOKG#OAG5[ M(T"!W>4K&->K*=P[8]Q&!+B:SHCIXJL6[P/33\<,>`N!O_RN6P$Z_+\YCO%H M6E:#5%*O,]0Z[;.80MO@G:3?$NB33+C\/D/`/P&%;A^I]4`_`KDFV0)V[MU= MC[-%:?NIL1V\FV/^)R7N[:-3=X0%F%OB.0'Q;`2F".AVN+YW`K<)J"*<6V(* M]S8"4[@7,;6F]K?DX_.ZT_M,78S>R7TV6EO8YUG@TB16VHM?VZ?M_L^OUX`I M0@%U_/5X_LZ2&M9\UMI_"K"RWU-,9KYZ=!Q8N,NT++C4X9_]CT7$('YU1#$, MKW`/P/68-0IRSL=CTS*)3Y?9FW;G[CT=+=KLK.M+Y;>CL?AG!201L.>&8:($ M$^O<>,![$W`5VWW(GB7`9/*3CCVO2\:,87]8$0[ MF"MQ/L27//BW(G?FS%*3"8=BD$7D3_>43_SWKR%5-^6 MX==@,%0['<&+PI!5A,N6:AS%:MCN;8Q,\A9\*!JA(D9\]\PWMFG]\L)W`_KB M=4EPK$_$##BB;&OXZK>.ZSJ/X)$7N@MR%TC%5#N!!KN:0!MC6LH$.MO9!"J;H[D3 M*`?3(;@DO2*(+MKXW3M/H9E:!4MI\):D%3:#]Q/-#@&KGVI_@^^.%Y* M2[KS-S[ST98'].L''NO-KBP]LC)>*8Y3^910P[7S.4ID73]L2G2R8^G,ZVM1 M@F48&T4+K7_WR7E8I$7F]?7\"2=8+)NH-2G.0I60UJ*9UP^;%&K_[EKW%TF1 M>7U+WRN;#EHMZ-#NAJQ/6[;,ZUO[9G66".TLN^XF\_JF=3<[$86/Q`]Q#`*MW-O8XK2KT&_:!5<4N`*+4/6EK)VJ_8I36+CY;SY13 M,&;S;.KDFNVJA*\Z#X4CI6I[F%'=G!FU*5*7N$28YE6W>K36KJ';>#[MADTE MX5/M?,*AO,_D";?6)%;U3.JQ`CMS;%(C/)!U2020Y>V5Z04NS1G.%5>O@5(% ME-AI)BUCM;Q7(UKL-)>6L_&B+K38<3:MWI*QXWQ:5CW20*L--3(KH',JHY>S MN%,CK':<*,RQ"S4AAMH!E?>4$2=D7:]@0?K73IV(L<.\:<:2:*]&I"AMH;=. MPEYAL4O"Z5U*#76()8.UH,9NL^,UM_M9H6GI(>OR"LQ:3I2MZTH;BE45`J_5 M2.`KI$5!5:@.U,%`JPDY,O>?Y^Y+W\PGW'A=+4MUEN)/LS80?'O[N\`U[?O/ MK`L8.S7K$WUDORQMZ)"79>YD7%^M)Q*%:T4`*QN3PL9PG4F^0TQVDZ:L)QN[EY9U5$20MGNU-CS*MI):`/"D:@/%SLY%QY@=]BH1;:#M:YZM@!F`H@20"QU'\NU/Z&N`.2#24:F9?J[%<).;YAL M4+82U M??G=!Y,ZSM3'Y_TBT( ME^,BJITU/,0EX*:TH64Y.N;VLN\7776J[SNHJKV442P$5GJ';=:-Y]A]]I[U ML7G[%-\B^K">/Q+7N)[AC5[B;*5/`3NGH*0U/_:2:.J+?KB%HZGN?%10-IK[ MIV&!8/6(:,@.;O>N;#Z7BZJ7TFFXM`G)=ABR4YK9,Q&:=<-PJ6+%'R-4Q.&J M=4-@:Q9%Y[@<\D1>0+,B93C7ABJ4&I;7V*V969Y_T:I1DLO0KRO%2Y/E9E/< M6\M:K4WUBC3D',VW492K")!AS(Z2"AS'0Z9!<5MRC,JG(/I1+QEN;Z_'X?D@ MW-LZ]Y)O7U9GV,_9>9)Q?0W'HC!HB(=I/U#/?W/%_D%ZA`_$.F'EKK:\3;U9 M:.#&IP%NCL0^L@5?OB#AH]4L'LVS^#TQ759B<`Z4F$9ZC^K`9%RP6)XP6PO% MSYT_YV2R$H!+F?A9;_EB>M_>NW1U#]1-J)/?%:'+V@NW.UH)$[HH6I71,.34 M.SQUA]K&CFC(6S27H1*+(E4Y!?]P+!C&,OVGW=&P>UJ9%&:CE3I(RG5T2@WO MO>M,X\[+H6JL@`!9"Y'#8;(_R7*0YGI\B\O)ON;OJ*>[YBS7'FZD9J\?\!Q6 M?G9AJOGW<@#F2#VFGL=:1;^GA:I2"D2Q\*`76+@2$'=$9QY.U@_%"@@[9^J@ MG^)'"NZ:X50`H79ER!3P.RM@4'_0:S<'IS(91&?$-,1:AEBO/+>-3XZME[OM M:)T#9C;$>;[R?C5R%9"BY*.(-B3%W'ZL8I1(Z.",UVY2H-O)NKZ)J'.G?#F` MVZ&@#>]^#[)JC`&%P-H&A=M')\*B5QP+X8GPR._6$;>"8?PZP\5'J@?\7*EZ M,*A``?EF6%5#CUUPNT"GA,U)$E6>C,>F3MW5.8MJ78:UL%X&>PFXE6UM*\&- M:?C(UQ4GTX99'U8%SBN(B&51X^W3_!&VI6WYJO(PVJ4UZ@E:;4F+2$.(']9( M?5562%6,5+]J;4UCK9X&0A=DHK!2;E+IS3BP"PF4G1NKF[0LSQ.WAROD914- M4@5'MF\:I@5Z]8'&\L5/&*0&1LDX;0-?G-QX25P;>\R'Y=^\KFU'!5<+"\ZE M`+\/:JQ5)KGJC_,LWI]13;/JH@-DF]K]:"KO24CSJ MFF-QMV?^0]\H:N>TP_X#_[3;58>S[^'/^*(WBNVXX#6(:P_$-<$7G+OZR$H$ MXHL6]7WJGG@SHH.'D+ANVO1D,G>SX\XFQ/;>*"3PG9\4I,T)L6!6O`%4B>N+ M2Z9M4'QQ&^%C5WSP2KTQC()CV?0GY7%B^I2]-0'VHVDXCS"Z"A\=UXB!8@,! MZ*-O)HR%`WJ^ZWRC)_"$/Q&_3XE[;]K\RXO_<^__]'_(=/;3_ZC]]D_(C=4*@QRX0W%I]47(+#&DJO4Z^>`OHIE'Q_5XG8'V""[!P"!#%IEY M0*WP4XI>*XCS0M&I98F!V4%3^'U&#$-\3]#F!&UM,G5@ABT>.#^$C0$3T M;_)#&22C9ND[I>/Q3\81T>+%:+PVG=W MJ<.$ZCSAX\'5TYY4;;NEBC",_%WA(",+QHV,IO@M-.D8YG&ULY4 M,Z>.).GVFAE"`);953IJ:PF!SC-Z]K)G+2O!8=ES:6BU2H M"6#U@&+/Y*DVD!.Z?JCU3SO=SJ!7PIK7[ET2I.,;18M$1BR\+V%+:.(Z3<*W MN-3M'KWGS\HV2_'D>%D`TV9Q,D^EG-2*I]5Q="TAUIJ$\(&CM\T,;2ZB:\[0 MYB*Z&X?D`/S]O&Q(KD?"R]L.-P\D\Q!5FT-)M_6T\2&E:#:*8!N`H]0E4I=( M75)#4=EM]<#A:;;#P^@H[-$&JJ&1N!TH_PX/HV/@FIQU,KN2,8_#36]RO5`N MIS9F.;4I,VR+I=.FH'C@AG(GSL#S9](=:#8'Y;R37).S3CKA6[@(!C)R=9\ MW-:WLZ]9;T#\GCA*:_-VDME=*2_'8ZIC[^9H##Q.ZPO5'5LW+9-U;6Y26\IV M"8[8X32BS!;U1'O*^,]IS[17[6NV9._*TGI75N()E[Y^+?:[)YI,]==N_U<< MJ/7"C(HIN'4VH@AAE0I"[P5FE=$13#)Q;TS4MFX8)"DY1\F-VY54-0TV;470 M2^QP7EGI\]9QOBDF\_.45Y;C>3\J8S"@BC.CXO3Z)63)V%*]B5@M'::D/>VK MZZ=>J?U^JZ,-2P;TQP+C:>70+W.8DG8<%Z%?M],Z&PY*!G21?M4O+J\$"@*M MJ6/#0QC[F.R,.,#'15_SP=3ILCE3D5-645'A6:NK]O8$4[TI,VBI2TW&]C#M MN`-I-GS1$=F'+.6]3JO?E6*^)]+L5Y\O\V$O)G@:/;A'R@.Q`G[4);$LYQ'/ M:M^EGUS=8FPYTK1S^!(2JK:[+:V_S&TKZ+V7.ITDQZOC^%FGI7;VPO!]F^0% ML>J&0L53]8I/OBN4)_RWD=9NM;+:S94$PPE&%BTEBMDU5!O6B71WKHHDSVS[#)_VIBC4^PWR(\9DE!9>3Z#5?XEF]J+-DU6I^ M^7#;U::,]:-5BW/9*VUY_NO*A28F)$`P''8+FF5"%0UNAA\"_/#9-4%L9A8, MZ(R5E'0P40S"NU]'S[W&\:,O,\GG&O(YK6EVS+!%IT:R<&T6WDXHZF,Q'3$O M8]H0E)HPJN?#A2D6@>"<]>%&+`LA]A.F^?$`[M0U8AN*";<^3AS+>CIQ'FT8 M#"].R5^.:_KA)2\8>:9A$M>DWJER;EEP`Q`?7VCB,HTNQAL1"X-CCXW!>$AT MMHR@3,@#54:4V@JUS"F`"V"?+A7`U\).)`Z97V*?DG;LJX>FT`-JPEN\AEDN M.4$JL64@$S@A(JFHBP&3[)8F3;*0F[292V>$KSN'QFNUE3-MO`GI"N8**.!/ M%*+K=(8/P`?`U0>JP=B1+WM/;6S28#W%-\(@^+:OMHG?;GQF-P"$\RG`K1/% MI7\'I@O7DL;3=T`JOE&%1I8&K1[QO&`ZXT;/GQ!?(2PF8T\"?H[+`)LB7.P5 M<#_U@4(0G8T@1/--))=+'Z@=B!%%1H=_<:F%M(@EWC`]W7*\P&7Z#6T=H`N4 M$0.SAQ)CGR;F2O3IVH;;%,>^=Y!4(^*9`$,25@LQPMRG@(=:RBCP M@:&^@M8=4?0=',+Q:`@RTLL+]`D,0:<`EQ<6'HBL%<,!W@M,<0-BP2>#@D0` MOR%>!1^`C@,+1G]@]X1I>+8BA3&\C[\*?G.D,Y+VV=C?)A`%W!>0A!$FIN<[ M*`D6XP:X0?AN?(N#JP.NZ01P'U#,S>"_BXZ/90)+&0U&2!'B.3:KE82I"`\Q M43==/9B"9".@+2$O7F!Q,8%Y"J1#,6>_,!XQY$$$D6E_!<8]GQ!DY`1&B*[K>G]IKR[I[[T-/-.FG@=,'*%GB;0_MXUK!/DS`#PA^&AX MUVW"+95)CB,S,XN.82@62E)ZZN(=2@Y+7_#X6)@TR.``./>V^8_PO4(#IC-_ MS.!F,FG*F/G%'Y@O!@,`?5&KNXYEH2EDZ0JP0:'+)T:"#W[\W3.9WX!>9TN9 M@K$&S\00=YA@S0C\Q6PJ.V^,SWPKXEU/?X`7OX'<**-;R6KI"36?A!U/GN1\7R^O8BCG%/!*!+WJXYW=N MM8>S_DQ3!S^!N77\R,"MS("0*0S-_"W,@EC\_6CO""#H$JR$.,%MKR(%X3R( M]$5L").IFA"L)2__2&QRSY)YF/8RZ2.\-59"PBQCIF/F^'`36W.*3!LP"OP1 MA,$#00/_2D>J8/8,TR:NHK,:3IXE3.97F.5'5X"[;JEL"4_.A4X$OA_$_(GE M1H3/!._#Y$UV&L1.@D>_FQY;7Z-VWDN8+SB'L`*4Y;F8Z&4B%:A3:G#6Q/Y& M+D^S4"KT+G,,KXC>AA""\Q,"F^"TC=E''!I=3^)-E+$%,XVYA;IPLW@^*'8J M03HX*L@C=+P,YIN8R:PO@RO;*QX+^4\3.)DN0WP?750#,.MM4!*8AQKQ=4^> MCF+)NQ'U'W$YDI$1U-@WH$24)\OD"5O3G,3Y3!NNC7`#E6#">C[?)NY9RKT+ M*WRD"W=D-F'1A1/EGR`,]5G8E(R5_MKQL9!-0;:4HA-+#[BA,#-2.>1[F/:( MUB59^L3VK2>%AF6%FLN1LZ!<;XD`7MER>LXZ++V<>>NA_CP-,E+)'L)(" MAJ8`0 M\'28`[&3EQ^*B<%9!*9'&POC]^-R0P%ZF5XR:6_:H:P)=F%I@F-PI@I6GL)0(OWC1>BA; MF9LZ+CVQS&_4>CH!#6"?1!DK8-D_.0MS5W980<1JLT)=S)S3=`T8&A`3E+R' MRV@*>2"FQ7)%/'GSP+,Z-KTG[`M]@'O9,F6\%BFL$5>5Q.)F"/,W^"-ZQ#@< M*/29XQ+W*:EN6[@\^->\3>.I*J8`6XQJ,XO8-L/%1ZUZ;T9%,L$\?!"8G.,G419Q,%;X)QH9GE.*$1^LY6 M09TQ>Q+E@LM(5#289@I_+RM#Q&2E\5?@<34O)">C"$X8-/XD0!7H/#<&%'XP M/;QUWH=9.[65DYJ:VVN&/.%<^&)ZWRX`%-/'3S*#=>@J<#&#E1('MMN,B8." M\B`S6LUEM'17FL["]Y'1-&TL)>+A%KT*30_AFA]FP=A`>`OQ)C)&::K$R$G?>!8F8I1_>7QE%_UH]@%S5.!6\JR+ M2Q,S''Q4F,C`&]P^`+[LB-C?O-4I[*Q%=#\"E4S!95@YS3-%C\`,:.W[^!>:FQ4#8-:3HO\05A-MB\3EGI#"@@=13=53/?\#ZQ#.4I%,]54))M^Q4TG@PK[%[.LH(ND@/^TEK==KL%$R<> MC=T77LZC0RMT,LP'B@X*V-K8._/;]Z&CWS@P\IJ':^_&-,VV;Q@@Z#0OP?%0<1^!XCZC%$T<+[3]PO&.%2 M\Q0P"ET;,.8<&4`M3B3P_B1\VVB,+J_=_WIZRK?#LD54W'V13&*@Z+-;.>;1>F2\B20DM"B_B:HD$2)BVT$*!>Z] M83X%YB5#G(R!);$3I?9:0IK"RGZV.=B<1H\RVID`SW^<1URT;J%W@ZTQ#(>C M83(W9VKZV,V,&8THNY/,@X.WQY]AFU3A(4_8%+%]^`:[T'#'KLUA6M<96M?# M27I'[XGI_H%;&#[RG<[XE'2+CE+)+KI%*!P*DPXE(1[2%VHPCZ4OU'06,L\' M79XS+>WNY,Q69N#>18W"O(27H;Q*/"Z&3/S\8XM[&C2YWU`$]+@"PRM9P>+K MHA8JBNVQYHIMGN/&650_XS9.8O+^"XS%V#$K40_]BN#"CNGS(7^,ZEK#]6$< M8(HM'HCQ0&QT/+`]A-B^%U;N1J^*QS5YAS-L``[V.]&9-*HL%F/,"#;SAU>Q M#:3\[=.8E*)\-FO)BM-.(9;GX!9)<`)-;X*)IR3E)B8X>JX^>9JO^$:\A<.& M;>6^@[/W#XTV3&(Z:80'[XB2MUD@F,K6D.;N#.S%>]D&5(X'J\1;OG3&AF4LQ\VQ(_9VQE=!K=0[I*)IIJ*1MJ+Q+$R6&P>^ M:<6ME.(45Q1DH@9-:*OIO`V)FTWRS298"1R'<'E[/+`NV+%7WA=U(4SL<,!0 MD[^3-V!*`!>FH5?WP<;>!3!FX+I1>\MDFG\^9,S=PY%\.=?8D:5JQ0T:HM6# M9481>V%2+*,N:A@W,V!\/TTP$X9LA/D(825R#*4HB2AD\C)%2X`!#Q$<>:$= M9A:8G#X(&&OZ9.HA#1YH(3A4LOO;>2"7:4"5:T`ZRLUD6CCOMM4^[NS_QGB.3 M.'?>=V8_+3N[F$OL?KFY].C:L\&I.MQ-WQ_TM!5U?4@7IGOUL)XH MUPOQ!BO;`\WW=^"@70Z5/II$C^^'9XE;?MU;CES!8]<6I"N#U6F:;7O#5H#5 M0\!W),A:K<7WBLLL;W&-.^="L>^\#@6?OP"TBO[:0\^$1[+9>"VT)%QDHL?<8I*[$@R'8M M8MNMA-^_ANS'I]O)58-&>L"2875AV#G+TRY4#*8*!6&R+V1E$L%VE)2).BS' M^9]U%Z@++S(G5Z:O^39M^_X#Q7,YWK-=TA\QY1U,/Y,GEMYY%]`+WC@IP&:3<=M&AY&.;]J[4Y_,(S16@_"#7"[LF\? MG3]9#>@NT!NHO8&V-GHQD)MAB(F:!N`8@;D1EN_!@:P_DA&4B*,UM;^]><PUJOF%EB$__I9;UOS8XZ#?L""IJ7&']9+8D09`F.8OX2(0;E`-RH+C3^HE`S\$(_*'W MED.6.C3MN]^#+#`RKB^=1IW.X$P;]I-0)B!8=^Y_8>M;&,/MTB?3AKWVFHI@ M`=#-,=VMA];1NNW-D=W<44N-L5-_K=,]VP[C+=TV)W`;X+:%4&[#UYVBVAEH M6[&U'(QWZ9-WSK0M]-2<:[[9(+OU/(?]+3B\N0,:C[$3/W30VT:0YUKZX\F@ M%`!@_U[9HJ;?@^?PYG/;.,?34:GQ(9&BJ<)Y3:'8[6K#0:J]VP9@[@31;6?H ML-_IEHEHR.];YYR?*_;9Q=:#X&-9Q/;A\4NXRG?15,Y%;=#NQ;@5AZPR?$H) M;4+(V!;@MUCNA!5)U/;83J)SW&#-^[Z\?8IO$6B^]ZTPA7!)B=SU^1T<[F"HG:1][&3`E`EW^?"A'4/XK6BR< M\PX+7\*-A(B%2]BIS[?4G69+T+HH+I6?7S]K?ZH?^^]BUNP!S3*IG-`Z!5^O M-9'*&Z"YQ.G[`J-?\H-'/]$=:(.NNLQM3T-3)MC;.C.=LL$63NP7MFUX!^Z8 MIO4[:A$,TH`50^8F@#D/U\1#Y6BOY>CT"C)D'K0D0F*JXO&P7W`F)>?6$A.N M#N[.9RX"VTLAD7D=WL^/BO`OL0-VI";FKG-U<7=K^A:]'E]%1^FR>]^Q&BC' MS;;\Z?G5[Z7,[3(4,T]`@VC*L75POYE:BBX+:KZE-AV;_KG_GN(N>XLE70&R MI_AYW(E>O5.A=CMG?#ODS!;SHL3M=_O:,/]$>:"[6*\LM^)/NUP`S]^ M[X^P>_IYU#R]NUJ^,`DD?'?Z!@/6C<)"$J2"RQZPW?'\:*OW]Y@7V741G. M;1<#?;_[S6(9];`CMM<4JUHM,O/H&R7\M/-M8R/'!_64LTOE:.2(KVA?+K2,E2)5D4AE;`/X'QT<]?'X M@*0M^L-'7]Q7GDUD=)M7[ZP=GO99I6WG3.WVAX,.,JV15-IJKAPH,0I(R;1AJ]=N2Y'9L?;FF[BD[FZK_95&MV&D M*,&9:2;&VTVI@Z+!4IW;T;KL[(2#IL"^%*MTBV/5.CA0$3M:M2)5ZRK5VCV3 MJE7ZK%4KUK,#%;"C52I2L:Y2K`--*E;ILU:O6H>-$K'GSZ1RE(>%F66U=9 MK57LR-IMSZS1>MU^5^TGSRXH#&"5>&U[Y`S$M]J@VRL?KX(GII3-IS[<>M9> M@L[R4U'*0F-;M@S:O7YW6!X:B6-9\\YM;I=,Z6S="-0-\3,;8]$VD/ MQ+CV)P6/"=_VQ*OA4LW%X"@)TJW/^NX,E]J,$%1V/,G"S^L=FU+V?&IK_8$J M3DXI#EI5V&S+B5Z_@V[)!MCD>#$J25]!NV6F]/6)$!I)^#$D!PW$[5PZ;^[.OLQA^="QD)2DE&RP"+"MI2L M-B,?'K712YRN,0?;%5*4>OX25$,:Y@]2B+-+A\G9/%O@D!6UP(`\:\A&[`Y: M:J_`\21K@;D6_EHY9,P<9ALRKAXP04:UW^H7(N,Z8-:V90=[[(98Q`7O3SE1 MKL=C\,U7EP"4HE&W$+FBW-3:A7KQ5@-4O4FC=EK:4D&O@6P76)6=(S?VWC@8 M%IU(P8ECR9)8NW12JRO+*4=&=@Y?0N[Z[=9@6$(,4NH< MD0ROCN&=7FLX7%9W6QG#=VLX%X2H6VZDO-YPE96';!5,[!JJI*.F#5K#[CJ* MI[MSM2-9O!6+S\Y:';5`<4_9'%Y9.;/-\D%R&>+:O2>V^0\K%[AP;*:(>>V` M;7QVJ8<=\_#K]?B]:1-;-XEU`U#H" M4,'2A6$^)#C"UC$2LX*3_C5??"BPW"",5%?33@=:&F_:)[\S$C>)" M*"GL6L8J1V(I(Y*C$V+\%7A^"$1V$5B>L[N3%1%`$/XKKF96SD(.+@9?@A8M)"89`RB(((MNC$?Y!Q=P+_/MD"! M"V1ZVQ_GDQ)Z*^R\Y/;VDR%+SE$XV;5$)>2"\)V?JH0VU!N@I%G&B9/R[[R)U3A?#_3 MM/9/%\YT1NRGZ`J0P'&3-T0O2-SRH_)(/,6T=<>=.2Z85@.^*#@R,[2*,P8H M'HA!3A,2%GVZA?O$:Q7#=*GNPUCPQ^&5F6#182@@]OV$7?82X*\5/6GQT>&P& MV/G$?5)`VF$`FZ`\(/,LY]Y1#.K!+/$R[(2@9 M6Z=N08]([0G>G4]#F\PH,2Y-&=P/68)Q5Z,2M] MGPGX9`0<&L]7)J;G.^!-P./@7P6NB]A8O*Q]#.1..C,(AXE/&O2!6LZ,P0IT MO$',*!N$X,B`Q!N'!-X/;0[\#'.`:HE\V#OS`Q%ACT^>T M?U*`S8#LC++II`0S9-PHO#4)/A<$, MG&&?P:$['M+0#73$-(]^P-\QT8%1X"`2$[ZAJ^L3VT=)QK2?KY"1$_A,+@2M MP7<,T8!WHC":^'[&^I30[L59E,JL8?9(,FPCZY-2N?QWKN)9M.>9WQ>B1]#]_W$"T-EV2[FEWXEWJBSHUS"XC()*>`TJ!CX& M4U%"#^O4!*M&[!`TT)-8$XH:'536/=MA(!07BV5QE)D+F@B&Q9^#V6D2`4`( M5"5[WY1\`YT5N&QC#M%!X7-MRX9QV-5YU(R`&1\\SD"JI&9(N%1)#6-88K*. MJ`5>"G=-P:-(S5&F'D8T\H9P%XUP4W7B392Q!03@_B%_.N%AL6>IS1Y*N".H M%-#+R\B0^?->.M,LBO-`N5]N`[44_Y%:H*NF@-J$*SV7`IMIB]U";#N(_;"T M>Q^Y/@`!PVF%^RZ53VUE^?FSA=S+*$,/C626IN[E\EGGMIK.P6%Y;N-:A`PYSV0J, MM%,>ID,?)XYE/9TXCS8,AA>GY"_'-?WP4FII73D'#W\*KW'QA1CTNR+_"R2S ML"6/R&HC#XG._?PX?PYQQQ3`!;#E,G53!5#JD.:S<,'#(&+5G6Q M\9+=VI3 MEX!+$-\H5IV_VB9^8^5[S,4XGP+<.@E7=;WYI!];":"A3N$+I)X73&=A`1_Q M%3(>4]T7B^2X-HJ`35GE?[Q2WDHNBK?B=0DG44T3IY!1\-O(=<60XP'N):.?6PM5IEP*_1Q9] M'7@4E[TM\X'=$_5MQ/H&MDB,OPI^!:9%V4R43==/9CBRK=. M!?F!'H'%Q8277:"8LU]X+08B#R*(3/LK,.[YA(@7RW7LZXD_(BGH7%E&L@@C M@A,9",`9)DZ.&::209!XJ01#SG,"-X^,Y[J/:>H09N"$92B&"=+OAMETE(:( MKM)!;JJNEMFOIC%LP1U^&Y8/@>(;8<"*^JHN/K'D<,.FI-2J)5?4@-OCW-OF M/\+C#,VVSKQ0@SL'J2I*=#KP!^:!P@!`7W0%7<>RT`$P1>>NT-$5(\$'/_XN M2@;1UVXI4W!1`EQ)YG>88,,)_,4\">:\,0<=?N2W,[\[=/WH=W2KF0?DS<"! M&YNQBPT`X_)X7CW@ESGU@LDNM)*@GH6>)A89>Z_FSV!]% M-T04'O(U<+Q!F0:>S_TO05X#V,)"#@H.3[CDGZ)&5%`41PTP@'#)#>'%!M@Q M-,>W).A1S2RB"UXB*"?HD>K<.9VY#M9T@K/K$]/BA`*W]X&YE(D`)B9<2SB# M(B@QHF&9AV>GP.?^IG@=]S_Q;IASYH-IH+\V)UL+OJ$0+>89,W>72T/HQAE) MN<@D@?06&J:(),.:QK!Y-NW0D;R,PVS0/A\<^_X$8W1#X=V3I4O97*F2+F73 M62AV^F*=\XRW!$'_P)QB%A)+D7!E$ZC&=^4D\GWA)F=U\!,6//N1F[`R?T:F M,#3S6S&'9HF=QJP:$3>ZX/[B$SSB2"2PHC+(V)U()OI"L):\/%'TB4X3?82W MQDI(.#>8)YLYN,69+>I&YT0`H\"K0QB\1($6YEXQZ>8J^H38]Y3GF)/9.>8_ MH4/%7>!4KHVG=D-7#-\/8O[$,FO"\X3W8>HO.XEF)\&CWTV/+6!3.^\ES*>> M0Q@W,O%,7O0RD4C6*34X:V*O+9>G62@5>ISA=9-]QF!RYPU\P`AX.GP#F)&+S\$%8.SR),'XXS$T?MQN:H` MO4PON>1CVJ&L"79A08]C<*8*5G)A8@BS0!%7N:39:*K..7*S$>\L;3(3Y]?' M\3!M3*)D*0"QS`F@XN2%CT]A"5ZX(YS?QU9VIXY+3RSS&[6>3D`'V"=1K@Y; M&N4L[%[98>4=JVD,M3%S3].UDVA"3%#S'B[#*N2!F!;+DO&TU0//9]GTGK`O M%+M;L(7N>"U;V".N+(G%#1%FKEA7(?")V79TBFE=;)Z84+@M7%[^:]ZJ\20= M4X$M1C5L.,3:_H3-B*)B4YT5`$:F(][;GD<41O8'0?6X=0=A/(ELEM"U?IQ? MXS@X(=%9CC+B;*)05#`N-+0<)S1#W]DJNC-F3Z)<6[F*9E M39J9HA>2DU$\*DP:?Q*@"G0J>H8X#Z:'M\Y[,7*S?3,TB\SE-8UA"[D\UI'2 M]N/-`QR[SF>V"S.;^U:>'^8#V4!X"_$F,EIKJL3(2=]X%B9BM7]Y M?&V?-7K%#YBM`_>:YY]\U8E,C73ER*M=AA@./-0RU>+K5F M4Z><#&*:QK#%6EKB8A;&4SY35[F9@!Z0H4MSV2N]F*:S\"WQ3%VAX:R+5)G.R3O38B#L&E)TZ>*RVFVQ^)PS4ACC86_E MQ*#A33Z>33@+7'U"P*EY)"Z(=(X3]SZQ1NGE'H:`6,&'#DL8NT@.^$MK==O\ MX/MH-'9?>#F/#JW0[S(?*/ILS"=D(^(BP_RZ<5C]$BY>9_%5,-0+]V'Q%=(X MCPY`G+`'X8TR`=T,12-]MQTQ[/FS0]AS]0E&B=-JB7ZR-Z@21TR^2QP\=,..J;B$ M6`"F*",@-N;, M;"-U@E+Z#GY3]S?&F%UQU0<0\3WJNLH-!DA$@W]8Q2X5XRI.YB7_/RE,1ZB$CFG:J\EI"G<1L0Z.IC3 MZ%%&.Q/@^8_SB'4B+?0:L8N3X7`T3.8^3DT?>Y,RHQ$E$I-++NPL%WR&]16` MASQA4T3/AQMLF,8=YC:'23J9M==*N5#-6QSIAS:&ISF^X7O+Q3HQ7 M!!=239\/^6-441_68^``4VQ-1(P'P@Y?P[9&8L-TN&<@>E4\KLD[DKK@;%I/ MR6;KT9X&,<:,@`N%KV);]OG;IS$I1>%^UA(QIYU"+,_!3>G@"9O>!+.:2MN`E@G.>+(FW4H`EM-9VW(7%S:+[-#7<@Q'%L MWNXRW(_@V"OOB[H&)_968;S-W\E;!R:`"](CCR0OOJ+#`Y?1`PUJS0U$,:+@*XU%ZES2ZS62<@6FZF M!0ZW>\+[\/26:%X(T\;,F;F&T>1'3^/KP@V58[:;DN!4P4T?WANI1!NJ1`O: M07[ZIP!``*AV->UTH$7=0K@]EIJFU[PU:`U4/$=R3*6JT%^(I++3^5`C?MAH(;2>R M*C790P:$\3JVC6&;-N-OTI MVH6*U%0A*DSVA<1,(MZ.\C+1X0!Q"FAY6O>U83[@MY]?!][)/2&S-]?N/;'- M?UB=0^I\Y'/;^)PHE[@>1[4G-U$6)UZ]@+L3QY_'U6KAX>>W0.ZWEJ-_^_7Y MLY_#=W]P0%`^@47W;EUBX!C72(0O+!^#"B?Q@F@`=OH9?/E"Q[^\N."?[][_ M>7G75N]^)_8=$O.VW;[C_]]>WW74.Z!V^OJ+7Q+"R/%]9QI.AJ718A1%R$0V5.D%K%E89-0;%#]?GGY0OEQ>7 M5W^W-5DBKVWE/1VY`;;UZC!O M4&LI'SY>*!;X1^#QH;/<11'/_H<3R)\H%O-G4F2/Y'D@!'AL\\.'B5(&A MSF>N:2E#/@Y;SCL/[O%(++6=')N5:NCL*"@%;3KZ>.#SO(2[>NTVKW@-;`\7 MZ+"/O>.+QH[1(6-C=K(8+C\&E%="B_K5SJF2:A'&&W22P/);\=-B[2NYUVM$ M++;J>T??F1[I;#0=AH?'F"$-_.B M9'POQV;*=O>S'6[+R*MD^O)8NLHU;D^'V,`CR:50+ M,PX0P]3Q#F[D]/*V8^%B6T@58/[+D_9)GGL?._0;.=5)K_Q&GP``%KT>OQ.M MV6[)=W[0#PSV(8Y!;G&T*OSR0]6]C;7ZJY7OXH(;0Q982''*OYA??]-ZG=TO MOF50:L06[Q$IB\P\('#X:>?+<#S.RXZ6YB4YRY')#IX6YH"`*@HKU=/>=@,F M)9LS.Z(J?T&!1SOXF9RE(22&,'20PBI3%H46\L@3,;SP6= M("G)*-FIGI(%ERS$-%BN<:J;'R6Q+[&`L/58+AJ6F@!6#RCV3)ZM)?E_=)W2 M\7AI9NQL@:&U-4`M M0L',\=:GX#I@%:)@>TT*]KK]5E?M5T[!75J,'*`NDOU'Q-9>#.(PG,,2A(-1 MG>J@U1DNFQ3':U7.6L.S=H,-2D'X_BN:ZARVF/?ZK:$S/-!VE[%@!6%>4;M;3_B2U\(+7"UR)#!P%Z5L?C?#RL M"OKUI*MU-*T7PYQZ?[6`W46[>"[_#DS_":L6'1LW]9Q_-[T[OO!U@^M>'UF1 MXSPBWSWSC6U:O[SPW8"^>+U78,^C^M7/Q#2N[`LR,WUBU1_P+Q2[^E(C/!,F M&^*FR,RMR[JR/.U&:@KHA>5T/!MJ;:T".JX&K$9S;VM@]S7WM@9\H[E76YG9 M:.X!P/_?R8GRWG%\+/!7;BAO7G5R@KA8IOWMS5C\]@&^*-_9)?]I!LX)Q5/7 M#6J\$%==!UV6B>_/WKQ^_?CX>/I]Y%JGCGO_6FNW.Z_QY]=XXXMH:/`94B/" M=^([;CC@Q$7(_^<*D+Y3PXL6&5'``/ZY$S^\7@#UW$V/2UP]?!P^KH!3W/%Z M3'3_)!PQ?!SW&*1>'K['^>5%2,0[[05O"/;+"_6TG0!O#70[>>AV]HEN)Q/= M[O;H]O+0[>T3W5Y5Z/;ST.WO$]U^)KJ#[=$]RT/W;)_HGF6B.]P>7;6=JZO: M>U56[4R,5;4$E+55N+LK=O:+[!7C02;&)1@G-=5<$Z7MU41IV2:J%,'.M5':7FV4EFVC2A'L7".E M[=5(:=E&*E>PP^%2T+G4NU MK?Q.;-95I)?L_#%R7-=YQ+XBFCC6..J=\8Y:\&9LDO$^L(W6BBX8V%2#86=Z M&6U!\(RY$;;`#S.%V,(BV2>DMZ1/R"(P;#S6*`,73W$L;'Z';\27/9J6A:W\ M[W$+"Q6'YWE>P%IG(-R/CC*%>\S$V=4I;/[EI(SWO>PS?L\?5[T%^XMUB&&-]^>ZQ"SC_IZZQ)3*\T%Y M/.<=?3I+V5L:#V$6X;GI$0O^K0`)$Q1$?K*3.JI@)RZ4F';`NMW4E[7#\EB+ MC6?PK"R#G:/*4."360OG=[A-^Y/SP)L-:?UL0>AH@Y:VN21<)70++OK.#3_7 M)4ICBJ0"'4#VK@6>/XNFG#K@8&;:(XZL..\F[N4$$Y+S868!7SED1HP+:^\* M8HY%?_RZH_294L997,@T*3=`4FSPI*AJN8*MJB5)]KOX')\G4"<*M__S_;(Z M3#!X\]L;D"Z+/CJN/U'^`)ZQPXP^?+AHL>Y9%CM'"$^G`7/%3N01>_0\07GV M-@?D4FT-.WS41M"+EAP0P,6OQF5ED/G*UP\^50LJT3]4VTS7LX41+/M%_3V@3!A,2 M#N!"@8878U>X"F>W5F)@\9$\*2HW4?.6XF4G$52\=UP\J/`*>.'Y*`?88.]S MIM^1*0`@/:R9&#LLRZ!3N,9L1J1*8@`$'5]VN;M[3TS;\_,,1\F4+='!O]9] MAQT&WL^FKMI+D/?2F`;,_[=,/`Q@M:^WPM/3%CR]\$?&C.B\3]1\(6N$X*)> MA?DSXH<11+I&H-$]96BP(]0-$9]=..[,X768,*6\">6#X$_7MQ=OWZ(V8=W8 M``0\%5[T3L2FF$P&0G^$4TAT+4A11.FM852MT7Z8X_.A,>*!Q*"Y'%Q2Z,L)"=&1^NM M(35,4@S`Y*7&\"@``CJ<``!4`'`!L;6YK+3(P,30Q,C,Q7V-A;"YX;6Q55`D``]"B>570 MHGE5=7@+``$$)0X```0Y`0``[5W?<^(X$GZ_JOL?4NPS8_BW;OWO57#3M+RTPO'6ZT7[U=M^[U__7'W MZ$TA1%U,N$#$>Y52:O+D^A\_?NS%_RN;44!'@,7RP!"\+&'`@)B M0=F/!!`?_)6Y2E\5'<<.0KVMO@)% M"67;(Y-V%8_[&/'G>/`CWIT@-),D]#_T(!!\]8D:PP_==_V4@Y_2C[\/.)>] M7D>,`1&K#@+T#$'<[?>"=KV:S;Q&?#H@OOKQ^;\1GJ-`FL$'XAHQMI03[!\H MB$!COJ7\+NL#MHT0,6_5B?QUB_+L'$A;]'@4AK&V+A80KN3'C(;:(4[[I7L! MH#)5,C_ZM3-X52.N?`_@* MPNQ^%K+NLL%3??+]!F:48W%/!IYT(?F;[(+G#+ZNL;NCK;,Z M'=[W+DV+!P8SA/W/+S,@',Q3H:"]NX08#$\Y^=G(26]G.3ZI%=JX-->_)A^2 M.C3KJ$4>NF.IBXOH`Z,S8&+Y(#U2R+5$)0&S4)HK5Q%MT-").4R)WO!JE\MJ M&+K%1`*^PW/PAT068A,LU_@$I)XCDZ##+)E,=W'=O1=38*F-E'C&,%;0WF%6 M"BS^<\'5.\8=1L\XD"DC6"QN>8WK]N2;")[H"`(U<@^(V1FN$VK4IXN'?]>_ M=1!<7+MOX-FBU-UJU18F-FUV<5$>>!Z-B.`/:*E*;IE(R$]8!'ZIR5Y*2TNH M*X7)>AT_T:7C45#OQY0&8UK?ZY*PY"2V!+C(]1,TT8]O'BH M,X],,X:[N#@,?!\G5CP@++/H:S3#0IE4'(V*)%K"2Z']+BX@(Q`($_`_(T8P MF7`9)*,PBE./&QAC#^O6#1OAEI!F`\7%:N^)`>(16UJ%NKS&+>$GSW1SP=<] M[65[(]61^4^I1=PL6K>G5U.^.I"X:JG8]7M-MNK4,J^2$2S">-.6^'(&"!E% M@7C2;D/N52C52KZTB%Q,`*I)[=M&4U[+@XK`:L[]<"'_C9V'CM7^`$KW=P\Z M`%2@M,:30`46U!ZB>#PITXU:?5S:;5K[M(1`ZIQ\`2*'*U!/+_P0$\R%&KPY MI(;IIJJE@D:G;Q$EF>EJ"<9Z96PN(71C+MPG/9/)D$@KX8YRW73(;5U_I3H' M$FFG[6N31KU:,[C9LG-EL9M)W:$1LP449"TWIVG-UY5NA)&OE-#MD38O3!J9 MNOU[2`0P.>9FHS,M&_5NX[#O^GC&?'.TZ=8?;KX@3+B:JL#OR><7A2["?*J\ M_'ZLMN(T!%G(MHLR"T#6Y>2IAZG71>!6$I,4Y9$YD#26%>71GDU>WQ"^B_%X#22- M(U=`8*S=B"^4:`N[.:8?5H57\SS^<1T<[\?JU<3;@"X.?1R?K[/&I_'Y!M0? M\%7?#XS.L41UM?S&U1G[=Q_LZ^M7`6DGM2=4!*UJ#$[8D*9E<:!N- MB]%UX/\GXO$.[2UE@Y`R@?\7#X[V2%JA3,L)TR!S<;?Z!F8,/&SB:[M9RRG: M!N/B(;3'*6)PA22P:QJJ5=S$3Y%`RYDJ@F7]9E*]2:8Z4@N;14<';WY,%.2_^8XR39ONI0BW4[A MT3F!'>S4*7YYTYM,LL:ED4>]49##I8U02_FR@99R\JO+&_8N5]U#,I=`#JRZ M`?&MUPE#5R3XP'X\4[(Q@T!2\/I&+V8BS-)0UG.53H:<"X^ M@MRT^'%*F7@"%I:@<$?FB/C;0>;B(\AM=YNE8=QX0$TO=D049L&UX'8%)U:O M_#M0'X!AZN]60+JCV*74-+`OUL#&7V,ON.Q!:FC58%U>[9HK.(V0\%ZR+ M2V0S:?@1,IX+MJ'W5%>/1V?)XU%$?)0\'H7TQ1E?7:$1[',\QEKU&Y^2L;;C M1&[YJG5;(SF1EQIG1E,DT.R]E>6)*GI59Q>7BRM["NX1!8C9NF"N0-M)*\+E MXN*O$H'0B[X_( MI*#1"6))6/9PMATV%V/=VO9D>A]`K$%!JXDU8#LH`E:9;/8KR3;[]:>;_6:N M@ZCN_39OW!`_Y#R*@]DCL#GV]E?5!G[W1U?+EU<66/9/Q!@B@A_* MGT9/V\G30'/QL5Z1"TX1F<"0K/(.V2!Y#T5==I[P$@1TD7X!=LFX74IY&_RA M2KS./"Z\J"2#NZ@_@[MHJKI>\_J%Z=^R+Q)HJN1:V[$^Q:->F(^_['I,V0(Q MOQ0:G18GBJ]\HHIJ+BM<+E?4KP#45D4I)A.!5I.60*CI*[]W.B^=+Y71T`)6 M2F-R,47*V"]_67V6Y@4CX!)"?.M_O!.(`CX,9P@S=8@WN3:SS+3;LX,6.$35 MD!W]EE47DY*-O6G]-R0;)1N?@`?E5\Y,D'Q"C#,EQ=**A*-4M>A^.5@5A9JZ MKX$+Y@J_(FC_X+DZ MB:0[4%5246.7,UO99W&`;#]];GSC0RFR"^]L+H?5K0?P-B5M=Z MEU9YT9NO)'3=09ZFP`"-A?:)^?XJ3\X]-L&;[S)LZ`Z& M-A:--]IO6;?6X.)LE(954Q]N*G)^YFT0NL^4V\3:UE)08JBL!MS1=0+T'T.Y ME\"HJL[+:#L-+SB"DBX&4E4MMZOL)+S@",JV!$=%]=JNLM-P@O:79A)'9379 MCJX3<('*RJ^>LN)9=B7_^#]02P,$%`````@`,EC+1B1WD+CD$P``U%L!`!4` M'`!L;6YK+3(P,30Q,C,Q7V1E9BYX;6Q55`D``]"B>570HGE5=7@+``$$)0X` M``0Y`0``[5U;4]PX%G[?JOT/%/-,2)/)SB2UV:WF-D45"120F7US&5L-VKAM MQK*!GE^_DMM]<;>NMN0CL_TR0T"2SW<^7<]%^N>_7Z?)WC/*"<[2+_NC=^_W M]U`:93%.'[[L?[\[/_AU?^_?__K[W_Z9X/3'?4C0'JV0DB_[CT7Q]/GP\.7E MY=WK?9Z\R_*'PZ/W[S\<+@KNSTM^?B6X4?KEPZ+LZ/`_7R]OHTJ-/GSX=5G^E10G^3*KZEUD4%A4$I5Q[PA+L7P>+8@?L5P>CHX,/ MHW>O)%[*1*GDRPE68+C ML$#Q;4'_2[$65Y/;(HM^/&9)3"?<4S3!$::3[>SLSQ(7L_V]3=`)GB!2S!): M.<91F*2H>,GR'^^B;'I8@6_SE8[`+E(Z33_@^P21&!4A3D@+N3F-=!3K%-T7 M[>59KVU!D--Y4Z.6DBRKVQ/E#KT699AT$VC12$>Q_@CS/$P+"ACJ*=X,2-KZOP[R8W='V21BQG4X'_:E:[#SW3:>X8%,1&:`C#)[JJCCX>HJ0@B]\P MQ7X\>#^J=](_U;\.EF)1Z.B"_D@67TG">Y14WP[$A0-Z5#F$$ODNO%_U(9FX M5<%@5(NZHGN<-X6F^YE%<_76QNBL,,FSJ8["ZD]F*FFSG/:0+_NT1DFH)-D3 MDYF-V+WY?NES1(<>[:%G256/CBKTP'[87_X]R0B*O^P7>8D`>9KW;#IK/&5I M-6F\8JU>QJL7'#EA4;+?EK"Z9$K!J`B(F."^N=J0\+1Q?.-PQ"T??'#"C>A4 M*2%&I'`^3T(P;XZ?X'1A07#+4]-.X9JH%2HA87WSQ;9(65HM]%\;5@8.5UME M@Y_=\,.S>FQS(QP-?$ZXTOLS<,9QC.A$^X"!,E*=)ZP<+)[-&7=/H8Y(E=EP5QG MS&,G(V*S;/!I,#SP1/=H@JKZR04A)8I/RYS*=XURG,6_ATF)KHI'Z72EK!N, MW@^&)RTLOLUDVP+7_:T=<#R@=7\_J,3O]N. M$O:;8#S-\@+_587@7$T6?C`=IDRJ!R-0ZX0./\9P:E9^\6#4?4/%11IE4W29 M$=F@:I0+1J`&"9,QLRUWK?Q?1=J-0/CZ=%4O6$N,L`W<,RB!>#S[&OXW MRT^2D*C\A`:M>.$U-&*8WTL,(?MCAI<(OA+[6SA%2L^684O@/DE#RHQY%X'> M<>^1OQ.F$WCH%[VD>^Z4H/%#CN81%"B?JKT\DEJPOM(6XY+/K0+A(`;S;SG= MTH_O29&'4=%N%#>:@/6R=MO.F6#TR)DA$9L>W-IQ2BO"^F--N#!FLT;GSP"M M9Y*3C!2RS?-Z,5C?;'=Z-K%X-*":5JA-?++X$VE%6/]M=\;4Z#QR+5Y,GT*< MST.W-T6]2&L&4,+4T&'$MHI,!AWS(+\"K$&P(9.^"7"[&DB`OU"A*C,?7_Z!&_9$24W' ML_6_*.QZ^HWX9=;C,\KO!V88_=E=KDNG--=L%P:WQIGI7'0\WI)1.5\):KBR,.FGGHFTK4G."H;'`Z@].[XL*;9HZF,)N451F=/YE8+` MA&3Y[%M6(/E:(JD":^23]'?.RJ*`86.$"'3^/27F6I=6`DZU,-*[$HB5I<-, M]5=I.^TOZP'G6-@@H('%BF74C(.[EZP5!\MZT`D4-DAH@K&206'(`JW4;BRL MU83.A[#"Q`8<*QD19ER<9V7>BHI51>@\!AM,;*"QDKU@1L0M>D9I*R;6:D+G M'-B@8A..RTP#@0AG^.&Q:,7%6DWH_`(;7&S"\2B_X+1$=]F:Y08CP)>@G.I[V'9JQO,AU%YNQB\WX?X[-L.,.&VS$A1#.6_2W0(=9")5MYF;Q*JS" M(CM^>\/,:>K#&R:R0.'G=C;15478<`M)WS>PPS7`N#S%M'+1R&O!YOF8Z5^- M!,!%=HM?VUE`%_5@\W.LC(`&%H^2!Y;@CK,\SU[8!8\:MC5)+8_\^#I[:CD0 MCRQF'$G-"/+$T<]7M#8[:UY^YU:P%G:O#=./'ZY]'97K0'&Y=#0^S<_EY);S MQ7/?3L<+`)X:I1;/I.Q,4SO3U,XTM3--[4Q3.]/4SC0U.-.4Y4#M`9FC%#"& M%:@](#.4$L@@`[6';X5J8($(U+82(NR/A:DM#QMH`(*U;00(^V%0ZN27:(`! MB-.V$Q[LAYFIDWF\B08@4-N&H\X36Y0E3]V:8`0N6`$'%WGHE1\C]86)N)% M2F4KFJ5@!&*@ZGQZX#2MC M#)/].L<1HD)7$LN($U0)CD""-MI0)4-@Q1MAZQ+CIW#&-DEDPUXF84=8)S@" MB>UH08\<@LI;T6<8\^)%W5.HIP]HIST."=UJ95.VTH=S4JE,#U6,Z_%L5>1Z MKM/Q2YC'EUKQSET;AXZ-5LA/1`!,`JD[?0,FZMH&K8)YU:9B!A[./0>C]M8T MROD6OMV91'X_V<+LCU6F/>85J#2^3L)4ZS%/%Y\#CR[?HEA+O) MDN0\R]D?76SFI1^$SA9PN)-UIB^/W!L607XK59YXV]^"3I1PU3^<]\>5^M[. M?/A;986Y2. MS+`ZI$"!'CFMI=ZEZH]+*"B/,$'2_F;<&'3V3\_=J95^?'*P=QX/%2YFQ7.^ ML]OZ%GB&T]#F+I[^?(H4L*?0/Q!+U$#Q^!GEX0-:#+_*BGS(*PI#'BV MV"!.R2;*]&E9[D<#\!T:/-\.I*>!=OOUK,`A='6A\99[ZG/5W>U)`9[8.*0N M;UGM0S(%J*!S#I=0G=]0%/!GR-[2"&BC^R'M=-3XY^@\&`0&@H"_V/:VAH"I MYM^F305HJZ\I`71^[*"ZO$65N[P9JA+R0`/(P1:2&\1HH]J\Q!.D2@2V_1WP M+&+[QA-W>O)MLKQ7P[LW'L1+^"=96D$OPX3E!QRI)LY^I8%,H';2N23S(X!F M/3.+=-"`>(40:6#DL*>WD`8R\7Q`/;VM9MV^A]%:?1=45)P2'%59J@ZW!?P/ M`27*^[POD"CJ;3H#FX#[<9$TOPEY(8";GN+UJR-SX*>0-" M[]W3G095*S!@PC'8VTE=E[]=WO$N[]AB',HN[WB7=[S+.P9/%=WE'>\ZTR[O M>)=WO,L[MIYW++#@U=_2O*:77_KM9?$JP+HTJC1 MJ0N3]JI0*$?[NEAL+YH$1>\>LF<*\)F>I-FL]J'^F9'U86T^F_\VN*C^QWK5 M0M15H);@,E[-FC`YH494&2#Q+2*SC;WG/,3YW*A$>^-T&9:'H@+%SCQKRH_" MI&H:]9-^E#"D:$?1JL0#>H/)C_,741]G6<10C$YIYICAX4PC=#J^"#I.O**0'F+K5C70.+RJ4RV#UM^;CS- M\@+_-3\"(!+E^$EV=-6I"Y1/9WYVU0;C\N',]>]N'J//L_P6Y<\XXEZP;U(= M*,/+G!,3/*J7-/MTV*^]C3*[HS(3"I%-RD`WAI\SE.@2/R,69D%7$WR?L+4" M%43'-Z]3'=;[+I%0W[VN:@3"?ZZK>I6'7`?;P%W@6T_"JAY,Y97WRR6NPYIH M*RD`YY.[DON$KPECGGB@A5XMOX7Q1*LWX@C1W[O*[`98H^\]NOB*>?9[<*N_.+:RZB9 MXM7DK6#Y.29;<>3+*K#X6M%.4T$(/*#\OTUB^DG&*`E_0S._AG&5*)+K# M>%Q!I]",S]6K#7RA<#M#M"D^CXYUUSEZ"G%/VH_3N-O61K-_R'U3JLJ M0WJH#0@1N:RUX/FS_#";$;D.9VP'M(8>(U)M??$$H_A$R:I!*Y!>[\[TFN+T M:-0N@OSJKBDA_>DNJWP&N55])G,!22H`G2WI!W&I*!4H9Q]!IV<9-,IKO(Y"%V+V;52 M;!N<1K2+M;TXPL`R=BD))%%7,@L?,1!+%/XAK]!GJ(>>U=ME4_.(<-W'%` MWH/-'#-N\]!Y'[Y*D;G.EY5@LM+MJ;T!Q&7&.7<9>LG,5;^L!)AC;D7U#2!6 M3K]"U0OWV9H67_T6`+/)VVU)38!Y9#>ZHMN_D`E[B4*"R`U%4!M3OE*U3\LI M^TV8R#S&NDT`)GZ;T<,_#IO`],<`+);ZMJ1[=_J[6FS990#ZC0#F6KOEF`=T M$,/X&Y(9&Z7U(!.8W;*Y`.=RM9RGU7$6$]'B**P`F=+<75:+$*;%]ZVICQN'@\RGJ_FDQPA'+5]6"RXI#^2BN+D@B3*M>]3X\*W>T0]&?) M%LQGM+I_N_>+MYMBR#PMJBH@:;I-690)N9SB(%=72U0H\!0*)!]Z8NT&+(W4 M6GX-+Y)K!1SI,>IG(NVVD.ID35$=^&1:L7CM\8:T MRNN/N>6!$VYEXT.+(Q\3;>]PP<)R+M*8W:[&MISR)8E;WHOD6:,%20C#(R/< MEHQ_X.*Q"L-BB1*/^.DN.Z-'!HU$$,.6P!-BA>QHDJF&Y_$`[(]E7]8^UW1[ MN!Z>XAQ%M&WE0M@L")O^VF*<\1GS4_4FE`\6O1J M2W/"-2ZZNB*J`S44V!P`"K`+WB5 MW[#;919/&=RR^V=P%:+:PCK@C)J.[8,Z7EL2[T-R"X#I^H/*I][ M$!>&]$.:LJ)`X5&2$+??U&]THBKQ8G4!Z**SR((U6K4'Z;&T.N"T@'J4;+00 M<)S&5(!1W7W>\_SYVH&6']TZ+:H$I'IQHP%SS[(8B#T&PE&<.'D7>9-`W0UN9^\ M(Y?%=&J3R`H'H^&9<@0HED=T[UA9FQ]6BW-U#E+M5K3:"(Z&9Y,Q`[>@5FA^ MX83@';+OLO?_Z#_^!U!+`P04````"``R6,M&%&7L#QY+```CW`0`%0`<`&QM M;FLM,C`Q-#$R,S%?;&%B+GAM;%54"0`#T*)Y5="B>55U>`L``00E#@``!#D! M``#E?>MSXS:6[_=;=?\'5':WIE,EI]O=Z4PZ=V=VY5='$[?EM=7)3G5MI6@1 MLKFA2(6D_)B__@+@4R(!`N#C'&4^S,1MXQS@!YX7#@Z`?_^/Y[5/'FD4>V'P MEZ^.OWGS%:'!,G2]X/XO7WU>7!Q]_Q7YC[_^W__S[[X7_';GQ)0P@B#^RUG;Y[O(O^;,+I__?;-FW>O\X9?I2U_>(Z]G=9/[_*VQZ__^]/E M[?*!KITC+X@3)UB65)Q-$]WQAP\?7HN_LJ:Q]T,LZ"_#I9,("*WC(M(6_%]' M>;,C_JNCX[='[XZ_>8[=K_@<1*%/;^B*B.Y_2%XV]"]?Q=YZX_-AB]\]1'35 M/`8_BEYS^M%\V.&5$KW^ M*QECA--;C;A".=)8KZC=W!9T M8\TI,W;4;DY+RA['FM3':3R1Y0QR2\U_OF3][XR,/B_GH7+[9H&R31@:I]XROW7?`IV1AS1 M.-Q&2VH$/_T*NT-S[G[]_ML/?W[_[?'QG]_-WIH,C7DVQH8[5AH&WGN\NR"Y?ONWC[/9NP_?OOGNXF\? M?_I53C^"=GWWM]F;]]]^=SG[Z:?WQ]^]_?['R]DGQ8AJ$I<)6=F.\(9C*]`X M*,;0$4,)V54-LVD80R-.F5I&CC]COO#Y)_K2YGD4A&-[&A4&B?AD#8EH25A3 M4#\R!(#1O42K)#5Z!3G5L#(_95[(Y9[HPG?N3#/5.#*?^HZTYPOVN]C&H#^=[RPL_=)H*K5K4>X<8WI#N8I'(2]J(B%8(+6;#]]`TDU7*41QS MN%Z'P6T2+G^[?7#89YYO$UZGS.`@RR_T)#-MEH,%0L[_5HY\9U`N(V/[AUGPY7L_6OJ)W'^&ZYM[RO:EOWZ M5Q[R4)XWF*\NO,`)EI[C7X>QUU(GVVAKS'A"675#Y/LB>^+X_,0(DU)*$QRY MX8Z(3N=7M_/+V=ET<7Y&3J:7TZO3MLT6WK7"1,H+V) M#)NL"BEM_P,J_Z&-X?/-S?G5@J0*4<,`[B24H^.ST<33Y-2)HA<6+/[L^-O6`A5#9E!.0Q=K3189@3CE(WZHD$Z(DY"< MF@CRWI4MJ1SJ&PGFDO]`2U(4KA,_JDWM*"X0,G)$3NB]%P1<*L,5>:%.;3^P M)[3E86DXK+PL2X(2+'`R,JO*>$J/T]ANXRI,:,R&=1DZ07Q#EY0-[,ZG5S3) M')IIR*7!$#K\TL&\+[>\+8F*MN-ZAZ'1,-T+:,)US_']\(FG+%#%FL-`Y/_X MUV_?3MZ_>8,N*M562ZT(M9V;OMF1':&G&YX(F0?3)3-N:4JDM:Y"10ES2%Z" MHE86EK8C\X!46R(X`F\((`R(4[;L??QN5F] MF_P%]VM*&=?82(#2R>LHW-`H>;EF4RPNNV&>=<-C$A;]FCLU%2]XWZ9$6O<* M:?,)$03I[4J8VH5D%&\U.&Q> MMN2IE.2!$M];\O@+17"`]LO8;B_T!8C<%7L*=VE]$I(]A=X`4E$>)T,'%CKI M64)E+-7"8FS;/F=*'V7=LPFQ2Q5(F$"'4S)L^T(HVF51.BE;(MHA,$,RT#*I M2^S7!P#PZ$ZI*UIA73,'F"2'678#.JTA760W+ZX!DQE-(YTOII>DN:`0+'MA M.$[@=(5!GF)T?;KTG#O/]Q)/;-&)2O^'T'>9M>?+MN3%MO91GR^TIS68@=HN M;TDJEOA5XC^1E!R5*^N"=38]F5W.%K/S6S*].B.WB_GI3S_.+\_.;V[_1,[. M+V:GL_.KT[^C\WRF$J[E#+69`NIS>_5RH\U2<8#RHTI4LKKE"M'HQWB)8:$-, M;].C;;T,]Y+&\0]%38.X0J=>;P@63378"V7X5&T_>OYMN0RW01)?.R^\B)8WB-V_>'/,D M?'KWR82P_B=OTO_E5RQ.M\E#&'G_H.[_(]]-CC^\GQPS&F[GW^\W%3>YN^)O MO.6WDP_?OVMN6;G-D$P3G>LXG9;=N,H0ITF`Z<= MW^P0CY[P=%UQ$MKQKQW/G06GSL9C2S;=B$9*#E:2*,532UT5+0EO>C0+CK+& M*`(:*R#\F.Z1%QPMFX'`%0JJI4Q=.2BA'5M3;FCB>`%USYV('^^(I\OE=KT5 M&[)G=.4M/>,=`1V.T,&.%NI]B!N]*)=5C9:X MB1+*5S>BD.QMAW%"YJN=^^G)+"`YBPDY/OY>1(Q';XZ*117@FL?&Y?\AYZ-# MT8/I?(0KLJRL;X@7D*0V'_R_^=)&MNK8_RV")8BV,FM$5`UD\+E4T^"IB0-T ML-2(2B>'RE0SB;R[;2+VT).09XNPE45H@4OW^T8Y*&)?\F"-)'7W-%CVCT;C MW'IW3"?P9].[@S@'/W]N;)<,@LT&;\9N"+,#H+MW?) M:NOGA7+EK;FVM;5FS*'C1-.YJ&5HBEN65V%$<@ZD*,8L>6`\UM0;^EC`OW-< M<:@`5W'/6"#!XQTKO=8KHS7B#%C7P!9K\T@\7^:*U?0UC43&13=0TF(%]AR, M%DYU`411^T!>S0)FKWS?B6+"R-/,U.@;`?T#S3;4BZUT-,&$@9BJ']C0X`.H M@FF&LZRBZ5!E5&<%'2ZH<:I5KU9?)%0P_2VN#3@KE)G>U6I5T+E)#5DU+1BI M\0'7O[0TS<+M[9(C<'5[>'1T;))5YF%S9GI0=A7):T2"P8DU"9JNX]JA!5<6 M]5/J9L9D[`?5S4R4^N7Q9ET"?%!]`'"[VA4.B*WK/H(AOG)'(7N->T)>#15< M=-M;,`76!@=?1-%@4.Q"BBHCT,J6=#A6I2TY*8K:E@*';3%'%L4#ANX=0%9M MX&Y-1FH/T809"MG3KZ?(Z,;6FUFP#-=4K,K7'=[TEK*!#BKD^.KU%5F;F!<$ MS9G7<$#>C^L)SNG\ZG9^.3N;+L[YWA7[SZ?SJ\4MF5^0^?7YS70Q8PW0.:<6 M<=3R2S(>XQ=^/])@J^^'RO90SJH6@\_BHS M%B>EL[?:8EL_(.<#[0@4".N!1YP=EL\;CWY6N7\H5`8%W.:WR9[F8D3"9/0* M5>HSGO.NO<#CH^%5P-GX='V"+C>P6P!TT=:BK91P0C+2]`*H M'>)"^U#XG.Y([RM(G5VDD(^`=I([#9^FR0K:XW7U=/@\7%-E6WJM4LV_(2JR MMD"!]@E=F8Q9>;3QWY%*E\#!?;J@N@QC[:5,(RF4CVK&44NIL5^3"_9=`9?^ M78?/Q9*$PPW?O/JVO\&#N4*%&BC]7A/=V"I\%0;A[C`R:V*[OM-@".T&=3`W MOU&6MB:OLO:XRESL87D9K,Q-?HUO!:@MIEJ.LYW;^$GVA#)Y20P7?S4R*`]: M'W_#HY^B11Y1HO"I51?DS`@NX1\U^QLB$<: MNGA-&Z`B&F7P:`U>OV]0]'!/R_#PP&,#;?74B@W:N:$)T76C!`4#J'A!A:DY MF8,C`.\)3-@4=@]0>F.^'+?],/M+"#0!1ZOV*$,/.35,&0XW3#P%E=Y7O66C M*G-1)W051C1MMW">:L%3O0R2^A:O#_-*-ED^@)0&E?9E?(,-!3H MP&?8>=;)*9*T`W(=A8]>S'Y#+L+"\HD.4050`!.VEP@D=^F$;8H)XP=;,XN4 M##)A]KL7ASA=X"'>",;/H'!LF''`.!0VQLRCG="`KAJO&I4LY"7D<"DH&9Y] MI;@>ST[8):40`C&/)/5AS(J!(TQ7*96D)6W53#OZ^I$FROU9=>)]EQ@Z.MO' MLB]*[._$9W]"="D)V)`[[26!S;-U8&4[9/#@IE$_]?:Q=BCQK4BO:73BQ-YR M&KAGGK]-J&MT>TF'#F"#$+LY:8S=^54F^>DMW@[S/2>]@V=TQ;V[O!VRL*"# MZ&L$#C; M$_`PH)LN:<4+EEV,?X5W=C"/#:V'EQ&UF,$]DJB'M7YL)XA#WW/%6QH%$VX1 MLGN_O^3$_X,B-K#&V7A(E9]1;;X_%O!=10.A;7EB48<3F%(N^-V(IBY\GQK: M-=?02,]ZDR^BR>A:-/#PP=U=LSQIWF2^0PJF":E&LM79)@S$.\+/GO;YAQ8F MX.Y(@JUV97[J;,IVS.^PELA\3L]@X'V,2O+T?$LCA[$U:6\09^':\0)3UR)A M`NUA9-C:A(Y\29OBX6DUW1ANZ]R5==U[.C,J)$\A2_55?2V^FAFTWVO#VO)8 M,K^=;JC'DCL\+&$(ZCI]+9EDKR7SN^F8O`?\F3^F5$]>\K#WGB"(<0#ZCN"N M7TL=]1Z24'*"?D?:+!Z04<-=-29!H_$F--0[T-V`-+QDC<;UJF6KY,K,C2JZ-L[(52O!4;!6%(L_/FQ'1#EGVM?OXX1.N-4G2R[*69*/K0->7 M(!`^_Z!SNS[V5QZP8.C\*K31$PYW^9L'MXWWLO>$QOIQ:`TLNV]#RX"`N^]N M[S7`/](@PH;T'9VS;<1&<"V^K'@-3APTUO?DK8S@''L[QKJ?%"\W""*24I&4 M;)*^?SA)SV$C\?SF`'ES\>YLN-I-C3DQ/]C$?"F_!94?I+=J:Q4BM[)`H MKS`GZ:\OPNB61H_>4O_M"4.F&)UK$W8+1YO]D5_*D#-"[W9UH$OUFZMT+$&* MTO-*A=S:"]ZKJZ"*/NPD:&G\83KR5A/0 MY\SJVP)_'?S&-?S;X[>9?O/?_#I=AU'B_4,<[INO?G&BR`D2+:W>L8UFO,9V MT89(:[NC%4HNL$\9;58\H?12PX;:?:+,VDI?+!@ULCCD+^:&RRU/P8O>$0'] M!CR"LK$XC8&3$2/`0X2G3OQPX8=/UF^6J7G!QT)*I(I7+/G+L(R""!)DH8T1 M)L53EJ?3VQ_)Q>7\%WQ/6>J(J-F!J"9&`-<-\4&(NZE%IS!+KBUF86:6!?*N7-')%NJE.2C/SPX,-R5@%N]LI#! M=>1PX2Z6M99S]8VSYFS'+V?_WVV<"!>R"&\HGSS/ISN7$2W"[C:@I89WB#%` MN_*!9K9>JUUT0Y*0%!T1?D=6?L4V[^QK_F>AEGF'Y.Z%O.)]$B_XNM$@`=X\ M@'!NHV)N@^S^,?Y;_O.23^LVG4D\I@Y`Z0P"G4$&`&<^V?JHNGS2C8,4#*#" M'14FU6H9P4D^DZ'/UAO'BT2]XO+!B>YQO&+4U^2#A5*M&J&,F.348VOV&=TP M>^_)E%EI6W=IH0.1/23[4E3],Z*RA@ZC!O>M3;*CY1-W"$'*C$\@!O=BYE*O^^Z&+EMX/;^.*%LEN,9/N;;Q`;S3N@UAPXL. MHBD_B9W^]#67YXP.V1.P]N@8I$T&J?_]^D[OPPZ*"?+:;2U=:[M=6\T$WH*( MLN$R925L?P]10B-7A!%",WJIQ/+P0+Q!F#;%'@D8HN-A@$#G](RNA\=EK='E M!&WH,,8S"MVTC66:6,);H>ER&6Z#)+YV7O@]J]/`9;^)MDQ6R@C4/KK1XXXG MYM&<#K,O#HD?&UEQB-*9JVR&"0V'/'C@46'^O93&1%J ML,%;O-E_T>8A%&LV;:30)"V1$E51N[GJ@@Y%''>`,,V?G1T?Y`%4H&H%H@;L MD)BE6?!(XW[J26UZ@$Z=6\"$E&0N8\%U0009]; MU022#SX,TIM8!QJ\^1%.TP^1A,1MQ#+Z6FK@;P%SR%2EV_(3I8U48T<PGT\#EK[]L>!/32,.$,W2$830+*BW+R$E./R&"PT1D M?0LFJ,*,;MC92!]XCB9<,I!63:/^0>]O-@((-'5>:ZKA5-&;#%NY[J MF.9IY(@LS=.,6IH:*$["G>0GX6;!UXW+)LQ)'T/0>3YD%)B])7T&!(DMZ:-0 M79ND3Q,[)$;JP@N<8#EDTD?9`W1(9C4K;4F?@OK0DCX6L"M)GU4!^P"3/AIZ MT"7IHV(_^F(L"I>4NC&7U1LJ'DBZ=E@@=4;OM"\/4?.`"DE:D-5B[*QY*KX9 M`1$4Y*SA7FR0B*,3IBC#M&$4F-RNC@@J':V2`:1"W3Z$4;*@T5JB3>JEDYP1 MM*-4853+H&A]E+#F($HU$*JX1`5UA;ZM*)DLNJ5<8)W6)DL&S%?V3FN?!PZG M54.F%L-7)04)5U]C=5NMJ(HF/-^%ZDT*'<$S<%5[#/"N`H=;_<$[,Z-9:$UP M-"WW4'FY?N!6[ZP:!;(R<840,+C/-U?NGI>THYLS/JYIX/+_\/3_H^-SVYI> M+[Y?"JH;)9CQA(H:#)$W"7FU\IGS01$W](#+JYR+60Z!RSRCWB>J5V[UZ%,3 M0+!8R48=E;&3$<.QC<\\NG>"['*LTS"(0]]SQ3_8B*^97.6U-O-59BH=O[PM MVC;)WE.GT!%87W.WKRE5OEBOSAP#^X3L?)E5<">52\SEWO2J M;UJ13S\]'I1=.O/BI1_&VX@?E+SU[@-OY2UY@45ZBI(_WL+X+5FPMZ#/R0F# M\9MN8#7^N*"",X`O,(@Q*(5H2#X<\H4/B(@1X7@T'=EW0!.G05D( M9:PW^J#&MLL?P]!]\GR?C7#&L`3W'C^.+NZGJ`S?,BXT9`X=_YG.1?WX;DZ$ M]H;T<2""1V564JT5?9EQ1JG-QC&2*5>H",<8O4*Z480*W0%=+:97'V4.7U'OD][Q89U@:64#[RV9<^S)X&3H!*9MB=AN*#Z7E M')KHQQ8V/MWQ59BPH#)R7!YYBKO'*D/KX`DLF4,Y!-NY:!+A>$($IPD1O,3: M,[V3L,*NNCA%M_#L;3;FTRMRHE)!:.P09=1PSUM(T#0+ MV)`NROR9)OW!GY\L4+C43B,&?'E#)?(M+V\TD@(3,>W7EDI64$[ M/37.VL-?JAMGB_OWD+I&8ZBZJ,!]I8:PZAXVE_(9_8%#C?MK.ZPSK=F#/8YH M/1]MDHW"S_4([_1T_IF_VWX]_3M?/9+IU1EAO[SY?'Y&SO_[^OSJ%E&NLJ.8 MJ]\TM.0-<&M\N*8+Y[G[VE+)"MK7JG$V7-7+GU!FS?&ZU$$0@;M3#7G4?:1! MR@>!CAG[3#4/P%<65,A40HC"\YF._^IT_NF<+*;_C;%W0/C6TUZFAV9>HVX1-\D/HNS2*_T32YIC-<_/GT;+(>Z2C9P(K,YT. MA:?\.UAD`X9@^4(#S%J2R^!Y!EN)1R(I*-V!!9KISVZ M(;]`6D$[?G5?>=/3@@TJYA?-A4&'4K\V?M!K%@W$]:M4JO>858FPN<&Q08(O MV'3E5[,"LH49%NWLL*PS8@FUL#/#K2_)*-9P'<&=7TX7YV?D>GJS^#M9,*=^ M.SU=S.97>#)V%E*K7,V9\!O]NI1PO?:2]'1RX)Z&XF`<#98[VU^VSM20.;1G M-9V+VNVW);TH_MCA@-730H$&][Q6DJ_EALTXH]1X8[=LRA7LDB13]&;RCG&Q MW1_T^:=/L\6GLQ-\$S.>3V_/_^LR,/3G_^;PA\PJWU=8F9NJM-2GU^(%8Y483<1?)BTIC M6H)9%2]H\]V"M!YB59I/TLN$7LB7[+^`856?(*\CCP40&WYL-5SMWL:$SDWI M2*KFRDC!:&S]^QS3^>H\3KRUD^B_P[9/!>68:J/?%[#/Z4N!11-,BM0/(C0> MJ5F2E&YHCV1LV3_9QEY`XYBM;.Z\P$EW";*#U?D[D_-5WJJ:M.SHJ'KL&-JK M]3F'^Z*>4Y$J\\JM!]6W0(NVU2XP:3NN643G77O712U7W%^OHY?KKS>.%_%L MS#PZ\^)-&#O^?'49!O>7WB-UTYN'VLU4<[&V%6^P\GZ[F:B5S1=L2!B1G!$W M+9S5D>!%4F:8S,J04W+^Z/C;XB94,0U^91K01!Y==$%]Z,"&,=C!G8Y!B9P/ M=(RA0"@_O(-)2?M'A_"5E38Y-#L1!ZU5IWPF@B02YN_&BW\[C:CK)?PG_=U` M!0NXK3\5KH8D5-F:\$83DA)D_\"C8[VCY0FI$BH:9Z'+ZT<_1.5'@ M!??\X9+;!R>B'3U8*SMH1]:.MQ:"912$D1!!@TGG!@>+SLEI2JS>6<,67N._ M@?A4N18^"@/VXS*]1CX=FN5RTIPOE'.TF('ZDU1/.V]`[##!I+M#3D#Y:$9E M*FX3)W"=R,6S;K05>*5_-68ZMII?L"7MSVQA3S]1AY?L\*'IZK?2-AHPAG;$ M)G.P+^"W%#46<2U_K<]U])JCY0-UMSZ=K]*,%:W=06]> MA63"$JPNR0AWK;@GHR;S%>95!F.M(-L>ZAF/"8D[854N\GO541@65#,(C-`-*L!<8E3G2B:3=0J MC'#8J!%UR"`PZ;5CN-BEXS7HK7S@HQ3MN[JK%D80'7$JDMV8#FTU>D.Y7:^= MZ(4;@%B`3#A(EU$AC#^ZW%C>Q@1.YW1N@.TGLK#K"TLD83E3*I^GO"J]PA2! MPD--D9-/T:8R14XV151R.S6:.*"+=AGY?:N.X&Q.N?9DJ[!\OS\+1DYH0%=> MTFIR6HRU11?PT8'-O*BT9W>-7]:.%.N/5QG7KQ&8F)'G9A.%CU[,UQCIVD+, M30)55]._-!M%)>;\X8S'^6I%EPE;X!0#O6'KQAO*9Y@9.K&PZ2M@L>D+3\!B M-5,JG2D85FT)YTEVF2*P)E!3%.U.!/N-L"F$_9S9&/9_FZU(="0D>:!D15T: M.3Z)$R?9,NUY(1$;`N*8QEX!#6,:BX[@S-(97=$HHBX;99IN82&8R1*JQ0,8 MLH>/94SG0Z54.2]A;[)-&;X0P+5&&G%"$LK\=<0S)Z['E"2B3*_%C#!C0ZA0 M&YXC#9>>2*D^>*Z72C'G,>`,F11LOP$)](QGR-EOE5VI_R$%/=.SR.2,D5@>$:;)-GMPXB"$TMM M,8Q,3'L9VWK,-Y27=P?WE]2)*5O475)FXKH\(V'"$2KX,$*]+]L%,4FIQ8$W M0;][F]G@RFY^GTTGW-GV]-H+O/5V37S.@F=;RZO=(GXMN)\M7]`$">8BKHP+ M#-AUOH]_'MT[0;8%R]EN'=_JV0DE']`7*-0(:ZI7:4VRYD/>$ZK4L$%`O*YGK_E*9!;NMQ&8F%R_KSTMRYU M+]B4G(IWHA\+D M`SIY^>3\;QB=^DX<3Y\][3L"C5A"!0YFN&NK9[5XG[P0P8(('FQ-P[C@V)<8 M%/:=#FPP[V\AZ4H?;\(/D5:7([MRUO0L7#M>;0'9>LS.E#VT3S>?#S/1G^P( M/F=$OJ2LT_N(BM.LO#(]_D37=S32 M]?)*%E!>78UK7Y:SUJ1H3D1[\B6EP.&QS2!]NKXD=5@R0&"^6$/^E+Y718_( MUUYZ`9TE=-T4.MO:I@I/Q%ZUBMPPBOS":8D@/ACG.1!_GVEY^V1N6S[:<=W/E6[B`;3>WH:NI2/56"W$8;R_^0U!'U@D4"G_?^;,, M'\:X=,6=+.OOX]9SG6!9VT,=!EQV6+H_/!]2/`&]YV<,X`0-KHI`R\*IRP/4 M+`"?%*D-9A9DDDO%"Q!I"8,7W'\,0_?)\VO?OO6R^$Y]04=Q'6=*]?1(@V^8 MD))G]@#'JX(MR?GV7UQH'S`.-S_+!R>ZQQ5;#@?69VNNL2TV(JC@H7/'2\``\MXMM=?>`2(+TS#,*_J<+)ZH_T@_A4'RT.<#CPUJ6C%`4%#V@=]"7#!1'"X<2+D? M3CR0S4:/YH!S/-"(0#(93/2^/^"0H"KP/<<$@O4!J#QK.WQ,D/9R>"%!-CM] MF@!&<^`!@612F$A^^`/$`U6%&"@<$%UTOF*G[*S]@IT=<]E&/;:';D53?R&^ MT+@1KM(Q\:]=H,!=H-,7!)#+%QOQ% M].'PVM^P90TXW>TG::5/!I(X!2VR>[?,E+?]"BY-?IV-#C\K.%_M=Z$5(,A( M0:(#*8Y]L1(OB,U7=7L!'Q:882A5O]0*!(%!=Q!(@@2U9L@C!`D=GH7^YYBN MMOZEM^IQ65_EB7<1OX/<:,D^(2DMX<0HHHF.:'<2$!L:>:&K95$0K]?KP@'$Z[:AJITP8^U)28!R<=X5$Z95NA66J"!` MXHFU=$?ND-7DW;-L<;SE)YCX8QIWR2*:[$5TOU9(UY MA"V>Z5V$I"1`X3@[@&(.DC_+2Y*0_$@=/WD@IZQ+;RG6X1=^&'FN@VCI;012 M?"TO1\H0.D5K9$OM=H5K7UXK>'0V"%/7%4<;F9%Q'WDG%?9:GE[-`,31MV"J M19=%'H^3X5'9`/[0W703>3[Y,"%,0-ZFCQIO[[=Q0H[?I+]# M$![T,@N%G4`2+>BHGSQ84%*/?N%'&-PGV3/IOU#^G`YUITS6G7O*EBJ4"4ER MTVQ4U'O%R)XJXI#OH`A,_QK]- M8K:8%6=C[QR?2_*$K_.9)0JV:S0.W5+2]6[^T.0)^*K=0QB)V_I$$"*Y2K[E M=<`F'O`/7S8B4UV1+@B.DEQCH>Z#!X*%X)5)N2QJ/B79P&!LS;JA/C_Z>.U$ MRKK1/)IRAO:;1+.P+;]:$B#:`EY;W]C4,'(8! M6TC)EMY2WJCA3910_J$118L$`EZ8K3V?&G:R@:QSHJ'*4WI=M3R/TD0.FFEL MQ-,B'D-=3FV?=3-"L>&MD.77Y&+5GE=KH!T]O-Z)0UAO)J^U2(C!`FH)EEK( MN1MF3@AOB^FEE2&`P`7-*@E31\N-E.`:8O?NB90-=``LQZD^*27AT#K'$6^ M-!7MT2C\$-CV=&7";T1+-TY6$3]'X6XI^=LVH.3XO=BJ?4]>'6-ZM+PWY,@6 MGEHZV;X&5;,9RG+,`Y.XH)T)2'"@@4W?9#`J1'%")V@6%N,MAOK//D&3,,`2 M5NBJH#RV:.4PE)E8/(7]Q1@59AC#C"I6?;/!J`XGVM"#>!CF8QSP)'D*#R/N MJ*FJ=>A1XFAEIL!OO^K<; M?85:EC#CBKG\3W+\YM_*,K:Q9J"WP,MR"DC"Z7`'7PT6R#C\JO(8RE+R6[?Z MB\"JW#"&8#MH]P!1F!UZLF)DAQ&'U376.A"K ML!K*OMS21QITC\1VV&"*Q';QZ9L408<]$M,%I[V@>_DBK!0!>S0^W481"U*F@7O%IB3[A_SB&V6MF#%[Z%)$\_FH MWLJV7OC`G@C3D#X[W=KM<.Z7C M3@EEM>N7K.-K?F-8?:'17/BESPVF"M(`;:,K(<7AZAE(P#R5A`KW6[ M8+VDCVCQGLK MNC9:Y2JXH#FQMH].?7`MK[LL!MN+\QY[*%JH(D^0=/B>2"$);"XTSY!46PQRY4E57RXUB&RO0V*$5I^Y9+,@Z MZP'@R4W&?Y+CM[7JGS.Z%!PKN?$_8]JU[VL>P,JO[=5+-_!HX3/83KWWW,,^ M?V>QM*5M#[&&J<+1DV%$&))9*]W0@Y*/#="`U1-+M+H8$/`O4R MWG.ODH)ON._@:,FF`>X;X!IWI\*`+B.'+P2HR[U>%4"%KM^=P=:]0,5R0<4' M=BFN1-BV_P>ZW=<7*!P;??U^HG)?`L..GJ5B:"^B%4SZ-0%75._!JCH1_%9_ M.O8V<1EBSZK+ICW*E>/^.M)MODY6:A`<"$32[HUK!`&S%IL"D*7C8 M;JYN_4SJI864&ECC'3=@89@'K7"Q2JJ\Z MW2:BEHVRC\Y6+_?&;Z29<(9V&D:ST"B/)?5D]V6T"4E9D)('*@_3';I74)=; MQ%'#FW#@KL=Z4*R4%^=@:Q(LCXFOGA;_&MG>8S'?BV%MYU,URQ:8.TH@U MM(JR?ZX#G7NT$'4M M_VC"=_1,2!(N?^-/F5/WC!F9X)XY:R]T?W;\+;VB3^(O^@43>LS`$G*:6&NY M!4Y'4D*24I*4=$($\80P\K1!3:I'741V19J_:<^+E9;A>AT&).:L>@>U"6,O M\1['077A>!%YY*W2(BR'C9AX@@^:@,%(#]595BU.2.S,K?@8*D.CSJ5IE!K2]@R#66:$)IGJCFZ,!OJT53O49G#!8R,S_=5+8^NQ'-U2.>(I M:CZXZ\A;4C8J,23M($A*#Q;WR!'5A-+)'AU/%4XTYP8G-38X8AM]-*<5C2(; M@84?_8J;L,!Y_A9Y4SM[&?'XKTMOG!>>K(CWGG$W=>D*1M!>7(6Q?O(_;RO4 M:??J,`3UG9TP<4@H#S"T2J'F(^XR+F-K59Y+SY('\CQ;HV6144/Y(2F:6@28 M-43A;SJ/&LRSJ*5'Z50MR!&9KU8L9HG0N1&UV&GY$`D+(`6Z87T;.H\F2BC'T8A" MIB0W8EL01$'L!W_3,%8POR$7&J7/:"`;6]SGR0.-LG%<>LZ=YWN)O=]HXP;M M/UK1[DN9(""YHE1(<&Y`VN%#YTWTA%++J[2P&G]YL@S7=.$\GS]O:!#3$QK0 ME9>'=S;%E3-&Y;4_J4+KJ-!Y1&A1'U[@,=C=(Q67)V M2!RK`J]4PU*2D33,/I5JCC!KBM7_M:I?MXMY?9'6OH/,T/H@I\>%$;S^*U]/U!&)%L]=0R> M=+G!G=/51"O5^CPI,&I491./6$/%EB(PD]"64[Q:K,!T,%U)Z>N@EK5KXXK% M/;>BE^MDED;`I)/#0,::5C"38",GVL(26=!MZBC1>D@+-<2D?CUAJRQKW8P8 MSR)]2#C@WKX/-X_%9ABL`XJF-Y3/GN=[XO>VZ_8^>X:.$WJ=Q7W-.%^MZ)(? M.:U:,7YA$MEE,2'3=;CEMQD.MY*WWZ<8=(IV&_(31Z("B#_UF%4$.0E996@I#>XZJOG3L&K$7N: M.UOCQ14TSU\4S/=I<@N'8&MHZ'D[",1796?^?" M$\:+Y,P0Q#T]SL/.S039%2"\V#D>"JW]LSF]?GB^%HQV/_RR92J0O;33P3*T MO\!CPWPH6_>+$T5.D,0ZAJY^'[0Y4Y`;PRVPZYNTG`N\.1L$>`$/@_T:^=,^ M*;`C>8C(5JWEU[4;'7H$4VFJ\NLV6>XTG[8PH@4J7W>-NV+%)V1HC>8)>/X4UA.S&,Q"4[>'DU0 MU+_NF>6V[+L;O6`X7&_"(+U6J#:^:5`]T&MZ6M:*-5AIL=4\-*R@,BX\-]QD M.IQ@YXR[(H<.5R5J+Q+JTE$+OE!;V\6XLFQT<'\9QO$I"RI>6%3%`BW7^%I8 M(];0[M=L'J3;X:7@3TC!@7`69(<'(J_9#?D53?+4*0/*\ZEDR4E(3D->T>>- M%U&2/$3A]OZ!O'WS[BW.RIQ^9R`C01V.#E]X*\>O\#"MV]FGAB[7 MJ:'1,TM-U[,`;/1HHS#-TH*7L31+F5;URAYI#Z\)[O$UR2?*TZ\F;$'W2XSP M:Z@/HFSB0*!1Y1.'_K!\(\1)/RRZ7&(_VJ>[YV'`$]QYLQ_RWV4;TC>4?RK* M%U7B7B['CV?KC>-%7+AX^*'_>DY?O:$)#FQG2RN8X#\7?\C8\X>UT@[$XC_O M8D+*3DC:"\8HI*_IJH"5G%C&$Z=T4BBSN,:N*W"3\S%B`^F<`,FXH,MUY.BT M5%XT1A#J&*,1->_DGO^UJ(0O(X#7?IF-&[?.'QH=OHS$CK;9)1]2%N!V0VMO M4\](`VU:ZIEUK:VT1G/2L+6(,2S0`OAS^PZA/98/*9:`WO.G*W&@P1/"M&]D M6L\,N!&I[!-=4>LCP5)VZ,*1&EXM0\*:8HY*6D'Q?82JX\8=AO0`!U_55UKZV(0I< MK2@5,HVZQ#KMZ`]02'<>S_E>M/#O9\U'TM1O"&CSA?:I!C-0>[Y!4;8P(24Y M.6LXY`GH<3M`;MG"WX7M8CS;:BKQ>N]LE+S8^ M3H,+B*O30=?XY'1&0U*B,1R?R0T;O6#[4PX.F2?4EDBY0VQG@>KY=_'_)TY, M75ZW2(-8Z+=5XMN^'VB_V6&&;!Z-%_\]NN,L294GOBQ[GQ-3?7(=52%@[U\_ MJR6(J,]S=B0)TU>O2?K%EQ4^Z"**KK:B^^/SJDY&?\'1%\RIVSRH;"M3-[>O MRPWLI4==M+77'W-"J67+BP00Y/BM4>[@P70=N36B6XE5RM'AJ;$T4T3U2YEZ MK$8/TI8/U-WZE+]ZWC2N*:_+NJ?B9?23E[+-=?I:^I0OT!;\N6CCJ*V_CL'# MN![GL*8K&6\R7V56[J1NY:H=D).7G899)T3T0KZ(?G!=#3[*](4KN9/8F;Z[ MEYV&6M,''S[UK<5Z\51OO8X>8(FN62_39T^[5G./""QZ`NJ;G@H<8P-@6*SO\\8FN[_2/2>X107GC_;%+ M#CB1+VD+',ZXZZ#!?'&CI"A]\2X%.E\LT\Y++Z"SA*[--T-ZZ!&]G]69M<:D M4\OBN67MS-D3P?_`'++]?*E7RRV+9<5\X??X#WZ*-VE91^)$"=IIWIF:L:;D/)">Y,,U(>=IS"&9 MC<-=/+2YCV'7$M+>#\W]?DSOB@G2^BU9T>@@L5-CUX>ZJ&B>QR&=[L?L.JN@ M*$X=IO048CFA-YNB%,IQ`@KB:9^#\V.E0=;"B!C+R0:AW#H2XGF>1W2 MKE5Z+(W;'VKMH#>GHA5U7Y_RN,WW8>S<^`HS8O36U#^NDSW\C\5@:;3T&!#M M\,R",UCT93,+PQJAM!]`$S3<1!5_PQ,Y66N!.C`R9WMX<8\8.2_]A$F?-@S@ M\&.>^IR.8&QX?WEN[P\6[^C.9S^YTC'F$S8+J#.CE39_P,A18O5&BAOW>S\T MKU')6_Y"O?N'A+I39B&<>YI[PNO(6U*^K[@"*S;0'MFAY@RMOL)HFTSYD$@V MIB(F)F)4.&YQ0O4I6F8,3[0-9CW&*HC0'=8?U&X#EE"HAW7H*P/]^1^MW*+% MZ/P3U6%8?9'Q'><_6=F&X5?Y9RWFZ#)-_SPE'CI.;^S"#^68T`48TD-LC7O! MAD&&7;39YY#0+@5[G7>;X$)]FX6RKL1P78.SXF30#W!PE2C]FX%N2[L>QW-P M)K=A&WK4Q5WOXT._RNO_BPQJD1LK8M"99>R?Y`]03S.0)1GX>@3+P1V@'<]J M1E!%SX:C.M@`VG3V![;8M?(A=/8:YV=`6)L$8A>&#:?-AH3.$NOOSV/:)=$> M%OKXN;?Y'ZVJ"IGM13W]`Q1AC3W]:*JS[+S?'[UF"TT:7W=,W=_)*0V6>J1' MM:'>4'Z3''_,QUM1LV=U>N\4YA6>_N=N`+]3=$5X7[B>^AE^`G?1]P[9#9=; M/B8Q;GR8?=;P&_`%RZ"&1O%:4M\]@BPW[MK'?V>\%US@.PT#@6WK^`L:K=]: M+3W&'B**9MH=,!#]0X5!P\VFP-D/XJ^B.@,['`8[$3NS<+H:1`LZ!^;T(,%YL-: M)67,/5#7A[8A6UDR["(".%6\/P"T!2\=YG2T',;0!@_T('#KM`)G(<;6E#X* M4ZQ[/^`,PBZ2ID3!H/DDU4@./<6KG.71T@"@5A#/_*(O7AA4G4?)O2J&T7G= M_HO#AY$LZ#-/!A@5&LA(0)4U_1H\$M$0)OEFLH2N MLW"G]S3-5QG_.+T4DY(4DHRC7?\)HJB MR1Z0ABORE"/U4J1.3)9#(K5/Y`P-%:2,I:N:Z69BM+C9K31BNOSF/GQ\[06/ M-$[X.N-=]C.W1N\J*XSTM[_.Q'^X$.2C*0](G3E):VI$F\W83E@?7SV!F).4 MIJ-%:;J568=U M<7:1+A/JRG;ZAUE[:(SD8!?P.K,\P#X5[S;;HJIT+(Y8BZZ'V:OO?!IDK!DN MIB%IF(;#7<1KJ_2PB_CV81S,QDX3E!LO_NTBHCPS09F6)#<:49CQ>?#R^S,:+1_T#O*6G+\4?]@2L M]FC^$(;UY]!G;'PO>0&+2F5#^4/$I=)YAC"GY2#^H*&I]FQ79N*/&Y2J=7R\ ML%0RCK'MYW44+BEUXPOV"?@&![_NKMSR,(TJV[A!AX2M:/=5(B<@7$1)3L)W MQG(B1/4[QNB$;13EUY6]/E01I3&DZB0J7%I;/A.&4!S]9/O.!^ M>A_1]-+!3]3D`=)6-J#%4TI\^W)6-B9E:_(E;3]Z-6'_H)R\-7GRD@=RZ[BN M3Y^89#V0G]EOMPS$<&CM:Z4ZPXV154.U*UU[#92"1V>C<$9]UNB>1A?;P)5: M@[KA:Z0#B16:$=0RE'DKPIL-)_KZQY_Z'SR,"U1(D-SC-1%UEN4;RE;Q?-$? M)2\+YDIC9\D-4'MYO%Q]=5F".CYMW/7KT`0A$92D0EK6I@.6V,,`QN4^S$2Z MW95H\AL_`48WCN?R=%P0T]-M%/&L7>!>L7E+_Z&;_]?A!)6^UT)93WX)(I)1 MH7U&'?XV++5P.?O,!;;]=9PCR^H4OJ/?)#:Z9NLVLOT-EIZ]FI'37/&9&4 MTX2DO$C&+-\CBTG)#M:.6&+;O`;2%.S3RT M)7,HIVT[%WV8@PG)^"&XI:.O>>`BA\;)=Q)TI=^WXXQ;T6?!XBG\.W4BXRUI M^WX.*QS8F:%^+(`7$,:3"*8'&Q,HYX7)YG<''@S4-6.`<*#2"7H[P3JG,DO1 M@R7>[>$P0H.]6>G/.G"N$/9A^#EATOCG`XT5FG2@QX!AASUV:W#!Y&Z4L*'2 MT:'%#=4YZLTT<*8''SFH9H8)Z/<''SK4U&.0V*'L!;VY\!Z'C1TJ'1Q*Z%"= MD_[,`V-ZL(&#:D:8('XXV+BA)OZ]A@TE=]QF8/%`(^JL$OWBM.[]'%;,L#-# M_=B$DN7!Q@O*69'C.["@H:X=`\0,E4YPVXIAXH1#"0YZTO[^-3Y,''_`$*!) MOWF7!^KX!_#V*-7VS/R5&&OVA^#0SY0/=.AK,N/#_NC%2\<7,3WYE-];=[`U M!>JIR8H)\K*B@_3H#*?9]^&_E.?SK"0;;X:ZR1^_"^-O5+93^XW?SV63BX;7R)@/?ASM%O MW(LQ#KICO]_#P7CU7O;H"TT_V,WYUKDXV%WY9MGOU[/CWH=/ASC$!OP^9_2. MO9W!7ZF^5"U+J]![DE; M2.I,S"Y^6HQ65V)VF=1"4D\AN21--,=^:Y@&IH.Z-&S15"1B,R6#Z,?TV6M= M+;80@UP>IL"BJ0R\]?BZT!<28!4PD0^%BU!3#B+P9^':\'U:Q0><2"GR: M:I"VQ^X4=%`=E%?8%4,[MY#Q&$1-Y@$UN%2RA0,:#U%%I:,97: MD5XLFSQXD4LV3I1XD#?*#H4Q#"ABQUC3+C/O6)(/LV9Z"GNZ7KK""9VCK*+4 MLP6\GN1G[Z[ITX?(BY-P\T`CP)MT_-12=F0IV[M(SS'9UMHH^"'9IE,A;M^GXVWS,UZ3 M8KLNXX"OE,8$K#BJX[^02+0`]Y*V`FNR:2=GAD!:PVNP+T)HH:CM6"+1ZFOJ.TITWTF^+QJBLU4.QD5 M:O?9C"H[]$T!#WW;"$TG3\DY]/1J:,,JUF@]J>`"NGQ4H9,]$MJ4@<&S+C1& M%*[(LB']@BCEVAA'61%ZZ$Q2"C3)P#P];1,KK16S37BT=?&JY6W9.NSTW#-5Q6- M9E2ZNFFD!5L)-R.I+8"S9G\BU88HWD_41#!=AUOF9D087#8D3DS86I%LG!U&),@:\IM9 M,R+:R0Y\@!MDU9?2,LJ-#,:6MX67^'2^F@6N]^BY?*M2XRQ%"S&4:99AJ2WO M>3MNV,J6DI,48$9,^5F45JR9$ERL?O&2!_'\,S.J\8.W683G0>(E+V8G&:S9 M0QL_\_EH?#P\:\Q7@FESZ=$'I:(4U20:N1RU(-4DS+E45'#68[]+>44J MN(5K^W0V0>!E?T6=^^%E:R%G/8'7Q@(DJ]Z*JU6J,A+`BLPA4$D++@&2W\9H M%@^4)-EG<;UXZ8@)^TM<8J6/>/+;>AHF3V:WT(^>N10^7]W2)7\^Q*/QJ>/[U#UYR=K%64/M'%7G;J"68=WG MI[;)Q3ERGYJU)6P))QI/2,J7_ZWD3%+6Y.XE)X@+"@S%[_U/4`&SW'#?E&9C MO6;V(D["Y6_@X4?/.J1<('?MH_-")N-X_KSQ4J-]YB1FMV%).(`6#0H0H3S9QHMO9A> M1]Z2%G\L[$W3B1E]V]G.'%4XH#$7!D%`SHT(=I4V!^#W+6:B5.,,]H;3XO;M MNL)O[M%;.8^M_/D(IH&;#F&^3>+$"5QF<4U3$6I>T&F(%J32*)4?NDX)2(4" M4?*A"[`H!1;*@8&OSW4D5&MMKF0T^N8EO4M.PX#%@[Q>,/TIH>XLB)-(!%9I M89BVG]7G![;AJ8^XMA7*2$E).R$%-2G))R1E@,!W=H#*'$.P]#:.3YQ*9:!@ MX-WYE+B,-8KZQ@X8;_GJ/E_]KUC0$]/HD<="24ABQW5]^A1&R4/E8-"$_.SX M]5N[X7;`#;57O3>NRPR=C;I]<)BXI<<$C,_0FW*'CA^,9\/2BJ5LLJ-(B,*, M?O`O*_B7!7ZO@C].\7O#X.^R'])Y!F2&3^QSW39:/G3AF)U1T`K0#%F/;PXW M8>RQ^#&.:1)?L3DT>]I:3@\7DDD1U94W;4K2MA-2MD81<)D"(?R0!=^B8S]C M.3)B@<)I#'D!XR*UBK3$01)B@,.%2TK=^(*!/2UC;VZ>C*LS5*R@(QHUSOK* M)&U-N`R02GMR-L2:I$,Q1@=8U:76AOV"^>HP>B%!6-]"`??$&F*J>VQ1R@=B MR5'Z>WYG@DD"9)\2,M510]$8#E<#?]X.A2_M:_"@R_-F*6I=B.^1PRICJ=9>+NIQ%1*= M3LHE8_]7]C/[SYT34_:'_P]02P,$%`````@`,EC+1G\M*N&F*P``BSL#`!4` M'`!L;6YK+3(P,30Q,C,Q7W!R92YX;6Q55`D``]"B>570HGE5=7@+``$$)0X` M``0Y`0``[5U;<^NVM7X_,^<_[-E]WG&DM$UVY^1TY%O&4V_;8SO-Z1.'IB`9 M#44JO-A6?_T!2$HB*=P):I&P7]K$(2!\:RT`"^OZ/W]_6X6?7E"2XCCZ^?/D MN^\_?T)1$,]QM/SY\Z^/EU]^^OSI[__[W__U/R&.?G_R4_2)#(C2GS\_9]GZ M;R%W<;(\F7[__0\GVP\_EU_^[2W%C:]??]A^.SGYOV_7#\$S M6OE?<)1F?A3L1]%I6.,F7[]^/2G^*_DTQ7]+B_'7<>!G!03INCYQOZ#_]F7[ MV1?ZIR^3Z9KZ')# MO$!IM@G1"LUQX(<1RE[CY/?O@GAU0K\]$4YWTFVI9W&4QB&>^QF:G_HA9!&O45(PL2NQ.9-: M7/;#]A=N%P]9'/S^'(=SN[&#/V7'1M\G2C_!_3,^0QO".2[F*R.&]Q$\A,J%4?73'A5S'?G2/`H1? M_"?ZM?9:6A-T7,XY>LI,CG)'A?1$ M(]=AMGDD,Z9^8'IA<:?J?)JO5C@KCENB()%S."/:++DLL)%4B6;K*F7Y4XK^ MR,G4%R_(C*T'4UB\5-;D^C(D&G,:>Y?,H]_]JJGFL'#"&Z^F-KCOTSXS7:/J MS/9._@[,;<]AZ;@U7E%K`GOGFM\ZB8Q7*)_3XH$R1YF/PZ[GR786>\>)^;H8 MD]A;UGDYXZ3;NG:S6%_8(WK+WOKF])/-V-_+WWS-"I/VOFQSR5"? MV[(QH\/^Y\RDM4"6ER],DO(7(K2D8DA]?%^ICV_RUP)"]>=K_PDQ2-UV&'YM MS%4..OG?3\=8X1U*<#R_B,R6VAI]U#4_9&3K=UAU;?R1UOT89WYHM.+:R".M M]0:9T78W[E@T)3<[,J/I?J3%M6:'Z]0FY)Z"Y)1:)R@E1U=AK[@FRV@LD)RW M*)JC^7:)=`)+OO\B4B,.&C\7TMB(.)&=W_0OGFCRV5.:)>2^WDX44KS%])[R M6._[SY].E!=9D:0@=XJ"[Y;QR\D< M7R3QRH""U5IB.90X(4KTSY_)F#PEBXS7="JJ1QR#"6<$2N*'5T36W_Z!-D(N MM+[UIB-F`P-+Q8?)L1DQ(SCF%,MEZ"\Y#&A\X_TP2L(?8*@(/CTVP<_RA,*\ MQ"DYN_^%_(2H6>?DXN+0GO>Y]^=1LD$$I^+(#\?FR!;-(YF6PX7Z)]Y?1DGY M-H2*VG^&HO;NC2$0?N:WWE]'3?\#+!4C_@+%B'(OELNZ)']+)*IF/)76*;0`U*=);NOO9\<8$@#3<6.'V'4U-]0&/XCBE^C!^2G<83F5VF: MHX3#%.$8[^LH62/%5#'H)Q@&_3,.A)5RIX]V@=)]203`.;N>>7:(@W&?-#6X!I]]*#85`A*6=$]UC&B?C%W?C2 MFXSYP7T(99-QOKS90+;T/_K[N]J?\6H5 M1X4?^>&9H$]O\XSFE]&T-O%A)1CH3<;Y*%=$MF49[X%^TK9IMREAV<[-SQTS M$J"%GSX5A,_3+TO?7U,I^LL)"K-T^Q9F<7-8LS0EQ%0`T/P0RD"N2\[F/N!CX5K(";X%(M=\Z245K+]8_`M* MGN*=3PN&EY56HLS2UO=0-G<^;T0\9"S>"5;2]$`:J$'^C\8^O?AA$;J1G?E) MLB%G]3_],&<9U+3&0UGYI2QD.A7(K&/)="0_?M7:<;<_SI).W(;F5;J-90$2VO)]8#V7^QU">"$UF MB0'P_7!C.I3O$K3V\?RBC-"6;T3F]U">#4J?_7\$(TQ<;.$)KU`P?P]9E=GW97#"-T8SZ5YC?TG'!)]O'A('696*1B+ M5*<`\R'9,0UJP81^=%H7#G7;(7\0F`O+B(52*6"A<\+$>)ZCQ[B6B;?'*F`[ M?Q"87TR19VQ&2_"XP6CTI&`UK'WE38!M3F:L;`%PXW#>U@FX*^L$D`-M5M8) M.*212/M2G\6;`!NHC)BO"]"-I[*6#+`H`6S(,F(U!X>M5S&DFBXL61-@TY8%74P&SXUSWNA-)J(GL+G+`N,EZ-PXPFL!65*??NM3;PIL_)(PB+^= M#U`XH6?/YG-%#RZRH"Q(C!NG-'WM`))A.87 M?A*1.R@E*F:^RHNW8UF*7'16RP=[4W#+F0';%7&Y<5H_)LA/\V2C=%X??NQ- M@4UC1ASFX.BL<+,JYPQ`[]+2M[PIL-7+B*,<'+9<44/V='3P<'C3X9C%+!BV M^1A[>TH/)GF@V<;E(Y/`BOH;AO$K)?%EG)S'^5.VR,.M66X?M:E@J]299^1Y M"+I0G7@GU5Z`9!_>)@4-YX5B<8>2(BU)[17,&PV=PM!-*!0!NO&D.LA'F^79 M@_*C0@_S?1; ME6'0R1"6.=Y"YD8H8,-<4.)4-9*47T-G2'1C,@>0K2A"!F\A7U6<#I-'%KFR MGOV.;PJ/*,X(B'?3/7I!42[<)-M/H%\[`JKQC,/[A3OR=DD+-W25#Z62.,\; M`OU*T6:F"(@;KY$'%)(YE[^@B)QD(0TBFJ]P5!33S?`+JH"+;#-*$T"_442, MY!B,E7$YN77P5/-=?6$OHFA@OA0COLU?8[)2_R(\9S@.>T]'/XBJ/Q6#&/:_[\AO'PFN&9D&?X2W>2K)Y3< M+@J8-==KBPH"^3&;$#PS7EMX.N#D]X@8M9^SYA.N!\V6&0XH"C95=#%<**EA M`J'">`BGZ&YACS0"4@5!\2&T@U29GAPWRP$82^Z4$"JYHL)3$N`L7JWCJ$CD M?<,BA4PX#MIO>L@D"3-Y(,;-VQ:J\WCEXTC`4^;WT)Y0*8_8K.5B&3=+:_%I MWQ"]\M6B],IOH1V?7)[PO)Z,]3OAO.;DX4HY*AP'[0O5Y*X4BQO6]';NK93' M[`'0_D]-YO)!N!$?WX@@E;*4\36TZU.3GQP$;OBO=QH&>9RBPJ*NHO?N/H;V M:FHKNXV5VSIEP9XOW7+#@=V3;)[P^,=:O25]:%VTW27+23*H7:B1?\+HBP9> M9T>#D>M8."#0TZ[H/316VVH@VV_U,0^W;QFY\D?I0IL5EG M.'C9:Q7F:@.R%0LRRE">H602*^S6PY6[$831]1$-7:.ZXRNZ5IJZDMPO:7ONX2^(73)ASNODUI9W<=KEYLR##+V4!/H74->W)!A0!PV0']_(SP.F$ MN]9,LP&V5YCQ2T7QL1<7`VFXF,W_G:=ESP+:7BB(HP`7':OW2!]C>\=$'S\' M'9IC4\3ZHH\;401[ZI"W8_UIJ21QK3'084!]L5HF6`PR.'$]G2.RV@#+Y*'^ M&72LT'%%H(W<6ND,2+L[??Z<^H0H-(@#1:F,_>P!T'%%QQ4$/@W<\,$1HM%` M'72.RO^OD:D*KU.KNZ8X"700TW&%1X\N;H1&'6*^2]#:QW.56A_BH=!A4WKL M5!6)0XQ.E`5A$(MZL??[2-9;7&T"Z'"L?F2"A[2S&C)0T5!I]*DE*BH3@D>` M]2,[RM"A%1B.6_@0474TTJ!_GC-8.`@\`*P+HQ7AN=&W2=T\9,6\#AXA9MGB MJ@/;A7)$',A7T0M*;7EE!),-)Z;,AEM&!A3:+,JY+L[1FE9QOR7WWA\Y+NNY M\VX)UK?@P5^&[&#<$EQX3CPHB#Y3O=L+>`DB%"-G6[:Y"_THHZ5NR5_7]!/! M)E>?!#QNS(I<&.)VXYVA3D$KUP)X8)I5B='$[;`Z4;4+L:-.""8;3E"<#75" M!A3Z]6GI4DKB`*%Y48[K'A7]D>]\6%XB5O+_I_]/WUXH=T6Y0)76V3KT!B=*;Q MID-)BM52,K4ANBL>,[)-DF1#=D21#ZHM%ZWQWG241DQU;+928^&K)!Q)'H:2 M#-N'/%C,AAU$OL]MLO2C;6#OL5MQU7Y[GW=$A26:W]4@UQJN[E.2%"PH5N:' M2!;JM/!SG`9AG.8)]=P_X&6$%X3S45:Y]6G"-YDO(&K0(Q&=4P+C][YH:+`4 MZ$0E:S+#/F4@R-F?@>38A]45F39:XJ<0'3T-\930FPAZWVOSA;V_]4&[LSNO8S^Z1P$BNA,MSG[THJ?;7U91 M#1A?0VPV2K+T)L[(B9WX M[_64:=US[`$@/2/J/@.53<0>`+U+^`1E;Q0^"G=VPC92>5U&*OO1W"\CE=&V M0_?Q0XS*.I1,9>*A$!<`;TUZ5X#&+-"7@`H3 MV->")DAWMAYMY8;+2AW4KU^T.EZBB+K'CKW[!$O1>J5HS0.Q+Y46J+(U]2:" MWIW:?.&$H&B#=F>W/N1/*?HC)[-?O"`M=<[2DZ+U^RHE9CE#0%Y$K;4HO8!X M8Z"WDXBPG+>/"$I?A4,A0[765:#'1\C60$*V&HLMPG`V:O<Z9Z$S)8DSE3M+;YV&#'&&0!>+[EM.!+#= MZ,1'B!806B0%E>YQ^OL963?.Z#^)U6'>*.BJT?UKPR+DT!WX++F8_23"T9*F M719EL=7/"4B>YN5;"AVL4\FUH3X+M)754N*9)F(GC*M;S#$]S'"&BC=V&_9E MGE$"UIHP596OBXVL(TPV?@;:L&M9VFR1I$?S+T1V%LP=,>8E46I81[Q./8!N%Q>+ M!:+E+=&.`/=^AK;]"F5/A?-JT01^^90C-UTW M54%K1NC(E(XRI(VUQ^@2J&P\7?4`-"?/^AN6F8FY7>-M]ZBGZ>P-BQ+K-&:!MEWJ,9"ME!J M=UA'/0E<2N/[V8\"_(>?&XRL*7]"W.,J> M#:U'"A-#.R:ZRH:VQ"G2Y!W*W+^0GSR^QM9$K9IOP`Z-HTE8C11N!/0;P"<_ M+_*W&\XX8#_)<:5K2PPWZDGJ$^`RSD6N-K,)H;TN0Y&N+2W<*"9I@)]\:U>X MR+<#=MX<5[@J6O18G1+^W5Z%3GZ\WE6CM/<_HQBCS1TP\E>T'!SP6X7#P-I! MT(X!H8&^M"2IOV2=JAJC02.CA3QA\%`=TC`92B-W;A?MI?,8R/X:ZC%HQ#`^ M!-Z_-;%Y,8KJR\7-M"KR93IAW[T3T*$'ZA(7OG,`DI^P6H-0L]^-J*HMDDA:*R*1P$K7!R M*,6XX:0PAJF)7*5I3C"ZIB& M$J`$JK<`-HAJQ4"9S@Z6*U;.5CX:Q^B30\3TR9K)%0`^?.P(A328^_!@ZO$:/57)VPV<$<]XP]45R,WLY M7T)'J;`)S'BGL)<^[@W6/'C(KTD.5^;WT)$@9NDR30H$VT>GQ[38R8]UN''0>JA7N-=!`6]7T&/CX&ALQ<#<./!O4 M"@>;<*#C3S592&.RS9BX'PF>M6F'C2U`T)W(]1A)PY^-^+@?Z$V@#3$VV-C" M`]TZ7(^+#^@%149LK(WT)L#V%BM\;`.RU>+;+&M>CXT7U'5FQ,;:2&\";)&Q MPL8V(%M=M2&+'S0(A$OC(?N)$X>!-@LY$)(W5%H@`)6HF? M9P%L''OUQ6^JI=_1L-N89;75F\";`%N:NO/9`#!L#34%)QE%L8.DXBMK#/`F MP`8H2TP5`W2H/UL1Y@%4I.@CX.HBJ\=]S.T]:9+_&+F3U^/Q`ZDD?``PTS;@/.,/W13">ZU*LI'@4>Q*/%/#F6 M<;FD'_";F?5].VYPP3HF>Z^!!MHE/2R3+720CTV+[8_NQ-B=QDD2O]+^?`H/ M*\&H0<4#-3@EX2P;BB,Z[!Z<'E<'$Q_$YHXR2VN108.RI#6DU\BH&97]4@IE7.;+[ADU+I@O&VB@S9<0Z1C0 M1DH;3&SA@>V9=OQ4C"'9(8U=>`TXXTJGL9.(,13[8R=G4!./K7R:HVQ$"[[T MP1@E+3G3:V;)SJDT8W"G#\9H:<.?7C-?=DZ@&8M#?:A)B88>]5I.XD_C8*&E M9+:AV5Q,V-@&5#'RZZB3V?*G%/V1$Q)>D(M>R5+*'@&?KVAF+!6@&7MXQ"$T MNQ,8]GX7?P^<="CFDQ-4:DI%SU%96,;3YQVI6 M\8^#->$5H-1:,3`^!4\(%!"^M*; M0G;FT6,M:^G0M>HL*%;.EC1018B*`KY%F2`;]X<5+8 M=PD.$,%;@!5QG3/$FT(V[M'DLP@#M)_/#F?OT=K?%!V(6Q8%`6NY8[PID,7+ M@+=B$+T5TCMV&L,L".*<@%R7:JPC%"3/%K-PEY`;P$Z4J=.P!T"D. M1JSE0W'!1%&ANR>0E+E:^Q@ZO:$+1ULP>LO5.R(W;[-GE%3PKK'_A$.L5C52 M/!`Z.\*(RW)(;I@DMCI-1:0MC30%0&,6Z+0+TSVO@\^6L2*+,S^$U'BO(O*/ MZ-%_0RE06_O="K2R=P6C8'3;:CF52?,416B!L[,XRG"4XVAYNT9)P3\5Q=U@ M-FBM6,(/GE9LA-,)E;DZ3.P*COFDT*JWH2BPY:H;&5P2KTM$L/CA`0WD,L0; M":W1=^.M4%Y$D)T2BCA!>!F9"`5G)/0#H$^A$$!VX8$O)IWQ70/]".A1(@2( MK=D(VL^"HX8*GU*AP!S;^H,O)7S MZ#U7WIN9<_?I/0KB*,`A+G>-5>NGY$=<-XHJP`>MU6M9Z)HH.72:;+TR:L_LZ([*D*4B215%L$&V)A:0[(LWBUBJ-::"M1LAY0\H(#9G2O MZ530UM8^Q:@+3099S9J#Y3<_2?PH2[O*"7<>:.LKE)`(">)"N`YO`'O.$TJP98,[%7WUU?D1V3/ M[2XVA]`=#AV:?CRJ33QP\6H=1V5NQ<%Y,HOJ$6@J(2#ZLXWRF6R(<]QU60Z` M5D=5M+R.T_2,Z$.;19R\^LE.$)G;2(U"8F&[G!Z#?C/T>)<8D<>&!>$"-7Q*"3T>BB@'0S\-^)60' ML;=G("3'M0Q0*K83X`B>?F6!C;=S#8ROI6!$:$EK)@U%-&JD8C=Z5!P)':G3 MKT@<8K55.&.`YB*@3I'`1B.9\PBEBI4\^2-&9=!1P.+D2]Q1RXT".X=DG8&- M6.1#),\'7#HA),4^5:>`LN$8RX,.,!<2<8;N[(4L.&8Y# M`B>]^".GI71A\OW+'U?0N)H?6E&R#HF@J&M)!T*K7(?$8FA92BB%0W!N)`D)1;_XWU,_17-JYD%16C!19LKK])#@=:-*.U41`VI=9:.5%V]7FP#*6=950-31]5AB[=@*]M;#K*U6 MH(];_JJS6=J_LO$==,Q<7ZQD"\X!=#?L`S(:\DAX MK=0:L^ODT#%S1[C)[!!I[#V238EP6^!,;_,LS?QH3E[D]W$87I;NLCY$4_B# MT`%\=F3)LIQ**?:^#])#\MSDLB[2MG\+.MBP/]GJ79;W!+0DQNO2HICY2392 M4?ZE3#>(2MNHU(1L_]>@`R7')LX<$CKB]>A(G'W(S8Y"/4HSX]>@2["-39HY M)'3#_2)V0-'_N*,"2@*<(J&P:D_F38"Z:(,)HQF)W.B?,VZ==@(Q%!9>5TOU6*_4UM.;W+\L%O>1-HC\[(9)E-05L]ELG#X,LP(0)M%<45>!-W',3P6T6'Z/#V9%ZR/T7X18$*7P[(<(]HM M/8(7HN)0O?R.-QVK>UE@V>V/4@Z]")[DE'G2/CYVE*,-#BC5+9`K.9@#:.E!$K2OI^-<:CW23'C>)P6J\*6C!D?%L$E/:#K($ M?`>Z7Q&,.$IQ4)3SZ%&38?^0-W702=TCJ5PH`V[Q(=2DU''L,K2L,$GXH'_4KJ4F@(^D8K1_UIJ#%98XMV?W1L#>5`;B`C79U[H\Z-A]U M;%C;[Z..#;,ZQT<=FX\Z-FTZ?=2QX4F$;1?Z1QV;CSHV'W5L#JP='W5LWG4= M&[$*KU@KG?VUBU5A)'"!SQ0.,\M4L-O%5H,O\WIG:9TL/-:JC(4JHR)A!H-S MJF@&=#>D*/AN&;^Y?$`4+S])(0G3[-:$N^_6--('?B@6"%,XQ$1@&+M0[1-F/6J-JZ6^=L%2<9 M_D_YW$)ID."UR,J@,A:L^H.^F4$93L7('P=F,*HON6TLN8R3!Y2\X(#9/TUG M.%AI`GV&ZB"J>/K3Z*-#[E%(.SK=^4FV>22`4T(?>@T!=1'E+4>AKZAL*&S@ MR26.<(:N\0NBD4Y$,Y6JL("632)"L9Q^W$?GLDY0V^/ M<_24*82-,+\?3OB("L-X>C,'F&/\50CU8(Z`CM;@\D>1G?"!%QS5Y]!P(\Q:<4J>;;_Z_X^0L M]--4YIS@0=0Z')9FU9X6$>V*UP1C35 M/,QPM)PM$U3&"XEO`_X(Z*8S!MQ@W`YB?`.*G[#_X#S=U/^+Y%I0GP2\>XN% M6T$/K2W_-M"E4(#=))2Y MP]C<&A"=4+[N$K3V\9RZO*,4G>4))?`LFM_$45#^B]`=+!L,ZQ+68";/1ZP$ MT`E)H$:G],[?T).O1CB,TN*E@A<8S<^D(J$Q"ZRCN;-LZ")U(PIZ&X58;0F! M)+2^A/5"=^8V"XT;<;\06"5W.WP60+,D9A;OTC5H^T%BVJC M=R@IHN-$_C'.$+#"XW;8+81E*U*UKKP?.[CD+%ZM<)&?DQ*]A59FHT_7*"!R M#11?(EH13H,P3O-$5$_-:!Z(R)/;-:)Y4-'R&ODI2B_SC"SH&WF;K/)5%8*: MWJ,`X1>J0B@@-IL0.B)%FT_LG6H.W@&[C!YX^?5M-!]TO(NY!-B0J!H1WIU` M746/K_&_D)^(C'^F4T*'V,"*59,.+K1)U,9/?AQ9%Z[=I-#!0.#BU:"$K2?K MF`3L,LX3V_*UFQ,ZQ@A:O!J$<*'(KC8!\(OUTVLW)W18$KATU0EAZSD^'NEZ M?$8)\A>9L-:8Z930\5&PLM6D@ZVTSO&(EC6!@@ZG@A6C6GA5]RS1.//#`0O/ MN;#-@>%,T-%91[1.M5"_E[<>@6W'(+6?"#Q6S(#=G>2FCON=6)\(:FMFI\9< MX`%HQQ:>%O1W=.Y8-"ZU9@./<0,0HB;X]V))*K#;,B$U)P,+CH,3HB;V]V(O M*J%;,A0U)P,+H@.4H0;V]V(5HH%)MLQ!C;G``O.@)*@%_;W8?LZ%?=X49P"+ M[H,2EGK4GWT+S_"BP;1[4[V;H#"-E&5>.2'Q@)$':LG!#2Q?D;563I:Q\'NH MN"@YP149!%WS1X,_W/Q?R0BH(",IS159--@Z/E8K-D#F`XFIKLBFP70]TN#6 M;83T&;8;!!7_8H]G#2C025HZ2L9KK,^WW2"HR!)[?&M`@4[%TN#;M2"17CX( MM`>0#66C@61H[;@$*K!BBKSZ#*!=?J2<87)3!YH3.=$M(\$]P5XE@%:6`OH7 M/]0PZ7*G`.W'H\=:)8.*$*A[/NP:W(>47LG]4E@&^#T*Q],K`ZZ MJ6N0;Y!&-$QS'&Q/F7XE80L/UKDL;+S`N#EYN@!W`&QOE2XL5,`%G2+/X5YE MTR]["3S&U>K]*/MU'4<7;RC(RZ8#4JYJ3P1;`ZT>>P]6RL7,,\5+;']OA M253+%/V14PWCI;`RP=2\:"]#P9/)&P+20Z6Y%FFW%,;GT,Y-$3G9VX.'8N2= M,5JH%'J?L$=`5X/@L4>-F>YT.CD$)N]UPAL#78I!P"5EML)[2GMA+-?5(_P> MNOB!D#]*+!V,1]4.5Q]Q1@N.745SVA:7JFGBPY?Y/73-`;VCEPMAY+U*#G#] MAK/GHB`=K>[^C->/\051RQ5JUFO.!%T4@,M01?[+T8W[Y#['"0K(W-(CN_DA M=#Z^`9_8##^$-6Y^MHX[D?]>-@0Z6;Z3TMQ``=93A&/>;2-3\]:+1T'GIHOH MSS#4RL$XH4)M@_,?XUGP1T[.FM,\)91)4Y3^DL2IT$8K&0KK9)7SCV.G54'E M@,>]**N^ZPI]F]S3#HDW.;UD;A;;??HZD.17'2<&=8C M:RHV-D##.NDY5T&UTHNW-4X*3IS[&3<;@_DQK']6EZ$2'-"AD3UN_HLWE`0X M147I[GV_^*V(BB)OC.:#]>1:W>A*4%W(S]XBFT7S$MIMGJ693UXYT5(@'Z)A ML*Y=4S&0(G(ADYIV7#Z+(W)64;]U^4\9;0-%J)-3+6FVBO,H$YT,JE/`.H!- MI4`+G0NIT5+`1;^'M`QOZ207C8E@VZ#T)AV'&*WE1H/*R#I.,3D:BQYQ2JW/ M>$-@^Z&8\UV`IN+PC^-6(.^2.$!HGEX2BE6"3=L"4HD71W7Q1GD3R`0.8V.! M!%#%[)_&O9V?LOV1M>W<=4\>1`]9T2Z(J+Z47TM1$(OZ)-X$,G6CRU&O@:^2 MBZ_C/@2:H&D_V;4%+M$U4 MIER22IS[]4=2DD5*0XE.TJZ\]LNN0LX,^7U#C68<9+0T][P MX$TOP#1,(D)GI[VO=^?]7WO!;Q]?O_K`PSE>H$`@-L/B"UI@OD0A/NW-A5B> M#`8QF6(N'F.\P!$)44RQ>$C8MX,P60P.WPS?#@^/AM*TZJ?B/&&+,9ZB-!:G MO>\IDLH$1[W@]2LY&\I/X@7]MJ'EUZ\"K;M6>WAX.'@X.DC83$J]&0[^^/WR M5D/H!6OADY@8`RF-U83%A<[10'5/$,>FBI*(Q%K)5'@WR#HM\;C!_A^7XMZ3FA>(8$CIQC'`]8$N-!+F:.D_+^#*'E M6G.*^$1KY1W*&>_Z;X9]Y8Z:6A\)X5:5G8Q,4H&YJ1HF*17LT>::X_!@EMP/ M\DXUZE%]U#!E3*YCEV[>J]=/73G"!-:3'0X5O`KGL([J<5!#Z+U%QB#KI.]SBP<;%DCL%DCV,TAJ?.A?E^ M('MM+RT9#EL6,V*A7L]3%(H^7BUC1)%(V..Y_-MB-*$T7<"&(L$&"NI`"O6E M%&8DM'3;%0TE%4L1I8E`0H;@&1-#5*K&<0X2FA1,].!LZ@'Q1JYB6B49#9 M"`PC'P95"X71E./HBG[4U])O7-K0&BH"YEJY"*11&O23E_2$:>P>8&!1_0+< M?TXH3V(2J>7X"<4J1M_.,18\(][=#;-^**F^E03AG'93/\@-!)F%/>553J^1 M#.YBCH52:^'?EH6=<>3OC.`7R^`_]\Z1'/&".YY,DR5F>AK`C>&0@YWRMLDI MZPX>)-/@:FUK[P[)SIJB:8O^-7T,^+S\SAY`&XI6`QVT'O_.TJ9"K2MG77& M%9LA2OYG)%=6"TSQOU0&17@8)SQE6/YAZNPLE1<2#IV128SS%6PVP$3^6B72 M4-E9'B\31&]PB,D]DCQD5%;:8#:/JVPJK:!4VUE&QW@B\LI)78'L#=]4V5.R M.TO9*-0;,WR)'M72D64B"D.6XD@6WYCRXA9O%X/)'E;)+@P%UYDE79B.,EO! M66YL9[UQ0>4EOD.K,K26#3##A_70JE0"K;.S1)HYJ9D?`^TPK4=56NTL=\=3 MV_\BQA`M=DO6?\%4OJU26G/] M0!L(3`L[2_CG9+$@0M=#(QK)2DD0.I,U*L'K(LPM`-/^ODJ[84+_J%E&=I;Y MVW3"\?=4HCJ[Q^N(46N%.:[57Z5>D"GN+*]F);J497^YE,$>F-]:66;J!K]< MY]J[NRUJE*EW""QX\V:8WUJA9B@&OV2JNTNNJKM,5HV_03H/P:U5N056GM.C6P651)B MD^9V,9CY6DW8F#WOW6$F9A$6B,1`ME=TP)37ZD0[V1MGRKM+L9&;60P#[3#! MM8K0RO;V_)9LY%P,:P2O.V"&:_4@Q'`PW'-<4GF'5R(M7JMQ=\-\-SVV*_G. M;>PNZ_9#N[$9/.`NF.VVQWK[&*)+1BLXFPT@JT>.HG%/I:3!CL-6"TQFK?ZS MR-SER&N09X5X)K1`Y=#+N">*T0!"G>Y6!>Y_+01?*A@V2@&(1(/MR3O'+5 M*JYNF'"@-H0(W_G?T?H;,%:@=G?#M-=*1.@]F7W<7N]16V17&V&*:W5AN4N] MI]5FT(H@CCZ0Y+>U,K%&\CYTN%Y,LM9TFQ!,?ZVP=+_$M%_U3:\S6;[PD(/= M42M&6Q[/[#W2RK05FOS%8?_4ZE,__^Q#6/7%,SOW<73"/JA5JK67T_XV]X7Z MCSI7XP9/`WU`Q8GZ3/ZTQ\EBJ;Y-@_&AZL>)1-;(/QUX@V'+_0VVQ\^%P>SY$+!37D.X_!&H_" M<8RIQP,5!S@6O&CIEZ9\43<<(=,T%T`MO^Z7)C:=`W1*C\\D3+WBC^=,`SKP MQVL>IN+ZKWYI9M.9U(X#\IG%6DE?/6-)U$\'\AF^U,HN^Z6!32=0/6G(9_A" M1UT\9^CJN4->8Q=*^FJST=N.UO()1C%CEI:*2,=#^=!0U7J&8^"3K3:;1$*_/&4> MS>>(/?TW4]L"(V1^]J">2_-16*,)%TPO2U7%J\'@8U#'AY<))^**CL+O*>&Z7N`F(+C?1+!(Y&V/V".$88IB#H+( MLD51=$VRXY$D.#PAXD60C19R1>6OF5Y-BVW5"\Y3')TG[!:S>Q)B$ZNWQK/1 MER[\8?`O:,BP3(?'./O_!U:&PDD^NW*=2.X"?XB3\5D<`"F58LN,63T31_D3_O``@\Z7U?#<3\$FC M5(?<4[Y/Z\;2(-,A).=JCPM?DGL<7'/]E)5XBT/Y^QE=LV1!.)>5[I=$X!J*1JDNP?DJXY@/H!:Y M+8!T1;U1&:);`.SN(?$%9HAN`["Y_'WUAF8*;P&X\R1EOMA,V2V`=HOO,?7% M9@EO`;@S,IL+7W"6<)?`WT;04[1(P M*W3X!9AM#"D6@"]8N+#IKFT`I".]<_L`[.W2ID'Q@D;Q).UM*+\=P'R>VVRNN@V$C/$4RV`325PCSK'@/E1LHK0%FT_F054- M&]5NH0[=]_4OG-R0/&2[A&R.&.Y_0AQ',@ZIAX?9\VZU\F9:\-.C(7.-'O4C M\@?$HANL,@`Y^4LRQ1`1+V[Z[\';!553YR3\#XK3%R;.9;M#S.51S7T#N00Z MA.%+JC+BZGL&(VZZRT#D)V[A4^[E3XOH+_;4*I^N^6K%&/.0D64%GY^XG_]^ MSO,L]0_?I+'ZW*5\@EBKB)J$NE0+C7$<.$+X* M'0H8T%*Z*_\)%^=RRV5^,I)(G,P?U:/S=((O-L(T6A'>`BD3^?F((B*'Y_E3 M=']$8WUSM&`JA+IT6T'SA+:S6N2Z#@EZ5M4BUW5(EX3JVZ[M3C+D.A7JG-^I MND/Z)DH=PIHE/H!O:LD1*-.M=WSR.B)+3N^2?,8RH_NZ3.C9"H=I]G(M!/() MNMNPCU/YNK>AZ&\1[-":S=/TL]629%;']MM`CGYKK&UL550%``/0HGE5=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`,EC+1AWM#J)>"@``CJ<``!4`&````````0```*2!.)D``&QM M;FLM,C`Q-#$R,S%?8V%L+GAM;%54!0`#T*)Y575X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`#)8RT8D=Y"XY!,``-1;`0`5`!@```````$```"D@>6C``!L M;6YK+3(P,30Q,C,Q7V1E9BYX;6Q55`4``]"B>55U>`L``00E#@``!#D!``!0 M2P$"'@,4````"``R6,M&%&7L#QY+```CW`0`%0`8```````!````I($8N``` M;&UN:RTR,#$T,3(S,5]L86(N>&UL550%``/0HGE5=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`,EC+1G\M*N&F*P``BSL#`!4`&````````0```*2!A0,! M`&QM;FLM,C`Q-#$R,S%?<')E+GAM;%54!0`#T*)Y575X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`#)8RT:S)NFBE0L``,R````1`!@```````$```"D@7HO M`0!L;6YK+3(P,30Q,C,Q+GAS9%54!0`#T*)Y575X"P`!!"4.```$.0$``%!+ 4!08`````!@`&`!H"``!:.P$````` ` end XML 55 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
Related Party Transactions (Details) (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Feb. 28, 2014
Related Party Transaction (Textual)        
Fund borrowed from related parties $ 100,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent $ 20,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent $ 737,200us-gaap_NotesPayableRelatedPartiesClassifiedCurrent  
Interest expense 59,250us-gaap_InterestExpense 17,500us-gaap_InterestExpense    
Short-term debt to related parties 1,050,905us-gaap_DueToRelatedPartiesCurrent 779,133us-gaap_DueToRelatedPartiesCurrent    
Dellinger Fund [Member]        
Related Party Transaction (Textual)        
Interest expense 7,500us-gaap_InterestExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= lmnk_DellingerFundMember
7,500us-gaap_InterestExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= lmnk_DellingerFundMember
   
Consulting agreement with Saddleworth Ventures [Member]        
Related Party Transaction (Textual)        
Expenses paid on behalf of the company 21,933us-gaap_PrepaidExpenseCurrentAndNoncurrent
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= lmnk_ConsultingAgreementsMember
171,772us-gaap_PrepaidExpenseCurrentAndNoncurrent
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= lmnk_ConsultingAgreementsMember
   
Unsecured promissory note, interest free, due June 15, 2015 (9)        
Related Party Transaction (Textual)        
Fund borrowed from related parties       100,000us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
Short-term debt to related parties $ 100,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
[1]    [1]    
Sale of Stock, Price Per Share       $ 0.10us-gaap_SaleOfStockPricePerShare
/ us-gaap_ShortTermDebtTypeAxis
= lmnk_UnsecuredPromissoryNoteEightMember
[1] In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015. Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company's common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11.
XML 56 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statement of Stockholders' Deficiency Equity (USD $)
Total
Common Stock
Additional Paid In Capital
Accumulated Deficit
Treasury Stock
Beginning balance at Dec. 31, 2012 $ (672,709)us-gaap_StockholdersEquity $ 25,205us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 6,934,025us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (7,622,702)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
$ (9,237)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember
Beginning balance, Shares at Dec. 31, 2012   25,205,101us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Issuance of common stock as incentive for debt 10,000us-gaap_StockIssuedDuringPeriodValueOther 500us-gaap_StockIssuedDuringPeriodValueOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
9,500us-gaap_StockIssuedDuringPeriodValueOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
     
Issuance of common stock as incentive for debt, Shares   500,000us-gaap_StockIssuedDuringPeriodSharesOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Issuance of common stock for services 11,550us-gaap_StockIssuedDuringPeriodValueIssuedForServices 130us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
11,420us-gaap_StockIssuedDuringPeriodValueIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
     
Issuance of common stock for services, Shares   130,000us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Amortization of warrants issued for services 157,780lmnk_AmortizationOfWarrantsIssuedForServices    157,780lmnk_AmortizationOfWarrantsIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
     
Net loss (423,225)us-gaap_NetIncomeLoss       (423,225)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
  
Ending balance at Dec. 31, 2013 (916,604)us-gaap_StockholdersEquity 25,835us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
7,112,725us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
(8,045,927)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
(9,237)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember
Ending balance, Shares at Dec. 31, 2013   25,835,101us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Issuance of common stock as incentive for debt 25,000us-gaap_StockIssuedDuringPeriodValueOther 250us-gaap_StockIssuedDuringPeriodValueOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
24,750us-gaap_StockIssuedDuringPeriodValueOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
     
Issuance of common stock as incentive for debt, Shares   250,000us-gaap_StockIssuedDuringPeriodSharesOther
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
Amortization of warrants issued for services 157,780lmnk_AmortizationOfWarrantsIssuedForServices    157,780lmnk_AmortizationOfWarrantsIssuedForServices
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
     
Net loss (489,202)us-gaap_NetIncomeLoss       (489,202)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
  
Ending balance at Dec. 31, 2014 $ (1,223,026)us-gaap_StockholdersEquity $ 26,085us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 7,295,255us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (8,535,129)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember
$ (9,237)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_TreasuryStockMember
Ending balance, Shares at Dec. 31, 2014   26,085,101us-gaap_SharesOutstanding
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
     
XML 57 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt
12 Months Ended
Dec. 31, 2014
Debt [Abstract]  
DEBT
4. DEBT

 

Short-term debt as of December 31, 2014 and 2013 were as follows:

  

    December 31,  
    2014     2013  
Short-term Debt to Related Parties            
             
Unsecured promissory note, interest free, due June 15, 2015 (1)   $ 200,000     $ 200,000  
                 
Unsecured promissory note, interest free, due June 15, 2015 (2)     75,000       75,000  
               
Unsecured promissory note, interest free, due June 15, 2015 (2)     60,000       60,000  
                 
Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)     75,000       75,000  
                 
Unsecured promissory notes, interest free due June 15, 2015 (4)     347,200       347,200  
               
Unsecured promissory note, interest free, due June 30, 2015 (5)     193,705       21,933  
               
Unsecured promissory note, interest free, due June 15, 2015 (9)     100,000       -  
      1,050,905       779,133  
Less: Current portion     1,050,905       779,133  
    $ -     $ -  

    December 31,  
    2014     2013  
Short-term Debt            
             
Unsecured promissory note, interest free, due on demand (6)   $ 26,000     $ 26,000  
                 
Secured promissory note, interest @ 12%   per annum, due December 15, 2015 (7)     150,000       150,000  
                 
Unsecured promissory note, interest @ 10%,   due December 15, 2015 (8)     75,000       -  
    $ 251,000     $ 176,000  
Less: Current portion     251,000       176,000  
    $ -     $ -  

(1) On January 5, 2012, LMC borrowed $200,000 from the Dellinger Fund, a shareholder of the Company. The note is interest free and has been extended to June 15, 2015. In the event of default, the Dellinger Fund has the right to request and will be granted the issuance of two million shares of the Company's common stock.

 

(2) On February 3, 2012 and March 1, 2012, LMC borrowed $75,000 and $60,000, respectively, from the Dellinger Fund, a shareholder of the Company. The unsecured notes are interest free and are due June 15, 2015. In the event of default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.

 

(3) On April 3, 2012, LMC borrowed $75,000 from the Dellinger Fund, a shareholder of the Company. The unsecured note bears interest @ 10% per annum and is due June 15, 2015. In the event of default, interest on the outstanding balance shall continue to accrue at a rate of ten percent (10%) per annum from the date of the default.

 

(4) On various dates from March 23, 2012 through November 26, 2012, LMC borrowed $327,200 from the Dellinger Fund, a shareholder of the Company. In February 2013, LMC borrowed an additional $20,000. The unsecured notes are interest free and are due June 15, 2015. In the event of a default, interest on the outstanding balance shall accrue at a rate of ten percent (10%) per annum from the date of the default.

 

On April 17, 2015, the Dellinger Fund notes in the amount of $757,200 plus accrued interest were converted into 6,000,000 shares of the Company’s common stock. See Note 11.

 

(5) During the year ended December 31, 2013 and 2014, Saddleworth Ventures LLC, a related party, paid expenses amounting to $21,933 and $171,772, respectively, on behalf of the Company. These advances are unsecured, interest free and are due June 30, 2015.

 

(6) On May 13, 2013, LMC borrowed $30,000 from Forbes Investment, LLP. The unsecured note is interest free and payable upon demand. In December 2013, LMC repaid $4,000 against the outstanding balance.

 

(7) On October 16, 2013, LMC borrowed $150,000 from Edmund Malits, a shareholder of the Company. The secured note bears interest @ 12% per annum and interest and principal are payable in full on or before February 16, 2014. LMC provided the Corporation’s shell on the OTCBB as collateral for the loan. In addition, LMC issued Edmund Malits 500,000 shares of the Company’s common stock with a fair value of $10,000. The note has been extended to December 15, 2015.

 

(8) On February 4, 2014, the Company executed an unsecured promissory note with Curt Maes and received $75,000. The promissory note bears interest @ 10% per annum and both principal and interest are payable on or before December 15, 2015. As additional consideration, the Company issued Curt Maes 250,000 shares of the Company’s common stock valued @ $25,000.

 

(9) In February 2014, the Company received from Saddleworth Ventures an advance of $100,000 that was used as an initial down payment for an acquisition. The advance is interest free and due April 15, 2015.  Saddleworth Ventures has the option to convert the note representing the advance, in whole or in part, into shares of the Company’s common stock at a price of $0.10 per share. On April 10, 2015, the note was repaid in full. See Note 11.

 

Interest expense for the years ended December 31, 2014 and 2013 amounted to $59,250 and $17,500, respectively.

XML 58 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangibles (Details 1) (USD $)
Dec. 31, 2014
Estimated amortization expense for intangible assets  
2015 $ 5,555us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2016 5,555us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2017 5,555us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2018 5,555us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2019 $ 5,555us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 110 209 1 true 23 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://lifestylemedicalnetwork.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Consolidated Statements of Operations Sheet http://lifestylemedicalnetwork.com/role/Consolidatedstatementsofoperations Consolidated Statements of Operations false false R5.htm 005 - Statement - Consolidated Statement of Stockholders' Deficiency Equity Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedStatementOfStockholdersDeficiencyEquity Consolidated Statement of Stockholders' Deficiency Equity false false R6.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R7.htm 007 - Disclosure - Organization Sheet http://lifestylemedicalnetwork.com/role/Organization Organization false false R8.htm 008 - Disclosure - Intangibles Sheet http://lifestylemedicalnetwork.com/role/Intangibles Intangibles false false R9.htm 009 - Disclosure - Loan Receivable Sheet http://lifestylemedicalnetwork.com/role/LoanReceivable Loan Receivable false false R10.htm 010 - Disclosure - Debt Sheet http://lifestylemedicalnetwork.com/role/Debt Debt false false R11.htm 011 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpenses Accounts Payable and Accrued Expenses false false R12.htm 012 - Disclosure - Income Taxes Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxes Income Taxes false false R13.htm 013 - Disclosure - Stockholders' Equity Sheet http://lifestylemedicalnetwork.com/role/StockholdersEquity Stockholders' Equity false false R14.htm 014 - Disclosure - Warrants Sheet http://lifestylemedicalnetwork.com/role/Warrants Warrants false false R15.htm 015 - Disclosure - Related Party Transactions Sheet http://lifestylemedicalnetwork.com/role/RelatedPartyTransactions Related Party Transactions false false R16.htm 016 - Disclosure - Commitments and Contingencies Sheet http://lifestylemedicalnetwork.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 017 - Disclosure - Subsequent Events Sheet http://lifestylemedicalnetwork.com/role/SubsequentEvents Subsequent Events false false R18.htm 018 - Disclosure - Organization (Policies) Sheet http://lifestylemedicalnetwork.com/role/Organizationpolicies Organization (Policies) false false R19.htm 019 - Disclosure - Intangibles (Tables) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesTables Intangibles (Tables) false false R20.htm 020 - Disclosure - Debt (Tables) Sheet http://lifestylemedicalnetwork.com/role/DebtTables Debt (Tables) false false R21.htm 021 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpensestables Accounts Payable and Accrued Expenses (Tables) false false R22.htm 022 - Disclosure - Income Taxes (Tables) Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxesTables Income Taxes (Tables) false false R23.htm 023 - Disclosure - Warrants (Tables) Sheet http://lifestylemedicalnetwork.com/role/WarrantsTables Warrants (Tables) false false R24.htm 024 - Disclosure - Commitments and Contingencies (Tables) Sheet http://lifestylemedicalnetwork.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) false false R25.htm 025 - Disclosure - Organization (Details) Sheet http://lifestylemedicalnetwork.com/role/Organizationdetails Organization (Details) false false R26.htm 026 - Disclosure - Intangibles (Details) Sheet http://lifestylemedicalnetwork.com/role/Intangiblesdetails Intangibles (Details) false false R27.htm 027 - Disclosure - Intangibles (Details 1) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesDetails1 Intangibles (Details 1) false false R28.htm 028 - Disclosure - Intangibles (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesDetailsTextual Intangibles (Details Textual) false false R29.htm 029 - Disclosure - Loan Receivable (Details) Sheet http://lifestylemedicalnetwork.com/role/LoanReceivableDetails Loan Receivable (Details) false false R30.htm 030 - Disclosure - Debt (Details) Sheet http://lifestylemedicalnetwork.com/role/Debtdetails Debt (Details) false false R31.htm 031 - Disclosure - Debt (Details 1) Sheet http://lifestylemedicalnetwork.com/role/DebtDetails1 Debt (Details 1) false false R32.htm 032 - Disclosure - Debt (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/DebtDetailsTextual Debt (Details Textual) false false R33.htm 033 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpensesdetails Accounts Payable and Accrued Expenses (Details) false false R34.htm 034 - Disclosure - Income Taxes (Details) Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxesDetails Income Taxes (Details) false false R35.htm 035 - Disclosure - Income Taxes (Details 1) Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) false false R36.htm 036 - Disclosure - Income Taxes (Details 2) Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) false false R37.htm 037 - Disclosure - Income Taxes (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R38.htm 038 - Disclosure - Stockholders' Equity (Details) Sheet http://lifestylemedicalnetwork.com/role/StockholdersEquityDetails Stockholders' Equity (Details) false false R39.htm 039 - Disclosure - Warrants (Details) Sheet http://lifestylemedicalnetwork.com/role/WarrantsDetails Warrants (Details) false false R40.htm 040 - Disclosure - Warrants (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/WarrantsDetailsTextual Warrants (Details Textual) false false R41.htm 041 - Disclosure - Related Party Transactions (Details) Sheet http://lifestylemedicalnetwork.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) false false R42.htm 042 - Disclosure - Commitments and Contingencies (Details) Sheet http://lifestylemedicalnetwork.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R43.htm 043 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R44.htm 044 - Disclosure - Subsequent Events (Details) Sheet http://lifestylemedicalnetwork.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -6 0. Process Flow-Through: 002 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Consolidated Statements of Operations Process Flow-Through: 006 - Statement - Consolidated Statements of Cash Flows lmnk-20141231.xml lmnk-20141231.xsd lmnk-20141231_cal.xml lmnk-20141231_def.xml lmnk-20141231_lab.xml lmnk-20141231_pre.xml true true XML 60 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stockholders' Equity (Details) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended
Feb. 04, 2014
Oct. 31, 2013
Dec. 31, 2013
Stockholders' Equity (Textual)      
Issuance of common stock, shares 250,000us-gaap_StockIssuedDuringPeriodSharesNewIssues 500,000us-gaap_StockIssuedDuringPeriodSharesNewIssues  
Issuance of common stock $ 25,000us-gaap_StockIssuedDuringPeriodValueNewIssues $ 10,000us-gaap_StockIssuedDuringPeriodValueNewIssues  
Stock issued related to share based compensation     130,000us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross
Share based compensation expenses     $ 11,550us-gaap_AllocatedShareBasedCompensationExpense
XML 61 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Debt (Tables)
12 Months Ended
Dec. 31, 2014
Debt [Abstract]  
Summary of short-term debt

    December 31,  
    2014     2013  
Short-term Debt to Related Parties            
             
Unsecured promissory note, interest free, due June 15, 2015 (1)   $ 200,000     $ 200,000  
                 
Unsecured promissory note, interest free, due June 15, 2015 (2)     75,000       75,000  
               
Unsecured promissory note, interest free, due June 15, 2015 (2)     60,000       60,000  
                 
Unsecured promissory notes, interest @ 10% per annum, due June 15, 2015 (3)     75,000       75,000  
                 
Unsecured promissory notes, interest free due June 15, 2015 (4)     347,200       347,200  
               
Unsecured promissory note, interest free, due June 30, 2015 (5)     193,705       21,933  
               
Unsecured promissory note, interest free, due June 15, 2015 (9)     100,000       -  
      1,050,905       779,133  
Less: Current portion     1,050,905       779,133  
    $ -     $ -  

 

    December 31,  
    2014     2013  
Short-term Debt            
             
Unsecured promissory note, interest free, due on demand (6)   $ 26,000     $ 26,000  
                 
Secured promissory note, interest @ 12%   per annum, due December 15, 2015 (7)     150,000       150,000  
                 
Unsecured promissory note, interest @ 10%,   due December 15, 2015 (8)     75,000       -  
    $ 251,000     $ 176,000  
Less: Current portion     251,000       176,000  
    $ -     $ -